学术周报 · IF≥10

心血管科领域文献阅读汇编

2026年第41周 (2026-10-08) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
收录论文
139
临床研究
75
基础研究
64
IF≥20
38
IF 10-20
101
子领域
46
期刊种类
44
数据日期
2026-10-08

★本周 Top 10 高影响力文献

#论文期刊IF
1Carbon nanoparticle-Fe (II) complex for ferroptosis therapy in refractory solid tumors: a phase I tr...Signal transduction and targeted therapyIF 81.2
2Adults with congenital heart disease: the growing impact of acquired cardiovascular risk factors on ...European heart journalIF 45.3
3Biventricular vs conduction system pacing after atrioventricular node ablation for heart failure wit...European heart journalIF 45.3
4Intravascular imaging from research tool to guidelines: a 35-year long journey.European heart journalIF 45.3
5Semaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental ...European heart journalIF 45.3
6Coronary autoregulation: the complex interplay between epicardial and microvascular resistance.European heart journalIF 45.3
7Myocardial bridging: a practical guide for clinicians.European heart journalIF 45.3
8Great debate: preventive percutaneous coronary intervention added to optimal medical treatment shoul...European heart journalIF 45.3
9Pharmacotherapy of cardiovascular diseases from herbs and pills to nucleic acids.European heart journalIF 45.3
10Lipid Burden and Efficacy of Preventive PCI of Vulnerable Atherosclerotic Coronary Plaques: Post Hoc...CirculationIF 41.3

Ŧ期刊分布统计

期刊篇数IF
Stroke23IF 11.1
Ageing research reviews10IF 15.5
Circulation9IF 41.3
European heart journal8IF 45.3
Redox biology8IF 16.2
Acta pharmacologica Sinica7IF 10.4
Pharmacological research6IF 12.2
Diabetes care6IF 22.6
Cardiovascular research5IF 12.5
Journal of advanced research5IF 17.1

1脑卒中/脑血管病 (28篇)

临床研究 (20篇)

Stroke IF 11.1 2026-10-07 PMID: 42841198
Subjective social status (SSS) represents self-perceived social position and may affect poststroke recovery. Despite impacting various medical outcomes, SSS remains understudied in stroke. We hypothesized that higher SSS is associated with better stroke recovery at 3- and 12 months poststroke. In this prospective cohort study, patients were enrolled between October 2016 and February 2020. We examined associations between 3-month SSS score and clinician-reported, performance, and patient-reported outcomes at 3- and 12-month assessments. Ordinal multivariable regression analysis evaluated 3-month SSS score as a predictor of 12-month modified Rankin Scale score. The 494 participants had a median age of 63.5 years; 200 (41%) were female, and median (interquartile range) acute National Institutes of Health Stroke Scale score was 4 (2-8). Scores on SSS showed no meaningful associations with performance outcomes and some associations with clinician-reported outcomes (eg, 3-month modified Rankin Scale: ρ, -0.12 [95% CI, -0.21 to -0.03], false discovery rate-adjusted P=0.017; 12-month modified Rankin Scale: ρ12mo, -0.18 [95% CI, -0.27 to -0.09], false discovery rate-adjusted P=0.001). Conversely, higher SSS showed strong, consistent correlations with patient-reported outcomes, including less psychological distress and higher Stroke Impact Scale-Activities of Daily Living (ρ3mo, 0.18 [95% CI, 0.09-0.26]; ρ12mo, 0.17 [95% CI, 0.07-0.26]; all false discovery rate-adjusted P<0.05). Item-level analyses of Stroke Impact Scale-Activities of Daily Living revealed that SSS remained most strongly and consistently linked to complex Stroke Impact Scale-Activities of Daily Living motor tasks over time. In ordinal multivariable regression adjusted for age, sex, stroke subtype, initial severity, and the selected objective socioeconomic status proxies (eg, educational attainment, employment, and marital status), 3-month SSS score significantly predicted 12-month modified Rankin Scale score (β, 0.14 [95% CI, 0.02-0.26]; P=0.014). In patients with predominantly mild stroke, 3-month SSS score may serve as a significant social determinant of health that is associated with long-term functional recovery, a relationship closely linked with psychological distress. SSS scores at 3 months poststroke may identify vulnerable patients, enabling development, validation, and targeted application of interventions that optimize stroke recovery.
中文摘要:主观社会地位(SSS)代表自我感知的社会位置,并可能影响卒中后恢复。尽管SSS影响多种医学结局,但在卒中领域仍研究不足。我们假设较高的SSS与卒中后3个月和12个月更好的恢复相关。在这项前瞻性队列研究中,患者于2016年10月至2020年2月入组。我们分析了3个月SSS评分与3个月和12个月评估时临床医生报告、表现及患者报告结局之间的关联。有序多变量回归分析评估了3个月SSS评分作为12个月改良Rankin量表评分的预测因素。494名参与者的中位年龄为63.5岁;200名(41%)为女性,急性美国国立卫生研究院卒中量表评分中位数(四分位距)为4(2-8)。SSS评分与表现结局无有意义关联,与某些临床医生报告结局存在关联(例如,3个月改良Rankin量表:ρ,-0.12[95%CI,-0.21至-0.03],错误发现率校正后P=0.017;12个月改良Rankin量表:ρ12mo,-0.18[95%CI,-0.27至-0.09],错误发现率校正后P=0.001)。相反,较高的SSS与患者报告结局显示出强且一致的关联,包括较少的心理困扰和较高的卒中影响量表-日常生活活动能力(ρ3mo,0.18[95%CI,0.09-0.26];ρ12mo,0.17[95%CI,0.07-0.26];所有错误发现率校正后P<0.05)。卒中影响量表-日常生活活动能力的条目水平分析显示,SSS随时间推移仍与复杂的卒中影响量表-日常生活活动能力运动任务保持最强且最一致的关联。在调整年龄、性别、卒中亚型、初始严重程度以及所选客观社会经济地位替代指标(例如,教育程度、就业和婚姻状况)的有序多变量回归中,3个月SSS评分显著预测12个月改良Rankin量表评分(β,0.14[95%CI,0.02-0.26];P=0.014)。在主要为轻症卒中的患者中,3个月SSS评分可能作为一个显著的健康社会决定因素,与长期功能恢复相关,这一关系与心理困扰密切相关。卒中后3个月的SSS评分可能识别脆弱患者,从而促进优化卒中恢复的干预措施的开发、验证和针对性应用。
EClinicalMedicine IF 12.8 2026-10 PMID: 42831062
The impact of SGLT2 inhibitors (SGLT2i), GLP-1 receptor agonists (GLP-1RA), and DPP-4 inhibitors (DPP-4i) on stroke risk in individuals with type 2 diabetes remains uncertain. Meta-analyses of randomised controlled trials (RCTs) show a protective effect for GLP-1RA but neutral findings for SGLT2i and DPP-4i, whereas observational studies often suggest broader stroke risk reductions. This study aimed to estimate the associations of SGLT2i, GLP-1RA, and DPP-4i with stroke risk in nationwide longitudinal data, and to contextualize these results within existing meta-analyses of RCTs and observational studies. This was a nationwide longitudinal study including individuals with type 2 diabetes first registered in the Swedish National Diabetes Register between January 1, 2013, and December 31, 2019. Individuals with a prior stroke or insufficient data for multiple imputation were excluded. The primary outcome was ischemic stroke. Treatments, comorbidities, and laboratory values were updated over time. Marginal structural models with inverse probability of treatment weighting and weighted Cox regression were used to estimate hazard ratios (HRs) for ischemic, hemorrhagic and total stroke pooled across five multiply imputed datasets. To contextualise the findings, PubMed was searched from inception to June 23, 2026, for meta-analyses of randomised controlled trials and observational studies reporting stroke outcomes for the three drug classes. We included 171,917 individuals with type 2 diabetes [59.2% males, baseline mean (SD) age 62.7 (11.6), mean (SD) follow-up 3.0 (1.9) years] contributing 1,617,462 clinical registrations. During follow-up, 2734 (1.59%) ischemic and 428 (0.25%) hemorrhagic strokes occurred. GLP-1RA use was associated with a lower risk of ischemic (HR 0.46, 95% CI 0.29-0.72) and total stroke (HR 0.51, 95% CI 0.33-0.79), whereas no clear associations were observed for hemorrhagic stroke. SGLT2i and DPP-4i showed no clear associations with any stroke outcome. The contextualisation identified 91 meta-analyses. RCT meta-analyses generally showed a protective effect for GLP-1RA and neutral effects for SGLT2i and DPP-4i, while observational meta-analyses suggested protective associations for GLP-1RA and SGLT2i. In this nationwide study, GLP-1RA were associated with reduced stroke risk, while SGLT2i and DPP-4i showed neutral effects. The overall direction of findings was consistent with evidence from RCT meta-analyses. Future research should investigate how these therapies can be optimally incorporated into treatment strategies for stroke prevention in individuals with type 2 diabetes. Sahlgrenska University Hospital's funds, the Swedish National Stroke Association, the Swedish Brain Foundation, the Swedish Heart Lung Foundation, the Bygg-Göta Foundation for scientific research, the Winberg foundation, and the Swedish state under the ALF agreement between the Swedish government and the county councils.
中文摘要:SGLT2抑制剂(SGLT2i)、GLP-1受体激动剂(GLP-1RA)和DPP-4抑制剂(DPP-4i)对2型糖尿病患者卒中风险的影响仍不确定。随机对照试验(RCT)的荟萃分析显示GLP-1RA具有保护作用,而SGLT2i和DPP-4i结果为中性,然而观察性研究常提示更广泛的卒中风险降低。本研究旨在基于全国纵向数据估计SGLT2i、GLP-1RA和DPP-4i与卒中风险的关联,并将这些结果置于现有RCT和观察性研究的荟萃分析背景下进行解读。这是一项全国纵向研究,纳入2013年1月1日至2019年12月31日期间首次在瑞典国家糖尿病登记处登记的2型糖尿病患者。既往卒中或缺少足够数据进行多重插补者被排除。主要结局为缺血性卒中。治疗、合并症和实验室值随时间更新。采用逆概率治疗加权的边际结构模型和加权Cox回归,在五个多重插补数据集中合并估计缺血性、出血性和总卒中的风险比(HR)。为进行背景解读,检索PubMed自建库至2026年6月23日,纳入报告这三类药物卒中结局的RCT和观察性研究的荟萃分析。我们纳入171,917例2型糖尿病患者[59.2%为男性,基线平均(SD)年龄62.7(11.6)岁,平均(SD)随访3.0(1.9)年],贡献1,617,462次临床登记。随访期间发生2734例(1.59%)缺血性卒中和428例(0.25%)出血性卒中。GLP-1RA使用与较低的缺血性卒中(HR 0.46,95% CI 0.29-0.72)和总卒中(HR 0.51,95% CI 0.33-0.79)风险相关,而未观察到与出血性卒中有明确关联。SGLT2i和DPP-4i与任何卒中结局均无明确关联。背景解读共识别出91项荟萃分析。RCT荟萃分析总体上显示GLP-1RA有保护作用,SGLT2i和DPP-4i为中性效应,而观察性荟萃分析提示GLP-1RA和SGLT2i具有保护性关联。在这项全国性研究中,GLP-1RA与卒中风险降低相关,而SGLT2i和DPP-4i显示中性效应。研究结果的总体方向与RCT荟萃分析的证据一致。未来研究应探讨如何将这些疗法最佳地纳入2型糖尿病患者卒中预防的治疗策略。Sahlgrenska大学医院基金、瑞典国家卒中协会、瑞典脑基金会、瑞典心肺基金会、Bygg-Göta科学研究基金会、Winberg基金会以及瑞典政府在瑞典政府与县议会ALF协议下的资助。
Stroke IF 11.1 2026-10-01 PMID: 42817886
Contrast-associated acute kidney injury (CA-AKI) after endovascular thrombectomy (EVT) worsens outcomes in acute ischemic stroke, but threshold-based definitions do not capture prognostic information from subthreshold changes. We tested whether early creatinine change within 48 hours of EVT conveys graded prognostic information beyond dichotomous CA-AKI. We performed a secondary analysis of the CAN-REST (Contrast-Associated Nephropathy After Endovascular Stroke Treatment; REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06596603) registry, a retrospective multicenter observational cohort study of 6638 EVT-treated adults with acute ischemic stroke enrolled at 73 centers in 16 countries between January 1 and December 31, 2023. Early creatinine change was quantified as the natural logarithm ratio of 48-hour creatinine to baseline creatinine (ln[48-hour/baseline creatinine]), with CA-AKI defined per Kidney Disease: Improving Global Outcomes criteria (≥0.3 mg/dL or ≥1.5× baseline rise within 48 hours). Multivariable logistic regression adjusted for prespecified baseline and periprocedural covariates examined associations with 90-day modified Rankin Scale shift and in-hospital mortality; linear versus restricted cubic spline specification was selected by likelihood ratio testing, and contrasts were estimated at ±10%, ±25%, and ±50%. Greater creatinine worsening within 48 hours of EVT was independently associated with an unfavorable 90-day modified Rankin Scale shift (adjusted common odds ratio per 1-unit log-ratio increase, 1.48 [95% CI, 1.07-2.04]; linear) and in-hospital mortality (nonlinear dose-response, of larger magnitude). A 10% increase in creatinine at 48 hours-well below Kidney Disease: Improving Global Outcomes threshold-was associated with worse functional outcome (adjusted common odds ratio, 1.04 [95% CI, 1.01-1.07]) and death (adjusted odds ratio, 1.22 [95% CI, 1.13-1.32]); a 10% decrease in creatinine at 48 hours was associated with lower odds of both outcomes (adjusted common odds ratio, 0.96 [95% CI, 0.93-0.99] and 0.74 [95% CI, 0.65-0.86]). The functional-outcome association concentrated at upper modified Rankin Scale cut-points (severe disability, death); effect modification by baseline renal function was not significant. Early creatinine change after EVT conveys graded, outcome-specific prognostic information extending below formal CA-AKI thresholds, with a dose-response detectable at changes as modest as ±10%, complementing binary CA-AKI as a framework for post-EVT renal risk assessment. URL: https://www.clinicaltrials.gov; Unique identifier: NCT06596603.
中文摘要:对比剂相关急性肾损伤(CA-AKI)在接受血管内血栓切除术(EVT)后的急性缺血性卒中患者中会加重结局,但基于阈值的定义无法捕捉阈下变化的预后信息。我们检验了EVT后48小时内早期肌酐变化是否在二分法CA-AKI之外提供分级预后信息。我们对CAN-REST(Contrast-Associated Nephropathy After Endovascular Stroke Treatment;注册:URL:https://www.clinicaltrials.gov;唯一标识符:NCT06596603)登记研究进行了二次分析,该研究是一项回顾性多中心观察性队列研究,纳入2023年1月1日至12月31日期间16个国家73个中心的6638例接受EVT治疗的急性缺血性卒中成人。早期肌酐变化量化为48小时肌酐与基线肌酐的自然对数比值(ln[48小时/基线肌酐]),CA-AKI按肾脏病:改善全球结局标准定义(48小时内≥0.3 mg/dL或≥1.5×基线升高)。校正预设基线和围手术期协变量的多变量logistic回归分析了与90天改良Rankin量表移位和院内死亡率的关联;线性与限制性立方样条设定通过似然比检验选择,并在±10%、±25%和±50%处估计对比。EVT后48小时内肌酐恶化程度越大与不利的90天改良Rankin量表移位独立相关(每增加1个单位对数比值的校正共同比值比1.48[95%CI,1.07-2.04];线性)和院内死亡率(非线性剂量反应,幅度更大)。48小时肌酐增加10%——远低于肾脏病:改善全球结局阈值——与更差的功能结局(校正共同比值比1.04[95%CI,1.01-1.07])和死亡(校正比值比1.22[95%CI,1.13-1.32])相关;48小时肌酐降低10%与两种结局的较低几率相关(校正共同比值比0.96[95%CI,0.93-0.99]和0.74[95%CI,0.65-0.86])。功能结局关联集中于改良Rankin量表较高切点(严重残疾、死亡);基线肾功能对效应的修饰不显著。EVT后早期肌酐变化提供了分级的、结局特异性的预后信息,其范围延伸至正式CA-AKI阈值以下,在低至±10%的变化即可检测到剂量反应,可作为二元CA-AKI框架的补充,用于EVT后肾脏风险评估。URL:https://www.clinicaltrials.gov;唯一标识符:NCT06596603。
Stroke IF 11.1 2026-10 PMID: 42804552
Prehospital stroke trials enable assessments of ultraearly administration of treatments and management strategies, but face unique challenges in their design, conduct, and analysis. We outline important considerations and recommendations for planning prehospital stroke trials, focusing on patient identification, consent models, randomization strategies, end point selection, and statistical frameworks. As this field evolves, multidisciplinary collaboration, pragmatic study design, and scalable technology integration are critical to ensuring scientific rigor and equitable access. This framework is intended to inform and support future investigators in designing effective, ethically sound, and operationally feasible prehospital stroke trials in conventional emergency medical services settings.
中文摘要:院前卒中试验有助于评估超早期给药治疗与管理策略,但其设计、实施和分析面临独特挑战。本文概述了规划院前卒中试验的重要考量与建议,重点关注患者识别、知情同意模式、随机化策略、终点选择及统计框架。随着该领域不断发展,多学科协作、务实的研究设计以及可扩展的技术整合对于确保科学严谨性和公平可及性至关重要。该框架旨在为未来研究者提供信息与支持,以在常规急救医疗服务环境下设计出有效、符合伦理且操作可行的院前卒中试验。
Stroke IF 11.1 2026-10 PMID: 42689359
Implementation science plays a pivotal role in advancing organizational change within stroke healthcare settings by systematically evaluating and facilitating the adoption of evidence-based practices. This topical review examines the use of key trial designs relevant to implementation science research that aim to change organizational practice, highlighting their unique design features and methodological considerations. It also provides case studies of stroke research that have used each of the methods discussed demonstrating the practical applications in real-world environments. This overview aims to guide researchers and clinicians in selecting appropriate trial designs to optimize the translation of research into sustainable organizational systems and processes.
中文摘要:实施科学通过系统评估并促进循证实践的应用,在推动卒中医疗环境中的组织变革方面发挥关键作用。本专题综述考察了与实施科学研究相关的关键试验设计,这些研究旨在改变组织实践,并强调其独特的设计特征和方法学考量。本文还提供了使用所讨论各方法的卒中研究案例,展示其在真实世界环境中的实际应用。本概述旨在指导研究者和临床医生选择合适的试验设计,以优化研究向可持续的组织系统与流程的转化。
Stroke IF 11.1 2026-10 PMID: 42689330
Stroke prevention requires that patients follow recommended health behaviors. However, few stroke behavioral interventions have been shown to produce clinically significant behavior change in clinical trials, likely thwarted in the design process by limited application of behavioral theoretical models and insight into mechanistic underpinnings during intervention testing. The National Institutes of Health Stage Model for Behavioral Intervention Development provides a systematic, nonlinear, iterative framework for advancing behavioral interventions from theory to practice. Here, we provide an overview of methods from behavioral medicine research that can be applied to improve the development of successful stroke preventive behavioral interventions. Behavioral change theories can provide a conceptual basis for theoretical frameworks for behavioral interventions as they identify individual-level influences on health behaviors using specified constructs tied to underlying psychosocial mechanisms. For example, interventions targeting self-efficacy behaviors for self-management after stroke may be guided by Social Cognitive Theory to deliver patient-centered care. Mixed methods that integrate qualitative and quantitative findings can be useful for identifying key patient barriers to target while designing behavioral interventions, and for evaluating intervention effects, including the extent to which they target putative behavioral mechanisms. Adaptive clinical trial methods such as SMART (Sequential Multiple Assignment Randomized Trials) for identifying optimal intervention sequences and JITAI (Just-in-Time Adaptive Interventions) that leverage real-time contextual data to tailor components can improve potency and personalization of theoretically supported behavioral interventions. Overall, in accordance with the National Institutes of Health Stage Model, successful behavioral trials to advance stroke prevention should be grounded in behavioral theory for intervention development, informed by design methods that enable assessment of behavioral mechanistic targets, and conducted with adaptive clinical trial methodologies to tailor interventions.
中文摘要:卒中预防要求患者遵循推荐的健康行为。然而,在临床试验中,很少有卒中行为干预被证明能产生具有临床意义的行为改变,这可能是因为设计过程中对行为理论模型的应用有限,以及在干预测试中对其机制基础的认识不足而受阻。美国国立卫生研究院行为干预发展阶段模型提供了一个系统、非线性、迭代的框架,用于推动行为干预从理论走向实践。在此,我们概述可应用于改进成功的卒中预防行为干预开发的行为医学研究方法。行为改变理论可为行为干预的理论框架提供概念基础,因为它们通过与社会心理机制相关的特定构念来识别个体层面对健康行为的影响。例如,针对卒中后自我管理的自我效能行为的干预可由社会认知理论指导,以提供以患者为中心的照护。整合定性和定量结果的混合方法可用于在设计行为干预时识别需要针对的关键患者障碍,并用于评估干预效果,包括其针对假定行为机制的程度。诸如用于识别最佳干预序列的SMART(序贯多重分配随机试验)和利用实时情境数据定制组件的JITAI(即时适应性干预)等适应性临床试验方法,可提高有理论支持的行为干预的效力和个性化程度。总体而言,根据美国国立卫生研究院阶段模型,推进卒中预防的成功行为试验应立足于行为理论进行干预开发,采用能够评估行为机制靶点的设计方法,并运用适应性临床试验方法开展以定制干预。
Stroke IF 11.1 2026-10 PMID: 42689322
Whether diffusion‑weighted imaging infarction patterns influence the efficacy and safety of early oral ticagrelor‑aspirin with intravenous thrombolysis in moderate acute ischemic stroke is uncertain. We assessed treatment effects by infarction pattern in this thrombolysis setting. This was a subgroup analysis of the TAPIS trial (Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis in Patients With Ischemic Stroke), a 60-center, randomized, double‑blind trial in China. Patients aged 18 to 80 years with noncardioembolic stroke (National Institutes of Health Stroke Scale score 4-10) who received intravenous thrombolysis within 4.5 hours of onset were randomized within 6 hours to ticagrelor‑aspirin or placebo. Diffusion‑weighted imaging patterns were centrally adjudicated as multiple acute infarcts (MAIs; ≥2 lesions) or non‑MAIs (single infarction or diffusion‑weighted imaging-negative). The primary efficacy outcome was modified Rankin Scale score of 0 to 1 at 90 days; safety outcome was symptomatic intracranial hemorrhage. Treatment‑by‑pattern interaction was assessed. Among 1307 patients (94.6% of full analysis set; median age, 65.5 years; 71.2% men; median National Institutes of Health Stroke Scale score, 6.0), 409 (31.3%) had MAIs and 898 (68.7%) non‑MAIs (20.8% diffusion‑weighted imaging-negative, 79.2% single infarction). MAIs were associated with poorer prognosis than non‑MAIs (excellent outcome: 58.9% versus 69.2%; adjusted risk ratio, 0.92 [95% CI, 0.84-1.00]). Ticagrelor‑aspirin was associated with a higher likelihood of excellent outcome versus placebo in MAIs (64.4% versus 53.4%; risk ratio, 1.21 [95% CI, 1.02-1.42]), whereas no significant benefit was observed in non‑MAIs (71.2% versus 67.1%; risk ratio, 1.06 [95% CI, 0.97-1.16]; Pinteraction=0.18). Early neurological improvement showed significant heterogeneity by infarction pattern (Pinteraction=0.02); the treatment‑by‑pattern interaction for the primary outcome was nominally significant after adjusting for rescue tirofiban use (P=0.04). Symptomatic intracranial hemorrhage occurred in MAIs: 1 of 205 (0.5%) versus 2 of 204 (1.0%); non‑MAIs: 1 of 448 (0.2%) versus 1 of 450 (0.2%). In thrombolyzed patients with moderate noncardioembolic stroke, MAIs were associated with poorer functional outcomes. Early ticagrelor‑aspirin showed directionally consistent benefits without excess bleeding in patients with MAIs, though the primary interaction was not significant. These hypothesis‑generating findings may inform future trials of diffusion‑weighted imaging infarction pattern as an imaging biomarker to guide antiplatelet therapy in early reperfusion. URL: https://www.clinicaltrials.gov; Unique identifier: NCT06316570.
中文摘要:在中等程度急性缺血性卒中中,弥散加权成像梗死模式是否影响早期口服替格瑞洛-阿司匹林联合静脉溶栓的疗效和安全性尚不确定。我们在此溶栓背景下按梗死模式评估了治疗效果。这是TAPIS试验(替格瑞洛联合阿司匹林双联抗血小板治疗联合静脉溶栓用于缺血性卒中患者)的亚组分析,该试验是在中国开展的60中心、随机、双盲试验。年龄18至80岁、非心源性栓塞性卒中(美国国立卫生研究院卒中量表评分4-10分)且在发病4.5小时内接受静脉溶栓的患者,在6小时内被随机分配至替格瑞洛-阿司匹林组或安慰剂组。弥散加权成像模式由中心判定为多发急性梗死(MAIs;≥2个病灶)或非MAIs(单发梗死或弥散加权成像阴性)。主要疗效结局为90天时改良Rankin量表评分0至1分;安全性结局为症状性颅内出血。评估了治疗与梗死模式的交互作用。在1307例患者中(占全分析集的94.6%;中位年龄65.5岁;71.2%为男性;中位美国国立卫生研究院卒中量表评分6.0分),409例(31.3%)为MAIs,898例(68.7%)为非MAIs(20.8%为弥散加权成像阴性,79.2%为单发梗死)。与非MAIs相比,MAIs与更差的预后相关(优良结局:58.9%对69.2%;校正风险比0.92[95% CI,0.84-1.00])。在MAIs中,替格瑞洛-阿司匹林较安慰剂与更高的优良结局可能性相关(64.4%对53.4%;风险比1.21[95% CI,1.02-1.42]),而在非MAIs中未观察到显著获益(71.2%对67.1%;风险比1.06[95% CI,0.97-1.16];交互作用P=0.18)。早期神经功能改善在不同梗死模式间显示出显著异质性(交互作用P=0.02);在调整挽救性替罗非班使用后,主要结局的治疗与模式交互作用名义上显著(P=0.04)。症状性颅内出血在MAIs中发生于1/205例(0.5%)对2/204例(1.0%);非MAIs中为1/448例(0.2%)对1/450例(0.2%)。在接受溶栓的中等程度非心源性栓塞性卒中患者中,MAIs与更差的功能结局相关。尽管主要交互作用不显著,早期替格瑞洛-阿司匹林在MAIs患者中显示出方向一致的获益,且未增加出血。这些产生假设的发现可能为未来试验提供信息,以探讨弥散加权成像梗死模式作为影像生物标志物指导早期再灌注中的抗血小板治疗。网址:https://www.clinicaltrials.gov;唯一标识符:NCT06316570。
Stroke IF 11.1 2026-10 PMID: 42663055
Antiphospholipid antibodies (aPL) are associated with an increased risk of thrombosis. However, individual studies have reported conflicting findings regarding the prevalence of aPL in patients with ischemic stroke and their association with first or recurrent events. Systematic searches of PubMed and Embase through May 13, 2025 were conducted to identify case-control, cohort, or cross-sectional studies investigating 3 questions related to aPL seropositivity (defined as positivity for either immunoglobulin G/immunoglobulin M anticardiolipin antibody, immunoglobulin G/immunoglobulin M anti-β2 glycoprotein I antibody, or a lupus anticoagulant): (1) the prevalence of aPL seropositivity among individuals with ischemic stroke; (2) the association between aPL seropositivity and the risk of first ischemic stroke; and (3) the association between aPL seropositivity and the risk of recurrent ischemic stroke. Random-effects models with inverse weighting were used to calculate pooled prevalences and odds ratios (OR) with 95% CIs. Risk of bias was assessed using the ROBINS-I tool. A total of 52 studies were included (40 case-control, 12 cohort). The pooled prevalence of seropositivity for any aPL among patients with ischemic stroke (51 studies, 9438 patients) was 19.1% (95% CI, 15.4%-23.0%; I2=95.8%). aPL seropositivity was associated with higher odds of first ischemic stroke (43 studies, 19 097 patients; OR, 2.93 [95% CI, 2.31-3.73]; I2=68.7%). The strongest associations were for lupus anticoagulant (OR, 6.69 [95% CI, 2.94-15.2]; I2=92.6%) and immunoglobulin G anticardiolipin antibody (OR, 2.56 [95% CI, 1.96-3.35]; I2=92.5%). The odds of recurrent ischemic stroke among patients with versus without any aPL seropositivity were not significantly different (OR, 1.20 [95% CI, 0.87-1.67]; 9 studies, 2873 patients, I2=11.4%). Seropositivity for any aPL was present in nearly 1-in-5 patients with ischemic stroke and was associated with increased odds of ischemic stroke at presentation.
中文摘要:抗磷脂抗体(aPL)与血栓形成风险增加相关。然而,关于aPL在缺血性卒中患者中的患病率及其与首发或复发性事件的相关性,单项研究报道的结果相互矛盾。我们系统检索了截至2025年5月13日的PubMed和Embase,以识别探讨与aPL血清阳性(定义为免疫球蛋白G/免疫球蛋白M抗心磷脂抗体、免疫球蛋白G/免疫球蛋白M抗β2糖蛋白I抗体或狼疮抗凝物任一阳性)相关的3个问题的病例对照、队列或横断面研究:(1)缺血性卒中个体中aPL血清阳性的患病率;(2)aPL血清阳性与首发缺血性卒中风险之间的相关性;(3)aPL血清阳性与复发性缺血性卒中风险之间的相关性。采用逆方差加权随机效应模型计算合并患病率和优势比(OR)及95%CI。使用ROBINS-I工具评估偏倚风险。共纳入52项研究(40项病例对照,12项队列)。缺血性卒中患者中任何aPL血清阳性的合并患病率(51项研究,9438例患者)为19.1%(95%CI,15.4%-23.0%;I2=95.8%)。aPL血清阳性与首发缺血性卒中的更高优势相关(43项研究,19097例患者;OR,2.93[95%CI,2.31-3.73];I2=68.7%)。相关性最强的是狼疮抗凝物(OR,6.69[95%CI,2.94-15.2];I2=92.6%)和免疫球蛋白G抗心磷脂抗体(OR,2.56[95%CI,1.96-3.35];I2=92.5%)。在aPL血清阳性与阴性的患者中,复发性缺血性卒中的优势无显著差异(OR,1.20[95%CI,0.87-1.67];9项研究,2873例患者,I2=11.4%)。任何aPL血清阳性存在于近五分之一的缺血性卒中患者中,并与就诊时缺血性卒中的优势增加相关。
Stroke IF 11.1 2026-10 PMID: 42657476
The "2026 Guidelines for Adult Stroke Rehabilitation and Recovery" replaces the 2016 "Guidelines for Adult Stroke Rehabilitation and Recovery." This updated guideline is intended to provide a comprehensive, up-to-date, evidence-based set of recommendations. The intended audience includes physicians, allied health professionals, and caregivers. A comprehensive search for literature published since the 2016 guideline, derived from research involving human participants, published in English, and indexed in MEDLINE, PubMed, Cochrane Library, and other selected databases relevant to this guideline, was conducted between June and October 2025. Other documents on related subject matter previously published by the American Heart Association were also reviewed. This guideline provides recommendations based on the most current evidence available for stroke rehabilitation and recovery. Key updates include new and revised recommendations across the stroke recovery continuum, including the assessment and treatment of medical comorbidities, fracture risk, fall prevention, technology-enabled rehabilitation, caregiver support, participation, and safe return to work and driving. Although this guideline reflects significant advances, it also highlights gaps in knowledge and underscores the urgent need for continued research to further refine and improve treatment strategies.
中文摘要:《2026年成人卒中康复与恢复指南》取代2016年《成人卒中康复与恢复指南》。本更新指南旨在提供一套全面、最新、基于证据的建议。目标读者包括医生、相关健康专业人员和照护者。2025年6月至10月期间,针对自2016年指南以来发表的文献进行了全面检索,这些文献来源于涉及人类参与者的研究、以英文发表,并收录于MEDLINE、PubMed、Cochrane Library及其他与本指南相关的选定数据库中。还审查了美国心脏协会先前发表的相关主题的其他文件。本指南根据目前可得的最新证据,为卒中康复与恢复提供建议。关键更新包括贯穿卒中恢复连续过程的新增和修订建议,涉及内科合并症的评估与治疗、骨折风险、跌倒预防、技术赋能康复、照护者支持、参与以及安全重返工作和驾驶。尽管本指南反映了重大进展,但也强调了知识空白,并凸显继续研究以进一步完善和改进治疗策略的迫切需求。
Stroke IF 11.1 2026-10 PMID: 42657473
Thrombolysis is infrequently delivered to children with acute ischemic strokes (AIS). We explored potential eligibility for treatment with tPA (tissue-type plasminogen activator) for pediatric AIS. This retrospective, multicenter, observational, cohort study reviewed children aged 29 days to 17 years with symptomatic AIS identified via Children's Hospital Westmead, John Hunter Children's Hospital, and Sydney Children's Hospital between January 1, 2010, and December 31, 2019. Medical records were examined to evaluate eligibility for treatment with tPA based on established multinational and the 2026 American Heart Association guidelines, reasons for exclusion beyond delay to diagnosis, and long-term outcomes as pediatric modified Rankin Scale scores. We also explored additional exclusions and outcomes among children with small-vessel AIS and AIS in the context of brain tumors, who are currently excluded from tPA. A total of 135 patients with 139 symptomatic AIS were identified-median age, 6 years; 36% female patients; 73% presented via emergency departments; mean follow-up, 43 months; 12% deaths. Irrespective of delay to diagnosis, only 26 of 139 (19%) AIS were potentially eligible for treatment with tPA. Among patients potentially eligible for tPA, acute neuroimaging revealed large-vessel occlusions, unilateral focal cerebral arteriopathy, or extracranial dissections. Thirteen of 26 (50%) had nondisabled outcomes without tPA treatment. One hundred thirteen of 139 (81%) AIS were ineligible for treatment with tPA, irrespective of delay to diagnosis. All deaths occurred among patients excluded from tPA, predominantly related to underlying disorders. Fifty-four small-vessel AIS accounted for 39% of AIS. Eighteen (33%) had no additional ineligibilities to thrombolysis, among whom 10 had nondisabled outcomes without tPA. Based on current recommendations, 19% of symptomatic childhood AIS were potentially eligible for treatment with tPA, irrespective of delay to diagnosis. Selected patients with small-vessel AIS may offer an opportunity to extend the role of tPA. These observations may be relevant for optimizing pediatric stroke management strategies.
中文摘要:溶栓治疗很少用于儿童急性缺血性卒中(AIS)。我们探讨了儿童AIS接受tPA(组织型纤溶酶原激活剂)治疗的潜在合格性。这项回顾性、多中心、观察性队列研究回顾了2010年1月1日至2019年12月31日期间通过Westmead儿童医院、John Hunter儿童医院和悉尼儿童医院识别的29天至17岁有症状AIS儿童。检查病历以评估基于既有多国指南和2026年美国心脏协会指南的tPA治疗合格性、除诊断延迟之外的排除原因,以及作为儿童改良Rankin量表评分的长期结局。我们还探讨了小血管AIS和脑肿瘤背景下AIS儿童的额外排除标准和结局,这些儿童目前被排除在tPA之外。共识别出135例患者、139次有症状AIS——中位年龄6岁;36%为女性患者;73%通过急诊科就诊;平均随访43个月;12%死亡。无论诊断是否延迟,139次AIS中仅26次(19%)可能符合tPA治疗条件。在可能符合tPA条件的患者中,急性神经影像显示大血管闭塞、单侧局灶性脑动脉病或颅外夹层。26例中有13例(50%)在未接受tPA治疗的情况下获得无残疾结局。139次AIS中有113次(81%)无论诊断是否延迟均不符合tPA治疗条件。所有死亡均发生在被排除tPA的患者中,主要与基础疾病相关。54次小血管AIS占AIS的39%。18例(33%)没有其他溶栓不合格因素,其中10例在未接受tPA的情况下获得无残疾结局。根据当前建议,19%的有症状儿童AIS可能符合tPA治疗条件,无论诊断是否延迟。特定小血管AIS患者可能为扩展tPA的作用提供机会。这些观察结果可能与优化儿童卒中管理策略相关。
Stroke IF 11.1 2026-10 PMID: 42644244
The prognostic significance of body weight in patients receiving thrombolysis for acute ischemic stroke remains uncertain. This study aimed to determine whether body weight modifies the comparative effects of low- versus standard-dose intravenous alteplase and to evaluate the associations of body weight and clinical outcomes in patients with acute ischemic stroke. A post hoc analysis of the ENCHANTED trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study), an international partial-factorial randomized controlled trial comparing low-dose (0.6 mg/kg) versus standard-dose (0.9 mg/kg) intravenous alteplase and intensive (target systolic blood pressure 130-140 mm Hg) versus guideline-recommended (target systolic blood pressure <180 mm Hg) treatment. The primary outcome was poor functional outcome at 90 days, defined as a modified Rankin Scale score of 2 to 6 (versus 0-1). For the first objective, the exposure was defined as alteplase dose and body weight, whereas for the second objective, body weight alone was considered as the exposure. Logistic regression models were performed to analyze the association between body weight and outcome. The association shape between treatment effect and body weight was evaluated using restricted cubic splines. Among 3206 patients (mean age, 66.6 years; female 37.9%) in the alteplase-dose arm, body weight did not significantly modify the comparative effects of low- versus standard-dose alteplase on functional recovery (Pinteraction=0.60), death (Pinteraction=0.56), or symptomatic intracerebral hemorrhage (Pinteraction=0.46). In the full cohort of 4458 patients (mean age 66.7 years; female 37.8%), a nonlinear relationship was observed between continuous body weight and 90-day modified Rankin Scale score, with an inflection point at ≈74 kg. Patients weighing <74 kg had a significantly higher likelihood of poor functional outcome (odds ratio, 1.41 [95% CI, 1.06-1.87]; P=0.017) and death (1.65 [95% CI, 1.04-2.61]; 0.03), but not an increase in symptomatic intracerebral hemorrhage. There was no evidence of effect modification by body weight on the effectiveness of low- versus standard-dose intravenous alteplase in patients with acute ischemic stroke. Low body weight predicts a poor outcome but not an increased risk of symptomatic intracerebral hemorrhage after thrombolysis treatment for acute ischemic stroke. URL: https://www.clinicaltrials.gov; Unique identifier: NCT01422616. URL: https://anzctr.org.au; Unique identifier: ACTRN12611000236998.
中文摘要:在接受溶栓治疗的急性缺血性卒中患者中,体重的预后意义仍不确定。本研究旨在确定体重是否会改变低剂量与标准剂量静脉阿替普酶的比较效应,并评估急性缺血性卒中患者体重与临床结局的关联。该研究为ENCHANTED试验(Enhanced Control of Hypertension and Thrombolysis Stroke Study)的事后分析;ENCHANTED是一项国际性部分析因随机对照试验,比较低剂量(0.6 mg/kg)与标准剂量(0.9 mg/kg)静脉阿替普酶,以及强化降压(目标收缩压130-140 mm Hg)与指南推荐治疗(目标收缩压<180 mm Hg)。主要结局为90天时不良功能结局,定义为改良Rankin量表评分为2至6分(相对于0-1分)。对于第一个目标,暴露定义为阿替普酶剂量和体重;对于第二个目标,仅将体重作为暴露。采用logistic回归模型分析体重与结局之间的关联。使用限制性立方样条评估治疗效应与体重之间的关联形状。在阿替普酶剂量组的3206例患者中(平均年龄66.6岁;女性37.9%),体重未显著改变低剂量与标准剂量阿替普酶对功能恢复(交互作用P=0.60)、死亡(交互作用P=0.56)或症状性颅内出血(交互作用P=0.46)的比较效应。在4458例患者的全队列中(平均年龄66.7岁;女性37.8%),连续体重与90天改良Rankin量表评分之间观察到非线性关系,拐点约为74 kg。体重<74 kg的患者发生不良功能结局的可能性显著更高(比值比1.41[95% CI,1.06-1.87];P=0.017),死亡风险也更高(1.65[95% CI,1.04-2.61];P=0.03),但症状性颅内出血未增加。没有证据表明体重会改变低剂量与标准剂量静脉阿替普酶在急性缺血性卒中患者中的有效性。低体重预示溶栓治疗急性缺血性卒中后的不良结局,但并不增加症状性颅内出血风险。URL: https://www.clinicaltrials.gov;唯一标识符:NCT01422616。URL: https://anzctr.org.au;唯一标识符:ACTRN12611000236998。
Stroke IF 11.1 2026-10 PMID: 42644243
The RNF213 p.R4810K variant, a susceptibility variant for moyamoya disease, has also been linked to intracranial atherosclerotic disease (ICAD). However, its association with extracranial carotid artery disease (ECAD), particularly whether this association is independent of concomitant ICAD and whether it differs by stenosis severity, remains unclear. We conducted a multicenter registry-based observational study of patients with acute ischemic stroke (AIS) or transient ischemic attack enrolled in the Fukuoka Stroke Registry. Patients were genotyped for RNF213 p.R4810K and classified as noncarriers (G/G) or variant carriers (G/A or A/A). ECAD was defined as ≥50% stenosis or occlusion of the extracranial carotid arteries. Multivariable logistic regression was used to assess the association between RNF213 p.R4810K and ECAD after adjusting for vascular risk factors and ICAD, and stratified analyses were performed by ICAD status. ECAD severity was modeled ordinally (none, moderate, severe, and occlusion) using a partial proportional-odds model. Of 15 569 registry patients with AIS or transient ischemic attack, 13 994 were included in the present analysis after exclusions (mean age, 73±12 years; 59.5% men). The RNF213 p.R4810K variant was identified in 359 patients (2.6%). ECAD was present in 2181 patients (15.6%), including 78 variant carriers. Variant carriers had significantly higher odds of ECAD after adjustment for vascular risk factors and ICAD (odds ratio, 1.69 [95% CI, 1.29-2.22]). This association was consistent irrespective of ICAD status (Pheterogeneity=0.32). In severity analyses, the association strengthened stepwise with increasing ECAD severity; the largest effect estimate was for occlusion (odds ratio, 4.55 [95% CI, 2.81-7.38]). The RNF213 p.R4810K variant was associated with ECAD independent of concomitant ICAD and showed a graded association with ECAD severity. Extracranial disease expression may involve modifiers distinct from those driving ICAD.
中文摘要:RNF213 p.R4810K变异是烟雾病的易感变异,也与颅内动脉粥样硬化性疾病(ICAD)相关。然而,其与颅外颈动脉疾病(ECAD)的关联,尤其是这种关联是否独立于合并的ICAD,以及是否因狭窄严重程度而异,仍不清楚。我们开展了一项基于多中心登记的观察性研究,纳入福冈卒中登记中急性缺血性卒中(AIS)或短暂性脑缺血发作患者。患者接受RNF213 p.R4810K基因分型,并分为非携带者(G/G)或变异携带者(G/A或A/A)。ECAD定义为颅外颈动脉≥50%狭窄或闭塞。采用多变量logistic回归评估在调整血管危险因素和ICAD后RNF213 p.R4810K与ECAD的关联,并按ICAD状态进行分层分析。ECAD严重程度采用部分比例优势模型进行有序建模(无、中度、重度和闭塞)。在15569例AIS或短暂性脑缺血发作登记患者中,排除后13994例纳入本分析(平均年龄73±12岁;男性59.5%)。359例患者(2.6%)检出RNF213 p.R4810K变异。2181例患者(15.6%)存在ECAD,其中78例为变异携带者。在调整血管危险因素和ICAD后,变异携带者发生ECAD的比值比显著更高(比值比1.69[95%CI,1.29-2.22])。该关联无论ICAD状态如何均一致(异质性P=0.32)。在严重程度分析中,该关联随ECAD严重程度增加逐步增强;效应估计最大的是闭塞(比值比4.55[95%CI,2.81-7.38])。RNF213 p.R4810K变异与ECAD相关,且独立于合并的ICAD,并显示与ECAD严重程度呈分级关联。颅外疾病表现可能涉及不同于驱动ICAD的修饰因素。
Stroke IF 11.1 2026-10 PMID: 42644242
In young adults, the risk factors (RFs) for cryptogenic ischemic stroke (CIS) remain unclear. We aimed to investigate the association between recent mechanical venous thrombosis RFs (VTRFs) and young-onset CIS in this multicenter sex- and age-matched case-control study. Five hundred forty-six patients aged 18 to 49 years (median age, 41 [34-46] years; 47.3% women) with a recent CIS and 546 stroke-free community-based controls were included in the study across 19 European centers between October 2013 and November 2022. Mechanical VTRFs, including surgical treatment, nonsurgical intervention, injury, and immobilization occurring within 90 days prestroke, were assessed using standardized, structured interviews. Conditional logistic regression was used to assess the association of mechanical VTRFs with CIS. Age, sex, level of education, and traditional and nontraditional stroke RFs were included as confounders. Mechanical VTRFs within 14 days prestroke were more prevalent in cases than controls (15.4% versus 9.6%) and independently associated with CIS after adjustment for demographics and traditional stroke RFs (odds ratio [OR], 1.67 [95% CI, 1.05-2.67]). In age-stratified analysis, this association remained significant after additional adjustment for nontraditional RFs in 18- to 39-year-olds (OR, 2.36 [95% CI, 1.02-5.46]) but was not significant in the 40- to 49-year age group (OR, 1.50 [95% CI, 0.73-3.08]). In addition, mechanical VTRFs were associated with CIS in cases with clinically relevant patent foramen ovale in a fully adjusted model (OR, 2.06 [95% CI, 1.21-3.51]) but not in those without (OR, 1.29 [95% CI, 0.76-2.18]). No significant associations were observed for mechanical VTRFs occurring >14 days before stroke. Baseline blood thrombophilia markers did not differ between cases with and without mechanical VTRFs 0 to 14 or 15 to 90 days before stroke. Recent mechanical VTRFs occurring within 14 days preceding stroke contribute to the risk of young-onset CIS, particularly in younger individuals and those with a clinically relevant patent foramen ovale. This risk does not appear to be conveyed by thrombophilic factors assessed. URL: https://www.clinicaltrials.gov; Unique identifier: NCT01934725.
中文摘要:在青年人中,隐源性缺血性卒中(CIS)的危险因素(RFs)仍不明确。我们旨在通过这项多中心、性别和年龄匹配的病例对照研究,探讨近期机械性静脉血栓形成危险因素(VTRFs)与青年起病CIS之间的关联。研究于2013年10月至2022年11月期间在19个欧洲中心纳入546例近期发生CIS、年龄18至49岁的患者(中位年龄41[34-46]岁;47.3%为女性)以及546名无卒中、基于社区的对照者。通过标准化、结构化访谈评估卒中前90天内发生的机械性VTRFs,包括手术治疗、非手术干预、损伤和制动。采用条件logistic回归评估机械性VTRFs与CIS的关联。年龄、性别、教育水平以及传统和非传统卒中RFs被纳入为混杂因素。卒中前14天内的机械性VTRFs在病例中比对照更常见(15.4%对9.6%),并且在调整人口学特征和传统卒中RFs后与CIS独立相关(比值比[OR],1.67[95%CI,1.05-2.67])。在按年龄分层分析中,18至39岁人群中,额外调整非传统RFs后该关联仍显著(OR,2.36[95%CI,1.02-5.46]),但在40至49岁年龄组中不显著(OR,1.50[95%CI,0.73-3.08])。此外,在完全调整模型中,机械性VTRFs与具有临床相关卵圆孔未闭的病例中的CIS相关(OR,2.06[95%CI,1.21-3.51]),但在无临床相关卵圆孔未闭者中不相关(OR,1.29[95%CI,0.76-2.18])。对于卒中前超过14天发生的机械性VTRFs,未观察到显著关联。有和无卒中前0至14天或15至90天机械性VTRFs的病例之间,基线血液血栓形成倾向标志物无差异。卒中前14天内发生的近期机械性VTRFs增加了青年起病CIS的风险,尤其是在较年轻个体和具有临床相关卵圆孔未闭者中。该风险似乎并非由所评估的血栓形成倾向因素所介导。URL:https://www.clinicaltrials.gov;唯一标识符:NCT01934725。
Stroke IF 11.1 2026-10 PMID: 42619594
Anti-inflammatory therapies reduce the risk of major adverse cardiovascular events (MACEs) in coronary disease, but efficacy has not been shown after stroke. It is uncertain if patients with atherosclerosis are more likely to benefit from anti-inflammatory prevention. We performed a post hoc analysis of the CONVINCE trial (randomized, open-label, blinded-end point assessed; Colchicine for Prevention of Vascular Inflammation in Non-Cardioembolic Stroke), comparing colchicine 0.5 mg plus usual care versus usual care. We performed a subgroup analysis in patients stratified according to the presence/absence of atherosclerosis (defined as cervico-cranial/aortic artery plaque, coronary disease, peripheral arterial disease, and carotid revascularization). The primary outcome was MACE. Analyses were adjusted for age, qualifying event, time from event to randomization, and coronary disease. Three thousand one hundred forty-four participants were included. There were 338 MACE events during follow-up (median, 33.6 months). On intention-to-treat analysis, there were numerically fewer MACE events in the atherosclerosis group assigned to colchicine (105 [11.1%], 3.88 [95% CI, 3.21-4.70] per 100 person-years) versus usual care (132 [14.2%], 4.83 [4.07-5.73] per 100 person-years), which was not statistically significant (hazard ratio [HR], 0.83 [95% CI, 0.64-1.07]). There was no difference in the rate of the primary outcome according to treatment allocation in the nonatherosclerosis subgroup (HR, 0.94 [95% CI, 0.64-1.39]; Pinteraction=0.60). There was a nonsignificant reduced risk of recurrent ischemic stroke in the colchicine arm (HR, 0.76 [95% CI, 0.56-1.05]) in the atherosclerosis group, but no difference in events was observed in the nonatherosclerotic group (HR, 0.92 [95% CI, 0.60-1.42]; Pinteraction=0.48). In the prespecified on-treatment analysis, colchicine reduced the risk of MACE in patients with atherosclerosis (HR, 0.76 [95% CI, 0.58-0.99]) but not without (HR, 0.95 [95% CI, 0.63-1.42]; Pinteraction=0.37). There were no significant between-group interactions for colchicine and atherosclerosis for MACE in intention-to-treat or on-treatment populations. However, outcome events were numerically fewer in patients with atherosclerosis assigned to colchicine, and significant benefit was observed in the on-treatment analysis in this group. Data suggest that the presence of atherosclerosis should be an inclusion criterion in future anti-inflammatory therapy trials. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02898610.
中文摘要:抗炎治疗可降低冠心病患者发生重大不良心血管事件(MACE)的风险,但其在卒中后的疗效尚未得到证实。动脉粥样硬化患者是否更可能从抗炎预防中获益仍不确定。我们对CONVINCE试验(随机、开放标签、盲法终点评估;秋水仙碱用于预防非心源性栓塞性卒中的血管炎症)进行了事后分析,比较秋水仙碱0.5 mg加常规治疗与常规治疗。我们按是否存在动脉粥样硬化(定义为颈-颅/主动脉斑块、冠心病、外周动脉疾病和颈动脉血运重建)对患者进行分层并开展亚组分析。主要结局为MACE。分析针对年龄、入选事件、从事件到随机化的时间以及冠心病进行了校正。共纳入3144名参与者。随访期间(中位数33.6个月)发生338例MACE事件。在意向治疗分析中,动脉粥样硬化组分配至秋水仙碱者的MACE事件数在数值上少于常规治疗组(105例[11.1%],每100人年3.88[95% CI, 3.21-4.70] vs 132例[14.2%],每100人年4.83[4.07-5.73]),但未达到统计学显著性(风险比[HR],0.83[95% CI, 0.64-1.07])。在非动脉粥样硬化亚组中,按治疗分配的主要结局发生率无差异(HR,0.94[95% CI, 0.64-1.39];交互作用P=0.60)。在动脉粥样硬化组中,秋水仙碱组的复发性缺血性卒中风险呈非显著性降低(HR,0.76[95% CI, 0.56-1.05]),但非动脉粥样硬化组事件无差异(HR,0.92[95% CI, 0.60-1.42];交互作用P=0.48)。在预先设定的接受治疗分析中,秋水仙碱降低了动脉粥样硬化患者的MACE风险(HR,0.76[95% CI, 0.58-0.99]),但未降低无动脉粥样硬化者的风险(HR,0.95[95% CI, 0.63-1.42];交互作用P=0.37)。在意向治疗人群或接受治疗人群中,秋水仙碱与动脉粥样硬化对MACE均无显著的组间交互作用。然而,分配至秋水仙碱的动脉粥样硬化患者结局事件数在数值上更少,且在该组的接受治疗分析中观察到显著获益。数据提示,动脉粥样硬化的存在应作为未来抗炎治疗试验的入选标准。URL: https://www.clinicaltrials.gov;唯一标识符:NCT02898610。
Stroke IF 11.1 2026-10 PMID: 42610235
Stroke imposes a substantial and growing health and economic burden in China, yet forward-looking estimates of stroke-related costs remain scarce. Annual age- and sex-specific incidence rates of ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage were projected from 2022 to 2050 using 2021 as the baseline year. Baseline incidence estimates were obtained from the Global Burden of Disease 2021 database, and future trends were projected using an exponential growth model parameterized by the average annual percent change estimated from 1990 to 2021 Global Burden of Disease data. Projected incidence rates were combined with China-specific population projections. A deterministic decision-tree model was used to estimate hospitalization costs, direct medical costs, and societal costs over a 12-month time horizon in China, using probabilities and unit costs from published literature. We used uncertainty intervals (UI) to quantify the plausible range of all projected outcomes. One-way sensitivity analyses were conducted to assess uncertainty in epidemiological and cost parameters. Total incident strokes are projected to increase from 4.35 million (95% UI, 3.09-5.89 million) in 2022 to 9.59 million (95% UI, 6.81-13.01 million) in 2050. By 2050, ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage incidences are projected to reach 7.89, 1.59, and 0.11 million, respectively. Total annual stroke hospitalization costs are projected to rise from $46.1 billion (95% UI, 44.94-47.24 billion) in 2022 to $91.2 billion (95% UI, 89.28-93.13 billion) in 2050; direct medical costs and societal costs are projected to increase from $67.6 billion to $133.9 billion and from $145.6 billion to $288.4 billion, respectively. Costs will be increasingly concentrated among adults aged ≥65 years, especially those aged ≥85 years. In 2050, stroke costs among men are projected to be approximately 1.3 times those for women. In sensitivity analyses incorporating incidence uncertainty, total annual hospitalization costs ranged from $39.9-$62.3 billion in 2022 to $65.0-$123.6 billion in 2050. Stroke incidence and costs in China are projected to increase through 2050, driven primarily by ischemic stroke and population aging, highlighting the need for targeted prevention, capacity planning for older adults, and long-term financing strategies.
中文摘要:卒中在中国造成了巨大且不断增长的健康与经济负担,但针对卒中相关成本的前瞻性估计仍很少。以2021年为基线年,采用年龄和性别别年发病率,对2022年至2050年缺血性卒中、脑出血和蛛网膜下腔出血的发病率进行预测。基线发病率估计来自全球疾病负担2021数据库,未来趋势采用指数增长模型预测,该模型参数由1990年至2021年全球疾病负担数据估计的平均年度百分比变化确定。将预测发病率与中国特定人口预测相结合。采用确定性决策树模型,基于已发表文献中的概率和单位成本,估计中国12个月时间范围内的住院成本、直接医疗成本和社会成本。我们使用不确定性区间(UI)量化所有预测结果的合理范围。进行单因素敏感性分析,以评估流行病学和成本参数的不确定性。预计总新发卒中例数将从2022年的435万例(95% UI,309万-589万例)增至2050年的959万例(95% UI,681万-1301万例)。到2050年,缺血性卒中、脑出血和蛛网膜下腔出血的发病例数预计分别达到789万、159万和11万例。年度卒中总住院成本预计将从2022年的461亿美元(95% UI,449.4亿-472.4亿美元)升至2050年的912亿美元(95% UI,892.8亿-931.3亿美元);直接医疗成本和社会成本预计分别从676亿美元增至1339亿美元,以及从1456亿美元增至2884亿美元。成本将日益集中在65岁及以上成年人中,尤其是85岁及以上人群。2050年,男性卒中成本预计约为女性的1.3倍。在纳入发病率不确定性的敏感性分析中,年度总住院成本范围从2022年的399亿-623亿美元到2050年的650亿-1236亿美元。中国卒中的发病率和成本预计到2050年将持续上升,主要由缺血性卒中和人口老龄化驱动,这凸显了开展针对性预防、老年人服务能力规划以及长期筹资策略的必要性。
Stroke IF 11.1 2026-10 PMID: 42605684
In acute ischemic stroke due to medium vessel occlusion, the relative effectiveness of intravenous thrombolysis (IVT) and endovascular therapy (EVT) remains controversial, and treatment benefits may vary across patients. We evaluated the interaction between thrombus perviousness and treatment modality on 90-day functional outcome in patients with medium vessel occlusion. This single-center retrospective cohort study analyzed 255 patients with imaging-confirmed medium vessel occlusion treated at a stroke center in China between 2018 and 2024 (154 IVT and 101 EVT with or without prior IVT). Thrombus perviousness was quantified using the thrombus perviousness index (TPI) from noncontrast computed tomography and computed tomography angiography. Multivariable logistic regression and inverse probability of treatment weighting evaluated the TPI-by-treatment interaction for 90-day functional independence (modified Rankin Scale score ≤2). Sensitivity analyses used alternative weighting strategies and a surrogate thrombus perviousness measure. The 90-day functional independence rate was similar between the IVT and EVT groups (51.9% versus 51.5%; P=0.96), and TPI was not independently associated with outcome. In the inverse probability of treatment weighting-weighted model, a significant interaction between TPI and treatment modality was observed (interaction odds ratio, 0.37 [95% CI, 0.24-0.56]; P<0.001). Higher TPI was associated with a greater likelihood of functional independence in IVT-treated patients (odds ratio per 0.05-unit increase, 1.73 [95% CI, 1.19-2.53]; P=0.005), but lower odds in EVT-treated patients (odds ratio, 0.65 [95% CI, 0.49-0.87]; P=0.003). Exploratory analyses in the IVT subgroup revealed a continuous increase in functional independence as TPI increased, without a stable cutoff. Rates of symptomatic intracranial hemorrhage and 90-day mortality did not differ between groups, and TPI was not associated with hemorrhage risk. In medium vessel occlusion, thrombus perviousness was associated with treatment outcomes, with higher perviousness favoring IVT-related benefits, whereas the use of EVT may be relatively advantageous in patients with low-perviousness thrombi.
中文摘要:在由中等血管闭塞所致的急性缺血性卒中中,静脉溶栓(IVT)与血管内治疗(EVT)的相对有效性仍存在争议,且治疗获益可能因患者而异。我们评估了中等血管闭塞患者中血栓通透性与治疗方式对90天功能结局的交互作用。这项单中心回顾性队列研究分析了2018年至2024年在中国一家卒中中心接受治疗的255例影像学确诊的中等血管闭塞患者(154例接受IVT,101例接受EVT,伴或不伴既往IVT)。血栓通透性通过非增强计算机断层扫描和计算机断层扫描血管成像得到的血栓通透性指数(TPI)进行量化。采用多变量logistic回归和逆概率治疗加权评估TPI与治疗方式对90天功能独立(改良Rankin量表评分≤2)的交互作用。敏感性分析使用替代加权策略和替代性血栓通透性指标。IVT组与EVT组的90天功能独立率相似(51.9%对51.5%;P=0.96),且TPI与结局无独立关联。在逆概率治疗加权模型中,观察到TPI与治疗方式之间存在显著交互作用(交互比值比0.37[95%CI,0.24-0.56];P<0.001)。较高的TPI与IVT治疗患者更可能实现功能独立相关(每增加0.05单位的比值比1.73[95%CI,1.19-2.53];P=0.005),但在EVT治疗患者中比值比较低(比值比0.65[95%CI,0.49-0.87];P=0.003)。对IVT亚组的探索性分析显示,随着TPI升高,功能独立呈持续增加,但未发现稳定截断值。两组的症状性颅内出血发生率和90天死亡率无差异,且TPI与出血风险无关。在中等血管闭塞中,血栓通透性与治疗结局相关,较高的通透性更有利于IVT相关获益,而对于低通透性血栓患者,使用EVT可能相对更有优势。
Stroke IF 11.1 2026-10 PMID: 42605679
Suboptimal clinical outcomes are common after ischemic stroke with large vessel occlusion despite current reperfusion treatment with intravenous thrombolysis and mechanical thrombectomy. Targeting residual distal arterial and microvascular occlusions with intraarterial thrombolysis has recently gained substantial interest as an adjunct to improve cerebral tissue perfusion. While recent trials provide promise in selected patients with anterior-circulation stroke, further high-quality, large-scale studies and pooled individual-patient analyses are needed. This review summarizes the evolving role of intraarterial thrombolysis over the past 3 decades and projects potential developments.
中文摘要:尽管当前采用静脉溶栓和机械取栓进行再灌注治疗,大血管闭塞性缺血性卒中后仍常见临床结局不理想。动脉内溶栓以残余远端动脉和微血管闭塞为靶点,作为改善脑组织灌注的辅助治疗,近来引起了广泛关注。虽然近期试验在前循环卒中的特定患者中显示出希望,但仍需进一步开展高质量、大规模研究以及汇总个体患者分析。本综述总结了过去30年动脉内溶栓作用的演变,并展望了潜在发展方向。
Stroke IF 11.1 2026-10 PMID: 42544483
Raised inflammatory biomarkers predict an increased short-term risk of recurrent vascular events after stroke or transient ischemic attack, but it is uncertain whether the hazard is maintained thereafter. In the absence of previous population-based studies, we aimed to determine the predictive value of biomarkers for the long-term risk of recurrent stroke in intensively treated patients following transient ischemic attack or stroke. We studied 12 blood biomarkers related to inflammation, neuronal cell damage, and thrombosis soon after transient ischemic attack or stroke in a population-based study (OXVASC [Oxford Vascular Study]; 2002-2011) with follow-up to 2025. We used Cox and negative binomial regressions to assess associations between each log-transformed biomarker (per SD increase) and recurrent stroke (first event and total number), adjusted for age, sex, and baseline vascular risk factors. Of 1292 consecutive patients (mean/SD age, 73.1/13.2 years; 47.8% male), 365 recurrent strokes occurred in 280 patients during 11 336 patient-years. All inflammatory biomarkers were associated with 10-year risk of recurrence, with little impact of adjustment for other risk factors (adjusted incidence rate ratio: IL-6 [interleukin-6], 1.21 [95% CI, 1.04-1.42]; CRP [C-reactive protein], 1.29 [95% CI, 1.11-1.49]; TNFR-1 [tumor necrosis factor receptor-1], 1.24 [95% CI, 1.05-1.46]; and NGAL [neutrophil gelatinase-associated lipocalin], 1.15 [95% CI, 0.99-1.33]). Moreover, number of elevated (top quartile) inflammatory markers was associated with higher burden of recurrence (incidence rate ratio, 1.31 [95% CI, 1.15-1.50]; P<0.001), with no diminution over time (90 days: hazard ratio, 1.24 [95% CI, 0.98-1.57]; 90 days-1 year: 1.24 [95% CI, 0.95-1.62]; 1-5 years: 1.22 [95% CI, 1.01-1.47]; and 5-10 years: 1.34 [95% CI, 1.06-1.68]), and similar associations for transient ischemic attack and minor stroke. Biomarkers related to neuronal cell damage or thrombosis were generally less predictive of recurrent stroke. Inflammatory biomarkers were more predictive of long-term recurrent stroke than neuronal or thrombotic biomarkers, particularly when several inflammatory markers were raised. Predictive value was independent of other vascular risk factors and did not diminish with duration of follow-up, supporting trials of anti-inflammatory strategies for long-term secondary prevention.
中文摘要:炎症生物标志物升高可预测卒中或短暂性脑缺血发作后复发性血管事件的短期风险增加,但其风险是否在此后持续尚不确定。由于缺乏既往基于人群的研究,我们旨在确定生物标志物对短暂性脑缺血发作或卒中后接受强化治疗患者长期复发性卒中风险的预测价值。我们在基于人群的研究(OXVASC[牛津血管研究];2002—2011年)中,检测了短暂性脑缺血发作或卒中后不久与炎症、神经元细胞损伤和血栓形成相关的12种血液生物标志物,随访至2025年。我们使用Cox回归和负二项回归评估每种经对数转换的生物标志物(每增加1个标准差)与复发性卒中(首次事件和总事件数)之间的关联,并校正年龄、性别和基线血管危险因素。在1292例连续患者(平均/标准差年龄,73.1/13.2岁;47.8%为男性)中,在11 336患者年期间,280例患者发生了365次复发性卒中。所有炎症生物标志物均与10年复发风险相关,校正其他危险因素影响甚微(校正发病率比:IL-6[白细胞介素-6],1.21[95% CI,1.04-1.42];CRP[C反应蛋白],1.29[95% CI,1.11-1.49];TNFR-1[肿瘤坏死因子受体-1],1.24[95% CI,1.05-1.46];NGAL[中性粒细胞明胶酶相关脂质运载蛋白],1.15[95% CI,0.99-1.33])。此外,升高的(最高四分位数)炎症标志物数量与更高的复发负担相关(发病率比,1.31[95% CI,1.15-1.50];P<0.001),且随时间未见减弱(90天:风险比,1.24[95% CI,0.98-1.57];90天至1年:1.24[95% CI,0.95-1.62];1至5年:1.22[95% CI,1.01-1.47];5至10年:1.34[95% CI,1.06-1.68]),短暂性脑缺血发作和轻微卒中的关联相似。与神经元细胞损伤或血栓形成相关的生物标志物对复发性卒中的预测作用通常较弱。炎症生物标志物对长期复发性卒中的预测作用强于神经元或血栓形成生物标志物,尤其是当多种炎症标志物升高时。预测价值独立于其他血管危险因素,且不随随访时间延长而减弱,支持将抗炎策略用于长期二级预防的试验。
Diagnostic and interventional imaging IF 11.1 2026-10 PMID: 42067491
Since its initial introduction to interventional cardiology over two decades ago, optical coherence tomography (OCT) has emerged as a powerful tool in neurovascular intervention. This intravascular imaging modality uses near-infrared light to provide cross-sectional visualization of the vessel wall with a resolution approaching 10 μm. The resolution of OCT far surpasses that of other imaging techniques. This higher resolution enables radiologists to directly assess arterial wall disease, including atherosclerotic plaque, aneurysm, and thrombus, as well as the interaction between therapeutic devices and the arterial wall in real time, providing actionable information during neurovascular interventions. The growing reliance on endovascular approaches to treat intracranial aneurysms and ischemia underscores the importance of precise vessel evaluation during treatment to provide accurate imaging guidance. However, digital subtraction angiography and cone beam computed tomography angiography often fail to reveal underlying arterial disease and other key features, such as the presence of thrombi, dissections, and malapposed stents, that could lead to incomplete treatment and acute and chronic complications. By enabling direct visualization of these microstructural details, OCT may overcome some of the most persistent challenges in neurovascular practice, ultimately improving diagnostic accuracy, procedural safety, and long-term patient outcomes. Nevertheless, integrating OCT into neurovascular settings remains challenging. There is still a lack of large-scale clinical validation, and existing coronary devices are not suitable for reliable use in tortuous intracranial vascular circulations. To overcome the technical limitations of current technologies, neuroOCT technology was designed specifically for neurovascular use and was evaluated in a first-in-human study. This technology will enable future clinical studies to investigate using neuroOCT to guide and optimize neurovascular treatments. This review article aims to provide a comprehensive perspective on the potential of neuroOCT in neurovascular practice. It highlights the technology's technical principles, current applications, limitations, and prospects for reshaping vascular imaging and therapy in the brain.
中文摘要:自二十多年前首次引入介入心脏病学以来,光学相干断层扫描(OCT)已成为神经血管介入中的有力工具。这种血管内成像方式利用近红外光以接近10 μm的分辨率提供血管壁的横断面可视化。OCT的分辨率远超其他成像技术。这种更高的分辨率使放射科医生能够直接评估动脉壁病变,包括动脉粥样硬化斑块、动脉瘤和血栓,以及治疗器械与动脉壁之间的实时相互作用,从而在神经血管介入过程中提供可操作的信息。颅内动脉瘤和缺血性疾病治疗对血管内方法的日益依赖,凸显了治疗过程中精确血管评估以提供准确成像引导的重要性。然而,数字减影血管造影和锥形束计算机断层扫描血管造影往往无法显示潜在的动脉疾病和其他关键特征,例如血栓、夹层和支架贴壁不良的存在,这些可能导致治疗不彻底以及急性和慢性并发症。通过直接可视化这些微结构细节,OCT可能克服神经血管实践中最持久的一些挑战,最终提高诊断准确性、手术安全性和患者长期结局。尽管如此,将OCT整合到神经血管环境中仍然具有挑战性。目前仍缺乏大规模临床验证,而且现有的冠状动脉器械不适合在迂曲的颅内血管循环中可靠使用。为克服当前技术的局限性,neuroOCT技术专为神经血管应用而设计,并在首次人体研究中进行了评估。该技术将使未来的临床研究能够探索使用neuroOCT来指导和优化神经血管治疗。这篇综述文章旨在全面阐述neuroOCT在神经血管实践中的潜力。它强调了该技术的技术原理、当前应用、局限性以及重塑脑部血管成像和治疗的前景。
Diagnostic and interventional imaging IF 11.1 2026-10 PMID: 41862395
The purpose of this study was to prospectively evaluate the contribution of intravoxel incoherent motion (IVIM) and diffusion kurtosis imaging (DKI) for predicting outcome after ischemic stroke. Patients with acute ischemic stroke who underwent brain MRI at 3 Tesla, including a multi-b diffusion-weighted imaging sequence were prospectively included. Mean, maximum (max) and minimum (min) of diffusion parameters, including apparent diffusion coefficient (ADC), D, D*, f, f·D* and K were extracted from the infarct core and normal-appearing parenchyma. The primary endpoint was 3-month modified Rankin scale (mRS). Associations were tested by univariable ordinal logistic regression with false discovery rate correction. Model performance was assessed using area under the receiver operating characteristic curve (AUC) analysis and the ranked probability score. A total of 157 patients were included. There were 83 men and 74 women with a mean age of 70 ± 16 (standard deviation) years (range: 23-100 years). In univariable analyses, ADCmin in the infarct core was the strongest predictor of worse functional outcome at 3 months (OR, 0.37; P < 0.001). Within the infarct core, nine other parameters were significantly associated with mRS (one ADC, six IVIM and two DKI metrics). In the normal-appearing parenchyma, eight parameters (two ADC, four IVIM and two DKI metrics) were significantly associated with outcome. In multivariable analysis, the model combining ADCmin and Kmin in the core with ADCmax in the normal-appearing parenchyma provided the highest prognostic performance, with an AUC of 0.81 (95 % confidence interval [CI]: 0.77-0.86) compared to ADCmin alone (AUC, 0.75; 95 % CI: 0.67-0.82) (P < 0.0001). A combination of advanced diffusion MRI parameters could predict functional outcome in patients with ischemic stroke with higher precision than standard ADC alone.
中文摘要:本研究的目的是前瞻性评估体素内不相干运动(IVIM)和扩散峰度成像(DKI)对缺血性脑卒中后结局的预测价值。前瞻性纳入因急性缺血性脑卒中在3 Tesla接受脑MRI检查(包括多b值扩散加权成像序列)的患者。从梗死核心和正常表现脑实质中提取扩散参数的平均值、最大值(max)和最小值(min),参数包括表观扩散系数(ADC)、D、D*、f、f·D*和K。主要终点为3个月改良Rankin量表(mRS)。采用单变量有序logistic回归并进行错误发现率校正来检验相关性。使用受试者工作特征曲线下面积(AUC)分析和排序概率评分评估模型性能。共纳入157例患者,其中男性83例、女性74例,平均年龄70±16(标准差)岁(范围:23-100岁)。在单变量分析中,梗死核心的ADCmin是3个月功能结局较差的最强预测因子(OR,0.37;P<0.001)。在梗死核心内,另有9个参数与mRS显著相关(1个ADC、6个IVIM和2个DKI指标)。在正常表现脑实质中,有8个参数(2个ADC、4个IVIM和2个DKI指标)与结局显著相关。在多变量分析中,将核心的ADCmin和Kmin与正常表现脑实质的ADCmax相结合的模型提供了最高的预后性能,AUC为0.81(95%置信区间(CI:0.77-0.86)),而单独ADCmin的AUC为0.75(95%置信区间(CI:0.67-0.82))(P<0.0001)。联合应用高级扩散MRI参数比单独使用标准ADC能更精确地预测缺血性脑卒中患者的功能结局。

基础研究 (8篇)

Pharmacological research IF 12.2 2026-10-07 PMID: 42843676
Ischemic stroke (IS) results from an acute interruption of cerebral blood flow and the ensuing collapse of energy metabolism. Although vascular recanalization can salvage the ischemic penumbra, its overall benefit remains constrained by a narrow therapeutic window and reperfusion injury. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, contributes to neuronal injury after IS and can amplify ischemia/reperfusion injury. By integrating energy metabolism, iron homeostasis, and redox balance, mitochondria can shape ferroptosis susceptibility within the energy-depleted, iron-dysregulated, and oxidatively stressed ischemic brain. However, most studies have examined iron metabolism and lipid peroxidation at the whole-cell level, leaving the temporal and interorganelle dimensions of mitochondrial regulation of ferroptosis insufficiently integrated. Here, we organize mitochondria-associated ferroptosis across the pathological course of IS, from metabolic reprogramming and substrate accumulation during ischemia to the reverse electron transport-associated reactive oxygen species burst during early reperfusion and subsequent disruption of mitochondrial quality control. We further examine mitochondrial crosstalk with the endoplasmic reticulum, lysosomes, lipid droplets, and nucleus, compare ferroptosis susceptibility across neurovascular unit cell populations, and map these mechanisms onto pharmacological interventions and mechanistically plausible therapeutic windows. Finally, we assess barriers to the clinical translation of mitochondria-targeted therapies and provide a stage-resolved framework for developing neuroprotective strategies in IS.
中文摘要:缺血性卒中(IS)由脑血流急性中断及随后的能量代谢崩溃所致。尽管血管再通能够挽救缺血半暗带,但其总体获益仍受限于狭窄的治疗时间窗和再灌注损伤。铁死亡是一种由脂质过氧化驱动的铁依赖性调节性细胞死亡形式,参与IS后的神经元损伤,并可放大缺血/再灌注损伤。通过整合能量代谢、铁稳态和氧化还原平衡,线粒体能够在能量耗竭、铁稳态紊乱和氧化应激的缺血脑组织中塑造铁死亡易感性。然而,多数研究是在全细胞水平考察铁代谢和脂质过氧化,致使线粒体调控铁死亡的时间维度和细胞器间维度仍未得到充分整合。在此,我们沿IS的病理进程梳理线粒体相关铁死亡,从缺血期的代谢重编程和底物蓄积,到早期再灌注时与反向电子传递相关的活性氧爆发,以及随后的线粒体质量控制破坏。我们进一步探讨线粒体与内质网、溶酶体、脂滴和细胞核的相互作用,比较神经血管单元各类细胞对铁死亡的易感性,并将这些机制对应到药理学干预和机制上合理的治疗窗口。最后,我们评估线粒体靶向治疗临床转化的障碍,并为制定IS神经保护策略提供一个按阶段划分的框架。
Advanced healthcare materials IF 11.0 2026-10-05 PMID: 42834627
Cerebral ischemia-reperfusion injury (IRI) is a key driver of poor prognosis in ischemic stroke. Idebenone (IDBN) shows promise for mitigating IRI, but its efficacy is limited by poor brain accumulation. Moreover, IDBN cannot be visually tracked, making it difficult to confirm whether it reaches the ischemic brain and exerts therapeutic effects. Here, IDBN functionalized with a reactive oxygen species (ROS)-cleavable bond is grafted onto phosphorothioate-modified DNA strands and co-assembled with ultrasmall superparamagnetic iron oxide (USPIO) to form USPIO-IDBN-SNAs, where SNAs stands for spherical nucleic acids. Exploiting upregulated class A scavenger receptors, USPIO-IDBN-SNAs target the ischemic area without targeting modifications and increase local IDBN concentration. Hydrophobic IDBN inside the SNAs limits water access to USPIO clusters, suppressing their contrast-enhancing ability. Under oxidative stress, IDBN is rapidly released and exerts remarkable protection. This release allows USPIO clusters to re-establish contact with water, activating their contrast-enhancing ability on T2-weighted imaging. Collectively, USPIO-IDBN-SNAs provide significant neuroprotection against IRI and offer a magnetic resonance imaging (MRI)-visible platform to monitor IDBN release in the ischemic brain, presenting a promising theranostic approach for precise, trackable stroke therapy.
中文摘要:脑缺血再灌注损伤(IRI)是缺血性卒中预后不良的关键驱动因素。艾地苯醌(IDBN)在减轻IRI方面显示出潜力,但其疗效因脑内蓄积不佳而受限。此外,IDBN无法被可视化追踪,因此难以确认其是否到达缺血脑组织并发挥治疗作用。在此,将经活性氧(ROS)可裂解键修饰的IDBN接枝到硫代磷酸修饰的DNA链上,并与超小超顺磁性氧化铁(USPIO)共组装形成USPIO-IDBN-SNAs,其中SNAs表示球形核酸。利用上调的A类清道夫受体,USPIO-IDBN-SNAs无需靶向修饰即可靶向缺血区域,并提高局部IDBN浓度。SNAs内部的疏水性IDBN限制水接近USPIO簇,从而抑制其对比增强能力。在氧化应激下,IDBN被快速释放并发挥显著保护作用。该释放使USPIO簇重新与水接触,激活其在T2加权成像上的对比增强能力。总体而言,USPIO-IDBN-SNAs对IRI提供显著神经保护,并提供一个磁共振成像(MRI)可见平台来监测缺血脑内IDBN的释放,为精准、可追踪的卒中治疗提供了一种有前景的诊疗一体化方法。
Stroke IF 11.1 2026-10 PMID: 42689339
The role of immune checkpoint B7-H3 in acute ischemic stroke prognosis and poststroke immunosuppression remains uninvestigated, despite the clinical significance of immune checkpoints with inflammaging and poststroke infections. In this study, we investigated the effect of regulating cerebral induction of B7-H3 after acute ischemic stroke and evaluated its longitudinal impact on brain damage, neuroinflammation, vascular integrity, host defense gene regulation, and functional outcomes. C57BL/6 mice were subjected to transient middle cerebral artery occlusion and injected (intravenously) with either B7-H3 small interfering RNA or a negative (nontargeting) small interfering RNA at 5 minutes after reperfusion. On poststroke days 1, 3, and 7, magnetic resonance imaging of the mouse brain was performed using a 9.4-T scanner to assess brain damage (T2, apparent diffusion coefficient, and kurtosis) and blood-brain barrier integrity (T1 with contrast). Real-time quantitative polymerase chain reaction and NanoString nCounter neuroinflammation panels were used to determine acute changes in overall neuroinflammatory functions mediated by B7-H3. Motor function was assessed between days 1 and 7 of reperfusion. Early inhibition of B7-H3 after stroke significantly reduced blood-brain barrier disruption and brain damage and promoted functional outcomes. Poststroke neuroinflammation was reprogrammed with B7-H3 inhibition to balance neuroprotective anti-inflammatory mechanisms without compromising the immune response, which is crucial for preventing poststroke infections. The longitudinal assessment of blood-brain barrier, infarction, and proinflammatory cytokines demonstrates that B7-H3 induction during the acute period after stroke mediates poststroke neuroinflammation and secondary brain damage.
中文摘要:尽管免疫检查点与炎症衰老及卒中后感染的临床意义重大,但免疫检查点B7-H3在急性缺血性卒中预后和卒中后免疫抑制中的作用仍未得到研究。本研究探讨了急性缺血性卒中后调控脑内B7-H3诱导产生的效应,并评估其对脑损伤、神经炎症、血管完整性、宿主防御基因调控和功能结局的纵向影响。C57BL/6小鼠接受短暂大脑中动脉闭塞,再灌注后5分钟静脉注射B7-H3小干扰RNA或阴性(非靶向)小干扰RNA。在卒中后第1、3和7天,使用9.4 T扫描仪对小鼠脑进行磁共振成像,以评估脑损伤(T2、表观扩散系数和峰度)及血脑屏障完整性(增强T1)。采用实时定量聚合酶链反应和NanoString nCounter神经炎症检测组合确定B7-H3介导的总体神经炎症功能的急性变化。在再灌注后第1天至第7天评估运动功能。卒中后早期抑制B7-H3显著减少了血脑屏障破坏和脑损伤,并促进了功能结局。抑制B7-H3后,卒中后神经炎症被重编程,以平衡神经保护性抗炎机制,同时不损害对预防卒中后感染至关重要的免疫反应。对血脑屏障、梗死和促炎细胞因子的纵向评估表明,卒中后急性期B7-H3诱导介导了卒中后神经炎症和继发性脑损伤。
Stroke IF 11.1 2026-10 PMID: 42689324
The meningeal lymphatic system contributes to hematoma resolution and neurological recovery after intracerebral hemorrhage (ICH). We previously demonstrated that intraperitoneal cilostazol administration promotes dural lymphatic growth and enhances clearance of intracerebrally injected red blood cells; however, the antiplatelet effects of cilostazol raise safety concerns in ICH, potentially limiting clinical translation. Here, we evaluated whether oral cilostazol at clinical-equivalent doses in mice enhances dural lymphatic function and improves outcomes after ICH. ICH was induced by collagenase injection to model microvascular rupture. Cilostazol was orally administered to ICH mice at clinically equivalent doses, given at different time points and for varying durations. Prolymphangiogenic effects of cilostazol were examined in healthy in vivo and ex vivo meninges. Flow cytometry and immunofluorescence were performed to assess lymphatic endothelial cell proliferation and dural lymphatic remodeling. Lymphatic function was evaluated by in vivo live imaging and histological analysis of fluorescent tracer drainage. Short- and long-term histopathologic and behavioral outcomes were also evaluated. Oral cilostazol treatment initiated either 3 hours or 3 days after ICH enhanced dural lymphatic coverage and function, accompanied by reduced hematoma volume, neuronal injury, synapse loss, and long-term neurological deficits. Cilostazol increased CD31+PDPN+ lymphatic endothelial cells in ex vivo meninges, induced dural lymphatic hyperplasia, and enhanced lymphatic drainage in healthy mice. Both pretreatment and delayed treatment of cilostazol did not increase hematoma volume but rather improved ICH outcomes. By promoting dural lymphatic remodeling and drainage, cilostazol facilitates hematoma resolution and neurological recovery after ICH. Cilostazol treatment does not exacerbate initial bleeding or provoke hematoma expansion in the experimental ICH. These findings support clinical translation and provide mechanistic and dosing rationale for an ongoing phase II randomized trial (URL: https://www.clinicaltrials.gov; Unique identifier: NCT06504576).
中文摘要:脑膜淋巴系统有助于脑出血(ICH)后血肿消退和神经功能恢复。我们既往证明,腹腔注射西洛他唑可促进硬脑膜淋巴管生长并增强脑内注射红细胞的清除;然而,西洛他唑的抗血小板作用在ICH中引发安全性担忧,可能限制其临床转化。在此,我们评估了小鼠口服临床等效剂量西洛他唑是否增强硬脑膜淋巴功能并改善ICH后结局。通过注射胶原酶诱导ICH以模拟微血管破裂。对ICH小鼠以临床等效剂量口服西洛他唑,并在不同时间点和不同疗程给药。在健康体内和离体脑膜中检查西洛他唑的促淋巴管生成作用。采用流式细胞术和免疫荧光评估淋巴内皮细胞增殖和硬脑膜淋巴重塑。通过体内活体成像和荧光示踪剂引流组织学分析评估淋巴功能。还评估了短期和长期组织病理学和行为学结局。ICH后3小时或3天开始口服西洛他唑治疗可增强硬脑膜淋巴覆盖和功能,并伴随血肿体积、神经元损伤、突触丢失和长期神经功能缺损减少。西洛他唑增加离体脑膜中CD31+PDPN+淋巴内皮细胞,诱导硬脑膜淋巴增生,并增强健康小鼠的淋巴引流。西洛他唑预处理和延迟治疗均未增加血肿体积,反而改善ICH结局。通过促进硬脑膜淋巴重塑和引流,西洛他唑促进ICH后血肿消退和神经功能恢复。西洛他唑治疗不会加重实验性ICH的初始出血或诱发血肿扩大。这些发现支持临床转化,并为正在进行的II期随机试验提供机制和剂量依据(URL: https://www.clinicaltrials.gov;Unique identifier: NCT06504576)。
Stroke IF 11.1 2026-10 PMID: 42663057
Angiogenesis contributes to vascular repair and functional recovery after ischemic stroke, yet how nitric oxide-mediated S-nitrosylation shapes this response remains unclear. We investigated the role of S-nitrosylation in postischemic angiogenesis and the underlying molecular mechanism. S-nitrosylation proteomics was performed in ischemic brain tissue from 8-week-old male mice subjected to transient middle cerebral artery occlusion and in brain microvascular endothelial cells exposed to oxygen-glucose deprivation/reoxygenation. Candidate modification sites were validated by cysteine mutagenesis and biotin-switch assays. Wild-type and C339A-mutant FKBP5 (FK506-binding protein 5) were compared in endothelial angiogenesis assays. Four-week-old male mice received endothelial-targeted adeno-associated virus 9 encoding wild-type or C339A-mutant FKBP5 and underwent transient middle cerebral artery occlusion 4 weeks later. Vascular and neurological outcomes were assessed through day 28. Protein-interaction and signaling analyses defined the downstream mechanism. S-nitrosylated FKBP5, but not total FKBP5, was increased in ischemic brain tissue and oxygen-glucose deprivation/reoxygenation-treated endothelial cells; inducible nitric oxide synthase was an upstream mediator. Mass spectrometry and mutagenesis identified cysteine 339 as the predominant modification site. C339A prevented FKBP5 S-nitrosylation and rescued endothelial proliferation, migration, sprouting, and tube formation after oxygen-glucose deprivation/reoxygenation. In mice, endothelial-targeted expression of FKBP5-C339A promoted peri-infarct angiogenesis and perfusion, reduced tissue injury, and improved chronic sensorimotor recovery. Mechanistically, S-nitrosylation strengthened FKBP5 binding to PHLPP (PH domain leucine-rich repeat protein phosphatase) and reduced AKT (serine/threonine kinase) phosphorylation. C339A weakened this interaction and restored AKT activation, whereas PHLPP inhibition with NSC117079 enhanced AKT signaling and angiogenic responses in vitro. We identify endothelial FKBP5 as a previously unrecognized regulator of poststroke vascular regeneration and establish S-nitrosylation at cysteine 339 as a molecular switch that restrains angiogenesis and functional recovery through PHLPP-dependent inhibition of AKT signaling. Targeting this modification may offer a strategy to enhance vascular repair after ischemic stroke.
中文摘要:血管生成有助于缺血性卒中后的血管修复和功能恢复,但一氧化氮介导的S-亚硝基化如何塑造这一反应仍不清楚。我们研究了S-亚硝基化在缺血后血管生成中的作用及其潜在分子机制。对经受短暂大脑中动脉闭塞的8周龄雄性小鼠的缺血脑组织以及暴露于氧糖剥夺/复氧的脑微血管内皮细胞进行了S-亚硝基化蛋白质组学分析。通过半胱氨酸突变和生物素转换实验验证了候选修饰位点。在内皮血管生成实验中比较了野生型和C339A突变型FKBP5(FK506结合蛋白5)。4周龄雄性小鼠接受编码野生型或C339A突变型FKBP5的内皮靶向腺相关病毒9,并在4周后接受短暂大脑中动脉闭塞。评估血管和神经学结局直至第28天。通过蛋白相互作用和信号分析确定下游机制。在缺血脑组织和氧糖剥夺/复氧处理的内皮细胞中,S-亚硝基化的FKBP5而非总FKBP5增加;诱导型一氧化氮合酶是上游介质。质谱和突变分析确定半胱氨酸339为主要修饰位点。C339A阻止了FKBP5的S-亚硝基化,并挽救了氧糖剥夺/复氧后的内皮增殖、迁移、出芽和管形成。在小鼠中,内皮靶向表达FKBP5-C339A促进了梗死周围血管生成和灌注,减少了组织损伤,并改善了慢性感觉运动恢复。在机制上,S-亚硝基化增强了FKBP5与PHLPP(PH结构域富亮氨酸重复蛋白磷酸酶)的结合,并降低了AKT(丝氨酸/苏氨酸激酶)磷酸化。C339A削弱了这种相互作用并恢复了AKT激活,而用NSC117079抑制PHLPP则增强了体外AKT信号传导和血管生成反应。我们确定内皮FKBP5是卒中后血管再生的一个此前未被识别的调节因子,并确立半胱氨酸339处的S-亚硝基化是一个分子开关,通过PHLPP依赖性抑制AKT信号传导来限制血管生成和功能恢复。靶向这一修饰可能提供一种增强缺血性卒中后血管修复的策略。
Stroke IF 11.1 2026-10 PMID: 42495739
Leptomeningeal collaterals form a critical vascular network that enlarges to support retrograde reperfusion after ischemic stroke, yet the cellular mechanisms governing their structural plasticity remain poorly defined. Here we identify an immune-responsive vascular niche and uncover a central role for bone marrow-derived monocytes in regulating collateral remodeling. GFP (green fluorescent protein)+ bone marrow chimeric mice and inducible monocyte-specific Ccr2-CreERT2 (C-C chemokine receptor 2 promoter-driven tamoxifen-inducible Cre recombinase-estrogen receptor T2)/EphA4f/f and Ccr2-CreERT2/EphA4f/f/Tie2f/f (tyrosine kinase with immunoglobulin-like and EGF-like domains 2) mice underwent permanent middle cerebral artery occlusion to assess monocyte recruitment, collateral remodeling, cerebral blood flow, infarct volume, and functional recovery. Mechanistic studies evaluated EphA4 (ephrin receptor A4)/Tie2-PI3K (phosphatidylinositol 3-kinase) α signaling in macrophages, while serum sTie2 (soluble Tie2) levels and immune transcriptomic profiles were analyzed in patients with acute large vessel occlusion and correlated with angiographic collateral grade. We observed rapid recruitment of EphA4-expressing monocytes to pial collateral vessels after permanent middle cerebral artery occlusion. EphA4 knockout chimeric mice show a marked increase in monocyte recruitment, enhanced collateral diameters, improved cerebral blood flow, reduced infarct volume, and accelerated motor recovery. EphA4-null macrophages exhibited elevated Tie2, p-Akt (phosphorylated protein kinase B), and PI3Kα, a phenotype reversed by PI3Kα inhibition or sTie2. We further show enhanced permanent middle cerebral artery occlusion-induced collateral enlargement, neuroprotection, and monocyte recruitment using Ccr2-CreERT2/EphA4f/f mice, which is attenuated in Ccr2-CreERT2/EphA4f/f/Tie2f/f double-knockout mice. Notably, we find that serum sTie2 levels are elevated in human patients with large vessel occlusion, and these levels correlate with improved digital subtraction angiography collateral scoring and key immune-specific bulk transcriptomic changes. Together, these findings establish immune cell-intrinsic EphA4/Tie2 signaling as a key regulator of leptomeningeal collateral enlargement and reveal a therapeutic axis for augmenting perfusion after stroke.
中文摘要:软脑膜侧支构成一个关键的血管网络,在缺血性卒中后其扩张以支持逆行再灌注,但调控其结构可塑性的细胞机制仍不明确。在此,我们鉴定出一个免疫反应性血管龛,并揭示骨髓来源单核细胞在调控侧支重塑中的核心作用。我们使GFP(绿色荧光蛋白)阳性骨髓嵌合小鼠以及可诱导的单核细胞特异性Ccr2-CreERT2(C-C趋化因子受体2启动子驱动的他莫昔芬诱导型Cre重组酶-雌激素受体T2)/EphA4f/f和Ccr2-CreERT2/EphA4f/f/Tie2f/f(含免疫球蛋白样和EGF样结构域的酪氨酸激酶2)小鼠接受永久性大脑中动脉闭塞,以评估单核细胞募集、侧支重塑、脑血流、梗死体积和功能恢复。机制研究评估了巨噬细胞中的EphA4(肝配蛋白受体A4)/Tie2-PI3K(磷脂酰肌醇3-激酶)α信号,同时分析了急性大血管闭塞患者的血清sTie2(可溶性Tie2)水平和免疫转录组谱,并将其与血管造影侧支分级进行相关性分析。我们观察到,永久性大脑中动脉闭塞后表达EphA4的单核细胞迅速募集至软脑膜侧支血管。EphA4敲除嵌合小鼠显示单核细胞募集显著增加、侧支直径增大、脑血流改善、梗死体积减小以及运动恢复加速。EphA4缺失的巨噬细胞表现出Tie2、p-Akt(磷酸化蛋白激酶B)和PI3Kα升高,而该表型可被PI3Kα抑制或sTie2逆转。我们进一步显示,使用Ccr2-CreERT2/EphA4f/f小鼠可增强永久性大脑中动脉闭塞诱导的侧支扩张、神经保护和单核细胞募集,而在Ccr2-CreERT2/EphA4f/f/Tie2f/f双敲除小鼠中该效应减弱。值得注意的是,我们发现大血管闭塞患者的血清sTie2水平升高,且这些水平与数字减影血管造影侧支评分的改善以及关键的免疫特异性整体转录组变化相关。总之,这些发现确立了免疫细胞内在的EphA4/Tie2信号是软脑膜侧支扩张的关键调控因子,并揭示了一条用于增强卒中后灌注的治疗轴。
Acta pharmacologica Sinica IF 10.4 2026-10 PMID: 42315909
Ischemic stroke is a leading cause of global mortality and long-term disability, with limited therapeutic options. Increasing evidence from experimental studies suggests that fibroblast growth factors (FGFs) play important roles in regulating key biological processes involved in brain repair following ischemia. This review examines the existing evidence to understand the functional roles of FGFs in ischemic stroke, highlighting findings from in vivo and in vitro models, as well as outcomes from clinical investigations. FGFs contribute to neuroprotection by supporting neuronal survival, modulating inflammatory responses, preserving blood-brain barrier (BBB) integrity, and enhancing angiogenesis. Despite promising data from experimental models, clinical translation of FGF-based therapies has proven challenging. Clinical trials have encountered issues such as safety concerns, particularly regarding optimal dosing and the risk of adverse effects, which complicates treatment response. These limitations highlight the complexity of translating FGF-based therapies into clinical practice in stroke treatment. Additionally, emerging FGF biomarkers may help predict therapeutic responses and guide patient selection and diagnosis. Future research should focus on optimizing delivery systems, identifying therapeutic windows, and improving clinical trial design, as successful clinical translation of FGF therapies relies on resolving subtype-specificity and refining delivery strategies to ensure targeted and effective treatment. Therefore, gaining a deeper understanding of the timing and context of FGF activity following ischemic stroke could pave the way for successful clinical applications, such as early neuroprotection, preservation of BBB integrity, and reduction of neuroinflammation. This understanding could also support the development of more targeted and effective interventions for ischemic stroke.
中文摘要:缺血性卒中是全球死亡和长期残疾的主要原因,治疗选择有限。越来越多来自实验研究的证据表明,成纤维细胞生长因子(FGFs)在调节缺血后脑修复相关的关键生物学过程中发挥重要作用。本综述审视现有证据,以理解FGFs在缺血性卒中中的功能作用,重点介绍来自体内和体外模型的研究结果,以及临床研究的结果。FGFs通过支持神经元存活、调节炎症反应、维持血脑屏障(BBB)完整性和促进血管生成,发挥神经保护作用。尽管实验模型数据令人鼓舞,但基于FGF的治疗的临床转化仍具有挑战性。临床试验遇到了安全性问题,尤其是最佳剂量和不良效应风险方面,这使治疗反应复杂化。这些局限凸显了将基于FGF的治疗转化为卒中临床实践的复杂性。此外,新兴的FGF生物标志物可能有助于预测治疗反应并指导患者选择和诊断。未来研究应聚焦于优化递送系统、确定治疗时间窗和改进临床试验设计,因为FGF治疗的成功临床转化依赖于解决亚型特异性并改进递送策略,以确保靶向和有效的治疗。因此,更深入理解缺血性卒中后FGF活性的时机和背景,可能为成功的临床应用铺平道路,例如早期神经保护、维持BBB完整性和减少神经炎症。这种理解还可支持开发更具靶向性和更有效的缺血性卒中干预措施。
Journal of advanced research IF 17.1 2026-10 PMID: 41534552
Intracerebral hemorrhage (ICH) is a devastating stroke subtype, yet the intrinsic mechanisms conferring genetic protection against it remain poorly understood. While risk-associated loci have been identified, the cell-type-specific pathways that actively preserve cerebrovascular stability remain largely unmapped. This study aimed to bridge the critical gap in understanding cell-type-specific mechanisms of ICH by identifying novel protective genetic drivers essential for maintaining neurovascular integrity, utilizing an integrative multi-omics approach. We integrated large-scale human genetic data with multi-omics approaches (TWAS, PWAS) and single-cell analysis to identify cell-type-specific risk genes for ICH. We validated our core findings using a collagenase-induced mouse model of ICH. To definitively establish causality, we further conducted in vivo gain-of-function studies via retro-orbital injection of adeno-associated virus (AAV) vectors. By combining Evans Blue extravasation assays, brain edema measurements, and neurobehavioral testing, we systematically evaluated the impact of LAMC1 on blood-brain barrier (BBB) integrity and neurological functional outcomes. Multi-omics analysis indicated that genetically determined reduced LAMC1 expression increases ICH risk, with single-cell eQTL pinpointing astrocytes as key drivers. In vivo, LAMC1 was downregulated in astrocytes and endothelial cells post-ICH. Crucially, LAMC1 overexpression attenuated brain edema and tissue necrosis, markedly improving neuromotor function. Mechanistically, LAMC1 preserved BBB integrity by inhibiting the degradation of the tight junction proteins ZO-1 and occludin. This study not only identifies astrocyte-derived LAMC1 as a "vascular guardian" essential for maintaining neurovascular unit integrity, but also provides definitive causal evidence via gain-of-function experiments that elevating LAMC1 levels effectively stabilizes the blood-brain barrier and improves ICH outcomes. Consequently, this establishes LAMC1 as a critical target for precision intervention aimed at enhancing vascular resilience and for the prevention and treatment of ICH.
中文摘要:脑出血(ICH)是一种破坏性极强的卒中亚型,但其内在的遗传保护机制仍知之甚少。尽管已发现与风险相关的位点,但主动维持脑血管稳定性的细胞类型特异性通路在很大程度上仍未被阐明。本研究旨在通过整合多组学方法,识别维持神经血管完整性所必需的新型保护性遗传驱动因素,以弥合在理解ICH细胞类型特异性机制方面的关键空白。我们将大规模人类遗传数据与多组学方法(TWAS、PWAS)及单细胞分析相结合,以识别ICH的细胞类型特异性风险基因。我们使用胶原酶诱导的ICH小鼠模型验证核心发现。为明确因果关系,我们进一步通过眶后注射腺相关病毒(AAV)载体开展体内功能获得研究。结合伊文思蓝渗出实验、脑水肿测量和神经行为学测试,我们系统评估了LAMC1对血脑屏障(BBB)完整性和神经功能结局的影响。多组学分析表明,遗传决定的LAMC1表达降低会增加ICH风险,单细胞eQTL将其关键驱动细胞定位为星形胶质细胞。在体内,ICH后星形胶质细胞和内皮细胞中LAMC1下调。关键的是,LAMC1过表达减轻了脑水肿和组织坏死,显著改善了神经运动功能。机制上,LAMC1通过抑制紧密连接蛋白ZO-1和occludin的降解来维持BBB完整性。本研究不仅确定了星形胶质细胞来源的LAMC1是维持神经血管单元完整性所必需的「血管守护者」,还通过功能获得实验提供了明确因果证据,表明提高LAMC1水平可有效稳定血脑屏障并改善ICH结局。因此,这将LAMC1确立为旨在增强血管韧性的精准干预以及ICH预防和治疗的关键靶点。

2心力衰竭 (18篇)

临床研究 (8篇)

European heart journal IF 45.3 2026-10-06 PMID: 42834810
Randomized evidence comparing conduction system pacing (CSP) and biventricular pacing (BVP) following atrioventricular node ablation in patients with refractory atrial fibrillation (AF) and heart failure (HF) remains limited. This study evaluated whether CSP with left bundle branch area pacing is non-inferior to BVP in patients undergoing atrioventricular node ablation. CONDUCT-AF was an investigator-initiated, multicentre, randomized trial conducted across 10 European centres. Patients with refractory AF, HF with left ventricular ejection fraction (LVEF) < 50%, narrow QRS duration (≤120 ms), and N-terminal pro-B-type natriuretic peptide > 600 ng/L were randomized 1:1 to CSP or BVP. The primary endpoint was the change in LVEF after 6 months, assessed by an independent core laboratory. Secondary endpoints included echocardiographic, clinical, and procedural outcomes. Analyses followed the intention-to-treat principle. Eighty-two patients were randomized (mean age 72 ± 7 years, 46% male). At 6 months, LVEF improved similarly in CSP {from 36% [95% confidence interval (CI) 33-39] to 46% [95% CI 44-49]; P < .001} and BVP group [from 34% (95% CI 31-36) to 46% (95% CI 43-49); P < .001]. The between-group difference was .4% (95% CI -3.1-3.8; P = .002 for non-inferiority). Changes in left ventricular volumes, clinical parameters, and composite endpoint of worsening HF or cardiovascular death were comparable between groups. Paced QRS [mean difference -14 ms (95% CI -19 to -9; P < .001)] and procedural and fluoroscopy times were significantly shorter with CSP compared with BVP. In HF patients with refractory AF undergoing atrioventricular node ablation, CSP with left bundle branch area pacing was non-inferior to BVP for LVEF improvement at 6 months, providing comparable clinical outcomes and a favourable procedural profile.
中文摘要:随机证据比较房室结消融后传导系统起搏(CSP)与双心室起搏(BVP)在难治性心房颤动(AF)合并心力衰竭(HF)患者中的作用仍有限。本研究评估在接受房室结消融的患者中,采用左束支区域起搏的CSP是否不劣于BVP。CONDUCT-AF是一项由研究者发起、在欧洲10个中心开展的多中心随机试验。难治性AF、左心室射血分数(LVEF)<50%、QRS时限窄(≤120 ms)且N末端B型利钠肽原>600 ng/L的患者按1:1随机分配至CSP或BVP。主要终点为6个月后LVEF的变化,由独立核心实验室评估。次要终点包括超声心动图、临床和操作结局。分析遵循意向性治疗原则。共82例患者被随机分组(平均年龄72±7岁,46%为男性)。6个月时,CSP组LVEF改善情况相似{从36%[95%置信区间(CI)33-39]升至46%[95% CI 44-49];P<0.001},BVP组亦然[从34%(95% CI 31-36)升至46%(95% CI 43-49);P<0.001]。组间差异为0.4%(95% CI -3.1-3.8;非劣效性P=0.002)。左心室容积、临床参数以及心力衰竭恶化或心血管死亡复合终点的变化在两组间相当。与BVP相比,CSP的起搏QRS[平均差异-14 ms(95% CI -19至-9;P<0.001)]以及操作时间和透视时间显著更短。在接受房室结消融的难治性AF合并HF患者中,采用左束支区域起搏的CSP在6个月LVEF改善方面不劣于BVP,提供了相当的临床结局和有利的操作特征。
European journal of heart failure IF 10.3 2026-10-06 PMID: 42834642
Kidney function decline in heart failure (HF) may accelerate during periods surrounding HF-related events, while sodium-glucose cotransporter 2 inhibitors slow kidney function decline. However, the temporal relationship between kidney function changes, HF-related events, and treatment effects has not been well characterized. We aimed to explore kidney function trajectories around HF-related events and to assess whether empagliflozin modifies these changes. In a pooled analysis of the EMPEROR-Reduced and EMPEROR-Preserved trials, we examined longitudinal changes in estimated glomerular filtration rate (eGFR) before and after HF-related events, defined as HF hospitalization or HF-related death. In the EMPEROR-Pooled analysis, HF-related events occurred in 12.7% of 9554 patients during a median follow-up of 20.9 months (14.7-28.6). Patients who experienced HF-related events had a steeper eGFR decline during the 12 months before the event than those without HF-related events: average -5.01 ml/min/1.73 m2/year vs -1.93 ml/min/1.73 m2/year; P < .001. During the 12 months after HF-related events, eGFR decline persisted at an average rate of -4.73 ml/min/1.73 m2/year. These trajectories were not materially altered after adjustment for concurrent NYHA class or natriuretic peptide levels. Compared with placebo, empagliflozin slowed eGFR decline in patients without events (between-group difference, 0.94 ml/min/1.73 m2/year) and before events (1.09 ml/min/1.73 m2/year). The post-event difference was smaller (0.29 ml/min/1.73 m2/year), without significant heterogeneity across periods (P > .10). Findings were consistent across trials and irrespective of prior HF hospitalization. Across the LVEF spectrum, kidney function decline accelerated before HF-related events and remained rapid thereafter. Empagliflozin attenuated eGFR decline without evidence of heterogeneity across periods.
中文摘要:心力衰竭患者的肾功能下降可能在心力衰竭相关事件前后加快,而钠-葡萄糖协同转运蛋白2抑制剂可减缓肾功能下降。然而,肾功能变化、心力衰竭相关事件与治疗效应之间的时间关系尚未得到很好描述。我们旨在探讨心力衰竭相关事件前后的肾功能轨迹,并评估恩格列净是否改变这些变化。在EMPEROR-Reduced和EMPEROR-Preserved试验的汇总分析中,我们检查了估计肾小球滤过率(eGFR)在心力衰竭相关事件(定义为心力衰竭住院或心力衰竭相关死亡)前后的纵向变化。在EMPEROR-Pooled分析中,9554例患者中有12.7%在中位随访20.9个月(14.7-28.6)期间发生心力衰竭相关事件。发生心力衰竭相关事件的患者在事件前12个月内的eGFR下降比未发生事件者更陡峭:平均-5.01 ml/min/1.73 m2/年 vs -1.93 ml/min/1.73 m2/年;P < .001。在心力衰竭相关事件后12个月内,eGFR下降持续,平均速率为-4.73 ml/min/1.73 m2/年。在校正同期NYHA分级或利钠肽水平后,这些轨迹未发生实质性改变。与安慰剂相比,恩格列净减缓了无事件患者(组间差异0.94 ml/min/1.73 m2/年)和事件前患者(1.09 ml/min/1.73 m2/年)的eGFR下降。事件后的差异较小(0.29 ml/min/1.73 m2/年),各时期之间无显著异质性(P > .10)。结果在不同试验中一致,且与既往心力衰竭住院史无关。在LVEF谱系中,肾功能下降在心力衰竭相关事件前加速,并在事件后持续迅速。恩格列净减缓eGFR下降,无证据表明各时期存在异质性。
European journal of heart failure IF 10.3 2026-10-01 PMID: 42820334
To assess the demographic, clinical, behavioural, and treatment factors associated with health-related quality of life (HRQoL) in heart failure (HF), examine the association between HRQoL and mortality, and evaluate changes in HRQoL over 1-year. We analysed the ESC EORP Heart Failure III Registry, including patients hospitalized with acute HF or outpatient HF visits. HRQoL was assessed using the EuroQoL 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Generalized linear models examined associations between demographic, clinical, behavioural, and treatment characteristics with baseline HRQoL. Cox proportional hazards models assessed the relationship between baseline HRQoL and 1-year mortality. Changes in HRQoL were classified as improvement, deterioration, or mixed change across EQ-5D dimensions, and determinants of change were assessed using fixed-effects models. Among 10 130 patients (acute HF: 38.6%; outpatient HF: 61.4%), those with acute HF had worse baseline HRQoL than outpatients. Older age, female sex, eGFR ≤29, NYHA class III/IV, and dyspnoea at rest were strongly associated with lower HRQoL in both acute and outpatient HF. Lower baseline HRQoL was associated with a higher risk of death at 1 year, with a 0.1-unit decrease in HRQoL on a scale of -0.59 to 1.00 (equivalent to 37 days of full health lost annually) associated with a 9% higher risk of death; a finding consistent across ejection fraction categories and sex. At 1-year, 45% of patients reported improved HRQoL, and improvements were more common in those with acute HF, mildly reduced ejection fraction, and women. Use of ACEi/ARBs/ARNIs was associated with a modest improvement in HRQoL at 1 year. HRQoL provides important clinical information and may provide additional insight into patients' health status and disease progression beyond conventional clinical measures.
中文摘要:评估与心力衰竭(HF)患者健康相关生活质量(HRQoL)相关的人口学、临床、行为和治疗因素,检验HRQoL与死亡率的关联,并评估1年内HRQoL的变化。我们分析了ESC EORP心力衰竭III注册研究,纳入因急性HF住院或门诊HF就诊的患者。HRQoL采用EuroQoL五维五水平(EQ-5D-5L)问卷评估。广义线性模型检验人口学、临床、行为和治疗特征与基线HRQoL的关联。Cox比例风险模型评估基线HRQoL与1年死亡率的关系。HRQoL变化按EQ-5D各维度分为改善、恶化或混合变化,并采用固定效应模型评估变化的决定因素。在10 130例患者中(急性HF:38.6%;门诊HF:61.4%),急性HF患者的基线HRQoL较门诊患者更差。年龄较大、女性、eGFR≤29、NYHA III/IV级以及静息时呼吸困难在急性和门诊HF中均与较低的HRQoL强相关。较低的基线HRQoL与1年内更高的死亡风险相关;在-0.59至1.00的量表上HRQoL每降低0.1个单位(相当于每年损失37天完全健康)与死亡风险升高9%相关;该发现在不同射血分数类别和性别中一致。1年时,45%的患者报告HRQoL改善,急性HF、射血分数轻度降低和女性患者中改善更常见。ACEi/ARB/ARNI的使用与1年时HRQoL的适度改善相关。HRQoL提供了重要的临床信息,并可能超越传统临床指标,为患者健康状况和疾病进展提供额外洞见。
European journal of heart failure IF 10.3 2026-10-01 PMID: 42817848
Heart failure (HF) remains a major cause of morbidity, mortality, and increased healthcare costs worldwide, and is recognized as the result of progressive cardiovascular-kidney-metabolic (CKM) syndrome. Obesity, type 2 diabetes, chronic kidney disease, hypertension, and atherosclerotic cardiovascular disease frequently coexist and interact through shared pathophysiological mechanisms that promote HF onset, especially with preserved ejection fraction (HFpEF). This European Journal of Heart Failure (EJHF) Expert Consensus Statement synthesizes contemporary evidence supporting pharmacological strategies to prevent HF across the CKM spectrum. Foundational therapies, including renin-angiotensin system inhibitors, sodium-glucose cotransporter 2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and incretin-based agents, demonstrate complementary benefits in reducing HF events, cardiovascular death, and chronic kidney disease (CKD) progression in high-risk populations. Early, parallel initiation of these therapies may modify disease trajectory and attenuate progression from at-risk and pre-HF stages to overt clinical HF. This document further emphasizes the need for an up-front, accelerated implementation strategy supported by structured monitoring, multidisciplinary CKM care pathways, and proactive management of laboratory abnormalities. Overcoming barriers such as clinical inertia, safety misperceptions, polypharmacy, cost constraints, and inequities in access is essential to translate evidence into population-level impact. Harmonization of prevention frameworks across cardiology, nephrology, endocrinology, and primary care societies is urgently required. Integrated, cross-disciplinary implementation of evidence-based CKM management offers a realistic opportunity to reduce incident HF and mitigate its growing global burden.
中文摘要:心力衰竭(HF)仍是全球范围内致病、致死及医疗费用增加的主要原因,并被认为是进行性心血管-肾脏-代谢(CKM)综合征的结果。肥胖、2型糖尿病、慢性肾脏病、高血压和动脉粥样硬化性心血管疾病常共存,并通过共同病理生理机制相互作用,促进HF发生,尤其是射血分数保留型心力衰竭(HFpEF)。本欧洲心力衰竭杂志(EJHF)专家共识声明综合了当代证据,支持在CKM谱系中预防HF的药物治疗策略。基础治疗,包括肾素-血管紧张素系统抑制剂、钠-葡萄糖协同转运蛋白2抑制剂、非甾体类盐皮质激素受体拮抗剂以及基于肠促胰素的药物,在高危人群中显示出在减少HF事件、心血管死亡和慢性肾脏病(CKD)进展方面的互补获益。早期、并行启动这些治疗可能改变疾病轨迹,并减缓从高危期和心衰前期阶段向明显临床心力衰竭的进展。本文件进一步强调,需要采取前置、加速的实施策略,并以结构化监测、多学科CKM照护路径和实验室异常的主动管理为支持。克服临床惰性、安全性误解、多重用药、费用限制和可及性不公平等障碍,对于将证据转化为人群层面的影响至关重要。迫切需要协调心脏病学、肾脏病学、内分泌学和初级保健学会之间的预防框架。基于证据的CKM管理的整合性、跨学科实施,为减少新发HF并减轻其日益增长的全球负担提供了现实机会。
MedComm IF 14.1 2026-10 PMID: 42812899
Postoperative follow-up for patients with implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators (ICD/CRT-D) is often delayed in remote areas because of geographic barriers and limited healthcare resources, increasing the risk of adverse outcomes. The "Make Changes" study, was a prospective, multicenter, open-label randomized trial evaluating a 5G-cloud technology platform (5G-CTP) for real-time remote device interrogation and reprogramming versus standard In-clinic care. Between October 2022 and February 2024, 206 patients from five centers were randomly assigned to 12 months of follow-up with 5G-CTP (n = 104) or In-clinic care (n = 102). For the primary endpoint of time from clinical event to intervention, the 5G-CTP group had a significantly shorter response time than the In-Clinic group (4.2 vs. 11.5 days; p < 0.001). For secondary endpoints, the 5G-CTP group showed greater improvement in life quality at 12 months based on Minnesota Living with Heart Failure Questionnaire (p = 0.012). Rates of unplanned visits and clinical interventions were similar between groups, with no procedure-related complications. This model integrates community hospitals with implantation centers through 5G networks, enabling timely specialist-directed care locally without long-distance travel. It is a feasible strategy for postoperative ICD/CRT-D management, particularly in underserved regions with limited access to specialized cardiac care.
中文摘要:对于植入型心律转复除颤器(ICD)和心脏再同步治疗除颤器(CRT-D)的患者,术后随访常因地理障碍和医疗资源有限而在偏远地区延迟,增加不良结局风险。「Make Changes」研究是一项前瞻性、多中心、开放标签随机试验,评估5G云技术平台(5G-CTP)用于实时远程设备询问和程控,对比标准门诊诊疗。2022年10月至2024年2月期间,来自五个中心的206例患者被随机分配接受5G-CTP随访12个月(n=104)或门诊诊疗(n=102)。主要终点为从临床事件到干预的时间,5G-CTP组应答时间显著短于门诊组(4.2天 vs. 11.5天;p<0.001)。次要终点方面,基于明尼苏达心力衰竭生活质量问卷,5G-CTP组在12个月时生活质量改善更大(p=0.012)。两组非计划就诊和临床干预发生率相似,且无操作相关并发症。该模式通过5G网络将社区医院与植入中心整合,使患者无需长途旅行即可在当地获得及时的专科医生指导下的诊疗。对于ICD/CRT-D术后管理而言,这是一种可行策略,尤其是在获得专科心脏诊疗机会有限的医疗资源匮乏地区。
MedComm IF 14.1 2026-10 PMID: 42780637
Cardiovascular-kidney-metabolic (CKM) multimorbidity is common among patients with heart failure (HF), but its prognostic impact in Chinese patients remains largely unclear. We examined the relationship of CKM multimorbidity with adverse outcomes and its interaction with guideline-directed medical therapy (GDMT) in patients with HF. We classified hospitalized patients with HF by CKM-condition count (atherosclerotic cardiovascular disease [ASCVD], chronic kidney disease [CKD], and type 2 diabetes [T2D]). Cox models assessed 1-year all-cause death, cardiovascular (CV) death, and rehospitalizations. Among patients with HF with reduced ejection fraction (HFrEF), subgroup analyses were conducted by GDMT use. Among 126,524 patients, 66.4% had at least one CKM condition and 5.1% had all three. All-cause death increased with CKM burden; three conditions conferred the highest risk (adjusted hazard ratio 2.43, 95% confidence interval [CI] 2.20-2.69) versus no CKM conditions. Associations were stronger in HFrEF. Although GDMT recipients had lower absolute death rates, associations of CKM multimorbidity with all outcomes were generally consistent regardless of GDMT use. CKM multimorbidity is common in Chinese patients hospitalized with HF and is associated with a worse prognosis. Although GDMT lowered absolute death rates, it did not substantially modify the relative associations between CKM multimorbidity and subsequent clinical outcomes.
中文摘要:心血管-肾脏-代谢(CKM)共病在心力衰竭(HF)患者中常见,但其对中国患者的预后影响仍很大程度上不明确。我们分析了CKM共病与HF患者不良结局的关系及其与指南指导的药物治疗(GDMT)的交互作用。我们根据CKM疾病数量(动脉粥样硬化性心血管疾病[ASCVD]、慢性肾脏病[CKD]和2型糖尿病[T2D])对住院HF患者进行分类。采用Cox模型评估1年全因死亡、心血管(CV)死亡和再住院。在射血分数降低的心力衰竭(HFrEF)患者中,按GDMT使用情况进行亚组分析。在126524例患者中,66.4%至少有1种CKM疾病,5.1%有三种CKM疾病。全因死亡随CKM负担增加而升高;与无CKM疾病相比,三种CKM疾病带来最高风险(校正风险比2.43,95%置信区间2.20-2.69)。这种关联在HFrEF中更强。尽管接受GDMT者的绝对死亡率较低,但无论是否使用GDMT,CKM共病与所有结局的关联总体一致。CKM共病在中国住院HF患者中常见,并与更差预后相关。尽管GDMT降低了绝对死亡率,但并未实质性改变CKM共病与后续临床结局之间的相对关联。
Redox biology IF 16.2 2026-10 PMID: 42612422
Heart failure (HF) progression is closely linked to oxidative stress. 5-Oxoproline (5-OP), a product of glutathione degradation, is normally metabolized by 5-oxoprolinase (OPLAH) but accumulates when the gamma-glutamyl cycle is disrupted. Here, we investigated the clinical characteristics of circulating 5-OP, its proteomic correlates, and the associations to outcome in HF. In serum of 823 BIOSTAT-CHF patients, 5-OP was quantified by validated liquid chromatography-mass spectrometry and analyzed for associations with clinical outcomes. Proteomic correlates were identified across 355 OLINK proteins using stability selection with Minimax Concave Penalty regression. Mechanistic context was evaluated in a multi-comorbidity, large-animal cardio-kidney-metabolic (CKM) model with regional OPLAH assessment. Higher 5-OP was associated with worse renal function (eGFR declining across 5-OP tertiles, 67.9 to 60.2 mL/min/1.73 m2; p = 0.0012) and higher all-cause mortality (HR 1.55, 95% CI 1.11-2.17, p = 0.010). Per SD increase in log-5-OP, risk for the 2-year composite endpoint increased (HR 1.27, 95% CI 1.05-1.53), with broadly similar associations across CKD strata (interaction p = 0.63). TGF-α was the most robust proteomic correlate (π = 0.70; empirical permutation p = 0.001). In CKM swine, circulating 5-OP was elevated and renal cortical OPLAH protein, but not cardiac OPLAH, was selectively reduced, consistent with a renal contribution to systemic 5-OP elevation. Circulating 5-OP identifies HF patients at higher risk and is robustly associated with TGF-α. In a translational swine model, selective loss of renal cortical OPLAH provides tissue context supporting a renal contribution to systemic 5-OP elevation in cardiorenal syndrome.
中文摘要:心力衰竭(HF)进展与氧化应激密切相关。5-氧代脯氨酸(5-OP)是谷胱甘肽降解产物,通常由5-氧代脯氨酸酶(OPLAH)代谢,但当γ-谷氨酰循环被破坏时会蓄积。本研究探讨了循环5-OP的临床特征、其蛋白质组学相关因素以及与HF结局的关联。在823例BIOSTAT-CHF患者血清中,采用经验证的液相色谱-质谱法定量5-OP,并分析其与临床结局的关联。利用最小最大凹惩罚回归的稳定性选择,在355种OLINK蛋白中识别蛋白质组学相关因素。在一个多合并症大型动物心-肾-代谢(CKM)模型中评估机制背景,并进行区域OPLAH评估。较高的5-OP与较差的肾功能相关(eGFR随5-OP三分位数升高而下降,从67.9降至60.2 mL/min/1.73 m²;p=0.0012),并与较高的全因死亡率相关(HR 1.55,95% CI 1.11-2.17,p=0.010)。log-5-OP每增加1个标准差,2年复合终点风险增加(HR 1.27,95% CI 1.05-1.53),且在各CKD分层中关联大致相似(交互作用p=0.63)。TGF-α是最稳健的蛋白质组学相关因素(π=0.70;经验置换p=0.001)。在CKM猪中,循环5-OP升高,肾皮质OPLAH蛋白而非心脏OPLAH选择性减少,这与肾脏对系统性5-OP升高的贡献一致。循环5-OP可识别风险较高的HF患者,并与TGF-α稳健相关。在转化猪模型中,肾皮质OPLAH的选择性缺失提供了组织背景,支持心肾综合征中肾脏对系统性5-OP升高的贡献。
Diabetes care IF 22.6 2026-10-01 PMID: 41940793
In prespecified analyses, the treatment effect for major adverse cardiovascular event (MACE) of tirzepatide compared with imputed placebo was estimated using SURPASS-Cardiovascular Outcomes Trial (SURPASS-CVOT) and Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) trial data. The indirect comparison with placebo was conducted for primary (MACE-3) and secondary outcomes of SURPASS-CVOT. The analysis included data from REWIND participants who would have been eligible for SURPASS-CVOT and all participants from SURPASS-CVOT. Propensity score estimation was used to adjust for differences in participant characteristics between studies. The indirect analysis of the treatment effect was derived by multiplying the hazard ratio (HR) for MACE-3 between tirzepatide and dulaglutide in SURPASS-CVOT by the HR for dulaglutide versus placebo in REWIND. Sensitivity analyses were performed using unadjusted analyses, including both the selected REWIND and the entire REWIND populations, and adjusted analysis in the entire REWIND population. Post hoc sensitivity analyses used data from a recent glucagon-like peptide 1 receptor agonist (GLP-1RA) meta-analysis that included REWIND. Analyses included 2,055 of 9,901 participants from REWIND and all 13,165 participants from SURPASS-CVOT. In indirect treatment effect comparisons, tirzepatide versus placebo was associated with lower MACE-3 (HR 0.72; 95% CI 0.55, 0.94), death from CV cause or heart failure events (HR 0.70; 95% CI 0.51, 0.96), and all-cause death (HR 0.61; 95% CI 0.45, 0.82). Sensitivity analyses, including nonadjusted or the entire REWIND cohort data or meta-analysis data for GLP-1RAs, were generally consistent. In this indirect prespecified exploratory comparison, tirzepatide compared with imputed placebo was associated with reduced CV outcomes and all-cause mortality in participants with type 2 diabetes and established atherosclerotic CV disease.
中文摘要:在预先指定的分析中,利用SURPASS-心血管结局试验(SURPASS-CVOT)和REWIND(Researching Cardiovascular Events With a Weekly Incretin in Diabetes)试验数据,估算了替尔泊肽相较于推算安慰剂对主要不良心血管事件(MACE)的治疗效应。针对SURPASS-CVOT的主要结局(MACE-3)和次要结局,进行了与安慰剂的间接比较。分析纳入了REWIND中本符合SURPASS-CVOT入选条件的参与者数据以及SURPASS-CVOT的所有参与者。采用倾向评分估计来校正研究间参与者特征的差异。治疗效应的间接分析通过将SURPASS-CVOT中替尔泊肽与度拉糖肽之间MACE-3的风险比(HR)乘以REWIND中度拉糖肽与安慰剂之间的HR得出。敏感性分析采用未校正分析,包括选定的REWIND人群和整个REWIND人群,以及在整个REWIND人群中进行校正分析。事后敏感性分析使用了近期一项纳入REWIND的胰高血糖素样肽1受体激动剂(GLP-1RA)荟萃分析数据。分析纳入REWIND的9901名参与者中的2055名以及SURPASS-CVOT的所有13165名参与者。在间接治疗效应比较中,替尔泊肽相较于安慰剂与较低的MACE-3(HR 0.72;95% CI 0.55, 0.94)、心血管原因死亡或心力衰竭事件(HR 0.70;95% CI 0.51, 0.96)以及全因死亡(HR 0.61;95% CI 0.45, 0.82)相关。包括未校正分析、整个REWIND队列数据或GLP-1RA荟萃分析数据在内的敏感性分析总体上一致。在这一预先指定的间接探索性比较中,替尔泊肽相较于推算安慰剂与2型糖尿病合并已确诊动脉粥样硬化性心血管疾病参与者的心血管结局和全因死亡降低相关。

基础研究 (10篇)

Cardiovascular research IF 12.5 2026-10-07 PMID: 42839539
The age-related decline in growth hormone (GH) secretion, termed the somatopause, parallels the structural and functional deterioration of the aging heart. How this endocrine withdrawal translates into myocardial failure at the molecular level remains incompletely mapped. GH/insulin-like growth factor 1 (IGF-1) signaling acts via PI3K/Akt/mTOR and Ras/MAPK/c-Myc cascades on four processes central to cardiac aging: Akt-dependent nuclear retention of telomerase reverse transcriptase (TERT), established primarily in non-cardiomyocyte models; PGC-1α-driven mitochondrial biogenesis; suppression of the p53/p16INK4a senescence program; and metabolic-epigenetic regulation of cell-cycle competence via α-ketoglutarate/KDM5 and JMJD3 chromatin gating. In mouse cardiomyocytes, positive transcription elongation factor b (P-TEFb) is rate-limiting for Myc-driven proliferation, plausibly explaining why adult cardiomyocytes retain latent cell-cycle machinery yet rarely divide. A candidate GHRHR-HIF-1α axis, presently supported by preprint evidence, is examined as an emerging hypothesis for cell-type-selective cardioprotection independent of systemic GH. We integrate these strands along a single tractable axis: IGF-1/Akt/TERT/p53/PGC-1α with metabolic-epigenetic modulation. The 2025 Marra trial (NCT03775993; 64 randomized, 45 completers; surrogate and functional endpoints not powered for clinical events) reports that physiological GH restoration improves peak VO2 (+3.1 vs -1.8 mL/kg/min, P<0.01), NYHA class, and quality of life in heart failure with confirmed GH deficiency. A meta-analysis of 25 studies quantifies the U-shaped IGF-1-heart failure relationship, with the HF-versus-control IGF-1 difference derived from six of those studies. Plasma proteomic organ-aging signatures show accelerated cardiac aging is associated with 2.5-fold heart-failure risk. We present a hypothesis-generating framework identifying GH/IGF-1 axis restoration as a candidate determinant of heart-failure progression, warranting event-driven confirmation.
中文摘要:与年龄相关的生长激素(GH)分泌下降被称为生长激素分泌减退(somatopause),其与衰老心脏的结构和功能退化相平行。这种内分泌撤退如何在分子水平转化为心肌衰竭,目前仍未完全阐明。GH/胰岛素样生长因子1(IGF-1)信号通过PI3K/Akt/mTOR和Ras/MAPK/c-Myc级联,作用于心脏衰老的四个核心过程:Akt依赖的端粒酶逆转录酶(TERT)核滞留,这一现象主要在非心肌细胞模型中得到证实;PGC-1α驱动的线粒体生物发生;抑制p53/p16INK4a衰老程序;以及通过α-酮戊二酸/KDM5和JMJD3染色质门控对细胞周期能力进行代谢-表观遗传调控。在小鼠心肌细胞中,正性转录延伸因子b(P-TEFb)是Myc驱动增殖的限速因素,这或许可解释为何成年心肌细胞保留潜伏的细胞周期机制却很少分裂。一个目前由预印本证据支持的候选GHRHR-HIF-1α轴,被作为不依赖全身GH的细胞类型选择性心脏保护的新兴假说加以探讨。我们将这些线索整合到一条可操作的统一轴上:IGF-1/Akt/TERT/p53/PGC-1α,并伴代谢-表观遗传调控。2025年Marra试验(NCT03775993;64例随机化,45例完成者;替代终点和功能终点未针对临床事件进行统计功效设计)报告,在确诊GH缺乏的心力衰竭患者中,生理性GH恢复可改善峰值VO2(+3.1 vs -1.8 mL/kg/min,P<0.01)、NYHA分级和生活质量。一项纳入25项研究的荟萃分析量化了IGF-1与心力衰竭之间的U形关系,其中心衰组与对照组之间的IGF-1差异来自其中6项研究。血浆蛋白质组器官衰老特征显示,加速的心脏衰老与2.5倍的心力衰竭风险相关。我们提出一个产生假说的框架,将GH/IGF-1轴恢复确定为心力衰竭进展的候选决定因素,值得通过事件驱动的研究加以证实。
European heart journal IF 45.3 2026-10-05 PMID: 42830666
Heart failure with preserved ejection fraction (HFpEF) remains a significant therapeutic challenge. While GLP-1 receptor agonists (GLP-1RAs) show clinical promise, it remains unknown if their benefits are driven solely by weight loss or involve weight loss-independent mechanisms. We investigated the weight loss-independent effects of semaglutide in two preclinical models of cardiometabolic HFpEF: the ZSF1 Obese rat and the Göttingen HFpEF minipig. Male ZSF1 Obese rats (n = 12/group) and female Göttingen minipigs with 'two-hit' induced HFpEF (early intervention: n = 5/group; delayed intervention: n = 4/group) were treated with semaglutide at doses empirically determined to be non-weight-loss inducing. Comprehensive assessments included invasive hemodynamic (LVEDP, PCWP), echocardiography, and histological quantification of fibrosis and lipid burden. Delayed intervention utilized Cardiac MRI to quantify subcutaneous and ectopic fat depots. In rats, advanced multi-omics (NULISA plasma proteomics, single-cell RNA sequencing and tissue proteomics) were utilized to explore molecular mechanisms. In ZSF1 Obese rats, semaglutide significantly improved diastolic function (reducing LVEDP by ∼60%) and attenuated cardiac hypertrophy (by ∼30%), interstitial fibrosis, and cardiac lipid deposition in the absence of a significant weight loss. These functional benefits were conserved in the minipig HFpEF model, where treatment attenuated cardiac hypertrophy, left ventricular E/e', normalized pulmonary capillary wedge pressure (PCWP) and reversed advanced hepatic bridging fibrosis. Delayed intervention in established HFpEF minipigs reversed diastolic dysfunction and significantly reduced ectopic lipid depots (intramyocardial, epicardial, and hepatic fat) without affecting subcutaneous fat or total body weight. Mechanistically, multi-omics analyses in the rat heart revealed that these benefits were driven by suppression of pro-fibrotic and hypertrophic signals and up-regulation of branched-chain amino acid (BCAA) catabolism and fatty acid oxidation pathways in cardiomyocytes. Semaglutide attenuates cardiac and hepatic remodelling in preclinical models of obesity-associated cardiometabolic HFpEF in the absence of profound weight loss. The conservation of these effects across male rodents and female swine supports their translational relevance, while future studies are needed to define dose equivalence and confirm GLP-1 receptor engagement in cardiac and hepatic tissues. These findings support further mechanistic investigation of weight loss-independent GLP-1 receptor agonist signalling in this HFpEF phenotype.
中文摘要:射血分数保留的心力衰竭(HFpEF)仍是一项重大治疗挑战。虽然GLP-1受体激动剂(GLP-1RAs)显示出临床前景,但其获益是否仅由减重驱动,还是涉及非减重依赖机制,仍不清楚。我们在两种心脏代谢性HFpEF的临床前模型中研究了司美格鲁肽的非减重依赖效应:ZSF1肥胖大鼠和哥廷根HFpEF小型猪。雄性ZSF1肥胖大鼠(每组n=12)以及通过「双打击」诱导HFpEF的雌性哥廷根小型猪(早期干预:每组n=5;延迟干预:每组n=4)接受司美格鲁肽治疗,剂量经经验性确定不会诱导减重。综合评估包括有创血流动力学(LVEDP、PCWP)、超声心动图以及纤维化和脂质负荷的组织学定量。延迟干预利用心脏MRI定量皮下和异位脂肪库。在大鼠中,采用先进的多组学(NULISA血浆蛋白质组学、单细胞RNA测序和组织蛋白质组学)探索分子机制。在ZSF1肥胖大鼠中,司美格鲁肽在无明显减重的情况下显著改善舒张功能(LVEDP降低约60%),并减轻心脏肥厚(约30%)、间质纤维化和心脏脂质沉积。这些功能获益在小型猪HFpEF模型中得到保留,治疗减轻了心脏肥厚、左心室E/e',使肺毛细血管楔压(PCWP)正常化,并逆转晚期肝桥接纤维化。在已建立HFpEF的小型猪中进行延迟干预可逆转舒张功能障碍,并显著减少异位脂质库(心肌内、心外膜和肝脏脂肪),而不影响皮下脂肪或总体重。在机制上,大鼠心脏多组学分析显示,这些获益由抑制促纤维化和促肥厚信号以及上调心肌细胞中支链氨基酸(BCAA)分解代谢和脂肪酸氧化通路所驱动。司美格鲁肽在肥胖相关心脏代谢性HFpEF的临床前模型中,在没有显著减重的情况下减轻心脏和肝脏重构。这些效应在雄性啮齿动物和雌性猪中的保守性支持其转化相关性,而未来研究需要确定剂量等效性并确认心脏和肝脏组织中的GLP-1受体参与。这些发现支持在这一HFpEF表型中进一步对非减重依赖的GLP-1受体激动剂信号进行机制研究。
Pharmacological research IF 12.2 2026-10 PMID: 42697419
Heart failure with preserved ejection fraction (HFpEF) is a major heart failure phenotype in type 2 diabetes mellitus, yet therapies directed at its underlying cardiomyocyte mechanisms remain limited. This review focuses on how diabetic metabolic, inflammatory, and structural stress remodel cardiomyocyte Ca2 + handling. Impaired sarcoplasmic reticulum Ca2+ reuptake, enhanced diastolic Ca2+ leak, reduced sarcolemmal Ca2+ extrusion, and disrupted mitochondrial Ca2+-energy coupling collectively delay Ca2+ clearance and sustain elevated end-diastolic cytosolic Ca2+, thereby contributing to impaired diastolic relaxation. Sodium-glucose cotransporter 2 (SGLT2) inhibitors may improve Na+-Ca2+ coupling by reducing sodium-hydrogen exchanger 1 (NHE1)- and late Na+ current-mediated Na+ overload, whereas metabolic interventions such as ketone supplementation and glucagon-like peptide-1 receptor agonists may support mitochondrial energetics and Ca2+ clearance. More direct approaches, including modulation of Ca2+-handling proteins, ryanodine receptor 2 (RyR2) stabilization, sarcoplasmic reticulum Ca2+-ATPase 2a (SERCA2a) restoration, and repair of T-tubule-associated microdomains, remain largely preclinical or early translational. Advancing this field will require human myocardial validation, biomarkers linked to specific Ca2+ defects, and stratification of patients according to the dominant mechanism of Ca2+ dysregulation.
中文摘要:射血分数保留的心力衰竭(HFpEF)是2型糖尿病中的一种主要心力衰竭表型,但针对其潜在心肌细胞机制的治疗仍然有限。本综述聚焦糖尿病相关的代谢、炎症和结构应激如何重塑心肌细胞Ca2+处理。肌浆网Ca2+再摄取受损、舒张期Ca2+漏增加、肌膜Ca2+外排减少以及线粒体Ca2+-能量耦联紊乱共同导致Ca2+清除延迟,并维持舒张末期胞质Ca2+升高,从而促进舒张松弛受损。钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂可能通过减少钠-氢交换体1(NHE1)和晚期Na+电流介导的Na+超负荷来改善Na+-Ca2+耦联,而酮体补充和胰高血糖素样肽-1受体激动剂等代谢干预可能支持线粒体能量学和Ca2+清除。更直接的方法,包括调节Ca2+处理蛋白、稳定兰尼碱受体2(RyR2)、恢复肌浆网Ca2+-ATP酶2a(SERCA2a)以及修复T管相关微结构域,仍主要处于临床前或早期转化阶段。推动这一领域发展将需要人类心肌验证、与特定Ca2+缺陷相关的生物标志物,以及根据Ca2+失调的主要机制对患者进行分层。
Redox biology IF 16.2 2026-10 PMID: 42641478
HFpEF is characterized by microvascular rarefaction and endothelial metabolic dysfunction, but the mechanisms linking these abnormalities remain unclear. HFpEF was induced in mice by a high-fat diet plus l-NAME. Whole-heart lactylome profiling identified altered lactylation sites. Mechanistic studies included endothelial-targeted AAV9 manipulation and NNT-WT/NNT-K1079R rescue in vivo, complemented by experiments in primary cardiac microvascular endothelial cells. Endothelial HSPA1A was markedly reduced in HFpEF. Endothelial-targeted HSPA1A knockdown aggravated diastolic dysfunction, microvascular rarefaction and exercise capacity, whereas HSPA1A overexpression alleviated these features. Mechanistically, HSPA1A interacted with BAG2 to restrain CHIP-dependent HIF-1α ubiquitination, thereby stabilizing HIF-1α and sustaining endothelial glycolysis and lactate availability. Endothelial HIF-1α knockdown attenuated HSPA1A-mediated protection in vivo. Consistent with impaired lactate availability, lactate levels and protein lactylation were reduced in HFpEF hearts, and NNT-K1079 was identified as a prominently decreased lactylation site. Lactate increased NNT lactylation, whereas p300 inhibition or knockdown attenuated this response. Compared with NNT-WT, the NNT-K1079R mutant showed reduced lactate responsiveness, impaired redox defense and angiogenic function. To test whether NNT-K1079 mediates HSPA1A protection, NNT epistasis and rescue experiments were performed. Endothelial NNT knockdown weakened HSPA1A-mediated protection, whereas NNT-WT, but not NNT-K1079R, restored microvascular density and diastolic function. In turn, loss of NNT-K1079 lactylation disrupted mitochondrial ROS/ATP homeostasis, thereby suppressing HSF1-dependent HSPA1A transcription. HSPA1A sustains NNT-K1079 lactylation and mitochondrial redox homeostasis through the BAG2-CHIP-HIF-1α-glycolysis/lactate pathway. In turn, NNT-K1079 lactylation sustains HSPA1A expression, forming a protective feedback loop whose disruption contributes to microvascular rarefaction and diastolic dysfunction in HFpEF.
中文摘要:HFpEF的特征是微血管稀疏和内皮代谢功能障碍,但连接这些异常的机制仍不清楚。通过高脂饮食联合l-NAME在小鼠中诱导HFpEF。全心脏乳酸化组分析鉴定出改变的乳酸化位点。机制研究包括内皮靶向AAV9操作和体内NNT-WT/NNT-K1079R拯救,并辅以原代心脏微血管内皮细胞实验。HFpEF中内皮HSPA1A显著减少。内皮靶向敲低HSPA1A加重舒张功能障碍、微血管稀疏和运动能力下降,而HSPA1A过表达缓解这些特征。机制上,HSPA1A与BAG2相互作用,抑制CHIP依赖的HIF-1α泛素化,从而稳定HIF-1α并维持内皮糖酵解和乳酸可用性。体内内皮HIF-1α敲低减弱了HSPA1A介导的保护作用。与乳酸可用性受损一致,HFpEF心脏中乳酸水平和蛋白质乳酸化降低,并且NNT-K1079被鉴定为显著降低的乳酸化位点。乳酸增加NNT乳酸化,而p300抑制或敲低减弱这一反应。与NNT-WT相比,NNT-K1079R突变体表现出乳酸反应性降低、氧化还原防御和血管生成功能受损。为检验NNT-K1079是否介导HSPA1A保护作用,进行了NNT上位性和拯救实验。内皮NNT敲低削弱了HSPA1A介导的保护作用,而NNT-WT而非NNT-K1079R恢复了微血管密度和舒张功能。反过来,NNT-K1079乳酸化缺失破坏线粒体ROS/ATP稳态,从而抑制HSF1依赖的HSPA1A转录。HSPA1A通过BAG2-CHIP-HIF-1α-糖酵解/乳酸通路维持NNT-K1079乳酸化和线粒体氧化还原稳态。反过来,NNT-K1079乳酸化维持HSPA1A表达,形成保护性反馈环路,其破坏导致HFpEF中的微血管稀疏和舒张功能障碍。
Pharmacological research IF 12.2 2026-10 PMID: 42624311
Cardiometabolic heart failure with preserved ejection fraction (HFpEF) is characterized by the frequent co-occurrence of obesity, central adiposity, insulin resistance, type 2 diabetes mellitus, and low-grade inflammation. How these exposures sustain myocardial remodeling remains uncertain. One-carbon metabolism provides a plausible biochemical interface between nutrient stress and epigenetic regulation: S-adenosylmethionine (SAM) donates methyl groups, whereas S-adenosylhomocysteine (SAH) inhibits methyltransferases. Altered nicotinamide N-methyltransferase (NNMT) flux, homocysteine-related SAH retention, and metabolic regulation of DNA methyltransferase (DNMT) and ten-eleven translocation (TET) enzymes could therefore reshape DNA methylation and hydroxymethylation. Direct human evidence remains sparse: available HFpEF methylation data are blood-derived rather than myocardial, and cardiac or adjacent models support individual components of the framework but not a continuous disease-specific pathway. We therefore view DNA methylation as a context-dependent regulatory layer that may amplify or stabilize inflammatory, fibrotic, and metabolic programs rather than as a uniform initiating cause. Accordingly, translational studies should prioritize compartment-specific target engagement, reversibility, and biomarker-guided patient selection rather than assume a role for methylation-directed therapy.
中文摘要:心脏代谢性射血分数保留的心力衰竭(HFpEF)以肥胖、中心性肥胖、胰岛素抵抗、2型糖尿病和低度炎症的频繁共存为特征。这些暴露如何维持心肌重构仍不确定。一碳代谢为营养应激与表观遗传调控之间提供了一个可能的生化界面:S-腺苷甲硫氨酸(SAM)提供甲基,而S-腺苷同型半胱氨酸(SAH)抑制甲基转移酶。因此,烟酰胺N-甲基转移酶(NNMT)通量改变、与同型半胱氨酸相关的SAH潴留以及DNA甲基转移酶(DNMT)和十-十一易位(TET)酶的代谢调控,可能重塑DNA甲基化和羟甲基化。直接的人体证据仍然稀少:可获得的HFpEF甲基化数据来自血液而非心肌,心脏或邻近模型支持该框架的各个组成部分,但不支持一个连续的疾病特异性通路。因此,我们将DNA甲基化视为一种情境依赖的调控层,它可能放大或稳定炎症、纤维化和代谢程序,而非统一的起始原因。相应地,转化研究应优先关注区室特异性靶点结合、可逆性和生物标志物指导的患者选择,而不应假定甲基化导向治疗具有作用。
Redox biology IF 16.2 2026-10 PMID: 42607499
Heart failure (HF) remains a leading cause of morbidity and mortality worldwide. A hallmark of HF progression is profound metabolic remodeling accompanied by mitochondrial dysfunction in cardiomyocytes. Impaired mitochondrial oxidative phosphorylation, excessive reactive oxygen species (ROS) production, and disrupted redox homeostasis collectively drive oxidative damage and compromise mitochondrial integrity, ultimately leading to contractile failure, for which no viable strategies currently exist. Although mitochondrial dysfunction is now recognized as a central driver of HF pathogenesis, the upstream molecular regulators that initiate or amplify these defects remain incompletely understood. Here, we identify myocilin as a fibroblast-derived mediator that drives cardiomyocyte mitochondrial dysfunction and ROS production in HF. Myocilin was consistently upregulated in patients with HF and in murine HF models induced by transverse aortic constriction and isoproterenol, and was predominantly expressed in cardiac fibroblasts. In vivo study using male mice showed that myocilin overexpression exacerbated cardiac dysfunction and fibrosis, whereas genetic ablation markedly alleviated pathological remodeling. Using transwell systems and recombinant protein stimulation, we found that fibroblast-derived myocilin impaired mitochondrial function in cardiomyocytes, as evidenced by reduced ATP production, increased ROS, and loss of membrane potential. Mechanistically, myocilin directly interacted with SLC3A2, the heavy chain that pairs with SLC7A11 to form the cystine/glutamate antiporter, on cardiomyocytes and promoted its degradation, thereby impairing cystine uptake. This led to glutathione depletion and redox imbalance, subsequently triggering ferroptosis-associated mitochondrial dysfunction in cardiomyocytes. Collectively, these findings identify a fibroblast-cardiomyocyte signaling axis in which myocilin disrupts cardiomyocyte metabolic homeostasis. Targeting the myocilin-SLC3A2 pathway may represent a potential therapeutic strategy for HF.
中文摘要:心力衰竭(HF)仍是全球致病和致死的主要原因之一。HF进展的一个标志是深刻的代谢重塑,并伴随心肌细胞线粒体功能障碍。线粒体氧化磷酸化受损、活性氧(ROS)生成过多以及氧化还原稳态破坏共同导致氧化损伤并损害线粒体完整性,最终引起收缩功能衰竭,而目前尚无可行策略。尽管线粒体功能障碍现已被认为是HF发病的中心驱动因素,但启动或放大这些缺陷的上游分子调控因子仍未被完全理解。在此,我们发现Myocilin是一种成纤维细胞来源的介质,可驱动HF中心肌细胞线粒体功能障碍和ROS产生。Myocilin在HF患者以及由横向主动脉缩窄和异丙肾上腺素诱导的小鼠HF模型中一致上调,并主要表达于心脏成纤维细胞。使用雄性小鼠进行的体内研究显示,Myocilin过表达加重了心脏功能障碍和纤维化,而基因敲除则显著减轻了病理性重塑。利用Transwell系统和重组蛋白刺激,我们发现成纤维细胞来源的Myocilin损害心肌细胞线粒体功能,表现为ATP生成减少、ROS增加和膜电位丧失。机制上,Myocilin直接与心肌细胞上的SLC3A2相互作用,SLC3A2是与SLC7A11配对形成胱氨酸/谷氨酸反向转运体的重链,并促进其降解,从而损害胱氨酸摄取。这导致谷胱甘肽耗竭和氧化还原失衡,随后触发心肌细胞中铁死亡相关的线粒体功能障碍。总体而言,这些发现确定了一条成纤维细胞-心肌细胞信号轴,其中Myocilin破坏心肌细胞代谢稳态。靶向Myocilin-SLC3A2通路可能代表HF的一种潜在治疗策略。
Redox biology IF 16.2 2026-10 PMID: 42600395
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous condition with incompletely defined myocardial mechanisms. Here, using a two-hit murine model of cardiometabolic HFpEF induced by high-fat diet and endothelial nitric oxide synthase inhibition, we define a mitochondrial metabolic phenotype characterized by altered substrate handling, redox stress, and S-nitrosylation remodeling. While global proteomic changes were modest, metabolomic profiling revealed selective remodeling of tricarboxylic acid cycle intermediates, increased dicarboxylic acids, and altered redox-associated metabolites, consistent with mitochondrial metabolic and redox imbalance in this experimental setting. S-nitrosylation proteomics demonstrated a highly organized and bidirectional remodeling pattern affecting proteins involved in fatty acid/lipid metabolism, carbohydrate metabolism, mitochondrial energy metabolism, amino acid and organic acid metabolism, nucleotide/co-factor metabolism, and redox defense. Stable isotope tracing showed reduced glucose-derived and increased palmitate-derived acetyl-CoA in HFpEF, whereas Na-βHB reduced palmitate contribution and increased βHB-derived acetyl-CoA without restoring glucose contribution, indicating substrate redistribution and preserved ketone oxidation. Na-βHB supplementation increased oligomycin-sensitive respiration in freshly prepared left ventricular tissue, partially normalized selected TCA-cycle intermediates, reduced mitochondrial ROS and the NADH/NAD+ ratio, restored the GSH/GSSG ratio, and improved diastolic function without altering ejection fraction. Together, these findings define a redox-sensitive mitochondrial metabolic state in the HFD/l-NAME model and identify ketone supplementation as a partial metabolic rescue strategy in this context. At the same time, these findings highlight an important limitation of the murine HFD/l-NAME model, which should be interpreted as an experimental system for studying high-fat-induced cardiometabolic stress rather than as a metabolic equivalent of human HFpEF.
中文摘要:射血分数保留的心力衰竭(HFpEF)是一种异质性疾病,其心肌机制尚未完全明确。在此,我们利用高脂饮食联合内皮型一氧化氮合酶抑制诱导的心脏代谢性HFpEF双打击小鼠模型,界定了一种以底物处理改变、氧化还原应激和S-亚硝基化重塑为特征的线粒体代谢表型。尽管整体蛋白质组变化轻微,代谢组学分析显示三羧酸循环中间体选择性重塑、二羧酸增加以及氧化还原相关代谢物改变,与该实验背景下线粒体代谢和氧化还原失衡一致。S-亚硝基化蛋白质组学显示一种高度有序且双向的重塑模式,影响参与脂肪酸/脂质代谢、碳水化合物代谢、线粒体能量代谢、氨基酸和有机酸代谢、核苷酸/辅因子代谢以及氧化还原防御的蛋白质。稳定同位素示踪显示,在HFpEF中葡萄糖来源的乙酰辅酶A减少而棕榈酸来源的乙酰辅酶A增加,而Na-βHB减少了棕榈酸贡献并增加βHB来源的乙酰辅酶A,但未恢复葡萄糖贡献,表明底物重分布且酮体氧化保留。补充Na-βHB可增加新鲜制备的左心室组织中寡霉素敏感性呼吸,部分正常化选定的TCA循环中间体,降低线粒体ROS和NADH/NAD+比值,恢复GSH/GSSG比值,并改善舒张功能而不改变射血分数。总之,这些发现界定了HFD/l-NAME模型中一种氧化还原敏感的线粒体代谢状态,并确定酮体补充是该情境下的一种部分代谢救援策略。同时,这些发现凸显了小鼠HFD/l-NAME模型的一个重要局限性,应将其解释为研究高脂诱导心脏代谢应激的实验系统,而非人类HFpEF的代谢等价物。
Acta pharmacologica Sinica IF 10.4 2026-10 PMID: 42552463
Heart failure (HF) represents the final stage of cardiovascular disease progression, characterized by high morbidity and mortality. Pressure overload in HF activates the PI3K/AKT pathway, and prolonged activation leads to pathological cardiac hypertrophy. However, the mechanism underlying sustained PI3K/AKT activation in pressure overload-induced HF remains unclear. In this study, we demonstrate that miR-203 overexpression in transgenic mice counteracts cardiac dysfunction and pathological remodeling in HF, whereas miR-203 downregulation exacerbates HF. At the cellular level, miR-203 overexpression significantly reduces Angiotensin II (Ang II)-induced cardiomyocyte hypertrophy and injury, while miR-203 knockdown aggravates these effects. Mechanistically, miR-203 binds to the 3' untranslated region (3'UTR) of insulin-like growth factor binding protein 5 (IGFBP5) mRNA, inhibiting IGFBP5 protein expression, thereby suppressing PI3K/AKT signaling and mitigating cardiomyocyte hypertrophy. Furthermore, we demonstrate that fibronectin-1 (FN1) is a critical functional partner for IGFBP5, as knockdown of FN1 attenuates IGFBP5-induced PI3K/AKT activation and hypertrophy. This study is the first to elucidate the role and mechanism of miR-203 in regulating pressure overload-induced HF, offering a potential genetic tool for HF therapy.
中文摘要:心力衰竭(HF)是心血管疾病进展的终末阶段,具有高发病率和死亡率。压力超负荷型心力衰竭可激活PI3K/AKT通路,而持续激活会导致病理性心肌肥厚。然而,压力超负荷诱导的心力衰竭中PI3K/AKT持续激活的机制尚不清楚。在本研究中,我们证明在转基因小鼠中过表达miR-203可对抗心力衰竭中的心脏功能障碍和病理性重构,而miR-203下调则加重心力衰竭。在细胞水平上,miR-203过表达可显著减轻血管紧张素II(Ang II)诱导的心肌细胞肥大和损伤,而miR-203敲低则加重这些效应。机制上,miR-203结合胰岛素样生长因子结合蛋白5(IGFBP5)mRNA的3'非翻译区(3'UTR),抑制IGFBP5蛋白表达,从而抑制PI3K/AKT信号并减轻心肌细胞肥大。此外,我们证明纤连蛋白1(FN1)是IGFBP5的关键功能伙伴,因为敲低FN1可减弱IGFBP5诱导的PI3K/AKT激活和心肌肥厚。本研究首次阐明miR-203在调控压力超负荷诱导的心力衰竭中的作用及机制,为心力衰竭治疗提供了潜在的基因工具。
Redox biology IF 16.2 2026-10 PMID: 42546417
Accumulating evidence highlights the pivotal role of ferroptosis in diverse cardiovascular diseases (CVDs) such as atherosclerosis, aortic aneurysm, aortic dissection, vascular aging, calcific aortic valve disease, myocardial ischemia reperfusion injury, cardiomyopathy, and heart failure. Studies on the molecular mechanism of ferroptosis have revealed potential targets for the treatment of CVDs, and a large number of studies have reported evidence of drug-mediated ferroptosis and iron metabolism mechanisms intervening in CVDs. This review delves into the latest molecular characteristics of ferroptosis, associated biological processes, and regulatory pathways. Notably, various compounds like iron chelators (e.g., deferoxamine, deferiprone), chloroiodohydroxyquin and its derivatives, antioxidants (e.g., vitamin E, lipoic acid, selenium), Ferrostatin-1 (Fer-1), etc., have demonstrated efficacy in animal studies against CVDs, offering cardiovascular protection. In summary, this review outlines the role of ferroptosis in CVDs, the regulatory effects of relevant drugs (including natural products) on ferroptosis within cardiovascular contexts, aiming to provide valuable insights for CVDs management and the development of novel therapeutics.
中文摘要:越来越多的证据强调了铁死亡在多种心血管疾病(CVDs)中的关键作用,如动脉粥样硬化、主动脉瘤、主动脉夹层、血管老化、钙化性主动脉瓣疾病、心肌缺血再灌注损伤、心肌病和心力衰竭。对铁死亡分子机制的研究揭示了治疗CVDs的潜在靶点,大量研究报道了药物介导的铁死亡和铁代谢机制干预CVDs的证据。本综述深入探讨了铁死亡的最新分子特征、相关生物学过程和调控通路。值得注意的是,多种化合物如铁螯合剂(如去铁胺、去铁酮)、氯碘羟喹及其衍生物、抗氧化剂(如维生素E、硫辛酸、硒)、Ferrostatin-1(Fer-1)等,在动物研究中已证明对CVDs有效,提供心血管保护。总之,本综述概述了铁死亡在CVDs中的作用,以及相关药物(包括天然产物)在心血管背景下对铁死亡的调节作用,旨在为CVDs管理和新型治疗方法的开发提供有价值的见解。
Acta pharmacologica Sinica IF 10.4 2026-10 PMID: 42362853
Endothelial-to-mesenchymal transition (EndoMT), a process in which endothelial cells progressively differentiate into a mesenchymal phenotype, is a pivotal contributor to cardiac fibrotic remodelling and heart failure (HF) pathogenesis following ischaemic injury. In this study, poly(ADP-ribose) polymerase 1 (PARP1) was identified as a critical driver of EndoMT in ischaemic HF. Single-cell sequencing data indicated that compared with other cardiac cell types, cardiac endothelial cells highly express PARP1. PARP1 was upregulated in patients with dilated or ischaemic cardiomyopathy, as well as in patients with myocardial infarction who developed HF. Similarly, PARP1 upregulation was observed in vitro in EndoMT models induced by hypoxia or TGF-β1(Transforming Growth Factor Beta 1)/IL-1β (Interleukin-1β) and in vivo in cardiac endothelial cells from mice with ischaemic HF induced by permanent left anterior descending (LAD) artery ligation. Pharmacological inhibition and knockdown of PARP1 expression significantly inhibited EndoMT. Moreover, treatment with PARP1 inhibitors or endothelial-specific AAV-mediated delivery of PARP1 shRNA prevented ischaemia-induced EndoMT, fibrosis and cardiac dysfunction in mice. Mechanistically, PARP1 catalysed the poly(ADP-ribosyl)ation (PARylation) modification of four-and-a-half LIM domains protein 2 (FHL2), a key regulator of EndoMT. PARylation of FHL2 at residues Asp50, Glu63 and Asp77 promoted its nuclear retention, enhanced its interaction with β-catenin, and potentiated β-catenin transcriptional activity. Abrogating FHL2 PARylation via site-directed mutagenesis abolished the pro-EndoMT effects of PARP1. These findings establish endothelial PARP1 as a promising therapeutic target for EndoMT in ischaemic HF.
中文摘要:内皮-间充质转化(EndoMT)是内皮细胞逐渐分化为间充质表型的过程,在缺血性损伤后心脏纤维化重塑和心力衰竭(HF)发病机制中起关键作用。在本研究中,聚(ADP-核糖)聚合酶1(PARP1)被确定为缺血性HF中EndoMT的关键驱动因素。单细胞测序数据表明,与其他心脏细胞类型相比,心脏内皮细胞高表达PARP1。PARP1在扩张型或缺血性心肌病患者以及发生HF的心肌梗死患者中上调。同样,在缺氧或转化生长因子β1(TGF-β1)/白细胞介素-1β(IL-1β)诱导的EndoMT模型中体外观察到PARP1上调,在永久性左前降支(LAD)动脉结扎诱导的缺血性HF小鼠的心脏内皮细胞中体内也观察到PARP1上调。药理学抑制和敲低PARP1表达显著抑制EndoMT。此外,PARP1抑制剂治疗或内皮特异性AAV介导的PARP1 shRNA递送可预防小鼠缺血诱导的EndoMT、纤维化和心脏功能障碍。机制上,PARP1催化四个半LIM结构域蛋白2(FHL2)的聚(ADP-核糖基)化(PARylation)修饰,FHL2是EndoMT的关键调节因子。FHL2在Asp50、Glu63和Asp77残基处的PARylation促进其核滞留,增强其与β-catenin的相互作用,并增强β-catenin转录活性。通过定点突变消除FHL2 PARylation可消除PARP1的促EndoMT作用。这些发现确立内皮PARP1作为缺血性HF中EndoMT的有前景的治疗靶点。

3心肌梗死/ACS (12篇)

临床研究 (2篇)

NEJM evidence IF 11.6 2026-10 PMID: 42770784
Beta-blockers are a cornerstone of therapy following myocardial infarction. The effect of different β-blockers on the outcomes of patients without heart failure after myocardial infarction is not well-studied. This observational cohort study used administrative data from French National Health Data System. Eligible patients were 18 years of age or older, hospitalized in the Paris area between January 1, 2008, and December 31, 2018, with a new myocardial infarction, and were dispensed either atenolol or bisoprolol within 2 days of hospital discharge. Patients prescribed β-blockers or loop diuretics or with a recorded diagnosis of heart failure (based on International Classification of Diseases, 10th Revision codes) during the 2 years preceding hospital discharge were excluded. Outcomes were followed for up to 2 years following hospital discharge and included major adverse cardiovascular events (cardiac arrest, all-cause mortality, reinfarction, stroke, or hospitalization for heart failure) (primary outcome) and all-cause mortality (secondary outcome). Targeted maximum likelihood estimation was used to estimate the average treatment effects (ATEs) comparing patients initiated on atenolol versus bisoprolol. Among 11,558 patients, 1523 (13.2%) initiated atenolol and 10,035 (86.8%) initiated bisoprolol within 2 days of discharge. Comparing the atenolol group to the bisoprolol group, the ATE was 2.9 percentage points (95% confidence interval [CI], 1.1-4.7) for major adverse cardiovascular events and 0.6 percentage points (95% CI, -0.2 to 1.3) for all-cause mortality. The weighted proportions of patients experiencing major adverse cardiovascular events were 10.8% and 14.1% in the atenolol and bisoprolol groups, respectively. The weighted proportions of patients experiencing all-cause mortality were 1.4% and 2.2% in the atenolol and bisoprolol groups, respectively. Among patients without recorded characteristics in an administrative database suggesting the presence of heart failure, initiation of atenolol after myocardial infarction was associated with a lower risk of major adverse cardiovascular events, but not all-cause mortality, at 2 years compared with bisoprolol. (Funded by PRAIRIE and others.).
中文摘要:β受体阻滞剂是心肌梗死后治疗的基石。不同β受体阻滞剂对心肌梗死后无心力衰竭患者结局的影响尚未得到充分研究。这项观察性队列研究使用了法国国家健康数据系统的行政数据。符合条件的患者为18岁及以上,于2008年1月1日至2018年12月31日期间在巴黎地区住院,发生新发心肌梗死,并在出院后2天内被配发阿替洛尔或比索洛尔。排除在出院前2年内处方过β受体阻滞剂或袢利尿剂,或记录有心力衰竭诊断(基于国际疾病分类第十版编码)的患者。结局随访至出院后2年,包括主要不良心血管事件(心脏骤停、全因死亡、再梗死、卒中或心力衰竭住院)(主要结局)和全因死亡(次要结局)。使用靶向最大似然估计来估计平均治疗效应,比较起始阿替洛尔与比索洛尔的患者。在11,558例患者中,1523例(13.2%)在出院后2天内起始阿替洛尔,10,035例(86.8%)起始比索洛尔。将阿替洛尔组与比索洛尔组比较,主要不良心血管事件的平均治疗效应为2.9个百分点(95%置信区间[CI],1.1-4.7),全因死亡的平均治疗效应为0.6个百分点(95%CI,-0.2至1.3)。阿替洛尔组和比索洛尔组发生主要不良心血管事件的加权比例分别为10.8%和14.1%。阿替洛尔组和比索洛尔组发生全因死亡的加权比例分别为1.4%和2.2%。在行政数据库中未记录提示存在心力衰竭特征的患者中,与比索洛尔相比,心肌梗死后起始阿替洛尔与2年时主要不良心血管事件风险较低相关,但与全因死亡无关。(由PRAIRIE等资助。)
Pharmacology & therapeutics IF 13.5 2026-10 PMID: 42471062
Standard modifiable cardiovascular risk factors (SMuRFs) and non-SMuRFs are commonly used for risk stratification and therapeutic guidance after ST-elevation myocardial infarction (STEMI) in the general population. Their prognostic relevance with a potential implication for pharmacological and therapeutic management in individuals with established diabetes remains uncertain. This systematic review with meta-analysis aimed to identify prognostic factors associated with mortality in individuals with diabetes and STEMI qualifying for potential therapeutic targets. Studies evaluating prognostic factors for mortality in individuals with diabetes after STEMI were included up to May 3, 2025. Data extraction was performed independently by two reviewers. Certainty of evidence (CoE) was evaluated (GRADE). Thirty-seven studies were included, of which 25 had a high risk of bias. Mortality after STEMI in individuals with diabetes was consistently associated with non-SMuRFs (age, female sex, chronic kidney disease), acute cardiac dysfunction (Killip class III-IV, heart failure, cardiogenic shock), and atherosclerosis extent (anterior infarction, prior myocardial infarction, peripheral vascular disease). Diabetes-specific risk factors, including glycemic control parameters and insulin treatment, were also associated with increased risk of mortality (low to very low CoE). Once diabetes is established, no increased risk of mortality was observed for traditional SMuRFs, such as hypertension, smoking status, dyslipidemia, and obesity. These findings highlight the need for therapeutic strategies beyond conventional risk factor modification, with emphasis on acute hemodynamic management, tailored pharmacotherapy, and optimized glycemic control in this high-risk population. REGISTRATION PROSPERo: CRD42022378193.
中文摘要:标准可调控心血管危险因素(SMuRFs)与非标准可调控危险因素(non-SMuRFs)常用于一般人群ST段抬高型心肌梗死(STEMI)后的风险分层和治疗指导。在已确诊糖尿病的个体中,这些因素与预后及药物治疗和治疗管理潜在意义的相关性仍不确定。本系统综述与meta分析旨在识别伴糖尿病STEMI患者中与死亡相关且可能作为潜在治疗靶点的预后因素。纳入截至2025年5月3日评估糖尿病个体STEMI后死亡预后因素的研究。由两名评价者独立提取数据。采用GRADE评估证据确定性(CoE)。共纳入37项研究,其中25项存在高偏倚风险。糖尿病个体STEMI后死亡始终与non-SMuRFs(年龄、女性、慢性肾脏病)、急性心功能障碍(Killip III–IV级、心力衰竭、心原性休克)及动脉粥样硬化范围(前壁心肌梗死、既往心肌梗死、外周血管疾病)相关。糖尿病特异性危险因素,包括血糖控制参数和胰岛素治疗,也与死亡风险增加相关(CoE低至极低)。在确诊糖尿病后,传统SMuRFs(如高血压、吸烟状况、血脂异常和肥胖)未观察到死亡风险增加。这些发现强调,需要超越传统危险因素干预的治疗策略,重点是在这一高危人群中实施急性血流动力学管理、个体化药物治疗和优化血糖控制。注册号:PROSPERO:CRD42022378193。

基础研究 (10篇)

Cell discovery IF 16.9 2026-10-06 PMID: 42838936
Myocardial fibrosis is a common pathological feature that affects the outcome of various heart diseases, typically in the context of myocardial infarction (MI). The role of T cells in heart failure has been increasingly recognized, but whether programmed cell death protein 1 (PD1+) T cells modulate cardiac fibrosis during the post-MI pathological remodeling process remains unclear. Single-cell RNA sequencing and mass cytometry were conducted to determine the proportion of PD1+ T cells in both human ischemic diseases and a mouse MI model. Bulk RNA sequencing and cytokine arrays were used to investigate the function of PD1+ T cells. Cardiac function and histology were evaluated in non-human primates and rodents post-MI. We observed significant enrichment of PD1+ T cells in the heart after MI, which was positively associated with cardiac fibroblast activation and, hence, collagen secretion. Unlike in tumors, PD1+ T cells in the heart after MI demonstrated activated characteristics. PD1 knockout mice exhibited reduced cardiac fibrosis, resulting in increased cardiac performance following MI. Mechanistically, activated PD1+ T cells were found to drive fibrosis remodeling by modulating the CXCL9/CXCR3 axis through direct interaction with cardiac fibroblasts - an effect that occurred independently of the PD1/programmed death-ligand 1 (PD-L1) signaling pathway. Notably, anti-PD1 therapy in both mouse and non-human primate MI models effectively attenuated fibrosis and improved cardiac function without eliciting detectable adverse effects in non-cardiac organs. Our findings reveal a distinct PD-L1-independent pro-fibrotic mechanism mediated by PD1+ T cells during post-MI cardiac remodeling. Therapeutic inhibition of PD1+ T cells effectively suppressed fibrosis progression, highlighting its potential as an immunotherapeutic target for post-MI cardiac repair.
中文摘要:心肌纤维化是一种常见病理特征,影响多种心脏疾病的结局,典型见于心肌梗死(MI)背景。T细胞在心力衰竭中的作用日益受到认识,但程序性细胞死亡蛋白1(PD1+)T细胞是否在MI后病理重构过程中调控心脏纤维化仍不清楚。研究采用单细胞RNA测序和质谱流式细胞术,检测人类缺血性疾病和小鼠MI模型中PD1+ T细胞的比例。利用bulk RNA测序和细胞因子阵列研究PD1+ T细胞的功能。在MI后的非人灵长类动物和啮齿动物中评估心脏功能和组织学。我们观察到MI后心脏中PD1+ T细胞显著富集,其与心脏成纤维细胞活化及因此的胶原分泌正相关。与肿瘤中不同,MI后心脏中的PD1+ T细胞表现出活化特征。PD1敲除小鼠显示心脏纤维化减少,从而在MI后心脏功能增强。机制上,活化的PD1+ T细胞通过直接与心脏成纤维细胞相互作用,经CXCL9/CXCR3轴驱动纤维化重构——该效应独立于PD1/程序性死亡配体1(PD-L1)信号通路。值得注意的是,在小鼠和非人灵长类MI模型中,抗PD1治疗均有效减轻纤维化并改善心脏功能,且未在非心脏器官中引发可检测的不良反应。我们的发现揭示了MI后心脏重构中由PD1+ T细胞介导的一种独特的、不依赖PD-L1的促纤维化机制。治疗性抑制PD1+ T细胞有效抑制纤维化进展,突显其作为MI后心脏修复免疫治疗靶点的潜力。
Cardiovascular research IF 12.5 2026-10-06 PMID: 42836375
Infarct macrophages undergo dramatic phenotypic changes in response to cytokines and growth factors and serve as central effectors in cardiac repair and remodeling. Transforming Growth Factor (TGF)-β superfamily members are key regulators of macrophages and signal predominantly through activation of Smad-dependent cascades. Although the involvement of TGF-β/Smad3 in regulation of macrophage phenotype has been documented, the effects of Smad1 signaling on macrophage phenotype and function remain unknown. We aimed at examining the patterns of activation and role of macrophage Smad1 in repair and remodeling of the infarcted heart. Macrophage Smad1 activation peaked 7 days after infarction. In vitro, TGF-β1, TGF-β3 and Bone Morphogenetic Protein (BMP)-6, potently stimulated Smad1 activation in bone marrow macrophages. To study the role of macrophage Smad1 in myocardial infarction, we generated mice with myeloid cell-specific Smad1 loss. Bioinformatic analysis of scRNA-seq data suggested broad activation of a Smad1-mediated transcriptional program in all clusters of infarct macrophages. Myeloid cell-specific Smad1 loss attenuated post-infarction adverse remodeling and ventricular dysfunction, increasing angiogenesis and decreasing extracellular matrix denaturation. Proteomic and transcriptomic analysis suggested that acquisition of an angiogenic macrophage profile in the absence of Smad1 is associated with upregulation of the angiogenic mediators CXCL12 and osteopontin and attenuated expression of the angiostatic chemokine CXCL4. However, myeloid cell-specific CXCL12 deletion in MyS1KO mice did not abolish the enhanced angiogenesis induced by Smad1 deficiency, indicating that Smad1-mediated suppression of angiogenesis likely depends on the coordinated regulation of multiple angiogenic pathways rather than on CXCL12 alone. We demonstrate for the first time that macrophage Smad1 contributes to adverse post-infarction remodeling by regulating the balance between angiogenic and angiostatic signals and by enhancing extracellular matrix remodeling.
中文摘要:梗死心肌中的巨噬细胞响应细胞因子和生长因子发生显著表型变化,并在心脏修复和重塑中作为核心效应细胞。转化生长因子(TGF)-β超家族成员是巨噬细胞的关键调控因子,主要经Smad依赖性级联激活进行信号转导。尽管TGF-β/Smad3在调控巨噬细胞表型中的作用已有报道,但Smad1信号对巨噬细胞表型和功能的影响仍不清楚。我们旨在研究巨噬细胞Smad1在梗死心脏修复和重塑中的激活模式及作用。巨噬细胞Smad1激活在梗死后第7天达到峰值。体外实验中,TGF-β1、TGF-β3和骨形态发生蛋白(BMP)-6可强烈刺激骨髓巨噬细胞中Smad1激活。为研究巨噬细胞Smad1在心肌梗死中的作用,我们构建了髓系细胞特异性Smad1缺失小鼠。对scRNA-seq数据的生物信息学分析提示,梗死巨噬细胞所有细胞簇中Smad1介导的转录程序广泛激活。髓系细胞特异性Smad1缺失减轻梗死后不良重塑和心室功能障碍,增加血管生成并减少细胞外基质变性。蛋白质组学和转录组学分析提示,Smad1缺失时巨噬细胞获得促血管生成表型与促血管生成介质CXCL12和骨桥蛋白上调以及抗血管生成趋化因子CXCL4表达减弱相关。然而,在MyS1KO小鼠中髓系细胞特异性敲除CXCL12并未消除Smad1缺陷诱导的血管生成增强,表明Smad1介导的血管生成抑制可能依赖于多条血管生成通路的协调调控,而非仅依赖CXCL12。我们首次证明,巨噬细胞Smad1通过调节促血管生成与抗血管生成信号之间的平衡,并增强细胞外基质重塑,促进梗死后不良重塑。
Circulation IF 41.3 2026-10-06 PMID: 42610276
Metrnl (Meteorin-like) is a secreted protein that plays a pivotal role in regulating insulin sensitivity, angiogenesis, and atherosclerosis. The circulating Metrnl levels are mainly derived from the endothelium and associated with atherosclerosis and arterial thrombotic disease in patients. However, Metrnl effects on platelets and thrombosis are not yet fully understood. By using global Metrnl knockout mice, platelet-specific Metrnl knockout mice, recombinant Metrnl protein, and Metrnl-neutralizing antibody, combined with visualization techniques, we investigated the effects of Metrnl on human and rodent platelet activation in vitro, and thrombosis in vivo as well as its action mode. To screen and verify receptor-mediated mechanisms for Metrnl, we used immunoprecipitation-based mass spectrometry, protein-protein interaction tests, and functional assays under antagonist and knockout conditions. Receptor binding domains, functional sites, and downstream mechanisms were further explored using various protein mutations, specific interventions, and signaling examinations. A myocardial ischemia/reperfusion model was used to better understand the effects of Metrnl on microvascular thrombosis obstruction and acute myocardial injury. Metrnl deficiency potentiated thrombosis via platelet activation rather than coagulation or the fibrinolysis system. Exogenous Metrnl administration could directly inhibit platelet activation and thrombosis without causing bleeding risk when using Metrnl alone or in combination with clopidogrel. Metrnl in platelets also inhibited platelet activation and thrombosis in a secretory manner. In a molecular mechanism, CD36 was identified as a receptor for Metrnl on platelets. Metrnl induced CD36 degradation via interaction with a previously uncharacterized domain (amino acids 280-439) and acetylation at lysine 403 of CD36, thereby decreasing the downstream signaling pathway (SRC-extracellular signal-related kinase 5 [ERK5]) in platelets. Further, mouse model experiments demonstrated Metrnl protein's antiplatelet function in mitigating microvascular thrombosis and acute myocardial ischemia/reperfusion injury. We identify Metrnl in both endogenous secretion and exogenous administration as a novel inhibitor of platelet activation and thrombus formation without causing bleeding risk. Metrnl is a novel ligand for the CD36 receptor, which has a specific Metrnl binding domain. Metrnl inhibits platelet activation by promoting CD36 degradation via acetylation at lysine 403 of CD36. Metrnl holds promise to be a novel therapeutic target for thrombotic disease, such as in the treatment of acute myocardial infarction.
中文摘要:Metrnl(Meteorin样蛋白)是一种分泌蛋白,在调节胰岛素敏感性、血管生成和动脉粥样硬化中发挥关键作用。循环Metrnl水平主要来源于内皮,并与患者的动脉粥样硬化和动脉血栓性疾病相关。然而,Metrnl对血小板和血栓形成的影响尚未完全明确。通过使用全身Metrnl敲除小鼠、血小板特异性Metrnl敲除小鼠、重组Metrnl蛋白和Metrnl中和抗体,并结合可视化技术,我们在体外研究了Metrnl对人及啮齿动物血小板活化的影响,在体内研究了其对血栓形成的影响及其作用方式。为筛选并验证Metrnl的受体介导机制,我们采用基于免疫沉淀的质谱分析、蛋白-蛋白相互作用检测以及拮抗剂和敲除条件下的功能实验。利用多种蛋白突变体、特异性干预和信号通路检测,进一步探索了受体结合结构域、功能位点及下游机制。采用心肌缺血/再灌注模型,以更好地理解Metrnl对微血管血栓阻塞和急性心肌损伤的影响。Metrnl缺乏通过血小板活化而非凝血或纤溶系统增强血栓形成。外源性给予Metrnl可直接抑制血小板活化和血栓形成,单用Metrnl或与氯吡格雷联用时均不引起出血风险。血小板中的Metrnl也以分泌方式抑制血小板活化和血栓形成。在分子机制上,CD36被鉴定为血小板上的Metrnl受体。Metrnl通过与CD36一个此前未表征的结构域(氨基酸280-439)相互作用以及CD36第403位赖氨酸乙酰化,诱导CD36降解,从而降低血小板中的下游信号通路(SRC-细胞外信号相关激酶5 [ERK5])。此外,小鼠模型实验证明Metrnl蛋白具有抗血小板功能,可减轻微血管血栓形成和急性心肌缺血/再灌注损伤。我们确定,内源性分泌和外源性给予的Metrnl均是一种新型血小板活化和血栓形成抑制剂,且不引起出血风险。Metrnl是CD36受体的新型配体,CD36具有特异性Metrnl结合结构域。Metrnl通过促进CD36第403位赖氨酸乙酰化介导的CD36降解来抑制血小板活化。Metrnl有望成为血栓性疾病的新型治疗靶点,例如用于急性心肌梗死的治疗。
Cardiovascular research IF 12.5 2026-10-05 PMID: 42831433
Vascular endothelial growth factors (VEGFs) and their endothelial tyrosine kinase receptors are crucial mediators of vasculogenesis and angiogenesis, with FLT1 (VEGFR1) acting as a decoy receptor for VEGFs. Alternative polyadenylation (APA) of Flt1 transcripts produces a truncated mRNA transcript encoding soluble (s) FLT1, which contains only the extracellular ligand-binding domain. The relative roles of full-length (fl) FLT1 and sFLT1 in angiogenesis are incompletely understood. Alternative polyadenylation is an important post-transcriptional mechanism of gene regulation that is increasingly recognized to affect the expression of many genes related to cardiovascular diseases. However, there are no in vivo models available to target APA and to examine the physiological roles of gene isoforms. We here generated mice by introducing silent mutations into the Flt1 exon 13/intron 13 5' splice site through homology-directed repair with CRISPR/Cas9 gene editing. Embryonic development, postnatal retinal vascular development, and reparative angiogenesis were evaluated in models of hindlimb ischaemia and myocardial infarction, complemented by assessments of cardiac functional recovery and cell phenotypes through snRNAseq, as well as in vitro assays examining endothelial cell phenotype and function. The introduction of specific splice site mutations within Flt1 to activate APA led to a complete loss of flFLT1 and an increase in sFLT1 expression. Using this mouse model, we demonstrate that sFLT1 alone is sufficient for developmental vasculogenesis, whereas the specific loss of flFLT1 enhances reparative revascularization and angiogenesis and improves cardiac recovery after myocardial infarction. Our findings show that APA can be effectively targeted to modulate FLT1 isoform expression in vivo. Our mouse model may help to understand diseases driven by an imbalance in FLT1 isoform expression. Given the widespread presence of APA signals, our approach could furthermore serve as a model for studying the function of other truncated gene isoforms.
中文摘要:血管内皮生长因子(VEGFs)及其内皮酪氨酸激酶受体是血管发生和血管生成的关键介质,其中FLT1(VEGFR1)作为VEGFs的诱饵受体发挥作用。Flt1转录本的选择性多聚腺苷酸化(APA)可产生一种截短的mRNA转录本,编码仅含细胞外配体结合结构域的可溶性(s)FLT1。全长(fl)FLT1与sFLT1在血管生成中的相对作用尚不完全清楚。选择性多聚腺苷酸化是一种重要的转录后基因调控机制,日益被认为可影响许多与心血管疾病相关基因的表达。然而,目前尚无体内模型可用于靶向APA并研究基因异构体的生理作用。我们通过CRISPR/Cas9基因编辑的同源定向修复,在Flt1外显子13/内含子13的5'剪接位点引入沉默突变,从而构建了小鼠。我们在后肢缺血和心肌梗死模型中评估了胚胎发育、出生后视网膜血管发育和修复性血管生成,并通过snRNAseq评估心脏功能恢复和细胞表型,同时通过体外实验检测内皮细胞表型和功能。在Flt1内引入特异性剪接位点突变以激活APA,导致flFLT1完全缺失和sFLT1表达增加。利用该小鼠模型,我们证明仅sFLT1足以支持发育性血管发生,而flFLT1的特异性缺失可增强修复性血运重建和血管生成,并改善心肌梗死后的心脏恢复。我们的研究结果表明,APA可在体内被有效靶向以调节FLT1异构体表达。我们的小鼠模型可能有助于理解由FLT1异构体表达失衡驱动的疾病。鉴于APA信号广泛存在,我们的方法还可作为研究其他截短基因异构体功能的模型。
Biosensors & bioelectronics IF 11.8 2026-10-01 PMID: 42828861
Copeptin is a clinically relevant biomarker for early diagnosis and prognostic assessment of acute myocardial infarction (AMI). Traditional antibody-based assays suffer from long testing time, high cost and complicated operation. Herein, we first screened high-affinity copeptin aptamers under serum-mimicking conditions and built a sensitive fluorescent aptasensor using terminal deoxynucleotidyl transferase (TdT)-assisted signal amplification. After three rounds of capillary electrophoresis-based systematic evolution of ligands by exponential enrichment (CE-SELEX), six candidate aptamer sequences were obtained. Among them, Apt31, showed the highest binding affinity and was further truncated and optimized to generate Apt31-1, which had a dissociation constant of 19.8 nM. This represented an approximately 2.5-fold improvement in affinity compared with the original full-length aptamer. Using Apt31-1 as the recognition element, a fluorescent aptasensor was constructed by combining TdT-mediated poly(thymine) extension with copper nanoparticle generation. For copeptin detection in buffer and human serum, the sensor showed a linear detection range of 10-200 pg/mL and a low limit of detection of 2.9 pg/mL. The results also showed strong agreement with those obtained by ELISA, with a correlation coefficient of 0.9920. Overall, this study presents a sensitive aptamer-based strategy for copeptin detection and demonstrates the potential of combining serum-compatible aptamer screening with isothermal signal amplification for clinical biomarker analysis.
中文摘要:Copeptin是急性心肌梗死(AMI)早期诊断和预后评估的临床相关生物标志物。传统基于抗体的检测方法存在检测时间长、成本高和操作复杂等问题。在此,我们首先在模拟血清条件下筛选高亲和力的copeptin适配体,并构建了一种利用末端脱氧核苷酸转移酶(TdT)辅助信号放大的灵敏荧光适配体传感器。经过三轮基于毛细管电泳的指数富集配体系统进化(CE-SELEX),获得了六条候选适配体序列。其中,Apt31显示出最高的结合亲和力,并进一步被截短和优化以生成Apt31-1,其解离常数为19.8 nM。与原全长适配体相比,其亲和力提高了约2.5倍。使用Apt31-1作为识别元件,通过将TdT介导的聚胸腺嘧啶延伸与铜纳米颗粒生成相结合,构建了荧光适配体传感器。对于缓冲液和人血清中的copeptin检测,该传感器显示出10-200 pg/mL的线性检测范围和2.9 pg/mL的低检测限。结果还显示与ELISA获得的结果高度一致,相关系数为0.9920。总体而言,本研究提出了一种基于适配体的灵敏copeptin检测策略,并展示了将血清兼容的适配体筛选与等温信号放大相结合用于临床生物标志物分析的潜力。
Acta biomaterialia IF 10.4 2026-10 PMID: 42633815
The repair of tissue injuries involving complex inter-tissue interactions remains challenging because conventional biomaterials are usually designed to target individual tissues. This study focuses on heart-bone paracrine interactions and proposes a biomaterial-based strategy to modulate reciprocal communication between cardiac- and bone-related cells for tissue repair. We show that strontium silicate (SS) biomaterials release bioactive Sr2+ and Si species that promote the functional activation of encapsulated CMs and bone marrow stromal cells, while also reshaping their secretory profiles. Using 3D-bioprinted co-culture models and local implantation in rodent injury models, we demonstrate that SS-modulated BMSC-laden constructs promote cardiac repair after myocardial infarction, whereas SS-modulated CM-laden constructs enhance cranial bone regeneration. Mechanistically, these effects are associated with altered secretion of candidate paracrine factors, including IGF-1, SDF-1, and BMP-2, and functional involvement of PI3K/AKT and MAPK/ERK signaling pathways. These findings suggest that silicate biomaterials may act as upstream regulators of heart-bone paracrine interactions by combining transient ionic stimulation with secondary remodeling of cellular secretory profiles. This study provides a proof-of-concept strategy for biomaterial-regulated inter-tissue communication and tissue repair. STATEMENT OF SIGNIFICANCE: This study introduces the concept of using silicate biomaterials to facilitate beneficial communication between the heart and bone for coordinated repair. We demonstrate that strontium silicate releases bioactive ions and modulates key signaling factors (SDF-1, IGF-1, BMP-2), activating PI3K/AKT and MAPK/ERK pathways. This not only enhances cardiac function recovery but also promotes bone healing in rat disease models. To our knowledge, this is the first report demonstrating a single biomaterial orchestrating multi-organ interactive repair by targeting inter-organ crosstalk.
中文摘要:涉及复杂组织间相互作用的组织损伤修复仍具挑战性,因为传统生物材料通常被设计为仅针对单一组织。本研究聚焦于心-骨旁分泌相互作用,并提出一种基于生物材料的策略,用以调控心脏相关细胞与骨相关细胞之间的双向交流,从而促进组织修复。我们发现,硅酸锶(SS)生物材料可释放具有生物活性的Sr2+和Si组分,促进被包封的心肌细胞(CMs)与骨髓基质细胞的功能活化,同时重塑其分泌谱。借助三维生物打印共培养模型以及在啮齿类动物损伤模型中的局部植入,我们证明经SS调控的载骨髓基质细胞(BMSC)构建体可促进心肌梗死后的心脏修复,而经SS调控的载心肌细胞构建体则可增强颅骨再生。在机制上,这些效应与候选旁分泌因子(包括IGF-1、SDF-1和BMP-2)分泌的改变,以及PI3K/AKT和MAPK/ERK信号通路的功能性参与相关。这些发现提示,硅酸盐生物材料可能通过将短暂的离子刺激与细胞分泌谱的继发性重塑相结合,作为心-骨旁分泌相互作用的上游调控者。本研究为生物材料调控组织间交流与组织修复提供了一种概念验证性策略。意义声明:本研究引入了利用硅酸盐生物材料促进心脏与骨骼之间有益交流以实现协同修复的概念。我们证明硅酸锶可释放生物活性离子并调控关键信号因子(SDF-1、IGF-1、BMP-2),激活PI3K/AKT与MAPK/ERK通路。这不仅增强了大鼠疾病模型中的心脏功能恢复,也促进了骨愈合。据我们所知,这是首次报道单一生物材料通过靶向器官间串扰来协调多器官交互修复。
Ageing research reviews IF 15.5 2026-10 PMID: 42526842
Myocardial ischemia-reperfusion injury (MIRI) in patients with acute myocardial infarction (AMI) after thrombolytic therapy or percutaneous coronary intervention is one of the diseases with threatening health and increasing mortality. Despite decades of research, the precise mechanisms of MIRI remain incompletely understood. Ageing is considered one of the factors that exacerbate MIRI. Emerging evidence highlights that protein post‑translational modifications (PTMs) serve as critical regulators in the pathogenesis of MIRI, particularly during the ageing process, these modifications exhibit specific changes. PTMs mediate protein conformational changes to regulate cellular activity, mitochondrial function, antioxidant capacity and inflammatory response, thereby participating in the pathological progression of MIRI. Multiple PTMs occur simultaneously and exhibit synergistic or reciprocal effects. It is noteworthy that PTMs of the same protein may exert bidirectional effects in MIRI across different age stages. However, most current studies mainly focused on young subjects, systematic investigation of PTM networks in ageing‑related MIRI is far from comprehensive. This review systematically summarizes six common PTMs that play important roles in MIRI: glycosylation, lysine crotonylation (Kcr), lactylation, succinylation, acetylation, and isonicotinylation, compares their roles in the pathogenesis of MIRI at different age stages, elucidates the role of ageing-specific PTM remodeling in MIRI, and highlights related drugs and potential mechanisms. We aim to emphasize the potential value of ageing‑specific PTMs as innovative therapeutic targets for treating MIRI.
中文摘要:急性心肌梗死(AMI)患者在接受溶栓治疗或经皮冠状动脉介入治疗后发生的心肌缺血-再灌注损伤(MIRI),是威胁健康且死亡率不断升高的疾病之一。尽管经过数十年的研究,MIRI的确切机制仍未完全阐明。衰老被认为是加重MIRI的因素之一。新出现的证据强调,蛋白质翻译后修饰(PTMs)在MIRI发病机制中作为关键调控因子发挥作用,尤其在衰老过程中,这些修饰表现出特异性变化。PTMs通过介导蛋白质构象变化来调控细胞活性、线粒体功能、抗氧化能力和炎症反应,从而参与MIRI的病理进展。多种PTMs可同时发生,并表现出协同或相互影响。值得注意的是,同一蛋白质的PTMs在不同年龄阶段的MIRI中可能产生双向效应。然而,目前大多数研究主要集中于年轻受试者,对衰老相关MIRI中PTM网络的系统性研究仍远不全面。本综述系统总结了在MIRI中发挥重要作用的六种常见PTMs:糖基化、赖氨酸巴豆酰化(Kcr)、乳酸化、琥珀酰化、乙酰化和异烟酰化,比较了它们在不同年龄阶段MIRI发病机制中的作用,阐明了衰老特异性PTM重塑在MIRI中的作用,并重点介绍了相关药物及潜在机制。我们旨在强调衰老特异性PTMs作为治疗MIRI的创新性治疗靶点的潜在价值。
Redox biology IF 16.2 2026-10 PMID: 42501697
Myocardial ischemia-reperfusion injury (MIRI) is an inevitable pathophysiological response during the revascularization process following myocardial ischemia. Despite its clinical significance, effective targeted therapies for MIRI remain an unmet medical need. Mixed-lineage leukemia 4 (MLL4), a member of the SET family of histone methyltransferases, exhibits particular methyltransferase action toward histone H3 lysine 4 (H3K4). This study establishes a protective role for MLL4 in MIRI pathogenesis. Utilizing cardiomyocyte-specific Mll4 knockout mice and an in vivo ischemia-reperfusion (I/R) model induced by left anterior descending coronary artery ligation, we observed significant upregulation of MLL4 expression in cardiac tissue following I/R. Genetic ablation of Mll4 in cardiomyocytes markedly exacerbated both acute and chronic phases of MIRI. In vitro, Mll4 knockdown in neonatal rat cardiomyocytes (NRCMs) amplified mitochondrial dysfunction and apoptosis under hypoxia/reoxygenation (H/R) conditions. Integrated analysis of Cleavage Under Targets and Tagmentation sequencing (CUT&Tag-seq) and RNA sequencing (RNA-seq) revealed that Mll4 deficiency induces a pronounced reduction in H3K4 monomethylation (H3K4me1) and histone H3 lysine 27 acetylation (H3K27ac) enrichment at the Stat3 genomic locus. Mechanistically, MLL4 functions as a transcriptional activator of Stat3 by depositing H3K4me1 and H3K27ac, thereby facilitating STAT3 transcription. This regulatory cascade ultimately governs STAT3-dependent mitochondrial homeostasis. Collectively, these findings identify MLL4 as a critical epigenetic regulator of MIRI and suggest its therapeutic targeting may offer a promising strategy for mitigating reperfusion injury.
中文摘要:心肌缺血再灌注损伤(MIRI)是心肌缺血后血运重建过程中不可避免的病理生理反应。尽管具有重要临床意义,针对MIRI的有效靶向治疗仍是尚未满足的医疗需求。混合谱系白血病4(MLL4)是SET家族组蛋白甲基转移酶成员,对组蛋白H3第4位赖氨酸(H3K4)具有特殊甲基转移酶作用。本研究确立了MLL4在MIRI发病机制中的保护作用。利用心肌细胞特异性Mll4敲除小鼠以及左前降支冠状动脉结扎诱导的体内缺血再灌注(I/R)模型,我们观察到I/R后心脏组织中MLL4表达显著上调。心肌细胞中Mll4基因缺失显著加重了MIRI的急性期和慢性期。体外实验中,新生大鼠心肌细胞(NRCMs)中Mll4敲低在缺氧/复氧(H/R)条件下放大了线粒体功能障碍和凋亡。对靶向切割及转座酶测序(CUT&Tag-seq)和RNA测序(RNA-seq)的整合分析显示,Mll4缺失导致Stat3基因组位点上H3K4单甲基化(H3K4me1)和组蛋白H3第27位赖氨酸乙酰化(H3K27ac)富集显著减少。机制上,MLL4通过沉积H3K4me1和H3K27ac作为Stat3的转录激活因子,从而促进STAT3转录。这一调控级联最终控制STAT3依赖性线粒体稳态。总之,这些发现确定MLL4是MIRI的关键表观遗传调控因子,并提示靶向MLL4可能为减轻再灌注损伤提供有前景的策略。
Bioactive materials IF 23.6 2026-10 PMID: 42232747
Vascular organoids show great promise for promoting angiogenesis post-myocardial infarction, but current organoid culture methods only form capillaries in vitro, while relying on Matrigel faces challenges due to its undefined composition and potential immune reactions, which hinder clinical translation. To address this issue, a splenic extracellular matrix-derived thermoresponsive hydrogel (SpGel) with type I collagen was developed. This matrix has defined components, avoids the immune response triggered by viruses in Matrigel, and demonstrates the ability to enhance arterioles and capillary differentiation in blood vessel organoids. The gelation time of SpGel/col-I was comparable to that of typical Matrigel/col-I matrix. Additionally, SpGel/col-I significantly boosted angiogenesis of human blood vessel organoids compared to the Matrigel/col-I group. Single-cell sequencing revealed significant upregulation of ITGA5 and ITGB1 in the endothelial cell population within the SpGel/col-I group, and the increase in endothelial and mural cell differentiation was mainly associated with the VEGF and PDGFB signaling pathways. To verify the in vivo reparative effects, SpGel/col-I with hBVOs were co-transplanted into a myocardial infarction animal model and showed improved cardiac function, reduced myocardial fibrosis, and enhanced neovascularization. In summary, we successfully improved the differentiation of arterioles and capillaries in human blood vessel organoids with decellularized splenic matrix, providing an ideal therapeutic approach for repairing infarcted myocardium in clinical settings.
中文摘要:血管类器官在促进心肌梗死后血管新生方面展现出巨大前景,但目前的类器官培养方法在体外仅能形成毛细血管,而依赖 Matrigel 又因其成分不明确以及潜在的免疫反应而面临挑战,阻碍了临床转化。为解决这一问题,开发了一种来源于脾脏细胞外基质、含 I 型胶原的热响应性水凝胶(SpGel)。该基质成分明确,可避免 Matrigel 中病毒引发的免疫反应,并显示出增强血管类器官中微动脉和毛细血管分化的能力。SpGel/col-I 的凝胶时间与典型的 Matrigel/col-I 基质相当。此外,与 Matrigel/col-I 组相比,SpGel/col-I 显著促进了人血管类器官的血管新生。单细胞测序显示,SpGel/col-I 组内皮细胞群体中 ITGA5 和 ITGB1 显著上调,且内皮细胞和周细胞分化增加主要与 VEGF 和 PDGFB 信号通路相关。为验证体内修复效果,将 SpGel/col-I 与人血管类器官(hBVOs)共移植到心肌梗死动物模型中,结果显示心功能改善、心肌纤维化减少以及新生血管形成增强。总之,我们利用脱细胞脾脏基质成功改善了人血管类器官中微动脉和毛细血管的分化,为临床修复梗死心肌提供了一种理想的治疗策略。
Trends in biotechnology IF 16.6 2026-10 PMID: 42034537
Local myocardial delivery remains an unmet need in cardiovascular disease, as systemic therapies are hindered by cardiac motion, heterogeneous perfusion, and post-infarction extracellular matrix remodeling. Preclinical microneedle (MN) systems enable direct, localized, and sustained epicardial delivery of drugs, proteins, growth factors, and cells while minimizing systemic exposure. Recent studies have demonstrated tangible benefits: galunisertib-loaded MNs reduced fibrosis from ~14% to ~7%, and vascular endothelial growth factor (VEGF)-based MNs increased vascular density from ~0.2 to ~0.5 vessels per field. Mechanically adaptive and biodegradable MN platforms maintain stable contact with the beating heart and support programmable release profiles. This review synthesizes the current preclinical landscape of cardiac MN technologies and outlines the engineering and translational considerations that will guide their advancement toward future clinical applications.
中文摘要:局部心肌递送在心血管疾病中仍是一项未被满足的需求,因为全身治疗受到心脏运动、灌注异质性以及梗死后细胞外基质重塑的阻碍。临床前微针(MN)系统能够将药物、蛋白质、生长因子和细胞直接、局部且持续地递送至心外膜,同时尽量减少全身暴露。近期研究已显示出切实获益:负载galunisertib的微针将纤维化从约14%降低至约7%,基于血管内皮生长因子(VEGF)的微针使每视野血管数从约0.2增至约0.5。机械自适应且可生物降解的微针平台能够与跳动心脏保持稳定接触,并支持可编程释放曲线。本综述综合了当前心脏微针技术的临床前研究概况,并概述了将指导其迈向未来临床应用的相关工程学与转化考虑。

4心血管疾病 (9篇)

临床研究 (4篇)

Circulation IF 41.3 2026-10-06 PMID: 42691142
The American College of Cardiology/American Heart Association Scientific Statement, "Clinical Considerations for the Care of the Tactical Athlete With Cardiovascular Abnormalities," was written to provide guidance and education for clinicians caring for the tactical athlete (ie, firefighters, law enforcement officers, military) with cardiovascular disease or risk for cardiovascular disease, and for the organizations overseeing the care and wellness of these athletes. The considerations are shaped by the interaction between occupational demands and fit for full duty assessments, including risk discussions about how a cardiovascular event in a tactical athlete could impact teammates' well-being, community safety, and overall mission success. This scientific statement is organized into 11 sections focused on cardiovascular disease processes and other topics that are relevant when considering the potential risks and benefits of performing tasks specific to the tactical athlete. Task forces, comprised of experts in tactical athlete domains, sports cardiology, and the respective topics covered, were assigned to each section, and specific "Clinical Considerations Tables" for clinicians to reference were prepared. Comprehensive literature reviews and an emphasis on tactical athlete-focused data, as available, were integral in the writing of all clinical considerations presented. The framework mirrors that of the recently published, "Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology." The specific sections in this document include: Section 1: Tactical Tasks Classification; Section 2: The Tactical Athlete Preparticipation Cardiac Evaluation; Section 3: Ethical and Legal Aspects of Tactical Clinical Management; Section 4: Genetic Cardiomyopathies; Section 5: Myocarditis and Other Acquired Cardiac Conditions; Section 6: Congenital Heart Disease; Section 7: Aortopathy, Bicuspid Aortic Valve, and Spontaneous Coronary Artery Dissection; Section 8: Syncope, SCA, Arrhythmias, and Devices; Section 9: Cardiac Channelopathies; Section 10: Older Tactical Athlete; Section 11: Environmental Exposures, PED/S, and Additional Cardiac Conditions and Considerations. Each section provides a summary detailing the rationale for key clinical considerations and the respective Clinical Considerations Table(s).
中文摘要:美国心脏病学会/美国心脏协会科学声明《心血管异常战术运动员的临床照护考量》旨在为照护患有心血管疾病或存在心血管疾病风险的战术运动员(即消防员、执法人员、军人)的临床医生,以及负责这些运动员照护与健康管理的组织提供指导和宣教。相关考量受职业需求与全面执勤适任评估之间相互作用的影响,包括围绕战术运动员发生心血管事件可能如何影响队友健康、社区安全以及整体任务成功进行风险讨论。该科学声明分为11个部分,聚焦于在考虑战术运动员执行特定任务的潜在风险与获益时相关的心血管疾病过程及其他主题。每个部分均设立了由战术运动员领域、运动心脏病学及相应主题专家组成的工作组,并编制了供临床医生参考的具体「临床考量表」。全面的文献综述以及对可获得的战术运动员相关数据的重视,贯穿于所有临床考量的撰写过程。其框架与近期发布的《心血管异常运动员参加竞技体育的临床考量:美国心脏协会与美国心脏病学会科学声明》相似。本文件的具体部分包括:第1部分:战术任务分类;第2部分:战术运动员参与前心脏评估;第3部分:战术临床管理的伦理与法律问题;第4部分:遗传性心肌病;第5部分:心肌炎及其他获得性心脏疾病;第6部分:先天性心脏病;第7部分:主动脉病、二叶式主动脉瓣及自发性冠状动脉夹层;第8部分:晕厥、SCA、心律失常与器械;第9部分:心脏通道病;第10部分:年长战术运动员;第11部分:环境暴露、PED/S及其他心脏疾病与考量。每个部分均提供摘要,详述关键临床考量的依据及相应的临床考量表。
European heart journal IF 45.3 2026-10-05 PMID: 40838984
Cardiovascular (CV) diseases continue to cause substantial morbidity and mortality. Risk factors are inadequately controlled, compliance with medication remains suboptimal, and treatments are not sufficient to fully prevent the progression of atherosclerotic CV disease, heart failure, arrhythmias, and valvular heart diseases. An increased understanding of the genetic basis of CV diseases and advances in the technology of therapeutics have led to the development of nucleic acid-based therapies (NATs) for prevention and treatment of CV risk factors and diseases. Nucleic acid-based therapies can target disease pathways at the translational level preventing the formation of disease-causing proteins that could not be effectively targeted by other pharmacological therapeutics and will likely improve treatment adherence by providing long-acting effects over many months rather than daily treatment. These therapies include RNA-targeted therapeutics, gene editing therapeutics, and gene therapies. Challenges around the use of NATs may be unique with each new drug and new target and may include long-term unanticipated side effects, and issues around specificity, targeting, and stability. Assessing NATs for marketing approval continues to pose challenges for regulatory agencies. These include their diverse nature, limited data on pharmacology, clinical safety and efficacy, and the lack of long-term results. Barriers in clinical practice may include the lack of specific education, fear of off target effects, costs, and ethical challenges. Implementation of these novel therapies will require careful patient selection and education. Despite potentially high treatment costs, possible long-term cost savings could result from fewer healthcare visits due to infrequent NAT administrations, and lower rates of disease progression, hospitalization, and CV events due to sustained improvement in control of disease pathways and risk factors.
中文摘要:心血管(CV)疾病持续导致显著的发病率和死亡率。危险因素控制不充分,药物依从性仍不理想,且治疗不足以完全阻止动脉粥样硬化性心血管疾病、心力衰竭、心律失常和心脏瓣膜病的进展。对心血管疾病遗传基础认识的加深以及治疗技术的进步,促进了核酸类疗法(NATs)的发展,用于预防和治疗心血管危险因素和疾病。核酸类疗法可在翻译水平靶向疾病通路,阻止其他药物治疗无法有效靶向的致病蛋白形成,并可能通过提供持续数月的长效作用而非每日治疗来改善治疗依从性。这些疗法包括RNA靶向治疗、基因编辑治疗和基因治疗。NATs使用的挑战可能因每种新药和新靶点而异,可能包括长期未预见的副作用,以及围绕特异性、靶向性和稳定性的问题。评估NATs以获批上市仍给监管机构带来挑战。这些挑战包括其多样性、药理学数据有限、临床安全性和有效性数据有限以及缺乏长期结果。临床实践中的障碍可能包括缺乏专门教育、对脱靶效应的担忧、成本以及伦理挑战。实施这些新疗法需要仔细选择患者并进行教育。尽管治疗成本可能很高,但由于NATs给药不频繁而减少就医次数,并且由于对疾病通路和危险因素控制的持续改善而降低疾病进展、住院和心血管事件发生率,可能带来长期成本节约。
JAMA network open IF 11.7 2026-10-01 PMID: 42826016
Iatrogenic menopause is common, but its long-term cardiovascular consequences remain uncertain, particularly by age at menopause. To quantify associations between iatrogenic menopause and cardiovascular morbidity and mortality and evaluate whether age at iatrogenic menopause is a modifier. In this systematic review and meta-analysis, Scopus, MEDLINE, PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, and PsycINFO were searched from January 2004 to March 2026. Observational studies and randomized clinical trials reporting cardiovascular morbidity or mortality among women with iatrogenic menopause before natural menopause age compared with naturally menopausal or age-matched controls were included. Data were extracted in duplicate by 2 independent reviewers, with consensus resolution. The study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guideline. Primary outcomes were cardiovascular morbidity, cardiovascular and all-cause mortality, and a composite of cardiovascular morbidity and cardiovascular mortality, quantified as random-effects pooled hazard ratios (PHRs) with 95% CIs, irrespective of heterogeneity and with age at menopause as a moderator. Meta-regression estimates were clustered by source cohort. Of 14 409 records, 36 studies were included with 2 617 942 women (mean [SD] age, 55.52 [12.41] years for the iatrogenic menopause cohort and 45.58 [16.02] years for comparators); median follow-up was 16.0 years (range, 4.8-36.0 years). Iatrogenic menopause vs comparators was associated with higher risk of all-cause mortality (PHR, 1.08; 95% CI, 1.01-1.16), cardiovascular events (PHR, 1.25; 95% CI, 1.12-1.39), coronary heart disease (PHR, 1.48; 95% CI, 1.07-2.03), and stroke (PHR, 1.22; 95% CI, 1.15-1.28). Mortality excesses were confined to iatrogenic menopause before age 45 years (cardiovascular mortality: PHR, 1.20 [95% CI, 1.04-1.37]; all-cause mortality: PHR, 1.15 [95% CI, 1.06-1.25]), with null estimates at or after age 45 years (cardiovascular mortality: PHR, 0.95 [95% CI, 0.81-1.11]; all-cause mortality: PHR, 0.99 [95% CI, 0.89-1.09]). In a post hoc meta-regression on the composite outcome, each increasing 5-year increment in age at iatrogenic menopause was associated with lower risk (HR, 0.89; 95% CI, 0.83-0.97) based on 37 estimates from 11 independent populations. In this study, iatrogenic menopause was associated with higher cardiovascular morbidity, most consistently stroke, and with cardiovascular and all-cause mortality excesses before age 45 years at menopause. Older age at iatrogenic menopause was associated with progressively lower risk of cardiovascular morbidity and mortality, supporting a period of elevated risk before age 45 years rather than a single threshold age.
中文摘要:医源性绝经较常见,但其长期心血管后果仍不确定,尤其是按绝经年龄分层时。旨在量化医源性绝经与心血管疾病发病率和死亡率之间的关联,并评估医源性绝经年龄是否为效应修饰因素。在这项系统综述和荟萃分析中,检索了Scopus、MEDLINE、PubMed、Embase、Cochrane对照试验中央注册库(CENTRAL)、CINAHL和PsycINFO,时间范围为2004年1月至2026年3月。纳入报告在自然绝经年龄之前发生医源性绝经的女性与自然绝经或年龄匹配对照相比心血管发病率或死亡率的研究,包括观察性研究和随机临床试验。数据由2名独立评价员双人提取,并通过共识解决分歧。本研究遵循系统综述和荟萃分析优先报告条目(PRISMA)报告指南。主要结局为心血管发病率、心血管死亡率和全因死亡率,以及心血管发病率与心血管死亡率的复合结局,以随机效应合并风险比(PHR)及95% CI进行量化,不考虑异质性,并以绝经年龄作为调节因素。荟萃回归估计按来源队列进行聚类。在14 409条记录中,纳入36项研究,共2 617 942名女性(医源性绝经队列平均[SD]年龄为55.52[12.41]岁,对照组为45.58[16.02]岁);中位随访时间为16.0年(范围4.8-36.0年)。与对照组相比,医源性绝经与更高的全因死亡率(PHR,1.08;95% CI,1.01-1.16)、心血管事件(PHR,1.25;95% CI,1.12-1.39)、冠心病(PHR,1.48;95% CI,1.07-2.03)和卒中(PHR,1.22;95% CI,1.15-1.28)风险相关。死亡率超额仅局限于45岁前发生医源性绝经者(心血管死亡率:PHR,1.20[95% CI,1.04-1.37];全因死亡率:PHR,1.15[95% CI,1.06-1.25]),而在45岁或之后绝经者估计值为无效(心血管死亡率:PHR,0.95[95% CI,0.81-1.11];全因死亡率:PHR,0.99[95% CI,0.89-1.09])。在对复合结局进行的事后荟萃回归中,基于来自11个独立人群的37个估计值,医源性绝经年龄每增加5岁与风险降低相关(HR,0.89;95% CI,0.83-0.97)。在本研究中,医源性绝经与更高的心血管发病率相关,其中卒中最为一致,并且与45岁前绝经的心血管死亡率和全因死亡率超额相关。医源性绝经年龄越大,心血管发病率和死亡率风险逐渐降低,支持45岁前存在风险升高期,而非单一阈值年龄。
EClinicalMedicine IF 12.8 2026-10 PMID: 42751178
Women veterans are a growing-yet understudied-population with a high psychiatric and cardiovascular disease (CVD) risk burden. This study evaluated the association of posttraumatic stress disorder (PTSD) with a wide range of incident CVD outcomes in a large, nationally representative cohort of women veterans. In this retrospective longitudinal study, Veterans Health Administration (VHA) electronic health records were used to identify women veterans aged ≥18 years receiving care from 1/1/2000 to 12/31/2019 in the USA. Women with prior CVD at baseline were excluded. Participants with PTSD (n = 101,448) were matched 1:1 to women without PTSD on demographic, clinical, and healthcare utilization factors. Diagnoses were based on International Classification of Diseases codes. Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for associations of PTSD with an incident CVD composite (IHD, stroke/transient ischemic attack [TIA], heart failure [HF], atrial fibrillation, peripheral arterial disease, pulmonary hypertension [PHTN], venous thromboembolism [VTE], and aortic valve stenosis [AS]), and each component outcome. The analytic sample comprised 202,896 women veterans (mean age = 39.1 years). Over approximately 6 years of follow-up, PTSD was associated with a greater rate of developing the CVD composite (HR = 1.24, 95% CI: 1.20-1.28). PTSD was also associated with greater incidence of IHD (HR = 1.30, 95% CI: 1.23-1.37), stroke/TIA (HR = 1.29, 95% CI: 1.21-1.38), HF (HR = 1.10, 95% CI: 1.02-1.18), PHTN (HR = 1.17, 95% CI: 1.02-1.35), VTE (HR = 1.34, 95% CI: 1.23-1.45), and AS (HR = 1.23, 95% CI: 1.03-1.46). Particularly strong associations were observed in women <40 years and in American Indian/Alaska Native and Hispanic/Latina women. PTSD is associated with a broad spectrum of CVD outcomes in women veterans. Results also indicate associations of PTSD with PHTN and AS, novel outcomes in the PTSD-CVD literature-including in women veterans. Targeted studies are needed to better understand underlying mechanisms. This research was funded by a grant from the Department of Defense Office of Congressionally Directed Medical Research Programs.The funder had no role in the study design, data collection, analysis, interpretation, or writing of the manuscript.
中文摘要:女性退伍军人是一个不断增长但研究不足的人群,其精神和心血管疾病(CVD)风险负担较高。本研究在一个大型、具有全国代表性的女性退伍军人队列中,评估了创伤后应激障碍(PTSD)与多种新发CVD结局的关联。在这项回顾性纵向研究中,使用退伍军人健康管理局(VHA)电子健康记录,识别2000年1月1日至2019年12月31日期间在美国接受医疗服务的年龄≥18岁女性退伍军人。基线时既往有CVD的女性被排除。将患有PTSD的参与者(n=101,448)与无PTSD的女性按人口学、临床和医疗服务利用因素进行1:1匹配。诊断基于国际疾病分类编码。Cox比例风险模型估计了PTSD与新发CVD复合结局(缺血性心脏病[IHD]、卒中/短暂性脑缺血发作[TIA]、心力衰竭[HF]、心房颤动、外周动脉疾病、肺动脉高压[PHTN]、静脉血栓栓塞[VTE]和主动脉瓣狭窄[AS])以及各组成结局关联的风险比(HR)和95%置信区间(CI)。分析样本包括202,896名女性退伍军人(平均年龄=39.1岁)。在约6年随访期间,PTSD与更高的CVD复合结局发生风险相关(HR=1.24,95%CI:1.20-1.28)。PTSD还与IHD(HR=1.30,95%CI:1.23-1.37)、卒中/TIA(HR=1.29,95%CI:1.21-1.38)、HF(HR=1.10,95%CI:1.02-1.18)、PHTN(HR=1.17,95%CI:1.02-1.35)、VTE(HR=1.34,95%CI:1.23-1.45)和AS(HR=1.23,95%CI:1.03-1.46)的发生率升高相关。在<40岁女性以及美洲印第安人/阿拉斯加原住民和西班牙裔/拉丁裔女性中观察到特别强的关联。PTSD与女性退伍军人中广泛CVD结局相关。结果还表明PTSD与PHTN和AS相关,这些是PTSD-CVD文献中的新结局,包括在女性退伍军人中。需要针对性研究以更好地理解潜在机制。本研究由美国国防部国会指导医学研究计划办公室资助。资助方在研究设计、数据收集、分析、解释或手稿撰写中均无作用。

基础研究 (5篇)

Ageing research reviews IF 15.5 2026-10-07 PMID: 42843463
Alternative splicing is a fundamental post-transcriptional mechanism that contributes to cardiovascular development, homeostasis, and disease. Serine/arginine-rich splicing factors (SRSFs), a conserved family of 12 RNA-binding proteins, regulate splice-site selection and other RNA-processing events through their RNA-recognition motifs and arginine/serine-rich domains. Growing evidence implicates SRSF dysregulation in congenital heart disease, cardiac hypertrophy and heart failure, ischemic injury, vascular remodeling, inflammatory myocardial injury, and cardiovascular aging. In this review, we summarize the structural characteristics, cardiovascular expression patterns, and physiological functions of SRSFs, and discuss their context-dependent roles across cardiovascular diseases. We further examine regulatory mechanisms involving phosphorylation, target-specific RNA processing, interactions with other cardiac splicing regulators, and non-coding RNAs. Finally, we evaluate emerging small-molecule and gene- or RNA-based strategies targeting SRSFs and highlight major barriers to translation, including target specificity, delivery, causal validation, and safety. These advances provide a framework for defining disease-relevant SRSF networks and prioritizing mechanistically supported therapeutic targets in cardiovascular disease.
中文摘要:可变剪接是一种基本的转录后机制,参与心血管发育、稳态和疾病。富含丝氨酸/精氨酸的剪接因子(SRSFs)是一个由12种RNA结合蛋白组成的保守家族,通过其RNA识别基序和富含精氨酸/丝氨酸的结构域调控剪接位点选择及其他RNA加工事件。越来越多证据表明,SRSF失调与先天性心脏病、心脏肥大和心力衰竭、缺血性损伤、血管重塑、炎症性心肌损伤以及心血管衰老有关。在本综述中,我们总结SRSFs的结构特征、心血管表达模式和生理功能,并讨论其在不同心血管疾病中依赖背景的作用。我们进一步探讨涉及磷酸化、靶标特异性RNA加工、与其他心脏剪接调节因子的相互作用以及非编码RNA的调控机制。最后,我们评估针对SRSFs的新兴小分子以及基于基因或RNA的策略,并强调转化面临的主要障碍,包括靶标特异性、递送、因果验证和安全性。这些进展为界定与疾病相关的SRSF网络并优先考虑心血管疾病中有机制支持的治疗靶点提供了框架。
Pharmacological research IF 12.2 2026-10 PMID: 42674122
Host-microbiota co-metabolism of tryptophan is increasingly recognized as a critical nexus linking diet, gut microbiota, immune function, serving as a core regulatory network governing cardiovascular function and systemic homeostasis. Its catabolism in vivo mainly proceeds through three distinct pathways: the kynurenine pathway, the serotonin pathway, and the gut microbiota-mediated indole pathway. Tryptophan metabolites exert multifaceted physiological and pathophysiological effects on the cardiovascular system via diverse specific receptors and non-receptor signaling pathways. Numerous clinical and basic studies have confirmed that the tryptophan metabolic network plays a dual role in the progression of cardiovascular diseases (CVDs), including atherosclerosis, myocardial ischemia/reperfusion injury, and heart failure. However, existing studies have largely focused on individual pathways or isolated metabolites, and an integrated, systematic view of the entire tryptophan metabolic network in CVDs remains lacking. This review summarizes the tryptophan metabolic pathways, the physiological effects of tryptophan metabolites including potential therapeutic targets, and their impacts on cardiovascular diseases. Furthermore, based on the complex pathophysiological regulatory mechanisms of tryptophan metabolism, we systematically elaborate therapeutic strategies including dietary intervention, gut microbiota modulation, and targeted pharmacological intervention against rate-limiting enzymes and core receptors. These multidimensional approaches hold promise for reshaping the tryptophan metabolic axis and providing novel therapeutic paradigms for the management and treatment of CVDs.
中文摘要:宿主与微生物群对色氨酸的共代谢日益被认为是一个连接饮食、肠道菌群和免疫功能的关键枢纽,并作为调控心血管功能和全身稳态的核心调节网络。色氨酸在体内分解代谢主要经由三条不同途径进行:犬尿氨酸途径、血清素途径以及肠道菌群介导的吲哚途径。色氨酸代谢物通过多种特异性受体和非受体信号通路对心血管系统发挥多方面的生理和病理生理效应。大量临床和基础研究已证实,色氨酸代谢网络在心血管疾病(CVDs)进展中发挥双重作用,包括动脉粥样硬化、心肌缺血/再灌注损伤和心力衰竭。然而,现有研究大多聚焦于单个途径或孤立代谢物,对CVDs中整个色氨酸代谢网络的整合性、系统性认识仍然缺乏。本综述总结了色氨酸代谢途径、色氨酸代谢物的生理效应(包括潜在治疗靶点)及其对心血管疾病的影响。此外,基于色氨酸代谢复杂的病理生理调控机制,我们系统阐述了治疗策略,包括饮食干预、肠道菌群调节,以及针对限速酶和核心受体的靶向药物干预。这些多维度方法有望重塑色氨酸代谢轴,并为CVDs的管理和治疗提供新的治疗范式。
Ageing research reviews IF 15.5 2026-10 PMID: 42476320
Cytoskeleton is an important component of cell structure and function. In the cardiovascular system, it is involved in the remodeling process of a variety of cardiovascular diseases, including cardiac fibrosis, valvular disease, atrial fibrillation, thoracic aortic aneurysm and vascular stiffness related changes. Recent studies have shown that there is a significant synergy between cytoskeletal regulation and epigenetic processes. Notably, epigenetic alterations have been identified as one of the core features of ageing, a major risk factor for cardiovascular disease. Together, these factors regulate the fate determination, function maintenance and pathological transformation of cardiovascular cells. This review focuses on how age-related epigenetic changes, such as DNA methylation, histone modifications, and chromatin remodeling, directly affect cytoskeletal dynamics and nuclear mechanics, and ultimately lead to cardiovascular remodeling. This review systematically summarizes the key molecular pathways that drive pathological remodeling of cardiomyocytes during contraction, phenotypic switching of vascular smooth muscle cells, and activation of fibroblasts. In addition, we discuss potential therapeutic targets, biomarkers, and intervention strategies in this rapidly evolving field to address current challenges and identify future directions for research in order to lay the theoretical foundation for precision medicine in cardiovascular disease.
中文摘要:细胞骨架是细胞结构和功能的重要组成部分。在心血管系统中,它参与多种心血管疾病的重塑过程,包括心脏纤维化、瓣膜病、心房颤动、胸主动脉瘤以及血管僵硬相关改变。近期研究表明,细胞骨架调控与表观遗传过程之间存在显著的协同作用。值得注意的是,表观遗传改变已被确定为衰老的核心特征之一,而衰老是心血管疾病的主要危险因素。这些因素共同调控心血管细胞的命运决定、功能维持和病理转化。本综述聚焦于年龄相关的表观遗传改变,如DNA甲基化、组蛋白修饰和染色质重塑,如何直接影响细胞骨架动力学和细胞核力学,并最终导致心血管重塑。本综述系统总结了在心肌细胞收缩、血管平滑肌细胞表型转换以及成纤维细胞激活过程中驱动病理性重塑的关键分子通路。此外,我们讨论了这一快速发展领域中潜在的治疗靶点、生物标志物和干预策略,以应对当前挑战并确定未来研究方向,从而为心血管疾病的精准医学奠定理论基础。
Journal of advanced research IF 17.1 2026-10 PMID: 41720159
Pericytes, as critical mural cells of the vascular wall, play multifaceted and context-dependent roles in maintaining vascular integrity, regulating microcirculatory homeostasis, and mediating interactions between the vasculature and surrounding tissues. Beyond their canonical functions in vascular stabilization and angiogenesis, recent preclinical and clinical studies have increasingly implicated pericyte dysfunction in the pathogenesis of various cardiovascular diseases (CVDs), including atherosclerosis, myocardial ischemia-reperfusion (I/R) injury, pulmonary arterial hypertension (PAH), and ischemic stroke. This review aims to comprehensively collate and analyze recent progress in understanding pericyte biology in major CVDs. Specifically, it determines the core roles of pericytes in atherosclerosis based on mediating plaque neovascularization, promoting plaque instability via detachment or pro-inflammatory activation, myocardial I/R injury based on regulating microvascular permeability, participating in post-infarction fibrosis and vascular repair), PAH based on abnormal proliferation and differentiation leading to pulmonary vascular remodeling, and ischemic stroke based on maintaining blood-brain barrier integrity, modulating neurovascular unit repair. By integrating evidence from preclinical models such as lineage-tracing mice, disease-specific animal models and clinical samples, this review elucidates the common and disease-specific mechanisms linking pericyte dysfunction to CVD pathogenesis, and highlights the therapeutic promise of targeting pericyte biology. Key scientific concepts explored include the interplay between pericyte phenotypic plasticity and microenvironmental cues, the role of pericyte-endothelial cell crosstalk in vascular homeostasis and dysfunction, and the clinical relevance of pericyte subpopulation heterogeneity. Ultimately, this work provides novel mechanistic insights into CVD progression and offers a framework for advancing pericyte-directed therapeutic development, bridging the gap between basic research and clinical application to improve outcomes for patients with cardiovascular disorders.
中文摘要:周细胞作为血管壁关键的壁细胞,在维持血管完整性、调控微循环稳态以及介导血管与周围组织之间的相互作用中发挥多方面的、依赖背景的作用。除在血管稳定和血管生成中的经典功能外,近期临床前和临床研究日益提示周细胞功能障碍参与多种心血管疾病(CVD)的发病机制,包括动脉粥样硬化、心肌缺血再灌注(I/R)损伤、肺动脉高压(PAH)和缺血性卒中。本综述旨在全面汇总和分析理解主要CVD中周细胞生物学的最新进展。具体而言,本文确定周细胞在动脉粥样硬化中的核心作用基于介导斑块新生血管形成、通过脱离或促炎激活促进斑块不稳定;在心肌I/R损伤中的核心作用基于调控微血管通透性、参与梗死后纤维化和血管修复;在PAH中的核心作用基于异常增殖和分化导致肺血管重塑;在缺血性卒中中的核心作用基于维持血脑屏障完整性、调节神经血管单元修复。通过整合来自谱系追踪小鼠等临床前模型、疾病特异性动物模型和临床样本的证据,本综述阐明将周细胞功能障碍与CVD发病机制联系起来的共同机制和疾病特异性机制,并强调靶向周细胞生物学的治疗前景。探讨的关键科学概念包括周细胞表型可塑性与微环境线索之间的相互作用、周细胞-内皮细胞串扰在血管稳态和功能障碍中的作用,以及周细胞亚群异质性的临床相关性。最终,本工作为CVD进展提供新的机制见解,并为推进周细胞导向的治疗开发提供框架,弥合基础研究与临床应用之间的差距,以改善心血管疾病患者的结局。
Journal of advanced research IF 17.1 2026-10 PMID: 41490839
Lysine lactylation has redefined lactate's biological role from a metabolic byproduct to a signaling molecule. This post-translational modification directly couples cellular energetics with gene regulation, creating a metabolic-epigenetic axis particularly relevant to cardiovascular pathophysiology. Ischemic and inflammatory stress drive glycolytic reprogramming and lactate accumulation in these diseases. Lactylation modifies both histone and non-histone proteins, enabling metabolic states to reshape chromatin accessibility and protein function. However, therapeutic translation faces critical barriers. These include incomplete characterization of the cardiovascular lactylome, absence of selective pharmacological modulators, and insufficient understanding of how lactylation effects vary across cell types, disease stages, and metabolic contexts. We systematically dissect lactylation biology across 5 cardiovascular pathologies to define regulatory mechanisms and therapeutic vulnerabilities. We examine glycolysis-lactylation circuits driving pulmonary arterial smooth muscle hyperproliferation in hypertension; dual roles in atherosclerotic plaque stability versus calcification; M2 macrophage-mediated repair versus fibrotic remodeling in myocardial infarction; the metabolic paradox of lactate accumulation with reduced α-myosin heavy chain lactylation impairing contractility in heart failure; and neonatal glycolytic metabolism enabling histone lactylation-driven cardiomyocyte proliferation with metabolic barriers in diabetic contexts. Key Scientific Concepts of Review: Lactylation functions through dual substrates: histone modifications orchestrate inflammatory resolution and cell cycle activation, while non-histone modifications (α-myosin heavy chain, Snail1) directly govern contractility and pathological remodeling. Context-dependent dichotomies emerge across diseases, with protective angiogenesis versus maladaptive fibrosis in infarction and plaque stabilization versus calcification in atherosclerosis. Critically, metabolic paradoxes challenge lactate-lactylation correlations: heart failure shows lactate accumulation yet reduced modification, while diabetic advanced glycation end-products competitively inhibit lactylation. Therapeutic strategies require integrating metabolic reprogramming, site-selective targeting, and temporal control. This review systematically dissects these mechanistic complexities to establish a translational framework that guides precision cardiovascular medicine through metabolic-epigenetic intervention strategies.
中文摘要:赖氨酸乳酰化重新定义了乳酸的生物学角色,使其从代谢副产物转变为信号分子。这种翻译后修饰直接将细胞能量代谢与基因调控相偶联,形成一条代谢-表观遗传轴,尤其与心血管病理生理学相关。缺血性和炎症性应激驱动这些疾病中的糖酵解重编程和乳酸蓄积。乳酰化修饰组蛋白和非组蛋白,使代谢状态能够重塑染色质可及性和蛋白质功能。然而,治疗转化面临关键障碍。这些障碍包括心血管乳酰化组特征描述不完整、缺乏选择性药理学调节剂,以及对乳酰化效应如何随细胞类型、疾病阶段和代谢背景变化理解不足。我们系统剖析5种心血管病理中的乳酰化生物学,以明确调控机制和治疗易感性。我们考察高血压中驱动肺动脉平滑肌过度增殖的糖酵解-乳酰化回路;动脉粥样硬化斑块稳定性与钙化中的双重作用;心肌梗死中M2巨噬细胞介导的修复与纤维化重塑;心力衰竭中乳酸蓄积而α-肌球蛋白重链乳酰化降低并损害收缩力的代谢悖论;以及新生儿糖酵解代谢通过组蛋白乳酰化驱动心肌细胞增殖,而在糖尿病背景下存在代谢障碍。本综述的关键科学概念:乳酰化通过双重底物发挥作用:组蛋白修饰协调炎症消退和细胞周期激活,而非组蛋白修饰(α-肌球蛋白重链、Snail1)直接调控收缩力和病理性重塑。疾病间呈现背景依赖性二分现象,如心肌梗死中保护性血管新生与适应不良性纤维化,以及动脉粥样硬化中斑块稳定与钙化。关键的是,代谢悖论挑战了乳酸-乳酰化相关性:心力衰竭显示乳酸蓄积但修饰减少,而糖尿病晚期糖基化终产物竞争性抑制乳酰化。治疗策略需要整合代谢重编程、位点选择性靶向和时间控制。本综述系统剖析这些机制复杂性,以建立通过代谢-表观遗传干预策略指导精准心血管医学的转化框架。

5高血压 (7篇)

临床研究 (5篇)

European journal of preventive cardiology IF 10.0 2026-10-01 PMID: 42817173
Preeclampsia is associated with future cardiovascular disease (CVD), yet systematic approaches to identify those requiring intensified prevention are lacking. We aimed to characterise these women and identify subgroups at particularly high risk of later chronic hypertension or CVD. Using Danish nationwide registries, we followed primiparous women with preeclampsia who gave birth during 2004-2018 until December 2022. Using Poisson regression models we estimated incidence rate ratios (IRR) of later chronic hypertension or CVD. Of 17,434 women with preeclampsia, 2,372 developed chronic hypertension and 373 developed CVD. Early-onset preeclampsia was more common among those who later developed chronic hypertension (13.3% vs. 7.4%) or CVD (12.1% vs. 8.1%). Higher IRs of both outcomes (IRRs [95% CI] for chronic hypertension and CVD, respectively) were found for smoking in pregnancy (1.20 [1.05-1.36]; 1.24 [0.86-1.80]), gestational diabetes (1.36 [1.19-1.56]; 1.25 [0.80-1.94]), pre-existing type 1 diabetes (2.09 [1.57-2.78]; 1.89 [0.77-4.59]) and type 2 diabetes (1.47 [0.93-2.33]; 1.47 [0.36-6.01]), and low education (1.50 [1.31-1.72]; 2.77 [1.92-3.98]). The regions with the highest IRR differed between outcomes, and IRs were higher than among Danish-born women for some regions and lower for others. IRs also increased with higher BMI and age, more steeply above 25 kg/m2 and 40 years. Early-onset preeclampsia, smoking, co-existing diabetes, certain ethnic origins, lower educational level, higher maternal age at delivery, and pre-pregnancy BMI ≥ 25 kg/m2 were identified as risk factors for later chronic hypertension or CVD among women with preeclampsia.
中文摘要:子痫前期与未来心血管疾病(CVD)相关,但目前缺乏系统性方法来识别需要强化预防的女性。我们旨在描述这些女性的特征,并识别后续慢性高血压或CVD风险特别高的亚组。利用丹麦全国登记资料,我们随访了2004—2018年分娩的子痫前期初产妇,直至2022年12月。我们使用泊松回归模型估计后续慢性高血压或CVD的发病率比(IRR)。在17,434例子痫前期女性中,2,372例发生慢性高血压,373例发生CVD。早发型子痫前期在后续发生慢性高血压(13.3% vs. 7.4%)或CVD(12.1% vs. 8.1%)的女性中更常见。两种结局的IR均较高(慢性高血压和CVD的IRR [95% CI]分别如下):妊娠期吸烟(1.20 [1.05-1.36];1.24 [0.86-1.80])、妊娠期糖尿病(1.36 [1.19-1.56];1.25 [0.80-1.94])、孕前1型糖尿病(2.09 [1.57-2.78];1.89 [0.77-4.59])和2型糖尿病(1.47 [0.93-2.33];1.47 [0.36-6.01]),以及低教育水平(1.50 [1.31-1.72];2.77 [1.92-3.98])。IRR最高的地区因结局不同而异,某些地区的IR高于丹麦出生女性,而另一些地区则较低。IR还随BMI和年龄升高而增加,超过25 kg/m2和40岁时上升更陡。早发型子痫前期、吸烟、合并糖尿病、某些族裔来源、较低教育水平、分娩时母亲年龄较高以及孕前BMI ≥ 25 kg/m2,被确定为子痫前期女性后续慢性高血压或CVD的危险因素。
Stroke IF 11.1 2026-10 PMID: 42741835
Early-life vascular risk factors are increasingly linked to midlife cognitive decline, though critical risk periods remain unclear. These factors also relate to structural brain changes, yet midlife alterations tied to cognitive decline are poorly defined. We leveraged data from the CARDIA study (Coronary Artery Risk Development in Young Adults) to identify critical periods and factors associated with midlife cognition and neuroimaging signatures. We utilized longitudinal cognitive and neuroimaging data from the prospective CARDIA study with vascular risk factor data spanning 35 years (1985-2020). K-means clustering of cognitive trajectories identified Declined and Stable clusters. A gradient boosting classifier identified factors predictive of cluster membership. Linear mixed-effects models assessed cluster differences in structural brain changes, and structural covariance analyses identified brain network remodeling linked to cognitive decline. Cross-sectional late-midlife cognitive data were used to examine associations between early adulthood (ages 18-40 years) systolic blood pressure strata and cognitive outcomes. Among 280 participants with longitudinal data (mean age, 50±3.5 years at baseline; 52% to 56% female, 40% to 41% Black race) followed for a median of 10 years, higher systolic blood pressure and smoking before age 40 years were critical factors for cognitive cluster membership in late midlife (feature importance ≈0.3 and 0.2, respectively). Accelerated accumulation of white matter hyperintensities, gray matter volume changes involving frontal and temporal association cortices, occipital pole and thalamus (β range, -0.0006 to -0.002; P≤0.02), and network-level reorganization predominantly involving the basal forebrain spanning early- to late-midlife distinguished clusters. A stepwise, dose-dependent association between early-life systolic blood pressure strata and late-midlife cognitive performance was replicated in 720 participants (mean age, 61±3.5 years). Before age 40 years may be a critical window to manage vascular risk factors and preserve midlife cognition. Linked white matter hyperintensity and gray matter changes suggest that vascular factors drive both cerebrovascular and neurodegenerative injury. A basal forebrain-centered neuroimaging signature, possibly reflecting cholinergic and glial responses to early vascular stress, may serve as an early biomarker for prevention trials.
中文摘要:早期生命阶段的血管危险因素与中年认知下降的关联日益受到关注,但关键风险期仍不明确。这些因素也与脑结构改变相关,然而与认知下降相关的中年期改变仍定义不清。我们利用CARDIA研究(青年冠状动脉风险发展研究)的数据,以识别与中年认知和神经影像特征相关的关键期和因素。我们使用了前瞻性CARDIA研究的纵向认知和神经影像数据,以及跨越35年(1985-2020年)的血管危险因素数据。对认知轨迹进行K均值聚类,识别出下降组和稳定组。梯度提升分类器识别出可预测聚类归属的因素。线性混合效应模型评估了聚类间脑结构改变的差异,结构协方差分析识别出与认知下降相关的脑网络重塑。使用横断面中年晚期认知数据,检验成年早期(18-40岁)收缩压分层与认知结局之间的关联。在280名有纵向数据的参与者中(基线平均年龄50±3.5岁;52%至56%为女性,40%至41%为黑人),中位随访10年,40岁前较高的收缩压和吸烟是中年晚期认知聚类归属的关键因素(特征重要性分别约为0.3和0.2)。白质高信号加速累积、涉及额叶和颞叶联合皮层、枕极和丘脑的灰质体积改变(β范围-0.0006至-0.002;P≤0.02),以及主要涉及基底前脑的网络层面重组,从成年早期到中年晚期区分了这些聚类。在720名参与者中(平均年龄61±3.5岁)重复验证了早期生命阶段收缩压分层与中年晚期认知表现之间逐步、剂量依赖的关联。40岁前可能是管理血管危险因素并保护中年认知的关键窗口。相关的白质高信号和灰质改变提示,血管因素同时驱动脑血管和神经退行性损伤。以基底前脑为中心的神经影像特征可能反映对早期血管应激的胆碱能及胶质反应,或可作为预防试验的早期生物标志物。
Pharmacological research IF 12.2 2026-10 PMID: 42669336
Kidney transplantation (KT) remains the optimal treatment for kidney failure, improving survival and quality of life. However, long-term graft outcomes have plateaued, largely due to transplant CKD and cardiovascular disease; agents such as mineralocorticoid receptor antagonists (MRAs) may help mitigate these risks. Mineralocorticoid receptor (MR) overactivation contributes to oxidative stress, inflammation, and fibrosis in both the heart and kidneys, suggesting a potential role for mineralocorticoid receptor antagonists (MRAs) in improving long-term patient and graft outcomes. Although evidence in KT is limited, MR blockade may offer clinical benefits by targeting aldosterone-mediated pathways. Proteinuria promotes sodium reabsorption in the aldosterone-sensitive distal nephron via epithelial sodium channels (ENaC), contributing to hypertension and volume overload. MRAs have been shown to reduce albuminuria and blood pressure in patients with diabetic nephropathy, even on background renin-angiotensin-aldosterone system (RAAS) blockade. The use of MRAs post-KT should be individualized, considering patient comorbidities and concomitant immunosuppressive therapy. While MRAs may provide cardiovascular and antiproteinuric benefits, the risk of hyperkalemia-though reduced with non-steroidal MRAs-must be carefully managed.
中文摘要:肾移植(KT)仍是肾衰竭的最佳治疗方法,可改善生存率和生活质量。然而,长期移植物结局已趋于平台,主要归因于移植后慢性肾脏病(CKD)和心血管疾病;盐皮质激素受体拮抗剂(MRAs)等药物可能有助于减轻这些风险。盐皮质激素受体(MR)过度激活可导致心脏和肾脏的氧化应激、炎症和纤维化,提示盐皮质激素受体拮抗剂(MRAs)可能在改善患者和移植物长期结局方面发挥作用。尽管在KT中的证据有限,但MR阻断可能通过靶向醛固酮介导的通路提供临床获益。蛋白尿通过上皮钠通道(ENaC)促进醛固酮敏感性远端肾单位的钠重吸收,导致高血压和容量超负荷。在糖尿病肾病患者中,即使已接受肾素-血管紧张素-醛固酮系统(RAAS)阻断背景治疗,MRAs也已被证明可减少白蛋白尿并降低血压。KT后使用MRAs应个体化,需考虑患者合并症和同时使用的免疫抑制治疗。虽然MRAs可能提供心血管和抗蛋白尿获益,但高钾血症风险——尽管非甾体类MRAs可降低该风险——必须谨慎管理。
Drugs IF 14.7 2026-10 PMID: 42625106
Baxdrostat (BAXFENDY™) is a first-in-class, highly selective and potent aldosterone synthase inhibitor being developed by AstraZeneca for the treatment of hypertension, chronic kidney disease (CKD) and primary aldosteronism, and for the prevention of heart failure. On 15 May 2026, baxdrostat received its first approval in the USA for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure (BP) in adults who are not adequately controlled on other agents. This article summarizes the milestones in the development of baxdrostat leading to this first approval for hypertension.
中文摘要:巴克斯司他(Baxdrostat,BAXFENDY™)是一种首创、高选择性且强效的醛固酮合酶抑制剂,由阿斯利康开发,用于治疗高血压、慢性肾脏病(CKD)和原发性醛固酮增多症,并用于预防心力衰竭。2026年5月15日,巴克斯司他于美国首次获批,用于与其他降压药联合治疗高血压,以降低其他药物控制不佳的成人患者的血压。本文概述了巴克斯司他在开发过程中迈向此次高血压首次获批的里程碑事件。
Blood IF 23.9 2026-10-01 PMID: 42485768
Complement-mediated thrombotic microangiopathy can be difficult to recognize when it presents in the setting of an apparent clinical trigger, such as pregnancy, severe hypertension, or kidney transplantation. These conditions can each cause endothelial injury directly but may also unmask complement dysregulation in susceptible individuals. In these situations, the critical question is not whether a trigger exists but whether it fully explains the syndrome and whether urgent complement blockade is warranted to prevent irreversible kidney injury. In this How I Treat article, we use 3 real-world cases to illustrate how we approach this decision in practice. We emphasize the bedside features that most influence our threshold to treat, including the pattern and severity of kidney injury, tempo of disease progression, and lack of improvement with supportive or trigger-directed care. We also address the interpretation of complement genetic findings, pregnancy- and transplant-specific risk stratification, and the individualization of treatment duration. Functional assays can support mechanistic assessment in selected cases but remain an adjunct to diagnosis and should not drive management decisions.
中文摘要:补体介导的血栓性微血管病在出现于明显的临床触发因素(如妊娠、严重高血压或肾移植)背景下时可能难以识别。这些情况均可直接导致内皮损伤,但也可能在易感个体中揭示补体调节异常。在这些情况下,关键问题不是是否存在触发因素,而是它能否完全解释该综合征,以及是否需要紧急补体阻断以防止不可逆的肾损伤。在这篇「How I Treat」文章中,我们通过3个真实病例来说明我们在实践中如何作出这一决策。我们强调最影响治疗门槛的床旁特征,包括肾损伤的模式和严重程度、疾病进展的速度,以及支持治疗或针对触发因素的治疗后缺乏改善。我们还讨论补体遗传学发现的解读、妊娠和移植特异性的风险分层,以及治疗时长的个体化。功能性检测可在部分病例中支持机制评估,但仍只是诊断的辅助手段,不应驱动管理决策。

基础研究 (2篇)

Food chemistry IF 10.4 2026-10-01 PMID: 42537539
The growing demand for multifunctional bioactive peptides has sparked interest in underutilized marine by-products as sustainable bioresources. This study explored Alaska Pollock (Gadus chalcogrammus) milt protein as a novel source of peptides with anti-inflammatory, anti-hypertensive, and anti-diabetic effects. Protein composition was analyzed via LC-MS, followed by in silico digestion and bioactivity prediction. Molecular docking identified peptides targeting DPP-IV, α-glucosidase, ACE, GLP-1 receptor, COX-2, MuRF1, and the 20S proteasome. Among the candidates, a promising peptide (CLPPH) was synthesized and validated in vitro, demonstrating inhibitory effects on nitric oxide production, DPP-IV, ACE, and α-glucosidase. These results highlight CLPPH's potential as a multifunctional bioactive peptide and support the valorization of Alaska Pollock milt as a sustainable source for functional foods and nutraceutical applications.
中文摘要:对多功能生物活性肽日益增长的需求,激发了人们对未充分利用的海洋副产物作为可持续生物资源的兴趣。本研究探索了阿拉斯加鳕鱼(Gadus chalcogrammus)鱼白蛋白作为具有抗炎、抗高血压和抗糖尿病作用的新型肽来源。通过LC-MS分析蛋白质组成,随后进行计算机模拟消化和生物活性预测。分子对接鉴定出靶向DPP-IV、α-葡萄糖苷酶、ACE、GLP-1受体、COX-2、MuRF1和20S蛋白酶体的肽。在候选肽中,合成了一种有前景的肽(CLPPH)并在体外验证,证明其对一氧化氮生成、DPP-IV、ACE和α-葡萄糖苷酶具有抑制作用。这些结果凸显了CLPPH作为多功能生物活性肽的潜力,并支持将阿拉斯加鳕鱼鱼白增值利用为功能性食品和营养保健品应用的可持续来源。
Kidney international IF 21.8 2026-10 PMID: 42508606
Thrombotic microangiopathy (TMA) is classically defined by the triad of hemolytic anemia, thrombocytopenia, and organ injury, most notably kidney involvement. Secondary TMA, which arises in association with specific diseases or external triggers, is more common than primary or complement-mediated TMA. Current evidence supports an important role for complement activation in the pathogenesis of secondary TMA, and emerging data highlight the contribution of the endothelial glycocalyx to complement dysregulation at the endothelial surface. The endothelial glycocalyx is an integrated matrix lining the luminal aspect of endothelial cells and plays a central role in maintaining endothelial homeostasis and preventing thrombosis. Its unique structure may represent a missing mechanistic link in several forms of secondary TMA that are relevant to children, including pneumococcal-associated TMA, Shiga toxin-producing Escherichia coli hemolytic uremic syndrome, calcineurin inhibitor-associated TMA, and hypertension-associated TMA. This mini review summarizes current evidence and understanding of the central role of the endothelial glycocalyx in these conditions and discusses the implications for future therapeutic innovation.
中文摘要:血栓性微血管病(TMA)经典定义为溶血性贫血、血小板减少和器官损伤三联征,最突出的是肾脏受累。继发性TMA与特定疾病或外部触发因素相关而发生,比原发性或补体介导性TMA更为常见。当前证据支持补体激活在继发性TMA发病机制中起重要作用,新出现的数据强调内皮糖萼在内皮表面补体失调中的贡献。内皮糖萼是覆盖于内皮细胞腔面的一体化基质,在维持内皮稳态和预防血栓形成中发挥核心作用。其独特结构可能代表若干与儿童相关的继发性TMA形式中缺失的机制环节,包括肺炎球菌相关TMA、产志贺毒素大肠埃希菌溶血性尿毒综合征、钙调神经磷酸酶抑制剂相关TMA以及高血压相关TMA。本小型综述总结上述疾病中内皮糖萼核心作用的当前证据与认识,并讨论其对未来治疗创新的意义。

6冠心病/心绞痛 (6篇)

临床研究 (2篇)

Cardiovascular research IF 12.5 2026-10-07 PMID: 42841236
Among women with suspected ischaemia and non-obstructive coronary artery disease (INOCA), the temporal effect of combination intensive medical treatment (IMT) with angiotensin-converting enzyme inhibitors or receptor blockers, statins, and aspirin on coronary plaque composition is not known. This prospective ancillary study examined changes in atherosclerotic plaque volumes and composition (percentage of total plaque volume) over time between IMT and usual care (UC). Participants from the randomized WARRIOR trial with the presence of plaque on their first coronary computed tomography angiography (CCTA) were enrolled for a follow-up CCTA at least 2 years after randomization. Volumes and volumetric composition (percentage of total plaque volume) of non-calcified plaque (NCP), low-density NCP (LD-NCP, defined as NCP <30 HU), and calcified plaque (CP) were quantified over the coronary tree in the serial scans.Participants (n = 186) completed both scans with good image quality (94 IMT arm and 92 UC arm). Overall mean age was 61.0 years (SD ±10.9), and there were no statistically significant differences in baseline risk factors, plaque volumes, or statin treatment between the arms.There was a greater bi-annualized increase in CP volume [ΔCP volume (mm3)] in the IMT arm, 6.2 (SD ±15.5) compared to the UC arm, 3.9 (SD ±16.0), P = 0.013, and a consistent greater reduction in NCP composition [ΔNCP composition (%)] in the IMT arm, -3.9 (SD ±7.7) compared to the UC arm, -1.5 (SD ±5.8), P = 0.003, with no increase in total plaque volume. In women with suspected INOCA, IMT reduces NCP volumetric composition to a greater extent than UC and may promote plaque stabilization.
中文摘要:在疑似缺血且存在非阻塞性冠状动脉疾病(INOCA)的女性中,联合强化药物治疗(IMT)——即血管紧张素转换酶抑制剂或受体阻滞剂、他汀类药物和阿司匹林——对冠状动脉斑块成分随时间变化的影响尚不清楚。这项前瞻性辅助研究考察了IMT与常规治疗(UC)之间动脉粥样硬化斑块体积和成分(占总斑块体积的百分比)随时间的变化。来自随机WARRIOR试验、首次冠状动脉计算机断层血管造影(CCTA)显示存在斑块的参与者被纳入,在随机分组至少2年后接受随访CCTA。在系列扫描中对整个冠状动脉树的非钙化斑块(NCP)、低密度NCP(LD-NCP,定义为NCP <30 HU)和钙化斑块(CP)的体积及体积成分(占总斑块体积的百分比)进行定量。参与者(n=186)完成了两次图像质量良好的扫描(IMT组94例,UC组92例)。总体平均年龄为61.0岁(标准差±10.9),两组之间在基线危险因素、斑块体积或他汀类药物治疗方面无统计学显著差异。IMT组CP体积的两年一次增加幅度更大[ΔCP体积(mm3)]为6.2(标准差±15.5),而UC组为3.9(标准差±16.0),P=0.013;IMT组NCP成分的降低幅度始终更大[ΔNCP成分(%)]为-3.9(标准差±7.7),而UC组为-1.5(标准差±5.8),P=0.003,且总斑块体积未增加。在疑似INOCA的女性中,IMT较UC更大程度地降低NCP体积成分,并可能促进斑块稳定。
Diabetes care IF 22.6 2026-10-01 PMID: 42579565
To determine whether soluble urokinase plasminogen activator receptor (suPAR) is modified by randomized diabetes and revascularization strategies in patients with type 2 diabetes and coronary artery disease and whether combined suPAR and hs-CRP classification refines residual cardiovascular risk stratification. In this ancillary analysis of Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D), we measured plasma suPAR and hs-CRP at baseline (n = 2,277) and 1 year (landmark cohort, n = 1,978). The primary outcome was all-cause death, nonfatal myocardial infarction, or nonfatal stroke. Associations were assessed using sequentially adjusted Cox models. Over 1 year, suPAR was not reduced by diabetes (insulin sensitizing vs. insulin provision) or cardiac (revascularization vs. medical therapy) treatment strategies (median 2.96-3.15 ng/mL; all-treatment arm P ≥ 0.75), while hs-CRP declined substantially (median 2.07-1.30 mg/L). suPAR independently predicted the composite outcome (adjusted hazard ratio [HR] 1.40 per SD; 95% CI 1.27-1.55), unattenuated after hs-CRP adjustment. In an exploratory analysis, suPAR modified the diabetes treatment effect (P-interaction = 0.005), with insulin provision associated with worse outcomes in the highest suPAR tertile (HR 1.33; 95% CI 1.03-1.72). Baseline suPAR predicted risk in participants whose hs-CRP normalized (HR 1.45; 95% CI 1.04-2.03). Joint classification revealed a threefold gradient in event rates (7.1% to 21.6%), with elevated suPAR conferring excess risk even after hs-CRP normalization. Over 1 year, suPAR was unmodified by diabetes or revascularization strategies in BARI 2D despite intensive guideline-directed medical optimization, in contrast to hs-CRP, which declined substantially. Combined suPAR and hs-CRP classification produced a graded risk hierarchy that hs-CRP normalization alone did not resolve.
中文摘要:旨在确定可溶性尿激酶型纤溶酶原激活物受体(suPAR)是否会受到2型糖尿病合并冠状动脉疾病患者随机接受的糖尿病治疗和血运重建策略的影响,以及联合suPAR与高敏C反应蛋白(hs-CRP)分类是否能细化残余心血管风险分层。在这项BARI 2D(Bypass Angioplasty Revascularization Investigation 2 Diabetes)辅助分析中,我们检测了基线(n=2277)和1年时(里程碑队列,n=1978)的血浆suPAR和hs-CRP。主要结局为全因死亡、非致死性心肌梗死或非致死性卒中。采用序贯校正Cox模型评估相关性。1年间,suPAR未因糖尿病治疗策略(胰岛素增敏 vs. 胰岛素供给)或心脏治疗策略(血运重建 vs. 药物治疗)而降低(中位数2.96-3.15 ng/mL;所有治疗组P≥0.75),而hs-CRP显著下降(中位数2.07-1.30 mg/L)。suPAR独立预测复合结局(校正风险比[HR]为每SD 1.40;95%CI 1.27-1.55),在校正hs-CRP后未减弱。在一项探索性分析中,suPAR改变了糖尿病治疗效应(交互作用P=0.005),在最高suPAR三分位组中,胰岛素供给与更差结局相关(HR 1.33;95%CI 1.03-1.72)。基线suPAR可预测hs-CRP恢复正常参与者的风险(HR 1.45;95%CI 1.04-2.03)。联合分类显示事件率存在三倍梯度(7.1%至21.6%),即使在hs-CRP恢复正常后,suPAR升高仍带来额外风险。在BARI 2D中,尽管进行了强化的指南导向药物治疗优化,1年间suPAR未因糖尿病或血运重建策略而改变,这与hs-CRP显著下降形成对比。联合suPAR和hs-CRP分类产生了hs-CRP恢复正常本身无法消除的分级风险层次。

基础研究 (4篇)

Circulation IF 41.3 2026-10-06 PMID: 42836285
Angiogenesis is essential for the recovery of ischemic hearts with coronary artery disease (CAD). PGPC (1-palmitoyl-2-glutamyl-sn-glycero-3-phosphocholine) is a major phospholipid oxidation product in atherosclerotic lesions. Autophagy participates in angiogenesis. However, whether PGPC affects angiogenesis in ischemic hearts by regulating autophagy remains unclear. Plasma PGPC concentrations were quantified and the effects of PGPC on angiogenesis were evaluated in cultured endothelial cells and in vivo using a subcutaneous Matrigel plug assay, as well as in hindlimb ischemia and myocardial infarction models in C57BL/6J mice. Autophagic flux and the expression and modification of proteins associated with autophagy and angiogenesis were also assessed. Plasma PGPC levels were increased in patients with CAD, and they were positively correlated with the severity of CAD and negatively correlated with coronary collateral artery formation. PGPC inhibited endothelial cell migration and tube formation. PGPC suppressed neovascularization in Matrigel plugs and reduced blood flow recovery in hindlimb ischemia. In a mouse model of myocardial infarction, PGPC attenuated angiogenesis in the ischemic myocardium. These proangiogenic effects induced by VEGFA (vascular endothelial growth factor A) in ischemic hearts were significantly inhibited by PGPC. Mechanistically, PGPC inhibited the expression of STX17 (syntaxin 17), a crucial molecule that controls autophagosomal-lysosomal fusion by promoting the acetylation and subsequent ubiquitination and degradation of STX17. PGPC upregulated the expression of NPC1 (NPC intracellular cholesterol transporter 1) through CD36 (cluster of differentiation 36). NPC1 not only promoted the acetylation and subsequent ubiquitination and degradation of STX17 through the recruitment of ACAT1 (acetyl-CoA acetyltransferase 1), but also competed with STX17 to bind VAMP8 (vesicle-associated membrane protein 8), leading to inhibition of the expression of eNOS (endothelial nitric oxide synthase), ERK1/2 (extracellular signal-regulated kinase 1/2), and nitric oxide production. Oxidized phospholipid-neutralizing antibody E06, STX17 overexpression, or silencing of NPC1 reversed the inhibitory effect of PGPC on angiogenesis by restoring autophagic flux. PGPC promotes the acetylation and subsequent ubiquitin-mediated degradation of STX17 by increasing NPC1, leading to a reduction in the level of STX17 associated with VAMP8, which inhibits autophagosomal-lysosomal fusion and angiogenesis. Targeting PGPC, NPC1, or STX17 may represent novel therapeutic approaches to promote angiogenesis in patients with CAD.
中文摘要:血管新生对于合并冠状动脉疾病(CAD)的缺血心脏恢复至关重要。PGPC(1-棕榈酰-2-谷氨酰-sn-甘油-3-磷酸胆碱)是动脉粥样硬化病变中的一种主要磷脂氧化产物。自噬参与血管新生。然而,PGPC是否通过调节自噬影响缺血心脏中的血管新生仍不清楚。我们定量了血浆PGPC浓度,并在培养的内皮细胞中以及体内通过皮下基质胶栓实验,还在C57BL/6J小鼠后肢缺血和心肌梗死模型中评估了PGPC对血管新生的影响。同时评估了自噬流以及自噬和血管新生相关蛋白的表达与修饰。CAD患者血浆PGPC水平升高,且与CAD严重程度正相关,与冠状动脉侧支动脉形成负相关。PGPC抑制内皮细胞迁移和管腔形成。PGPC抑制基质胶栓中的新生血管化,并减少后肢缺血中的血流恢复。在小鼠心肌梗死模型中,PGPC减弱缺血心肌中的血管新生。缺血心脏中由VEGFA(血管内皮生长因子A)诱导的这些促血管生成效应被PGPC显著抑制。机制上,PGPC抑制STX17(突触融合蛋白17)的表达,而STX17是通过促进其乙酰化及随后的泛素化和降解来控制自噬体-溶酶体融合的关键分子。PGPC通过CD36(分化簇36)上调NPC1(NPC细胞内胆固醇转运蛋白1)的表达。NPC1不仅通过招募ACAT1(乙酰辅酶A乙酰转移酶1)促进STX17的乙酰化及随后的泛素化和降解,还与STX17竞争结合VAMP8(囊泡相关膜蛋白8),导致eNOS(内皮型一氧化氮合酶)、ERK1/2(细胞外信号调节激酶1/2)表达和一氧化氮产生受到抑制。氧化磷脂中和抗体E06、STX17过表达或沉默NPC1通过恢复自噬流逆转了PGPC对血管新生的抑制作用。PGPC通过增加NPC1促进STX17的乙酰化和随后的泛素介导降解,导致与VAMP8结合的STX17水平降低,从而抑制自噬体-溶酶体融合和血管新生。靶向PGPC、NPC1或STX17可能代表促进CAD患者血管新生的新治疗策略。
Cardiovascular research IF 12.5 2026-10-06 PMID: 42834504
Epicardial adipose tissue (EAT) has emerged as an active regulator of cardiovascular disease, yet the cellular and molecular features of myocardial-associated EAT (mEAT) in coronary artery disease (CAD) remain incompletely defined. We performed single-nucleus RNA sequencing of mEAT from patients with CAD (n = 9), nonCAD cardiovascular surgery patients (n = 9), and forensic controls without cardiac disease (n = 2), integrated with histology, CT-based EAT volume assessment, matched right atrial myocardium analysis, and functional in vitro assays. mEAT contained diverse adipocyte, stromal, immune, and vascular cell populations. In CAD, we identified two disease-enriched inflammatory cell states, inflammatory adipogenic cells (IAC) and inflammatory stromal cells (ISC), characterized by immune activation, stress-response signalling, extracellular matrix remodelling, and impaired adipogenic features. Histological analyses confirmed enlarged adipocytes, increased fibrosis, and higher abundance of IAC/ISC-associated markers in CAD-mEAT. Exploratory integration with CT imaging suggested a possible association between increased EAT volume and enrichment of inflammatory cell states. Comparative analyses with published adipose and cardiac single-cell datasets indicated that IAC and ISC share features with previously described inflammatory adipocyte and stromal populations, while displaying a distinct marker combination enriched in CAD-associated mEAT.Cell-cell communication analyses identified THBS1-CD36 and SEMA4A/SEMA3C-NRP1/PLXNA signalling as predicted CAD-associated communication axes involving inflammatory mEAT populations and myocardial cell types. Conditioned medium from CAD-mEAT-derived adipocytes/IAC altered contractile properties of human iPSC-derived cardiomyocyte (CM) microtissues, while simultaneously impairing endothelial tube formation and migration. Recombinant THBS1 and SEMA3C partially recapitulated selected effects, whereas combined CD36 and NRP1 blockade partially attenuated endothelial and CM responses. Together, these data provide a high-resolution map of CAD-associated mEAT remodelling and identify IAC and ISC as inflammatory cell states linked to altered adipose-vascular and adipose-myocardial signalling. These findings support the concept that cellular and molecular features of mEAT may complement imaging-based EAT assessment and inform future studies on CAD-associated adipose tissue inflammation.
中文摘要:心外膜脂肪组织(EAT)已成为心血管疾病的主动调节因素,但冠状动脉疾病(CAD)中心肌相关EAT(mEAT)的细胞和分子特征仍未完全明确。我们对来自CAD患者(n=9)、非CAD心血管手术患者(n=9)以及无心脏病的法医对照(n=2)的mEAT进行了单核RNA测序,并整合了组织学、基于CT的EAT体积评估、配对的右心房心肌分析以及体外功能实验。mEAT包含多种脂肪细胞、基质、免疫和血管细胞群体。在CAD中,我们鉴定出两种疾病富集的炎症细胞状态,即炎症性成脂细胞(IAC)和炎症性基质细胞(ISC),其特征为免疫激活、应激反应信号、细胞外基质重塑和成脂特征受损。组织学分析证实CAD-mEAT中脂肪细胞增大、纤维化增加,且IAC/ISC相关标志物丰度更高。与CT影像的探索性整合提示,EAT体积增加与炎症细胞状态富集之间可能存在关联。与已发表的脂肪和心脏单细胞数据集的比较分析表明,IAC和ISC与先前描述的炎症性脂肪细胞和基质细胞群体具有共同特征,同时表现出在CAD相关mEAT中富集的独特标志物组合。细胞间通讯分析鉴定出THBS1-CD36和SEMA4A/SEMA3C-NRP1/PLXNA信号是预测的CAD相关通讯轴,涉及炎症性mEAT群体和心肌细胞类型。来自CAD-mEAT来源脂肪细胞/IAC的条件培养基改变了人iPSC来源心肌细胞(CM)微组织的收缩特性,同时损害内皮管形成和迁移。重组THBS1和SEMA3C部分重现了部分效应,而联合CD36和NRP1阻断部分减弱了内皮和CM反应。总之,这些数据提供了CAD相关mEAT重塑的高分辨率图谱,并鉴定出IAC和ISC为与脂肪-血管和脂肪-心肌信号改变相关的炎症细胞状态。这些发现支持以下概念:mEAT的细胞和分子特征可能补充基于影像的EAT评估,并为未来CAD相关脂肪组织炎症研究提供信息。
European heart journal IF 45.3 2026-10-05 PMID: 41895317
Coronary autoregulation is the intrinsic ability of the coronary circulation to maintain stable blood flow despite fluctuations in myocardial perfusion pressure, provided that metabolic demands remain constant. Central to this process is the dynamic modulation of microvascular resistance within the coronary microcirculation, which acts as the main determinant of coronary blood flow. This regulatory mechanism enables the coronary vasculature to adapt to variations in aortic pressure and epicardial resistance, preserving myocardial perfusion. Historically, the study of coronary autoregulation relied on animal models using implanted flow probes. In humans, modalities such as nuclear imaging and intracoronary Doppler have been employed. Most recently, continuous intracoronary thermodilution has emerged as a robust technique, allowing simultaneous and accurate assessment of absolute coronary blood flow, epicardial resistance, and microvascular resistance. Yet, despite its fundamental role in the understanding of coronary physiology, coronary autoregulation remains complex, often overlooked, and poorly understood. This review focuses on the pivotal role of the coronary microcirculation, specifically microvascular resistance, in maintaining stable resting flow in the context of epicardial coronary artery disease. It provides a theoretical framework, summarizes key animal and human data, and presents an integrative model illustrating the haemodynamic transition from rest to maximal hyperaemia from the perspective of coronary resistance. Finally, it highlights the importance of understanding coronary autoregulation and the interplay between epicardial and microvascular resistance when interpreting not only the clinical presentation of patients with epicardial disease but also the results of the coronary physiological assessment.
中文摘要:冠状动脉自身调节是指冠状动脉循环的一种内在能力:在代谢需求保持恒定的前提下,即使心肌灌注压发生波动,仍能维持稳定的血流量。这一过程的核心是冠状动脉微循环内微血管阻力的动态调节,而微血管阻力是冠状动脉血流的主要决定因素。这种调节机制使冠状动脉血管能够适应主动脉压力和心外膜阻力的变化,从而维持心肌灌注。历史上,冠状动脉自身调节的研究依赖于使用植入式流量探头的动物模型。在人类中,已采用核素成像和冠状动脉内多普勒等方法。最近,连续冠状动脉内热稀释法已成为一种可靠的技术,可同时准确评估绝对冠状动脉血流量、心外膜阻力和微血管阻力。然而,尽管冠状动脉自身调节在理解冠状动脉生理学中具有基础性作用,其仍然复杂、常被忽视且认识不足。本综述聚焦于冠状动脉微循环,尤其是微血管阻力,在心外膜冠状动脉疾病背景下维持稳定静息血流中的关键作用。它提供了一个理论框架,总结了关键的动物和人类数据,并从冠状动脉阻力的角度提出一个整合模型,用以说明从静息到最大充血状态的血流动力学转变。最后,它强调了在解读心外膜疾病患者的临床表现以及冠状动脉生理学评估结果时,理解冠状动脉自身调节以及心外膜与微血管阻力之间相互作用的重要性。
Ageing research reviews IF 15.5 2026-10 PMID: 42537807
Coronary artery disease (CAD) is a major global cause of morbidity and mortality, and population ageing is reshaping its clinical phenotype, disease trajectory, and therapeutic complexity. Chronological age alone cannot explain the heterogeneity of CAD outcomes in older individuals, highlighting the need to integrate biological ageing into cardiovascular disease research and management. Cellular senescence, characterised by stable cell-cycle arrest, metabolic reprogramming, and acquisition of a senescence-associated secretory phenotype (SASP), provides a mechanistic bridge between ageing and CAD. Senescent endothelial cells, vascular smooth muscle cells, immune cells, fibroblasts, and cardiomyocytes contribute to endothelial dysfunction, chronic inflammation, plaque instability, impaired myocardial stress tolerance, and adverse remodelling. Conversely, CAD-related stressors, including atherosclerotic injury, disturbed flow, myocardial ischaemia and ischaemia-reperfusion injury, can induce local senescence programmes and propagate inflammatory or extracellular-vesicle-mediated signalling beyond the initial injury site. However, whether CAD directly accelerates whole-organism biological ageing remains less established. In this review, we examine cellular senescence as a bidirectional but context-dependent interface between ageing and CAD. We summarise cell-type-specific senescence programmes in vascular and myocardial compartments, compare the strength of evidence for major molecular pathways, and discuss senescence-targeted therapies. We emphasise that senolytic and senomorphic strategies remain largely preclinical in cardiovascular disease and that their translation will require careful attention to disease stage, treatment timing, cell specificity and patient stratification. This framework may help refine ageing-informed approaches to CAD prevention, diagnosis and therapy.
中文摘要:冠状动脉疾病(CAD)是全球发病和死亡的主要原因,人口老龄化正在重塑其临床表型、疾病轨迹和治疗复杂性。实足年龄本身无法解释老年个体CAD结局的异质性,这凸显了将生物学衰老整合到心血管疾病研究和管理中的必要性。细胞衰老以稳定的细胞周期停滞、代谢重编程和衰老相关分泌表型(SASP)的获得为特征,为衰老与CAD之间提供了机制桥梁。衰老的内皮细胞、血管平滑肌细胞、免疫细胞、成纤维细胞和心肌细胞参与内皮功能障碍、慢性炎症、斑块不稳定、心肌应激耐受受损和不良重构。反之,CAD相关应激因素,包括动脉粥样硬化损伤、扰动血流、心肌缺血和缺血再灌注损伤,可诱导局部衰老程序,并将炎症或细胞外囊泡介导的信号传播至初始损伤部位之外。然而,CAD是否直接加速整体生物体衰老仍较不确定。在这篇综述中,我们将细胞衰老视为衰老与CAD之间双向但依赖情境的界面。我们总结了血管和心肌区室中细胞类型特异性的衰老程序,比较了主要分子通路的证据强度,并讨论了靶向衰老的治疗。我们强调,在心血管疾病中,衰老细胞清除与衰老表型调节策略在很大程度上仍处于临床前阶段,其转化需要仔细关注疾病阶段、治疗时机、细胞特异性和患者分层。这一框架可能有助于完善基于衰老信息的CAD预防、诊断和治疗方法。

7卒中/脑血管 (4篇)

临床研究 (2篇)

Ageing research reviews IF 15.5 2026-10-07 PMID: 42843467
This review evaluates the impact of Post-Acute Sequelae of SARS-CoV-2 on adults aged 25 to 55, focusing on the potential for accelerated biological aging and an increased incidence of acute cardiovascular events. By synthesizing evidence from 110 epidemiological and mechanistic studies, we examine the interplay between viral-induced immune dysregulation, endothelial injury, and systemic physiological decline in a demographic previously considered low-risk for severe outcomes. Our analysis indicates that chronic systemic inflammation, potentially maintained by persistent viral reservoirs in immune-privileged sites, may drive aging-associated molecular changes. While accelerated telomere attrition and altered DNA methylation patterns are reported, applying validated epigenetic clocks (e.g., Horvath's, PhenoAge) yields divergent results, ranging from no disparity to slight but significant epigenetic age acceleration. Alongside these evolving metrics, elevated neurofilament light chain and GDF-15 may indicate ongoing neuronal injury and cellular stress. Concurrently, the findings highlight an elevation in cardiovascular relative risks, where sustained endothelial dysfunction and microthrombi formation appear to contribute to a higher frequency of acute events, including myocardial infarction and ischemic stroke, within these younger cohorts. The review concludes that Post-Acute Sequelae of SARS-CoV-2 may represent an emerging driver of premature biological aging and heightened vascular vulnerability. We propose an exploratory clinical framework that prioritizes targeted, symptom-driven care pathways. While early pharmacological interventions remain strictly hypothesis-generating and confined to clinical trials to prevent iatrogenic harm, utilizing advanced biomarkers to evaluate high-risk phenotypes in symptomatic patients may guide future multidisciplinary research to mitigate the long-term societal burden of post-viral decline.
中文摘要:本综述评估SARS-CoV-2急性后遗症对25至55岁成年人的影响,重点关注其加速生物衰老以及急性心血管事件发生率升高的可能性。通过综合110项流行病学和机制研究证据,我们考察了病毒诱导的免疫失调、内皮损伤与全身生理衰退之间的相互作用,而这一人群此前被认为发生严重后果的风险较低。我们的分析表明,慢性全身炎症可能由免疫豁免部位中持续存在的病毒储存库所维持,并可能驱动与衰老相关的分子改变。尽管有报道显示端粒加速缩短和DNA甲基化模式改变,但应用已验证的表观遗传时钟(如Horvath时钟、PhenoAge)得出的结果并不一致,从无差异到轻微但显著的表观遗传年龄加速不等。伴随这些不断演变的指标,神经丝轻链和GDF-15升高可能提示持续的神经元损伤和细胞应激。同时,研究结果强调心血管相对风险升高,其中持续的内皮功能障碍和微血栓形成似乎导致这些较年轻队列中急性事件(包括心肌梗死和缺血性卒中)发生频率增加。本综述得出结论,SARS-CoV-2急性后遗症可能是早发生物衰老和血管易损性增加的新兴驱动因素。我们提出一个探索性临床框架,优先采用以症状为导向的靶向照护路径。尽管早期药物干预仍严格属于产生假设的阶段,并仅限于临床试验以防止医源性伤害,但利用先进生物标志物评估有症状患者中的高风险表型,可能指导未来多学科研究,以减轻病毒后衰退带来的长期社会负担。
Diabetes care IF 22.6 2026-10-01 PMID: 42611023
The epidemiology of diabetes and its complications is changing due to increasingly younger ages of diagnosis and increased life expectancy. How this changing landscape affects health care use, and for which conditions, is unclear. We examined age-specific excess burdens of cause-specific inpatient and emergency department (ED) visits associated with diabetes. We used 2019 Behavioral Risk Factor Surveillance System, National Inpatient Sample, and Nationwide Emergency Department Sample data to derive national U.S. estimates of inpatient admissions and ED visits in adults with and without diabetes. Complications were categorized as traditional, conditions emerging as diabetes associated, or other conditions co-occurring with diabetes. We calculated age-standardized absolute risk differences (ARDs) in people with versus without diabetes to identify leading causes of diabetes-related hospital use by age and setting. Traditional complications were dominated by sepsis, cardiorenal disease, acute kidney failure, myocardial infarction, and stroke, with ARDs ranging from 296 to 2,623 per 100,000 people with diabetes. Emerging conditions included pneumonia, device- and procedure-related complications (ARD range 125-473), and schizoaffective or other mental health disorders in younger adults only (ARD range 80-312). Other conditions included respiratory and fluid/electrolyte disorders across all ages (ARD range 100-363), while digestive and urinary disorders were more prominent in older adults (ARD range 229-482). ED visits showed a similar pattern, with lower ARD than inpatient admissions (ARD range 101-707). Diabetes drives substantial, age-specific excess inpatient and ED use, increasingly due to nontraditional rather than classic vascular and renal complications.
中文摘要:糖尿病及其并发症的流行病学正在发生变化,因为诊断年龄日益年轻化且预期寿命增加。这种变化格局如何影响医疗保健使用以及影响哪些疾病,尚不清楚。我们检查了与糖尿病相关的特定病因住院和急诊科(ED)就诊的年龄别超额负担。我们使用2019年行为风险因素监测系统、全国住院患者样本和全国急诊科样本数据,推导美国成人中伴糖尿病和不伴糖尿病的住院和ED就诊的全国估计值。并发症被归类为传统并发症、正在显现与糖尿病相关的疾病,或与糖尿病共存的其他疾病。我们计算了伴糖尿病者与不伴糖尿病者之间年龄标准化的绝对风险差(ARD),以确定按年龄和就诊环境划分的糖尿病相关住院使用的主要原因。传统并发症以脓毒症、心肾疾病、急性肾衰竭、心肌梗死和卒中为主,ARD范围为每100,000名糖尿病患者296至2,623。新出现的疾病包括肺炎、器械和操作相关并发症(ARD范围125-473),以及仅在较年轻成人中的分裂情感性障碍或其他精神健康障碍(ARD范围80-312)。其他疾病包括所有年龄段的呼吸系统和液体/电解质紊乱(ARD范围100-363),而消化系统和泌尿系统疾病在老年人中更为突出(ARD范围229-482)。ED就诊呈现相似模式,但其ARD低于住院(ARD范围101-707)。糖尿病驱动了大量且具有年龄特异性的超额住院和ED使用,且越来越多地由非传统并发症而非经典血管和肾脏并发症所致。

基础研究 (2篇)

Nature neuroscience IF 20.3 2026-10 PMID: 42697957
Neuromodulation aims to improve brain function by altering neural activity. While many rehabilitation strategies seek to restore normal, healthy-like dynamics, some adopt a complementary strategy, using neuromodulation to strengthen repurposed processes that support function. Here we formalize these approaches as 'restorative normalization' (RN) and 'compensatory amplification' (CA), respectively. Drawing on cognitive neurophysiology, we evaluate the following four factors that enable CA to be effective: multiple realizability, multiscale neuroplasticity, precision readiness and activity selectivity. We analyze the interplay between RN and CA across clinical goals, such as stroke rehabilitation, and identify opportunities in neurodegeneration, psychiatry and aging where CA could delay decline, facilitate remission or increase neural processing capacity. We propose that positioning CA alongside RN as a core design principle can sharpen target selection, guide stratified treatments and translate known compensatory signatures into testable neuromodulation protocols.
中文摘要:神经调控旨在通过改变神经活动来改善脑功能。尽管许多康复策略试图恢复正常的、类健康状态的动力学,一些策略则采用互补策略,利用神经调控来增强支持功能的重新利用过程。在此,我们将这些方法分别形式化为「恢复性正常化」(RN)和「代偿性放大」(CA)。借鉴认知神经生理学,我们评估使CA有效的以下四个因素:多重可实现性、多尺度神经可塑性、精准准备度和活动选择性。我们分析RN与CA在卒中康复等临床目标中的相互作用,并识别在神经退行性疾病、精神病学和衰老中的机会,在这些领域中CA可能延缓衰退、促进缓解或增加神经处理能力。我们提出,将CA与RN并列为核心设计原则,可以锐化靶点选择、指导分层治疗,并将已知的代偿特征转化为可检验的神经调控方案。
Ageing research reviews IF 15.5 2026-10 PMID: 42419491
Chronic neuroinflammation is a defining feature of brain ageing and neurodegenerative disorders, yet the molecular mechanisms responsible for its persistence remain incompletely understood. Although autophagy dysfunction, glial senescence, and inflammasome activation are well-established contributors to progressive neurodegeneration, these processes are often analysed independently or through pairwise interactions, leaving their collective contribution to persistent neuroinflammation and disease progression insufficiently defined. Here, we synthesise emerging evidence supporting an integrated 'Autophagy-Senescence-Inflammasome (ASI) axis', in which reciprocal interactions among impaired autophagy, senescent glia, and inflammasome signalling establish a self-sustaining cycle of neuroinflammation. We discuss how defective autophagy promotes mitochondrial dysfunction, oxidative stress, and danger signalling, while senescent astrocytes and microglia amplify inflammatory responses through the senescence-associated secretory phenotype (SASP). These intertwined processes converge on chronic inflammasome activation, with mitochondrial dysfunction emerging as a central mechanistic hub. Evidence across Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, stroke, and chronic neuropathic pain highlight the broad relevance of this pathological network. We further analyse current therapeutic strategies targeting autophagy, senescence, and inflammasome pathways, emphasising the limitations of single-target approaches and the potential of multi-target interventions. By integrating these processes into a unified framework, this review provides new insights into the possible molecular mechanisms underlying neuroinflammaging and identifies the 'ASI axis' as a promising target for neurodegenerative disease-modifying therapies.
中文摘要:慢性神经炎症是脑衰老和神经退行性疾病的标志性特征,但导致其持续存在的分子机制仍未完全阐明。尽管自噬功能障碍、胶质细胞衰老和炎症小体激活已被公认为进行性神经退行性变的重要促成因素,但这些过程常被独立分析或仅以两两相互作用的方式研究,使其对持续性神经炎症和疾病进展的共同贡献未得到充分界定。在此,我们综合了新出现的证据,支持一个整合性的「自噬-衰老-炎症小体(ASI)轴」,其中受损自噬、衰老胶质细胞和炎症小体信号之间的相互互作建立了一个自我维持的神经炎症循环。我们讨论了缺陷自噬如何促进线粒体功能障碍、氧化应激和危险信号,而衰老的星形胶质细胞和小胶质细胞通过衰老相关分泌表型(SASP)放大炎症反应。这些交织的过程汇聚于慢性炎症小体激活,线粒体功能障碍则成为核心机制枢纽。来自阿尔茨海默病、帕金森病、肌萎缩侧索硬化、多发性硬化、卒中和慢性神经病理性疼痛的证据,突显了这一病理网络的广泛相关性。我们进一步分析当前靶向自噬、衰老和炎症小体通路的治疗策略,强调单靶点方法的局限性和多靶点干预的潜力。通过将这些过程整合为一个统一框架,本综述为神经炎性衰老可能的分子机制提供了新见解,并将「ASI轴」确定为神经退行性疾病修饰疗法的有希望靶点。

8PCI/血运重建 (4篇)

临床研究 (4篇)

Circulation IF 41.3 2026-10-06 PMID: 42836296
Preventive percutaneous coronary intervention (PCI) of non-flow-limiting lesions (fractional flow reserve >0.80) that are high-risk plaques has emerged as a potential strategy to reduce cardiac events. However, identifying which lesions derive the greatest benefit from preventive PCI compared with optimal medical therapy alone remains challenging. This post hoc analysis evaluates the role of the near-infrared spectroscopy-derived lipid core burden index in identifying high-risk plaques that may benefit from preventive PCI. Among the 1606 patients enrolled in the PREVENT trial (Preventive Coronary Intervention on Stenosis with Functionally Insignificant Vulnerable Plaque) from September 2015 to September 2021, an investigator-initiated, multicenter, open-label, randomized controlled trial, this post hoc analysis included 598 patients (mean age, 64.1±8.8 years; 27.9% women) comprising 632 lesions with a plaque burden >70% and a minimal lumen area <4 mm2 by intravascular ultrasound in whom near-infrared spectroscopy evaluation was also performed. Lipid-rich plaque (LRP) was prespecified as having a maximum lipid core burden index over a 4-mm segment >315. The primary outcome was a composite of death from cardiac causes, target-vessel myocardial infarction, ischemia-driven target-vessel revascularization, or hospitalization for unstable or progressive angina. LRPs were present in 223 patients (37.3%) with 234 lesions. During median follow-up of 5.6 years, primary outcome events occurred more frequently in patients with LRPs than in those with non-LRPs (12.5% versus 4.7%; unadjusted hazard ratio, 2.08; 95% CI, 1.03-4.19; P=0.039) in the overall population. Within the LRP group, preventive PCI was associated with a lower risk of the primary outcome compared with optimal medical therapy alone (7.3% vs. 17.6%; adjusted hazard ratio, 0.23; 95% CI, 0.13-0.41; P<0.001). Conversely, no benefit of preventive PCI was observed in the non-LRP group (5.5% versus 4.2%; adjusted hazard ratio, 1.00; 95% CI, 0.54-1.86; P=0.97). A significant interaction was found between treatment strategy and the presence of LRP (Pinteraction<0.001). In this post hoc analysis of the PREVENT trial, preventive PCI was associated with a lower risk of the primary composite outcome in patients with near-infrared spectroscopy-defined LRPs, whereas no significant association was observed in those with non-LRPs despite their large plaque burden and small minimal lumen area. These findings suggest the importance of plaque composition, beyond morphological severity alone, in guiding preventive PCI. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02316886.
中文摘要:对非血流限制性病变(血流储备分数>0.80)且为高危斑块者行预防性经皮冠状动脉介入治疗(PCI),已成为减少心脏事件的潜在策略。然而,与单独最佳药物治疗相比,识别哪些病变从预防性PCI中获益最大仍具挑战性。此项事后分析评估了近红外光谱衍生的脂质核心负荷指数在识别可能从预防性PCI获益的高危斑块中的作用。PREVENT试验(对功能学上不显著的高危狭窄病变行预防性冠状动脉介入治疗)为研究者发起、多中心、开放标签、随机对照试验,于2015年9月至2021年9月共入组1606例患者;本事后分析纳入598例患者(平均年龄64.1±8.8岁;女性27.9%),包括632处经血管内超声评估斑块负荷>70%且最小管腔面积<4 mm²的病变,这些病变也接受了近红外光谱评估。脂质丰富斑块(LRP)预先定义为4 mm节段内最大脂质核心负荷指数>315。主要终点为心源性死亡、靶血管心肌梗死、缺血驱动的靶血管血运重建或因不稳定型或进展型心绞痛住院的复合终点。223例患者(37.3%)存在LRP,共234处病变。在中位随访5.6年期间,总体人群中LRP患者的主要终点事件发生率高于非LRP患者(12.5%对4.7%;未调整风险比2.08;95%CI 1.03-4.19;P=0.039)。在LRP组中,与单独最佳药物治疗相比,预防性PCI与主要终点风险较低相关(7.3%对17.6%;调整后风险比0.23;95%CI 0.13-0.41;P<0.001)。相反,在非LRP组中未观察到预防性PCI的获益(5.5%对4.2%;调整后风险比1.00;95%CI 0.54-1.86;P=0.97)。治疗策略与LRP存在之间存在显著交互作用(交互作用P<0.001)。在这项PREVENT试验的事后分析中,对于近红外光谱定义的LRP患者,预防性PCI与主要复合终点风险较低相关,而在非LRP患者中未观察到显著关联,尽管其斑块负荷大且最小管腔面积小。这些发现提示,在指导预防性PCI时,除形态学严重程度外,斑块成分也很重要。URL: https://www.clinicaltrials.gov;唯一标识符:NCT02316886。
European heart journal IF 45.3 2026-10-06 PMID: 42834703
Initially developed to overcome the limitations of angiography in visualizing plaque morphology, intravascular ultrasound and optical coherence tomography have advanced dramatically in resolution, acquisition speed, and analytical automation. These techniques now provide detailed, real-time assessment of coronary artery structure, enabling precise stent sizing, calcium characterization, and optimization of percutaneous coronary interventions. Clinical trials and meta-analyses demonstrated that intravascular imaging-guided PCI significantly reduces restenosis, thrombosis, target lesion failure, and cardiac mortality compared with angiography-guided approaches. These achievements underpin the current Class I, Level A recommendations for intravascular imaging-guidance of complex PCI in the most recent ESC and ACC/AHA/SCAI guidelines. Intravascular imaging has also become instrumental in studying atherosclerosis regression, plaque vulnerability, and the effects of lipid-lowering therapies such as statins and PCSK9 inhibitors, allowing the implementation of personalized prevention and intervention strategies. Intravascular imaging remains grossly underused in clinical practice but better reimbursement, improved and mandatory training and the integration of artificial intelligence for image interpretation may facilitate a wider application.
中文摘要:血管内超声和光学相干断层扫描最初是为了克服血管造影在显示斑块形态方面的局限性而开发,如今在分辨率、采集速度和分析自动化方面已取得巨大进步。这些技术现在可对冠状动脉结构进行详细、实时评估,从而实现精确的支架尺寸选择、钙化特征描述以及经皮冠状动脉介入治疗的优化。临床试验和荟萃分析表明,与血管造影指导的方法相比,血管内影像指导的PCI可显著减少再狭窄、血栓形成、靶病变失败和心源性死亡。这些成就支撑了最新ESC和ACC/AHA/SCAI指南中对复杂PCI采用血管内影像指导的当前I类、A级推荐。血管内影像也已成为研究动脉粥样硬化消退、斑块易损性以及他汀类和PCSK9抑制剂等降脂治疗效果的重要工具,有助于实施个体化预防和干预策略。血管内影像在临床实践中仍被严重使用不足,但更好的报销、改进且强制性的培训以及将人工智能整合用于图像判读,可能有助于促进其更广泛应用。
Annals of internal medicine IF 17.2 2026-10-06 PMID: 42832792
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text] Hematology: [Formula: see text].
中文摘要:普通内科/家庭医学/全科医学:[公式:见正文]。心脏病学:[公式:见正文]。血液学:[公式:见正文]。
European heart journal IF 45.3 2026-10-05 PMID: 41790132
Acute myocardial ischaemic syndromes frequently arise from rupture or erosion of non-flow-limiting vulnerable plaques. Despite major advances in lipid-lowering and anti-inflammatory therapies, a substantial residual cardiovascular risk persists under optimal medical therapy, driving interest in preventive percutaneous coronary intervention (PCI) to stabilize these high-risk lesions. Contemporary intracoronary imaging techniques, including intravascular ultrasound, optical coherence tomography, and near-infrared spectroscopy, can identify plaques at greatest risk of rupture, and preventive PCI, as demonstrated in the PREVENT trial, may reduce composite outcomes of cardiac death, myocardial infarction, revascularization, and unstable angina compared with medical therapy alone. Sealing such plaques may prevent future acute coronary events, particularly in high-risk patients with multivessel disease. However, these benefits were driven mainly by softer endpoints observed in an open-label design, and were not accompanied by significant reductions in mortality or hard outcomes. Concerns remain regarding the procedural risks and cost-effectiveness of preventive PCI, and the impact of novel and more intensive lipid-lowering therapies in this clinical setting has not been adequately explored. Although preventive PCI represents an intriguing paradigm shift that challenges physiology-guided treatment strategies, further studies are needed to confirm its safety, durability, and incremental value over contemporary medical therapy. This Great Debate examines whether preventive PCI should be considered the default management strategy for non-flow-limiting vulnerable plaques.
中文摘要:急性心肌缺血综合征常源于非限流性易损斑块的破裂或糜烂。尽管降脂和抗炎治疗取得重大进展,但在最佳药物治疗下仍存在显著的心血管残余风险,这促使人们关注通过预防性经皮冠状动脉介入治疗(PCI)来稳定这些高风险病变。当代冠脉内影像技术,包括血管内超声、光学相干断层成像和近红外光谱,能够识别破裂风险最高的斑块;如PREVENT试验所示,与单纯药物治疗相比,预防性PCI可能降低心源性死亡、心肌梗死、血运重建和不稳定型心绞痛组成的复合结局。封闭此类斑块可能预防未来的急性冠脉事件,尤其是在多支血管病变的高危患者中。然而,这些获益主要由开放标签设计中观察到的较软终点驱动,并未伴随死亡率或硬终点显著降低。关于预防性PCI的操作风险和成本效益仍存在担忧,并且新型及更强化的降脂治疗在这一临床情境中的影响尚未得到充分探讨。尽管预防性PCI代表了一种引人关注的范式转变,对生理学指导的治疗策略构成挑战,但仍需进一步研究来确认其安全性、持久性以及相对于当代药物治疗的增量价值。这场大辩论探讨预防性PCI是否应被视为非限流性易损斑块的默认管理策略。

9肥厚型心肌病 (3篇)

基础研究 (3篇)

Circulation IF 41.3 2026-10-06 PMID: 42610277
RASopathies constitute a group of rare genetic disorders caused by mutations in genes along the canonical RAS/mitogen-activated protein kinase (MAPK) signaling pathway, affecting cell growth and differentiation. These syndromes, which include Noonan syndrome (NS), are characterized by developmental delays, distinctive facial dysmorphia, and cardiac defects, notably hypertrophic cardiomyopathy (HCM). Despite their prevalence and impact, therapeutic options for RASopathies remain limited. Rigosertib, a novel dual RAS/MAPK and phosphatidylinositol 3-kinase (PI3K)/AKT pathway inhibitor, is currently in clinical trials for treatment of melanoma and recessive dystrophic epidermolysis bullosa. Here, we identify rigosertib as a candidate therapy for RAF1-associated HCM. We performed a drug screen of clinically relevant compounds in transgenic Drosophila models of RASopathies to identify candidate therapeutics. Cardiac-targeted Drosophila models expressing RASopathy-associated transgenes were used to evaluate the effects of rigosertib on cardiac hypertrophy and compare its efficacy with the mitogen-activated protein kinase kinase (MEK) inhibitor trametinib. Therapeutic efficacy was further assessed in a mammalian model using Raf1L613V/+ knock-in mice treated with rigosertib for 6 weeks. Cardiac structure and function were evaluated by echocardiography, histology, and molecular analyses, including assessment of cardiomyocyte size, fetal gene expression, and extracellular signal-regulated kinase/AKT signaling. Additional NS-associated phenotypes, including skeletal growth and craniofacial abnormalities, were also evaluated. Rigosertib was effective across a panel of transgenic Drosophila RASopathy models, suggesting activity against multiple disease variants. In cardiac-targeted fly models, rigosertib reduced cardiac hypertrophy and outperformed trametinib. In Raf1L613V/+ mice, 6 weeks of treatment significantly improved left ventricular chamber dimension, posterior wall thickness, heart mass, and cardiomyocyte size, resulting in reversal of cardiac hypertrophy. Rigosertib also normalized fetal gene expression and inhibited extracellular signal-regulated kinase and AKT signaling in primary cardiomyocytes. In addition to reversing cardiac pathology, rigosertib significantly improved other NS-associated features, including increased bone growth and correction of craniofacial abnormalities. Together, our findings suggest that rigosertib normalizes and reverses RASopathy-associated HCM and other NS-associated syndromic features, supporting its development as a promising treatment for RAF1-associated HCM and, potentially, other RASopathy-dependent pathologies. This study not only highlights the therapeutic potential of rigosertib but also demonstrates the utility of an integrated approach using Drosophila and mammalian models to elucidate drug effects across complex biological systems.
中文摘要:RAS病是一组由经典 RAS/丝裂原活化蛋白激酶(MAPK)信号通路基因突变引起的罕见遗传性疾病,影响细胞生长和分化。这些综合征包括 Noonan 综合征(NS),其特征为发育迟缓、特殊面容畸形和心脏缺陷,尤其是肥厚型心肌病(HCM)。尽管其患病率和影响较大,RAS病的治疗选择仍然有限。Rigosertib 是一种新型的 RAS/MAPK 和磷脂酰肌醇 3-激酶(PI3K)/AKT 通路双重抑制剂,目前正在临床试验中用于治疗黑色素瘤和隐性营养不良型大疱性表皮松解症。在此,我们将 rigosertib 确定为 RAF1 相关 HCM 的候选治疗药物。我们在 RAS病的转基因果蝇模型中进行了临床相关化合物的药物筛选,以确定候选治疗药物。使用表达 RAS病相关转基因的心脏靶向果蝇模型,评估 rigosertib 对心脏肥大的影响,并比较其与丝裂原活化蛋白激酶激酶(MEK)抑制剂曲美替尼的疗效。在哺乳动物模型中进一步评估疗效,使用 Raf1L613V/+ 敲入小鼠接受 rigosertib 治疗 6 周。通过超声心动图、组织学和分子分析评估心脏结构和功能,包括评估心肌细胞大小、胎儿基因表达以及细胞外信号调节激酶/AKT 信号传导。还评估了其他 NS 相关表型,包括骨骼生长和颅面畸形。Rigosertib 在一组转基因果蝇 RAS病模型中有效,提示其对多种疾病变异具有活性。在心脏靶向果蝇模型中,rigosertib 减轻了心脏肥大,并且疗效优于曲美替尼。在 Raf1L613V/+ 小鼠中,治疗 6 周显著改善左心室腔尺寸、后壁厚度、心脏质量和心肌细胞大小,从而逆转心脏肥大。Rigosertib 还使原代心肌细胞中的胎儿基因表达正常化,并抑制细胞外信号调节激酶和 AKT 信号传导。除了逆转心脏病理外,rigosertib 还显著改善其他 NS 相关特征,包括促进骨骼生长和纠正颅面畸形。总之,我们的研究结果表明,rigosertib 可使 RAS病相关 HCM 和其他 NS 相关综合征特征正常化并逆转,支持其开发为 RAF1 相关 HCM 以及可能的其他 RAS病依赖性疾病的有前景的治疗方法。本研究不仅突出了 rigosertib 的治疗潜力,还证明了使用果蝇和哺乳动物模型的整合方法来阐明药物在复杂生物系统中的作用的效用。
Circulation IF 41.3 2026-10-06 PMID: 41988707
Genetic variants in components or regulators of the RAS-mitogen-activated protein kinase (RAS-MAPK) signaling pathway are causative for severe and early-onset hypertrophic cardiomyopathy (HCM) in patients with Noonan syndrome (NS). Despite paracrine communication being considered to play a pivotal role in the etiology of cardiomyopathies, there is a paucity of knowledge about the underlying pathomechanism that leads to the development of HCM and cardiac fibrosis in NS. To dissect the impact of noncardiomyocytes in the development of NS, we employed two-dimensional and three-dimensional human induced pluripotent stem cell models of LZTR1 deficiency alongside induced pluripotent stem cells derived from patients with NS with pathogenic variants in key RAS-MAPK genes and analyzed these cells and tissues at the molecular, cellular, and functional levels. Our findings revealed that cytokine-mediated cellular crosstalk between cardiac fibroblasts and cardiomyocytes, predominantly activated in the disease state, serves as a primary driver of the disease. Cardiac fibroblast-specific IL-8 (interleukin-8) secretion induced fibrosis-related signatures, tissue stiffness, cardiomyocyte hypertrophy, and hypercontractility, identifying dysregulated IL-8 as a heart-autonomous signaling molecule independent of inflammation and immune cell involvement. Inhibition of IL-8-CXCR1 signaling by reparixin reversed the pathological effects in cardiac fibroblasts and cardiomyocytes. These data provide evidence that targeting aberrant IL-8-CXCR1 signaling may be an effective therapeutic option for patients with NS-associated HCM.
中文摘要:RAS-丝裂原活化蛋白激酶(RAS-MAPK)信号通路组分或调控因子的遗传变异可导致努南综合征(NS)患者发生严重且早发的肥厚型心肌病(HCM)。尽管旁分泌通讯被认为在心肌病病因中起关键作用,但人们对导致NS中HCM和心脏纤维化发生的潜在病理机制仍知之甚少。为剖析非心肌细胞在NS发生发展中的作用,我们采用了LZTR1缺陷的二维和三维人类诱导多能干细胞模型,以及来源于携带关键RAS-MAPK基因致病性变异的NS患者的诱导多能干细胞,并在分子、细胞和功能水平上分析了这些细胞和组织。我们的研究结果揭示,心脏成纤维细胞与心肌细胞之间由细胞因子介导的细胞间通讯在疾病状态下主要被激活,并作为该疾病的主要驱动因素。心脏成纤维细胞特异性分泌的白细胞介素-8(IL-8)可诱导纤维化相关特征、组织硬度、心肌细胞肥大和过度收缩,从而表明失调的IL-8是一种不依赖炎症和免疫细胞参与的心脏自主信号分子。瑞帕里辛抑制IL-8-CXCR1信号传导可逆转心脏成纤维细胞和心肌细胞中的病理效应。这些数据提供证据表明,靶向异常的IL-8-CXCR1信号传导可能是NS相关HCM患者的一种有效治疗选择。
Cell stem cell IF 23.3 2026-10-01 PMID: 42692018
Epigenetic regulation may underlie asymmetric allelic expression of many genes during development and disease pathogenesis. Allele-specific epigenetic modification could provide an efficient therapy for dominant genetic diseases due to heterozygous mutations. We developed an allele-specific epigenetic editing method ("Epi-Allele") for silencing pathogenic alleles and found surprisingly elevated expression of the non-targeted alleles, leaving total gene expression unchanged. Genome-wide screening revealed that such compensated allelic expression represents a common phenomenon, suggesting that the Epi-Allele approach could avoid the haploinsufficiency induced by current allele-specific silencing therapies. This notion was validated by allele-specific epigenetic remodeling of Myh6 and MYH7 genes in ameliorating cardiac phenotypes in a hypertrophic cardiomyopathy (HCM) mouse model and HCM patient iPSC-derived cardiomyocytes, respectively. Thus, Epi-Allele offers an allele-specific haploinsufficiency-free therapeutic approach for treating dominant genetic diseases.
中文摘要:表观遗传调控可能是发育及疾病发病过程中许多基因等位基因不对称表达的基础。等位基因特异性表观遗传修饰可为杂合突变导致的显性遗传病提供一种高效疗法。我们开发了一种等位基因特异性表观遗传编辑方法(Epi-Allele),用于沉默致病等位基因,并发现非靶向等位基因的表达出人意料地升高,而总基因表达保持不变。全基因组筛选显示,这种补偿性等位基因表达是一种常见现象,提示Epi-Allele方法可避免当前等位基因特异性沉默疗法所导致的单倍剂量不足。这一观点通过对肥厚型心肌病(HCM)小鼠模型和HCM患者iPSC来源心肌细胞中的Myh6和MYH7基因分别进行等位基因特异性表观遗传重塑并改善心脏表型而得到验证。因此,Epi-Allele为治疗显性遗传病提供了一种等位基因特异性且不引起单倍剂量不足的治疗途径。

10心肌梗死 (3篇)

基础研究 (3篇)

Science advances IF 13.9 2026-10-02 PMID: 42826207
Myocardial infarction (MI) triggers persistent inflammatory dysregulation, wherein macrophages undergo glycolytic reprogramming and adopt an inflammatory phenotype that impairs cardiac repair. However, the specific metabolic drivers underlying post-MI macrophage dysfunction remain unclear. Here, we identify enolase 1 (ENO1)-a glycolytic enzyme up-regulated in post-MI macrophages-as a critical regulator of macrophage metabolic fate and inflammatory function. To intervene, we engineered an acid-responsive nanocarrier (PECS) that externalizes phosphatidylserine within the acidic infarct microenvironment, facilitating selective macrophage uptake. Intracellular delivery of siENO1 suppressed glycolytic flux, thereby curbing lactate accumulation and relieving its metabolic inhibition of KLF4, which initiated anti-inflammatory reprogramming. In vivo, PECS-loaded siENO1 (siENO1@PECS) treatment attenuated infarct size, fibrosis, and cardiomyocyte apoptosis while improving ventricular function. Collectively, these findings identify ENO1 as a critical metabolic checkpoint in post-MI macrophage regulation and demonstrate a bioresponsive nanocarrier strategy for precise gene modulation to enhance cardiac repair.
中文摘要:心肌梗死(MI)会引发持续存在的炎症失调,其中巨噬细胞发生糖酵解重编程并获得促炎表型,从而损害心脏修复。然而,MI后巨噬细胞功能障碍背后的特定代谢驱动因素仍不清楚。在此,我们确定烯醇化酶1(ENO1)——一种在MI后巨噬细胞中上调的糖酵解酶——是巨噬细胞代谢命运和炎症功能的关键调控因子。为了干预,我们构建了一种酸响应性纳米载体(PECS),其可在酸性梗死微环境中将磷脂酰丝氨酸外化,从而促进巨噬细胞的选择性摄取。胞内递送siENO1可抑制糖酵解通量,进而减少乳酸蓄积并解除其对KLF4的代谢抑制,从而启动抗炎重编程。在体内,负载siENO1的PECS(siENO1@PECS)治疗可减轻梗死面积、纤维化和心肌细胞凋亡,同时改善心室功能。总体而言,这些发现将ENO1确定为MI后巨噬细胞调控中的关键代谢检查点,并展示了一种生物响应性纳米载体策略,用于精确基因调控以增强心脏修复。
Acta biomaterialia IF 10.4 2026-10 PMID: 42612941
Myocardial infarction (MI) generates a pathological microenvironment characterized by ischemia and hypoxia, and this increases mortality and morbidity worldwide. We fabricated p-hydroxyphenylpropionic acid-modified gelatin (GTN), a dual-responsive system capable of in situ gelation in the presence of hydrogen peroxide (H2O2) or iron ions. This feature enables GTN to cross-link in the infarcted myocardium, where excessive reactive oxygen species (ROS) and iron ions trigger ferroptosis. The successful modification of gelatin was verified, along with its time- and concentration-dependent responsiveness to H2O2 and iron ions in vitro. We further assessed the biocompatibility, ROS-scavenging activity, and cytoprotective effects of GTN in hostile MI microenvironments. Death receptor 5 fusion protein (DR5) was incorporated into the hydrogel to construct DR5@GTN, aiming to alleviate cardiomyocyte apoptosis. In vivo experiments demonstrated that GTN effectively targeted and accumulated in the infarcted region via transglutaminase-mediated recognition, thereby remodeling the pathological microenvironment. DR5@GTN significantly restored cardiac functions, increased the left ventricular ejection fraction, and reduced the infarct size. DR5@GTN attenuated myocardial fibrosis, promoted angiogenesis, suppressed cardiomyocyte apoptosis, decreased ROS levels, and inhibited myocardial hypertrophy. Collectively, DR5@GTN regulated the "ROS-iron-apoptosis" axis with favorable in situ gelation properties, and this represents a promising strategy for myocardial repair by ameliorating the harsh microenvironment following MI. STATEMENT OF SIGNIFICANCE.
中文摘要:心肌梗死(MI)会产生以缺血和缺氧为特征的病理微环境,并在全球范围内增加死亡率和发病率。我们制备了对羟基苯丙酸修饰的明胶(GTN),这是一种能够在过氧化氢(H2O2)或铁离子存在下原位凝胶化的双重响应系统。该特性使GTN能够在梗死心肌中交联,而梗死心肌中过量的活性氧(ROS)和铁离子会触发铁死亡。我们验证了明胶的成功修饰,以及其在体外对H2O2和铁离子的时间和浓度依赖性响应。我们进一步评估了GTN在不利的MI微环境中的生物相容性、ROS清除活性和细胞保护作用。将死亡受体5融合蛋白(DR5)掺入水凝胶以构建DR5@GTN,旨在减轻心肌细胞凋亡。体内实验表明,GTN通过转谷氨酰胺酶介导的识别有效靶向并蓄积于梗死区域,从而重塑病理微环境。DR5@GTN显著恢复心脏功能,提高左心室射血分数,并减小梗死面积。DR5@GTN减轻心肌纤维化,促进血管生成,抑制心肌细胞凋亡,降低ROS水平,并抑制心肌肥厚。总体而言,DR5@GTN调控「ROS-铁-凋亡」轴并具有良好的原位凝胶化特性,这代表了一种通过改善MI后恶劣微环境来促进心肌修复的有前景策略。意义声明。
Journal of advanced research IF 17.1 2026-10 PMID: 41621531
Senescent mesenchymal stem cells (MSCs) exhibit impaired self-renewal, limiting their therapeutic potential. While multi-omics have revealed downregulation of pan-tissue Fbn1 with aging, particularly in MSCs, the role of its derivative asprosin in MSC senescence is unknown. To elucidate the regulation of senescence/reparative function in aged MSCs by asprosin and evaluate its therapeutic potential for aged MSC-mediated cardiac repair after myocardial infarction (MI). Serum asprosin levels were measured by enzyme-linked immunosorbent assay, and asprosin expression in MSCs was determined by western blotting. Fbn1 expressiondynamics with aging were assessed using public transcriptomic/single-cell datasets. Gain/loss-of-function (lentiviral overexpression/CRISPR-Cas9 knockout) studies were employed to validate the role of asprosin. The effects of recombinant asprosin on senescent MSC proliferation, migration, and pro-angiogenic secretion were tested. Glycolytic flux (Seahorse), metabolites (glucose uptake, G-6-P, lactate), and lactylation (pan-lysine, H3K18la) were measured. Integrated H3K18la CUT&Tag/RNA-seq was performed to identify downstreamtargets, and therapeutic efficacy was assessed in an MI mouse model using intramyocardial injection of asprosin-overexpressing aged MSCs. Circulating asprosin was correlated with adipose mass in young obese mice but was attenuated in aged obese mice. Consistently, human cohorts (normal body mass index) showed an inverse age-asprosin correlation. Systemic and MSC-specific asprosin expression significantly declined with aging. Asprosin knockout intensified H2O2-induced MSC acute premature senescence, whereas its overexpression restored MSC self-renewal. Human recombinant asprosin protein (requiring post-translational modifications for bioactivity) enhanced proliferation, migration, and paracrine angiogenesis in senescent MSCs. Mechanistically, asprosin activated the PI3K/Akt-HIF-1 pathway to upregulate VEGF/TIMP1 (angiogenesis) and drive the glycolysis-lactate-H3K18la axis (proliferation/migration). H3K18la CUT&Tag/RNA-seq identified targets regulating DNA repair, proliferation, and migration. Asprosin deficiency impaired DNA repair. In MI mice, asprosin-overexpressing aged MSCs significantly improved retention and left ventricular ejection fraction, attenuated cardiac remodeling, and promoted peri-infarct angiogenesis. Asprosin is a novel MSC-specific rejuvenation factor that antagonizes senescence through metabolic-epigenetic interplay. Targeting the asprosin-driven "Glycolysis-Lactylation-Epigenetics" axis offers a transformative strategy to enhance MSC-based therapies for ischemic heart disease.
中文摘要:衰老间充质干细胞(MSCs)表现出自我更新受损,限制了其治疗潜力。虽然多组学已揭示泛组织 Fbn1 随衰老而下调,尤其在 MSCs 中,但其衍生物 asprosin 在 MSC 衰老中的作用尚不清楚。旨在阐明 asprosin 对衰老 MSCs 衰老/修复功能的调控,并评估其对衰老 MSC 介导的心肌梗死(MI)后心脏修复的治疗潜力。通过酶联免疫吸附试验测定血清 asprosin 水平,并通过蛋白质印迹法测定 MSCs 中 asprosin 表达。利用公共转录组/单细胞数据集评估 Fbn1 随衰老的表达动态。采用功能获得/缺失研究(慢病毒过表达/CRISPR-Cas9 敲除)验证 asprosin 的作用。检测重组 asprosin 对衰老 MSC 增殖、迁移和促血管生成分泌的影响。测定糖酵解通量(Seahorse)、代谢物(葡萄糖摄取、G-6-P、乳酸)和乳酸化(泛赖氨酸、H3K18la)。进行整合 H3K18la CUT&Tag/RNA-seq 以确定下游靶点,并通过向 MI 小鼠模型心肌内注射过表达 asprosin 的衰老 MSCs 评估治疗效果。循环 asprosin 与年轻肥胖小鼠的脂肪量相关,但在年老肥胖小鼠中减弱。一致地,人类队列(正常体重指数)显示年龄与 asprosin 呈负相关。全身和 MSC 特异性 asprosin 表达随衰老显著下降。Asprosin 敲除加剧 H2O2 诱导的 MSC 急性早衰,而其过表达恢复 MSC 自我更新。人重组 asprosin 蛋白(需要翻译后修饰才能具有生物活性)增强衰老 MSCs 的增殖、迁移和旁分泌血管生成。机制上,asprosin 激活 PI3K/Akt-HIF-1 通路以上调 VEGF/TIMP1(血管生成),并驱动糖酵解-乳酸-H3K18la 轴(增殖/迁移)。H3K18la CUT&Tag/RNA-seq 鉴定出调控 DNA 修复、增殖和迁移的靶点。Asprosin 缺乏损害 DNA 修复。在 MI 小鼠中,过表达 asprosin 的衰老 MSCs 显著改善滞留和左心室射血分数,减轻心脏重构,并促进梗死周围血管生成。Asprosin 是一种新型 MSC 特异性年轻化因子,通过代谢-表观遗传相互作用拮抗衰老。靶向 asprosin 驱动的「糖酵解-乳酸化-表观遗传学」轴,为增强基于 MSCs 的缺血性心脏病治疗提供了变革性策略。

11心房颤动 (3篇)

临床研究 (2篇)

JAMA network open IF 11.7 2026-10-01 PMID: 42832198
Long-term nursing home residents with atrial fibrillation (AF) and activities of daily living (ADL) disability are at high risk of bleeding and death, making the net benefit of anticoagulation uncertain. To compare the association of oral anticoagulant (OAC) use vs nonuse with ischemic stroke and major bleeding in long-term nursing home residents with AF and ADL disability. This cohort study used US Medicare claims linked with the Minimum Data Set (January 1, 2013, to December 31, 2022). Nursing home residents with nonvalvular AF and impairment in 3 or more ADLs were included. Three cohorts comparing use of apixaban, rivaroxaban, or warfarin with nonuse were constructed using incidence-density sampling. Initiation of apixaban, rivaroxaban, or warfarin use. Primary outcomes were ischemic stroke, major bleeding, and their composite. Propensity score (PS) matching balanced 111 covariates. Adjusted rate ratios (ARRs) with 95% CIs were estimated. Tipping-point analyses assessed the relative weighting ischemic stroke vs major bleeding required to favor anticoagulation. Direct active-comparator analyses compared apixaban with rivaroxaban and warfarin. The study comprised 26 940 nursing home residents (median [IQR] age, 82 [74,88] years; 17 504 [65.0%] female), including PS-matched cohorts of 7600 residents receiving apixaban, 2654 receiving rivaroxaban, and 3216 receiving warfarin. Compared with nonuse, use of all OACs was associated with lower rates of ischemic stroke (apixaban: ARR, 0.53; 95% CI, 0.38-0.73; rivaroxaban: ARR, 0.48; 95% CI, 0.27-0.87; warfarin: ARR, 0.47; 95% CI, 0.25-0.88) and higher rates of major bleeding (apixaban: ARR, 1.62; 95% CI, 1.29-2.03; rivaroxaban: ARR, 2.68; 95% CI, 1.84-3.93; warfarin: ARR, 3.02; 95% CI, 2.15-4.25). Only apixaban was not associated with a higher composite outcome (ARR, 1.08; 95% CI, 0.90-1.30), whereas rivaroxaban (ARR, 1.62; 95% CI, 1.20-2.18) and warfarin (ARR, 1.99; 95% CI, 1.50-2.63) were associated with higher rates. Findings were consistent across frailty strata, although stroke reduction with apixaban was attenuated among frail individuals. Tipping-point analyses indicated a more favorable benefit-risk balance for apixaban than for rivaroxaban or warfarin. Among nursing home residents with AF and ADL disability, OAC use was associated with lower ischemic stroke but higher major bleeding rates than nonuse. Apixaban demonstrated the most favorable benefit-risk profile among the OACs evaluated. These findings may inform individualized anticoagulation decisions.
中文摘要:长期居住在养老院、患有心房颤动(AF)且存在日常生活活动能力(ADL)受损的居民出血和死亡风险高,因此抗凝的净获益尚不确定。旨在比较口服抗凝药(OAC)使用与不使用与长期居住在养老院、患有AF且ADL受损居民中缺血性卒中和主要出血的相关性。本队列研究使用与最小数据集(Minimum Data Set)链接的美国Medicare索赔数据(2013年1月1日至2022年12月31日)。纳入患有非瓣膜性AF且3项或以上ADL受损的养老院居民。采用发病密度抽样构建了三个队列,分别比较阿哌沙班、利伐沙班或华法林使用与不使用。主要暴露为开始使用阿哌沙班、利伐沙班或华法林。主要结局为缺血性卒中、主要出血及其复合结局。倾向评分(PS)匹配平衡了111个协变量。估计了校正率比(ARR)及其95%CI。临界点分析评估了支持抗凝所需的缺血性卒中相对于主要出血的相对权重。直接活性对照分析比较了阿哌沙班与利伐沙班和华法林。研究纳入26940名养老院居民(中位[IQR]年龄82[74,88]岁;17504[65.0%]为女性),包括PS匹配队列中7600名接受阿哌沙班、2654名接受利伐沙班和3216名接受华法林的居民。与不使用相比,所有OAC使用均与较低的缺血性卒中发生率相关(阿哌沙班:ARR,0.53;95%CI,0.38-0.73;利伐沙班:ARR,0.48;95%CI,0.27-0.87;华法林:ARR,0.47;95%CI,0.25-0.88),并与较高的主要出血发生率相关(阿哌沙班:ARR,1.62;95%CI,1.29-2.03;利伐沙班:ARR,2.68;95%CI,1.84-3.93;华法林:ARR,3.02;95%CI,2.15-4.25)。仅阿哌沙班与复合结局升高无关(ARR,1.08;95%CI,0.90-1.30),而利伐沙班(ARR,1.62;95%CI,1.20-2.18)和华法林(ARR,1.99;95%CI,1.50-2.63)与较高发生率相关。各衰弱分层结果一致,尽管阿哌沙班的卒中减少作用在衰弱个体中减弱。临界点分析表明,阿哌沙班较利伐沙班或华法林具有更有利的获益-风险平衡。在患有AF和ADL受损的养老院居民中,与不使用相比,OAC使用与较低的缺血性卒中但较高的主要出血发生率相关。在所评估的OAC中,阿哌沙班显示出最有利的获益-风险特征。这些发现可能为个体化抗凝决策提供信息。
Stroke IF 11.1 2026-10-01 PMID: 42817893
Ninety percent of left atrial thrombi in nonvalvular atrial fibrillation arise in the left atrial appendage, which can be occluded percutaneously (left atrial appendage closure [LAAC]). Two 2026 trials (CHAMPION-AF and CLOSURE-AF) more than doubled the available randomized evidence comparing LAAC with oral anticoagulation. We evaluated pooled effects of LAAC on stroke, bleeding, and mortality by bleeding risk, anticoagulation eligibility, and comparator. In this systematic review and meta-analysis, we searched PubMed, Scopus, and Embase from inception to April 15, 2026, for randomized controlled trials comparing percutaneous LAAC with oral anticoagulation in nonvalvular atrial fibrillation. Risk of bias was assessed with the Cochrane Risk of Bias 2 tool. Cumulative-incidence outcomes were pooled as odds ratios using random-effects models, with prediction intervals, prespecified subgroups, and trial sequential analysis. Six randomized controlled trials (2014-2026; 358 sites in North America, Europe, and Asia; 7028 patients) compared LAAC with warfarin (2 trials) or a direct oral anticoagulant (4 trials); populations were predominantly anticoagulation-eligible with low prior-stroke prevalence, plus 2 high-bleeding-risk and 1 postablation trial. Overall stroke rates were similar between arms (odds ratio, 1.10 [95% CI, 0.78-1.56]). Ischemic stroke was more frequent with LAAC (odds ratio, 1.41 [95% CI, 1.07-1.86]) but did not reach the required information size. Nonprocedural bleeding was lower with LAAC (odds ratio, 0.58 [95% CI, 0.35-0.96]), the only outcome reaching a sufficient information size, in standard-risk and postablation but not high-bleeding-risk patients. LAAC is best positioned to reduce nonprocedural bleeding in anticoagulation-eligible patients at standard-to-moderate bleeding risk, rather than as a stroke-equivalent substitute for oral anticoagulation. URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD420261370546.
中文摘要:非瓣膜性心房颤动中90%的左心房血栓起源于左心耳,而左心耳可经皮封堵(左心耳封堵[LAAC])。2026年的两项试验(CHAMPION-AF和CLOSURE-AF)使比较LAAC与口服抗凝的随机证据增加了一倍以上。我们按出血风险、抗凝适用性和对照措施评估了LAAC对卒中、出血和死亡率的汇总效应。在这项系统综述和荟萃分析中,我们检索了PubMed、Scopus和Embase从建库至2026年4月15日的随机对照试验,这些试验比较经皮LAAC与口服抗凝治疗非瓣膜性心房颤动。使用Cochrane偏倚风险2工具评估偏倚风险。累积发生率结局以随机效应模型合并为比值比,并给出预测区间、预设亚组和试验序贯分析。六项随机对照试验(2014-2026年;北美、欧洲和亚洲的358个中心;7028例患者)比较了LAAC与华法林(2项试验)或直接口服抗凝药(4项试验);人群主要为适合抗凝且既往卒中患病率低者,另有2项高出血风险试验和1项消融后试验。两组的总体卒中发生率相似(比值比1.10[95%CI,0.78-1.56])。LAAC组缺血性卒中更常见(比值比1.41[95%CI,1.07-1.86]),但未达到所需信息量。LAAC组非操作相关出血较低(比值比0.58[95%CI,0.35-0.96]),这是唯一达到足够信息量的结局,在标准风险和消融后患者中如此,但在高出血风险患者中并非如此。LAAC最适合用于减少标准至中等出血风险且适合抗凝患者的非操作相关出血,而非作为口服抗凝药的卒中等效替代。网址:https://www.crd.york.ac.uk/PROSPERO/;唯一标识符:CRD420261370546。

基础研究 (1篇)

Ageing research reviews IF 15.5 2026-10 PMID: 42476318
Healthy aging is defined as remarkable longevity (beyond 90 years of age) accompanied by preserved functional status and absence of major clinical conditions. Although the incidence of cardiac arrhythmias, including atrial fibrillation (AF), increases with age, epidemiological studies revealed a paradoxical reduction of AF prevalence in centenarians compared to octogenarians and nonagenarians. Emerging evidence indicates that the apparent cardioprotection in healthy aging may be related to specific molecular and cellular adaptations observed in long-lived individuals. These include reduced systemic inflammation (c-reactive protein, interleukin-6), attenuated oxidative stress (reactive oxygen species), improved mitochondrial function (PGC-1⍺), and preservation of atrial structural integrity with reduced fibrosis (TGFβ, ⍺-SMA). Together, these mechanisms may limit atrial remodeling and maintain more stable electrophysiological properties, thereby reducing susceptibility to AF. In this review, we first discuss the concept of healthy aging as a state of intrinsic cardioprotection, and its relevance to prevent age-related cardiovascular disease. We then examine how centenarian-associated protective mechanisms may mitigate atrial arrhythmogenic remodeling, with a particular focus on inflammation-driven pathways. In addition, we evaluate the contribution of experimental models of healthy aging in the understanding of cardiac electrophysiology and arrhythmia mechanisms. Finally, we summarize current therapeutic strategies for AF in elderly patients and highlight the complex necessity of considering underlying aging-related substrates. Overall, this review emphasizes that healthy aging phenotypes may harbor intrinsic anti-inflammatory and anti-fibrotic adaptations that protect against atrial arrhythmogenesis. Understanding these mechanisms may provide novel translational opportunities for the development of preventive and mechanism-based antiarrhythmic strategies in the aging population.
中文摘要:健康老龄化被定义为显著长寿(超过90岁)并伴有功能状态保持良好且无重大临床疾病。尽管包括房颤在内的心律失常发病率随年龄增长而增加,但流行病学研究显示,与80多岁和90多岁人群相比,百岁老人中房颤患病率出现矛盾性降低。新出现的证据表明,健康老龄化中表观的心脏保护作用可能与长寿个体中观察到的特定分子和细胞适应有关。这些包括全身炎症减轻(C反应蛋白、白细胞介素-6)、氧化应激减弱(活性氧)、线粒体功能改善(PGC-1⍺)以及心房结构完整性保存且纤维化减少(TGFβ、⍺-SMA)。总之,这些机制可能限制心房重构并维持更稳定的电生理特性,从而降低对房颤的易感性。在本综述中,我们首先讨论健康老龄化作为内在心脏保护状态的概念,及其在预防年龄相关心血管疾病中的意义。然后,我们探讨百岁老人相关的保护机制如何减轻心房致心律失常性重构,特别关注炎症驱动通路。此外,我们评估健康老龄化实验模型在理解心脏电生理和心律失常机制方面的贡献。最后,我们总结老年房颤患者当前的治疗策略,并强调考虑潜在衰老相关基质的复杂必要性。总体而言,本综述强调健康老龄化表型可能具有内在的抗炎和抗纤维化适应,可防止心房心律失常发生。理解这些机制可能为在老龄人群中开发预防性和基于机制的抗心律失常策略提供新的转化机会。

12糖尿病心肌病 (3篇)

基础研究 (3篇)

Redox biology IF 16.2 2026-10 PMID: 42664805
Diabetic cardiomyopathy (DbCM) is a major complication of diabetes characterized by metabolic dysregulation in the heart. This study investigated the role of the long non-coding RNA Airn in the regulation of cardiac fatty acid metabolism during DbCM. Airn expression was markedly reduced in the hearts of diabetic mice. Cardiomyocyte-specific Airn overexpression improved cardiac structure and function, enhanced fatty acid oxidation (FAO), and reduced myocardial lipid accumulation, whereas Airn knockdown induced cardiac remodeling and dysfunction even under non-diabetic conditions. Mechanistically, Airn directly interacted with the RNA-binding protein quaking (QKI) and increased QKI protein stability. The present data further support the involvement of PSMD14, a deubiquitinating enzyme, in this process. In turn, QKI bound to QKI response elements (QREs) within the 3'UTR of Pparα mRNA and promoted its stability, while Airn preserved this regulatory pathway by maintaining QKI abundance. Functionally, activation of PPARα rescued the lipotoxic phenotype induced by Airn deficiency. Together, these findings identify an Airn-QKI-PPARα signaling axis that preserves cardiac FAO and limits lipotoxic remodeling, and highlight Airn as a potential therapeutic target in DbCM.
中文摘要:糖尿病心肌病(DbCM)是糖尿病的主要并发症,以心脏代谢失调为特征。本研究探讨了长链非编码RNA Airn在DbCM期间调节心脏脂肪酸代谢中的作用。Airn在糖尿病小鼠心脏中的表达显著降低。心肌细胞特异性Airn过表达改善了心脏结构和功能,增强了脂肪酸氧化(FAO),并减少了心肌脂质蓄积,而Airn敲低即使在非糖尿病条件下也可诱导心脏重构和功能障碍。机制上,Airn直接与RNA结合蛋白quaking(QKI)相互作用并提高QKI蛋白稳定性。现有数据进一步支持去泛素化酶PSMD14参与该过程。反过来,QKI结合于Pparα mRNA 3'UTR内的QKI应答元件(QREs)并促进其稳定性,而Airn通过维持QKI丰度来保持这一调控通路。功能上,PPARα的激活挽救了Airn缺失诱导的脂毒性表型。总之,这些发现确定了一个Airn-QKI-PPARα信号轴,该轴维持心脏FAO并限制脂毒性重构,并提示Airn是DbCM的潜在治疗靶点。
Acta pharmacologica Sinica IF 10.4 2026-10 PMID: 42486945
Diabetic cardiomyopathy (DCM) is associated with impaired calcium handling and downregulation of sarcoplasmic/endoplasmic reticulum Ca²⁺-ATPase 2a (SERCA2a), though the underlying regulatory mechanisms remain poorly understood. Here, we identify KCNE2, an auxiliary β-regulatory subunit of multiple ion channels, as a key regulator of SERCA2a protein stability in the diabetic heart. KCNE2 expression was significantly reduced in high fat diet/streptozotocin-induced diabetic mice and palmitic acid-treated cardiomyocytes. Using LC-MS/MS and co-immunoprecipitation, SERCA2a was identified as a direct binding partner of KCNE2. Knockdown of KCNE2 decreased SERCA2a protein levels without affecting its transcription. Cardiac-specific overexpression of KCNE2 via adenovirus-associated virus 9 delivery restored SERCA2a expression, improved sarcoplasmic reticulum Ca²⁺ cycling, and ameliorated systolic and diastolic dysfunction in diabetic mice. Mechanistically, KCNE2 competitively inhibited the interaction between SERCA2a and the E3 ubiquitin ligase Smurf1, thereby suppressing Smurf1-mediated polyubiquitination and proteasomal degradation of SERCA2a. These results reveal a novel protective role of KCNE2 in diabetic hearts and propose KCNE2 upregulation as a potential therapeutic strategy for DCM. Upregulation of KCNE2 ameliorates cardiac dysfunction by reducing Smurf1-mediated SERCA2a polyubiquitination and degradation, and re-establishes SR Ca²⁺ homeostasis in DCM.
中文摘要:糖尿病心肌病(DCM)与钙处理受损以及肌浆/内质网Ca²⁺-ATP酶2a(SERCA2a)下调有关,但其潜在调控机制仍知之甚少。在此,我们发现KCNE2——多种离子通道的辅助β调节亚基——是糖尿病心脏中SERCA2a蛋白稳定性的关键调节因子。KCNE2表达在高脂饮食/链脲佐菌素诱导的糖尿病小鼠和棕榈酸处理的心肌细胞中显著降低。利用LC-MS/MS和共免疫沉淀,SERCA2a被鉴定为KCNE2的直接结合伴侣。敲低KCNE2降低SERCA2a蛋白水平而不影响其转录。通过腺相关病毒9递送实现心脏特异性过表达KCNE2可恢复SERCA2a表达、改善肌浆网Ca²⁺循环,并改善糖尿病小鼠的收缩和舒张功能障碍。机制上,KCNE2竞争性抑制SERCA2a与E3泛素连接酶Smurf1之间的相互作用,从而抑制Smurf1介导的SERCA2a多泛素化和蛋白酶体降解。这些结果揭示了KCNE2在糖尿病心脏中的新保护作用,并提出上调KCNE2作为DCM的潜在治疗策略。上调KCNE2通过减少Smurf1介导的SERCA2a多泛素化和降解,并重建DCM中的SR Ca²⁺稳态,从而改善心脏功能障碍。
Bioactive materials IF 23.6 2026-10 PMID: 42253918
The dynamic crosstalk between pancreatic islets and the heart plays a critical yet poorly understood role in diabetic cardiomyopathy (DCM). Here, we present a vascularized multi-organoid-on-a-chip platform that enables the perfusion co-culture of human iPSC-derived vascularized cardiac organoids (VCOs) and vascularized islet organoids (VIOs). Under a gradient of hyperglycemic stress, this system recapitulated key features of DCM, including cardiomyocyte structural disassembly and vascular dysfunction. Crucially, co-culture with functional VIOs provided substantial protection against hyperglycemia, mitigating cardiac damage by restoring metabolic and contractile gene programs. Our study establishes a modular and physiologically relevant model to dissect the dose-dependent protective role of islets in diabetic heart disease and to screen for interventions targeting inter-organ communication.
中文摘要:胰腺胰岛与心脏之间的动态串扰在糖尿病心肌病(DCM)中起着关键但尚不清楚的作用。在这里,我们提出了一种血管化多类器官芯片平台,能够实现人iPSC来源的血管化心脏类器官(VCOs)与血管化胰岛类器官(VIOs)的灌注共培养。在高血糖应激梯度下,该系统重现了DCM的关键特征,包括心肌细胞结构解体和血管功能障碍。至关重要的是,与功能性VIOs共培养对高血糖提供了显著保护,通过恢复代谢和收缩基因程序减轻了心脏损伤。我们的研究建立了一个模块化且具有生理相关性的模型,用于解析胰岛在糖尿病心脏病中的剂量依赖性保护作用,并筛选靶向器官间通讯的干预措施。

132型糖尿病 (2篇)

临床研究 (2篇)

Diabetologia IF 10.4 2026-10-02 PMID: 42825923
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the consensus statement on the management of type 2 diabetes in non-pregnant adults, published since 2006 and last updated In 2022. The target audience is the multidisciplinary healthcare team providing diabetes care in the USA and Europe. A systematic examination of publications since 2022 informed new recommendations. This update has broadened the focus from the management of hyperglycaemia to the holistic management of type 2 diabetes and its risk of associated multiple long-term conditions. Fundamental aspects of diabetes care include promoting healthy lifestyle behaviours (healthy eating, 24 h physical behaviours including sleep, and avoiding tobacco and substance use), alongside the provision of psychological support and weight management interventions. For the management of people living with type 2 diabetes, earlier use, potentially from diagnosis, of sodium-glucose cotransporter 2 (SGLT2) inhibitors or/and glucagon-like peptide-1 (GLP-1)-based therapies to offer organ protection and improve long-term outcomes in type 2 diabetes is advocated. Furthermore, earlier combination use of SGLT2 inhibitors and GLP-1-based therapies should be considered in people with concomitant CVD, chronic kidney disease and heart failure. Finally, the ability to transform outcomes for people living with type 2 diabetes is within our grasp through the consistent, equitable and systematic implementation of strategies and therapies that are already available.
中文摘要:美国糖尿病协会(ADA)和欧洲糖尿病研究协会(EASD)召集了一个专家组,更新自2006年发布、最近于2022年更新的非妊娠成人2型糖尿病管理共识声明。目标受众是在美国和欧洲提供糖尿病诊疗的多学科医疗团队。对2022年以来发表文献的系统性审查为新的推荐意见提供了依据。本次更新将重点从高血糖管理扩展到2型糖尿病及其相关多种长期疾病风险的整体管理。糖尿病照护的基本方面包括促进健康生活方式行为(健康饮食、包括睡眠在内的24小时身体行为,以及避免烟草和物质使用),同时提供心理支持和体重管理干预。对于2型糖尿病患者的管理,提倡更早使用,可能从诊断时即开始,钠-葡萄糖共转运蛋白2(SGLT2)抑制剂和/或基于胰高血糖素样肽-1(GLP-1)的治疗,以提供器官保护并改善2型糖尿病的长期结局。此外,对于合并心血管疾病、慢性肾脏病和心力衰竭的患者,应考虑更早联合使用SGLT2抑制剂和基于GLP-1的治疗。最后,通过一致、公平和系统地实施已有的策略和疗法,我们能够改变2型糖尿病患者结局。
Diabetes care IF 22.6 2026-10-02 PMID: 42825450
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the consensus statement on the management of type 2 diabetes in nonpregnant adults, published since 2006 and last updated in 2022. The target audience is the multidisciplinary health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2022 informed new recommendations. This update has broadened the focus from the management of hyperglycemia to the holistic management of type 2 diabetes and its risk of associated multiple long-term conditions. Fundamental aspects of diabetes care include promoting healthy lifestyle behaviors (healthy eating, 24-h physical behaviors including sleep, and avoiding tobacco and substance use), alongside the provision of psychological support and weight management interventions. For the management of people living with type 2 diabetes, earlier use, potentially from diagnosis, of sodium-glucose cotransporter 2 (SGLT2) inhibitors and/or glucagon-like peptide 1 (GLP-1)-based therapies to offer organ protection and improve long-term outcomes in type 2 diabetes is advocated. Furthermore, earlier combination use of SGLT2 inhibitors and GLP-1-based therapies should be considered in people with concomitant cardiovascular disease, chronic kidney disease, and heart failure. Finally, the ability to transform outcomes for people living with type 2 diabetes is within our grasp through the consistent, equitable, and systematic implementation of strategies and therapies that are already available.
中文摘要:美国糖尿病协会(ADA)与欧洲糖尿病研究协会(EASD)召集专家组,更新自2006年发布、最近于2022年更新的非妊娠成人2型糖尿病管理共识声明。目标读者是在美国和欧洲提供糖尿病诊疗的多学科医疗团队。对2022年以来出版文献的系统性审查为新的推荐意见提供了依据。本次更新将重点从高血糖管理扩展为对2型糖尿病及其相关多种长期疾病风险的整体管理。糖尿病照护的基本方面包括促进健康生活方式行为(健康饮食、包括睡眠在内的24小时身体行为,以及避免烟草和物质使用),同时提供心理支持和体重管理干预。对于2型糖尿病患者的管理,倡导更早使用、可能从诊断时即开始使用钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂和/或基于胰高血糖素样肽1(GLP-1)的疗法,以提供器官保护并改善2型糖尿病的长期结局。此外,对于合并心血管疾病、慢性肾脏病和心力衰竭的患者,应考虑更早联合使用SGLT2抑制剂和基于GLP-1的疗法。最后,通过一致、公平和系统地实施已可获得的策略和疗法,我们有望改变2型糖尿病患者的结局。

14心肌纤维化 (2篇)

基础研究 (2篇)

Redox biology IF 16.2 2026-10 PMID: 42673885
Cardiac fibrosis is a key pathological driver of heart failure and cardiovascular mortality, with environmental pollutants being increasingly implicated. Tetrabromobisphenol A (TBBPA), a dominant brominated flame retardant (BFR), is environmentally pervasive and poses potential cardiotoxic risks. However, direct evidence for TBBPA-induced cardiac fibrosis in mammals is lacking. Additionally, its ability to adsorb onto nanoplastics, such as polystyrene (PS-NPs), raises concerns about combined toxicity, especially cardiotoxicity. To addressed this, we systematically evaluated the cardiotoxicity of TBBPA and PS-NPs in vivo and in vitro. In mice, environmentally relevant TBBPA exposure impaired cardiac function and induced inflammation and fibrosis, leading to cardiac remodeling, whereas co-exposure with PS-NPs only induced fibrosis. In H9C2 cells, TBBPA and PS-NPs individually promoted the expression of inflammatory, fibrotic, and hypertrophic markers, with co-exposure resulting in a synergistic exacerbation and a remodeling phenotype. Furthermore, transcriptomic and mechanistic data showed that ESR inhibitors blocked the H19/Wnt pathway activation induced by TBBPA or PS-NPs. Through gain- and loss-of-function experiments, we further confirmed that H19 mediates pollutant-induced Wnt/β-catenin activation and fibrotic responses, positioning H19 as a critical downstream mediator of the ESR/H19/Wnt axis. Overall, for the first time, this study elucidates the cardiotoxic profiles of TBBPA and PS-NPs and identifies the ESR/H19/Wnt axis as a key pro-fibrotic mechanism, highlighting a cardiovascular risk and a potential therapeutic target.
中文摘要:心肌纤维化是心力衰竭和心血管死亡的关键病理驱动因素,环境污染物在其发生中的作用日益受到关注。四溴双酚A(TBBPA)是一种主要的溴化阻燃剂(BFR),在环境中广泛存在,并具有潜在的心脏毒性风险。然而,缺乏TBBPA诱导哺乳动物心肌纤维化的直接证据。此外,TBBPA能够吸附到纳米塑料如聚苯乙烯(PS-NPs)上,这引发了对其联合毒性尤其是心脏毒性的担忧。为此,我们在体内和体外系统评估了TBBPA和PS-NPs的心脏毒性。在小鼠中,环境相关剂量的TBBPA暴露损害心脏功能并诱导炎症和纤维化,导致心脏重塑,而与PS-NPs共暴露仅诱导纤维化。在H9C2细胞中,TBBPA和PS-NPs单独暴露均促进炎症、纤维化和肥大标志物的表达,共暴露则导致协同加重和重塑表型。此外,转录组学和机制数据表明,ESR抑制剂阻断了TBBPA或PS-NPs诱导的H19/Wnt通路激活。通过功能获得和功能缺失实验,我们进一步证实H19介导污染物诱导的Wnt/β-catenin激活和纤维化反应,将H19定位为ESR/H19/Wnt轴的关键下游介质。总体而言,本研究首次阐明了TBBPA和PS-NPs的心脏毒性特征,并将ESR/H19/Wnt轴确定为关键的促纤维化机制,突出了心血管风险及潜在治疗靶点。
Biomaterials IF 13.6 2026-10 PMID: 41966554
Cardiac fibroblasts (CFbs) determine the topological arrangement and the anisotropy of the heart tissue which maintains tissue integrity and function through the production and remodeling of the extracellular matrix (ECM). Under pathological conditions, CFbs can activate into myofibroblasts and promote maladaptive ECM remodeling that may lead to heart failure. Yes-Associated Protein (YAP) - a key player in cardiac fibrosis onset - has been implicated in CFb activation but its role in coordinating the supracellular organization of CFbs and in shaping the instructive properties of the ECM remains poorly understood. We addressed these questions by generating CFbs from wild-type (WT) and YAP knockout (KO) human embryonic stem cells. YAP depletion reduced the expression of cardiogenic markers and altered the transcriptomic profile of ECM- and contractility-related genes. We further demonstrated that YAP expression is required for CFbs monolayer alignment, and its absence resulted in reduced ECM deposition, decreased anisotropy, and diminished force generation. Pharmacological inhibition of cell contractility closely mirrored YAP KO phenotype, suggesting that YAP regulates both monolayer organization and ECM structure through its control over contractility. ECM cross-seeding experiments confirmed the role of ECM as a structural guide for cellular alignment. Moreover, cardiomyocytes cultured on KO CFb-derived ECM exhibited impaired sarcomere organization and altered calcium dynamics. Together, these findings demonstrate that YAP activity in CFbs governs the structural and functional properties of the ECM, influencing both fibroblast alignment and cardiomyocyte activity. Moreover, they underscore the critical role of YAP in maintaining the supracellular organization and mechanical integrity of cardiac tissue.
中文摘要:心脏成纤维细胞(CFbs)通过细胞外基质(ECM)的产生与重塑,决定心脏组织的拓扑排列与各向异性,从而维持组织完整性和功能。在病理条件下,CFbs可活化为肌成纤维细胞,并促进不良适应性ECM重塑,进而可能导致心力衰竭。Yes相关蛋白(YAP)——心脏纤维化发生过程中的关键参与者——已被认为与CFb活化有关,但其在协调CFbs超细胞组织以及塑造ECM指导性特性中的作用仍知之甚少。我们通过从野生型(WT)和YAP敲除(KO)的人胚胎干细胞中生成CFbs来研究这些问题。YAP缺失降低了心脏发生标志物的表达,并改变了ECM相关和收缩性相关基因的转录组谱。我们进一步证明,YAP表达是CFbs单层排列所必需的,其缺失导致ECM沉积减少、各向异性降低以及力生成减弱。药理学抑制细胞收缩性可高度模拟YAP KO表型,提示YAP通过控制收缩性来调节单层组织和ECM结构。ECM交叉接种实验证实了ECM作为细胞排列结构引导的作用。此外,在KO CFb来源的ECM上培养的心肌细胞表现出肌节组织受损和钙动态改变。总之,这些发现表明,CFbs中的YAP活性调控ECM的结构和功能特性,影响成纤维细胞排列和心肌细胞活动。此外,它们强调了YAP在维持心脏组织超细胞组织和机械完整性中的关键作用。

15肺动脉高压 (2篇)

临床研究 (1篇)

Annals of the rheumatic diseases IF 24.0 2026-10 PMID: 42248770
A loss-of-function variant in deoxyribonuclease 1-like 3 (DNASE1L3), encoding Arg to Cys substitution at amino acid 206 (R206C), was previously identified as a heritable susceptibility factor for systemic sclerosis (SSc). We analysed mortality and pulmonary outcomes in patients with SSc with or without the DNASE1L3 R206C variant. Mortality, pulmonary hypertension (PH), and interstitial lung disease (ILD) were ascertained in the UTHealth Houston, Royal Free Hospital, and Johns Hopkins University cohorts. Mortality risk and precapillary PH time-to-event from SSc onset were estimated using Cox proportional hazards models. Meta-analyses were performed to generate overall risk estimates. In the mortality analysis (n = 2366 patients, 46.6% of whom were deceased), after adjustment for age of SSc onset and sex, DNASE1L3 R206C was associated with significantly greater mortality (hazard ratio [HR]: 1.16, 95% CI: 1.02-1.32). In the precapillary PH analysis (n = 1170 patients, 20.3% of whom had precapillary PH), after adjustment for age of SSc onset, sex, and the presence of ILD, DNASE1L3 R206C was associated with significantly greater precapillary PH risk (HR: 1.69, 95% CI: 1.31-2.19). The majority of patients with precapillary PH did not have ILD, indicating that they had WHO Group I, ie pulmonary arterial hypertension (PAH). We report a previously unknown impact of DNASE1L3 polymorphism on PAH susceptibility in SSc. The association between loss-of-function of an immunoregulatory gene (DNASE1L3) and PAH susceptibility supports further exploration of downstream sequelae of DNASE1L3 dysfunction in SSc pathogenesis and the mechanisms underlying the well-recognised but poorly understood susceptibility of patients with SSc to PAH.
中文摘要:脱氧核糖核酸酶1样3(DNASE1L3)的一种功能缺失变异,编码第206位氨基酸由精氨酸替换为半胱氨酸(R206C),此前被鉴定为系统性硬化症(SSc)的遗传易感因素。我们分析了携带或不携带DNASE1L3 R206C变异的SSc患者的死亡率与肺部结局。在UTHealth Houston、Royal Free Hospital和Johns Hopkins University队列中确认了死亡率、肺动脉高压(PH)和间质性肺病(ILD)。使用Cox比例风险模型估计死亡风险以及自SSc发病以来的毛细血管前PH事件发生时间。进行荟萃分析以生成总体风险估计。在死亡率分析中(n = 2366例患者,其中46.6%已死亡),校正SSc发病年龄和性别后,DNASE1L3 R206C与显著更高的死亡率相关(风险比[HR]:1.16,95% CI:1.02-1.32)。在毛细血管前PH分析中(n = 1170例患者,其中20.3%患有毛细血管前PH),校正SSc发病年龄、性别和ILD存在情况后,DNASE1L3 R206C与显著更高的毛细血管前PH风险相关(HR:1.69,95% CI:1.31-2.19)。大多数毛细血管前PH患者没有ILD,表明他们属于WHO第I组,即肺动脉高压(PAH)。我们报告了DNASE1L3多态性对SSc中PAH易感性的此前未知的影响。免疫调节基因(DNASE1L3)功能缺失与PAH易感性之间的关联支持进一步探索DNASE1L3功能障碍在SSc发病机制中的下游后遗症,以及SSc患者对PAH的公认但了解甚少的易感性背后的机制。

基础研究 (1篇)

Pharmacology & therapeutics IF 13.5 2026-10 PMID: 42486442
Pulmonary arterial hypertension (PAH) is a severe, progressive hemodynamic disorder characterized by pathological pulmonary vascular remodeling and right ventricular dysfunction, in which metabolic reprogramming is recognized as a pivotal pathogenic mechanism driving disease progression. This review synthesizes the metabolic pathways, key regulatory targets, and therapeutic implications underlying PAH pathogenesis, focusing on the major cell types involved in its pathogenesis: dysfunctional pulmonary arterial endothelial cells (PAECs), abnormally proliferating pulmonary arterial smooth muscle cells (PASMCs), activated pulmonary artery adventitial fibroblasts (PAAFs), infiltrating immune cells, and right ventricular cardiomyocytes (RVCMs) that undergo compensatory remodeling to counteract increased pressure overload. The primary highlight is its cell-specific analytical framework, which systematically delineates shared metabolic hallmarks and distinct cell-type-specific mechanisms. Shared metabolic features across these cell populations include enhanced aerobic glycolysis, impaired mitochondrial oxidative phosphorylation, and dysregulated amino acid metabolism. Cell-specific mechanisms encompass dysfunction of PAECs, phenotypic switching of PASMCs, PAAFs-mediated adventitial fibrosis, metabolic inflexibility of RVCMs, and inflammatory polarization of immune cells. By integrating these multifaceted findings, the review provides critical insights into the metabolic underpinnings of PAH, emphasizing cell-specific metabolic regulation as a strategy for targeted therapy to reverse vascular remodeling, mitigate right ventricular dysfunction, and improve clinical outcomes.
中文摘要:肺动脉高压(PAH)是一种严重的、进行性血流动力学障碍,以病理性肺血管重塑和右心室功能障碍为特征,其中代谢重编程被认为是驱动疾病进展的关键致病机制。本综述总结了PAH发病机制背后的代谢途径、关键调控靶点和治疗意义,重点关注参与其发病机制的主要细胞类型:功能失调的肺动脉内皮细胞(PAECs)、异常增殖的肺动脉平滑肌细胞(PASMCs)、活化的肺动脉外膜成纤维细胞(PAAFs)、浸润的免疫细胞,以及为对抗增加的压力负荷而发生代偿性重塑的右心室心肌细胞(RVCMs)。主要亮点是其细胞特异性分析框架,该框架系统描述了共有的代谢标志和不同的细胞类型特异性机制。这些细胞群共有的代谢特征包括有氧糖酵解增强、线粒体氧化磷酸化受损和氨基酸代谢失调。细胞特异性机制包括PAECs功能障碍、PASMCs表型转换、PAAFs介导的外膜纤维化、RVCMs代谢不灵活以及免疫细胞的炎症极化。通过整合这些多方面的发现,本综述为PAH的代谢基础提供了重要见解,强调细胞特异性代谢调控作为靶向治疗策略,以逆转血管重塑、减轻右心室功能障碍并改善临床结局。

16心律失常(非房颤) (2篇)

基础研究 (2篇)

Acta pharmacologica Sinica IF 10.4 2026-10 PMID: 42477142
Synthetic cannabinoid receptor agonists (SCRAs) are a large group of structurally diverse designer drugs (analogues of controlled substances) associated with intense and sometimes fatal intoxication. Cardiac symptoms, including tachycardia and arrhythmia, are common consequences of SCRA consumption. However, little is known about the mechanisms through which SCRAs may perturb cardiac rhythm. Here, we used electrophysiological techniques to screen 36 SCRAs on two ion channels responsible for cardiomyocyte repolarization, hERG (also called KV11.1) and KV7.1/KCNE1. We report that the majority of tested SCRAs inhibited hERG, primarily by reducing channel conductance, and some also inhibited KV7.1/KCNE1. In silico data suggest that SCRAs may use both a known drug binding site in the central cavity of the hERG channel, shared by established hERG blockers like astemizole, and a recently identified side pocket site. Experimental and in silico data suggest SCRA structural features associated with prominent inhibitory effects on hERG, with chemical moieties allowing bond formation and/or the ability to fit into binding sites being important. Structure-activity relationships (SAR) for SCRA effects on hERG, KV7.1/KCNE1 and the cannabinoid receptor 1 (CB1) varied, demonstrating the need to assess SCRA effects on multiple potential targets. In conclusion, we found SCRAs to be inhibitors of cardiac voltage-gated potassium channels important for cardiomyocyte repolarization, highlighting the importance of more extensive investigation of SCRAs on cardiac function.
中文摘要:合成大麻素受体激动剂(SCRAs)是一大类结构多样化的设计药物(受管制物质的类似物),与强烈且有时致命的Intoxication有关。心脏症状,包括心动过速和心律失常,是SCRA消费的常见后果。然而,关于SCRAs可能扰动心脏节律的机制知之甚少。在此,我们使用电生理技术筛选了36种SCRA对负责心肌细胞复极化的两个离子通道hERG(也称为KV11.1)和KV7.1/KCNE1的作用。我们报告,大多数测试的SCRAs抑制hERG,主要通过降低通道电导,部分也抑制KV7.1/KCNE1。计算机模拟数据表明,SCRAs可能使用hERG通道中央腔内一个已知的药物结合位点(与阿司咪唑等已确定的hERG阻滞剂共享)和一个最近鉴定的侧袋位点。实验和计算机模拟数据表明,与对hERG显著抑制作用相关的SCRA结构特征,其中允许成键和/或适应结合位点的化学部分很重要。SCRAs对hERG、KV7.1/KCNE1和大麻素受体1(CB1)作用的结构-活性关系(SAR)各不相同,表明需要评估SCRAs对多个潜在靶点的作用。总之,我们发现SCRAs是心肌细胞复极化重要的心脏电压门控钾通道的抑制剂,强调了对SCRAs心脏功能进行更广泛研究的重要性。
Bioactive materials IF 23.6 2026-10 PMID: 42164997
Congenital long QT syndrome (LQTS) predisposes patients to malignant ventricular tachycardias, yet existing in vitro models do not fully capture the clinical arrhythmic phenotypes that determine patient outcomes. We report the development of an engineered platform with mature, fully hiPSC-derived human cardiac tissues that reproduces genotype-specific ventricular tachycardia under physiologically relevant triggers. Using patient-derived and corrected hiPSCs, we engineered electromechanically matured cardiac tissues to model LQT8 and LQT2 syndromes. LQT8 tissues exhibited spontaneous early afterdepolarizations and sustained tachycardia, including monomorphic, polymorphic, and torsades de pointes-like waveforms. In contrast, LQT2 tissues remained stable under constant pacing but developed arrhythmias during dynamic rate acceleration, mirroring clinical trigger-dependent arrhythmogenicity. Frequency-domain analysis and activation mapping revealed re-entrant dynamics consistent with ventricular tachycardia-like activity. By unifying cellular-level electrophysiology with tissue-scale ECG-like arrhythmic activity, this platform enables physiologically inspired investigation of arrhythmogenic mechanisms in inherited arrhythmia syndromes.
中文摘要:先天性长QT综合征(LQTS)使患者易发生恶性室性心动过速,但现有体外模型未能完全再现决定患者结局的临床心律失常表型。我们报道了一种工程化平台的开发,该平台具有成熟、完全由hiPSC衍生的人心脏组织,可在生理相关触发条件下再现基因型特异性的室性心动过速。利用患者来源及校正后的hiPSC,我们构建了电机械成熟的心脏组织,以模拟LQT8和LQT2综合征。LQT8组织表现出自发性早后除极和持续性心动过速,包括单形性、多形性及尖端扭转型室速样波形。相反,LQT2组织在恒定起搏下保持稳定,但在动态心率加速时出现心律失常,再现了临床上触发依赖性的致心律失常性。频域分析和激动标测揭示了与室性心动过速样活动一致的折返动力学。通过将细胞水平电生理学与组织尺度类心电图心律失常活动统一起来,该平台能够以生理学启发的方式研究遗传性心律失常综合征中的致心律失常机制。

17冠心病/PCI (2篇)

临床研究 (2篇)

Diabetologia IF 10.4 2026-10 PMID: 42467085
Circulating proteins act as important hormonal signals of nutrient intake. We aimed to systematically characterise the time-resolved proteomic response to glucose ingestion in humans, and to assess its robustness following prolonged complete caloric restriction. We conducted oral glucose tolerance tests (OGTTs) in 11 healthy volunteers before and after 7 days of complete caloric restriction and measured the response of >2900 targets through high-resolution plasma protein profiling. We identified a signature of 44 proteins that changed significantly following glucose ingestion, which was reproducible after 7 days without food, and was strongly (20-fold) enriched for 'stomach-specific' proteins. We report that annexin A10 (ANXA10) shows the most significant post-glucose change observed, similar to the trajectories of secreted hormones. We present observational human evidence from multiple sources suggesting that ANXA10 is secreted upon sensing an increase in gastric pH, with the stomach as the major contributing tissue. Despite a profound metabolic shift after 7 days of complete caloric restriction, characterised by delayed insulin secretion and postprandial hyperglycaemia, only four proteins showed robust evidence for a differential trajectory during both OGTTs. This included plasma levels of tryptophanyl-tRNA synthetase 1 (WARS), for which we found a genetic association with glucose homeostasis and coronary artery disease. Our exploratory study identifies the proteomic response to glucose ingestion and demonstrates its reproducibility despite major shifts in glucose homeostasis. We characterise the gastrointestinal origin of these changes, and hypothesise a hitherto under-recognised role for sensing of changes in gastric pH on the plasma proteome.
中文摘要:循环蛋白质是营养摄入的重要激素信号。我们旨在系统地表征人类摄入葡萄糖后随时间变化的蛋白质组反应,并评估其在长期完全热量限制后的稳健性。我们在11名健康志愿者中,于7天完全热量限制前后进行口服葡萄糖耐量试验(OGTT),并通过高分辨率血浆蛋白质谱检测了超过2900个靶标的反应。我们鉴定出一个由44种蛋白质组成的特征,这些蛋白质在摄入葡萄糖后发生显著变化,该特征在无食物7天后仍可重现,并且高度(20倍)富集「胃特异性」蛋白质。我们报告,膜联蛋白A10(ANXA10)显示出所观察到的最显著的葡萄糖后变化,其轨迹与分泌激素相似。我们呈现来自多个来源的人类观察性证据,提示ANXA10在感知胃pH升高后被分泌,而胃是其主要贡献组织。尽管7天完全热量限制后出现了深刻的代谢转变,其特征为胰岛素分泌延迟和餐后高血糖,但仅4种蛋白质在两次OGTT期间显示出稳健的差异轨迹证据。这包括色氨酰-tRNA合成酶1(WARS)的血浆水平,我们发现其与葡萄糖稳态和冠状动脉疾病存在遗传关联。我们的探索性研究鉴定了摄入葡萄糖后的蛋白质组反应,并证明尽管葡萄糖稳态发生重大变化,该反应仍具有可重复性。我们描述了这些变化的胃肠道来源,并假设胃pH变化的感知对血浆蛋白质组具有迄今未被充分认识的作用。
Annals of the rheumatic diseases IF 24.0 2026-10 PMID: 42425799
Mosaic chromosomal alterations (mCAs) increase with age and are associated with many diseases, including autoimmune diseases. The associations between mCAs and systemic sclerosis (SSc) and its clinical subtypes have not been explored. We recruited study subjects from 2 independent datasets (set 1: 635 SSc, 4401 controls; set 2: 347 SSc, 2170 controls) and detected mCAs (loss, loss of heterozygosity [LOH], gain, and mosaic loss of the X chromosome [mLOX]) from their peripheral blood samples. Logistic regression analyses were conducted with covariates in each cohort, and the results were meta-analysed. We also conducted stratified analyses by age groups, the age at disease onset, clinical phenotypes based on the skin lesions, autoantibody profiles, and the presence of complications. We observed a trend of increased loss in SSc, especially in old age (P = .0063). The association of loss was strengthened in certain subtypes of SSc, including lcSSc (odds ratio [OR] = 2.22, P = .019) and SSc with vascular complications (digital ulcers, pulmonary hypertension, or renal crisis; OR = 3.30, P = .0054). The effect sizes of Loss increased in patients with high cell fractions (CFs). We also observed that mLOX was significantly associated with SSc, limited cutaneous systemic sclerosis (lcSSc), and anticentromere antibody-positive systemic sclerosis (ACA-SSc) only for subjects with high CFs. mLOX was significantly associated with lcSSc and ACA-SSc even compared with dcSSc and ATA-SSc, respectively. These associations were consistently observed in each of the 2 datasets. Finally, we identified majority of the associations of Loss were mainly driven by SSc with late age at onset. Loss and mLOX were significantly and differentially associated with SSc and its subtypes, underscoring potential phenotype-specific contributions of mCAs.
中文摘要:嵌合染色体改变(mCAs)随年龄增长而增加,并与许多疾病相关,包括自身免疫性疾病。mCAs与系统性硬化症(SSc)及其临床亚型之间的关联尚未被探索。我们从2个独立数据集(数据集1:635例SSc,4401例对照;数据集2:347例SSc,2170例对照)中招募研究对象,并从其外周血样本中检测mCAs(缺失、杂合性缺失[LOH]、获得以及X染色体嵌合缺失[mLOX])。在每个队列中采用逻辑回归分析并纳入协变量,结果进行荟萃分析。我们还按年龄组、发病年龄、基于皮肤病变的临床表型、自身抗体谱以及并发症的存在情况进行分层分析。我们观察到SSc中缺失呈增加趋势,尤其是在老年人群中(P = .0063)。缺失的关联在某些SSc亚型中增强,包括lcSSc(比值比[OR] = 2.22,P = .019)以及伴有血管并发症(指端溃疡、肺动脉高压或肾危象;OR = 3.30,P = .0054)的SSc。在高细胞分数(CFs)患者中,缺失的效应量增加。我们还观察到,仅在高CFs受试者中,mLOX与SSc、局限性皮肤型系统性硬化症(lcSSc)以及抗着丝点抗体阳性系统性硬化症(ACA-SSc)显著相关。即使分别与dcSSc和ATA-SSc相比,mLOX仍与lcSSc和ACA-SSc显著相关。这些关联在两个数据集中均一致观察到。最后,我们发现大多数缺失相关关联主要由晚发年龄的SSc驱动。缺失和mLOX与SSc及其亚型存在显著且差异化的关联,凸显了mCAs可能具有表型特异性贡献。

18先天性心脏病 (1篇)

临床研究 (1篇)

European heart journal IF 45.3 2026-10-06 PMID: 42834856
With improved survival, adults with congenital heart disease (ACHD) increasingly face acquired cardiovascular risk factors; however, their impact on late mortality remains incompletely defined. This study aimed to evaluate the contribution of acquired cardiovascular risk factors to mortality in ACHD. A total of 9826 ACHD patients (mean age 39.0 ± 16.4 years; 50.3% male) who attended our tertiary centre between 2000 and 2024 were retrospectively analysed. Clinical and demographic data were obtained from a prospectively maintained database. Cox proportional hazards models were used to assess associations between risk factors and all-cause mortality. During a median follow-up of 10.0 years (98 764 patient-years), 1371 patients died (mortality rate 1.39% per patient-year). In multivariable analysis, older age (hazard ratio [HR] 1.07 per year; P < .001), male sex (HR 1.30; P = .026), greater lesion complexity (HR 2.12; P < .001), coronary artery disease (HR 1.78; P = .005), sleep apnoea (HR 2.22; P < .001), depression (HR 1.45; P = .010), and current smoking (HR 1.67; P < .001) were independently associated with higher mortality, while higher income was associated with lower mortality risk. Both congenital lesion complexity and acquired comorbidities are associated with late mortality in ACHD. These data support the need for comprehensive, multidisciplinary management that incorporates timely modification of general cardiovascular and other risk factors alongside congenital heart disease-specific care.
中文摘要:随着生存率提高,成人先天性心脏病(ACHD)患者日益面临获得性心血管危险因素;然而,这些因素对晚期死亡的影响仍未完全明确。本研究旨在评估获得性心血管危险因素对ACHD患者死亡率的贡献。回顾性分析了2000年至2024年间在我院三级中心就诊的9826例ACHD患者(平均年龄39.0±16.4岁;男性50.3%)。临床和人口学数据来自前瞻性维护的数据库。采用Cox比例风险模型评估危险因素与全因死亡率之间的关联。在中位随访10.0年(98764患者年)期间,1371例患者死亡(死亡率为每患者年1.39%)。在多变量分析中,年龄较大(风险比[HR]1.07/年;P<.001)、男性(HR 1.30;P=.026)、病变复杂程度较高(HR 2.12;P<.001)、冠状动脉疾病(HR 1.78;P=.005)、睡眠呼吸暂停(HR 2.22;P<.001)、抑郁(HR 1.45;P=.010)和当前吸烟(HR 1.67;P<.001)与更高的死亡率独立相关,而较高收入与较低的死亡风险相关。先天性病变复杂程度和获得性合并症均与ACHD患者的晚期死亡相关。这些数据支持需要综合、多学科管理,在先天性心脏病特异诊疗的同时,及时调整一般心血管及其他危险因素。

19心肌肥厚 (1篇)

基础研究 (1篇)

Acta pharmacologica Sinica IF 10.4 2026-10-06 PMID: 42834168
Under conditions of chronic pressure overload, cardiac hypertrophy can progressively develop into arrhythmias and heart failure, and in severe cases, may lead to sudden death. Previous studies have indicated that protein kinases play significant roles in cardiovascular diseases. This study aims to elucidate the function of the WEE1 G2 checkpoint kinase (WEE1) in the progression of myocardial hypertrophy. We evaluated the expression of WEE1 in the hearts of mice with transverse aortic constriction (TAC). The functional role of WEE1 was investigated using siWEE1 in an angiotensin II (Ang II)-induced cardiomyocyte hypertrophy model. Furthermore, the contribution of WEE1 to cardiac hypertrophy was assessed in TAC mice via intraperitoneal administration of Adavosertib (WEE1-specific inhibitor). RNA-sequencing (RNA-seq) was employed to identify the downstream effector molecules of WEE1 in cardiomyocytes. The expression of both phosphorylated WEE1 and WEE1 was upregulated in hearts subjected to transverse aortic constriction and in cardiac cells treated with angiotensin II. Knockdown of WEE1 effectively alleviated Ang II-induced cardiac cell hypertrophy. Furthermore, application of the specific inhibitor Adavosertib significantly attenuated cardiac cell hypertrophy and improved cardiac function. Mechanistic studies revealed that WEE1 promotes the translocation of the transcription factor P65 from the cytoplasm to the nucleus, thereby activating the nuclear factor κB (NF-κB) signaling pathway, which ultimately upregulates the transcriptional level of Lipocalin2 (LCN2). LCN2 mediates the process of ferroptosis in cardiac cells by binding to the ferroptosis receptor solute carrier family 22 member 17 (SLC22A17), thereby inducing cardiac hypertrophy. Our findings indicate that WEE1 exacerbates cardiac hypertrophy by activating the NF-κB signaling pathway, which upregulates LCN2 expression and subsequently aggravates ferroptosis in cardiac cells. Inhibition of WEE1 significantly improves cardiac function, highlighting its potential value as a therapeutic target of cardiac hypertrophy.
中文摘要:在慢性压力超负荷条件下,心肌肥厚可逐渐发展为心律失常和心力衰竭,严重时可能导致猝死。既往研究表明,蛋白激酶在心血管疾病中发挥重要作用。本研究旨在阐明WEE1 G2检查点激酶(WEE1)在心肌肥厚进展中的功能。我们评估了横向主动脉缩窄(TAC)小鼠心脏中WEE1的表达。利用siWEE1在血管紧张素II(Ang II)诱导的心肌细胞肥厚模型中研究WEE1的功能作用。此外,通过腹腔注射Adavosertib(WEE1特异性抑制剂)在TAC小鼠中评估WEE1对心肌肥厚的贡献。采用RNA测序(RNA-seq)鉴定心肌细胞中WEE1的下游效应分子。在横向主动脉缩窄的心脏以及用血管紧张素II处理的心脏细胞中,磷酸化WEE1和WEE1的表达均上调。敲低WEE1可有效减轻Ang II诱导的心脏细胞肥厚。此外,应用特异性抑制剂Adavosertib可显著减轻心脏细胞肥厚并改善心脏功能。机制研究显示,WEE1促进转录因子P65从细胞质向细胞核转位,从而激活核因子κB(NF-κB)信号通路,最终上调脂质运载蛋白2(LCN2)的转录水平。LCN2通过与铁死亡受体溶质载体家族22成员17(SLC22A17)结合,介导心脏细胞铁死亡过程,从而诱导心肌肥厚。我们的研究结果表明,WEE1通过激活NF-κB信号通路上调LCN2表达,进而加重心脏细胞铁死亡,从而加剧心肌肥厚。抑制WEE1可显著改善心脏功能,凸显其作为心肌肥厚治疗靶点的潜在价值。

20冠脉夹层 (1篇)

临床研究 (1篇)

Circulation IF 41.3 2026-10-06 PMID: 42677491
Spontaneous coronary artery dissection (SCAD) is characterized by a separation of the coronary artery wall, causing myocardial infarction and sudden death. This study is one of the first to clarify the impact of pathological genetic variants in candidate SCAD-related genes on the histopathological and morphological properties of human SCAD lesions. A total of 28 SCAD cases were selected from the CVPath Autopsy Registry. Histological differences in collagen and smooth muscle cells were compared among 3 groups: culprit SCAD (C-SCAD), defined as the coronary segment containing a dissection in cases with SCAD; nonculprit SCAD, defined as unaffected coronary segments (ie, healthy arteries) in cases with SCAD; and non-SCAD controls. Whole-exome sequencing was performed, and the identified variants were filtered to isolate pathogenic or likely pathogenic variants. Protein expression corresponding to the identified variants was assessed by immunostaining. Collagen content was significantly reduced in C-SCAD lesions compared with controls, and immunohistochemical staining for smoothelin was reduced in the media of C-SCAD lesions compared with controls, whereas there were no significant differences between C-SCAD and nonculprit SCAD. Further, the nuclear height/width ratio of smooth muscle cells was increased, suggesting smooth muscle cell phenotypic modulation. In whole-exome sequencing analysis, pathogenic or likely pathogenic variants were detected in 25% of cases, which showed a higher frequency of multivessel dissection. In SCAD cases with pathogenic or likely pathogenic variants in COL3A1 (collagen type III alpha 1), FBN1 (fibrillin-1), or FLNA (filamin A), the expression of the corresponding protein was reduced in the media. Reduced medial collagen and smooth muscle cell phenotypic modulation may be possible predisposing conditions for SCAD, regardless of the presence of pathogenic or likely pathogenic variants. The presence of pathogenic variants in extracellular matrix-related genes may further compromise arterial wall medial integrity, contributing to more severe disease. These findings provide novel pathological and genetic insights into the pathogenesis of SCAD and may inform future diagnostic and therapeutic strategies.
中文摘要:自发性冠状动脉夹层(SCAD)以冠状动脉壁分离为特征,可引起心肌梗死和猝死。本研究是最早阐明候选SCAD相关基因中的致病性遗传变异对人SCAD病变组织病理学和形态学特征影响的研究之一。从CVPath尸检登记库中选取28例SCAD病例。比较3组间胶原和平滑肌细胞的组织学差异:罪犯SCAD(C-SCAD),定义为SCAD病例中包含夹层的冠状动脉节段;非罪犯SCAD,定义为SCAD病例中未受累的冠状动脉节段(即健康动脉);以及非SCAD对照。进行全外显子测序,并对鉴定出的变异进行过滤,以分离致病性或可能致病性变异。通过免疫染色评估与所鉴定变异对应的蛋白表达。与对照组相比,C-SCAD病变中的胶原含量显著减少,并且与对照组相比,C-SCAD病变中膜平滑肌蛋白(smoothelin)免疫组化染色减少,而C-SCAD与非罪犯SCAD之间无显著差异。此外,平滑肌细胞的核高度/宽度比增加,提示平滑肌细胞表型调制。在全外显子测序分析中,25%的病例检测到致病性或可能致病性变异,这些病例显示多支血管夹层的发生率更高。在COL3A1(III型胶原α1)、FBN1(原纤维蛋白-1)或FLNA(细丝蛋白A)中存在致病性或可能致病性变异的SCAD病例中,相应蛋白在中膜的表达减少。中膜胶原减少和平滑肌细胞表型调制可能是SCAD的潜在易感条件,无论是否存在致病性或可能致病性变异。细胞外基质相关基因中致病性变异的存在可能进一步损害动脉壁中膜的完整性,导致更严重的疾病。这些发现为SCAD的发病机制提供了新的病理学和遗传学见解,并可能为未来的诊断和治疗策略提供信息。

21心肌病/心肌炎 (1篇)

临床研究 (1篇)

Circulation IF 41.3 2026-10-06 PMID: 42639666
Implanted cardioverter-defibrillators (ICDs) have been used in patients with hypertrophic cardiomyopathy (HCM) to prevent sudden death, and have proven lifesaving for many patients. However, experience with ICD therapy has largely been derived from relatively small HCM cohorts confined to specific countries or regions of the world. Therefore, we sought to determine the effectiveness of ICDs in preventing sudden death due to life-threatening ventricular arrhythmias in a large international multicenter HCM population. Databases from 25 HCM centers (8 in the United States, 9 in Europe, 4 in Asia, and 1 each in Australia, Africa, Mexico, and South America) were retrospectively interrogated to identify consecutive patients with HCM with ICDs (1992 to 2024) followed for 7±6 years (up to 32 years) for clinical outcomes. A total of 3387 patients were identified (63% men). They had a mean left ventricular thickness of 22±7 mm. The participants had received ICDs at a mean age of 47±17 years. Over follow-up, 550 patients (16%) experienced ≥1 appropriate ICD therapy (2.6%/y), including 86 of the 247 implanted for secondary prevention (35% [6.4%/y]) and 464 of the 3140 implanted for primary prevention (15% [2.2%/y]). Appropriate therapy occurred in the 464 primary prevention patients at a mean age of 49±17 years, with a median time to first appropriate therapy of 4 years after ICD implantation; 16% of these received their first appropriate therapy ≥10 years after implantation, and 47% experienced multiple interventions. Independent predictors of appropriate ICD therapy included unexplained syncope, left ventricular apical aneurysms, left ventricular systolic dysfunction, and nonsustained ventricular tachycardia on ambulatory monitoring. Of the 3140 primary prevention patients, 2946 survived (94%) and 194 died (6%) (0.8%/y), including 68 due to HCM (0.3%/y), predominantly of end-stage heart failure (n=43) or stroke (n=9). In contrast, 11 patients (0.4%) died suddenly, with device failures occurring in 2.4% of those with life-threatening ventricular tachyarrhythmias. Survival free from HCM-related mortality at 10 and 20 years was 97% and 91%, respectively. In this international multicenter study, the largest to date, including >3300 consecutive patients with HCM and ICDs, device therapy terminated potentially lethal ventricular tachyarrhythmias in 1 of 6 patients, with low HCM-related mortality rates for patients with ICDs. These novel data demonstrate the effectiveness of the ICD initiative, which has probably favorably altered the natural history of many patients with HCM worldwide.
中文摘要:植入型心律转复除颤器(ICD)已用于肥厚型心肌病(HCM)患者以预防猝死,并已被证明对许多患者可挽救生命。然而,ICD治疗经验在很大程度上来自相对较小的HCM队列,且局限于世界特定国家或地区。因此,我们试图在一个大型国际多中心HCM人群中确定ICD在预防由危及生命的室性心律失常所致猝死方面的有效性。回顾性查询了25个HCM中心(美国8个、欧洲9个、亚洲4个,澳大利亚、非洲、墨西哥和南美洲各1个)的数据库,以识别连续接受ICD的HCM患者(1992年至2024年),并随访7±6年(最长32年)以评估临床结局。共识别3387例患者(63%为男性)。平均左心室厚度为22±7 mm。参与者在平均年龄47±17岁时接受了ICD。随访期间,550例患者(16%)经历了至少1次恰当ICD治疗(2.6%/年),其中包括247例因二级预防植入者中的86例(35%[6.4%/年])和3140例因一级预防植入者中的464例(15%[2.2%/年])。恰当治疗在一级预防患者中于平均年龄49±17岁时发生,首次恰当治疗距ICD植入的中位时间为4年;其中16%在植入后≥10年才接受首次恰当治疗,47%经历了多次干预。恰当ICD治疗的独立预测因素包括不明原因晕厥、左心室心尖部室壁瘤、左心室收缩功能障碍以及动态监测中的非持续性室性心动过速。在3140例一级预防患者中,2946例存活(94%),194例死亡(6%)(0.8%/年),其中68例死于HCM(0.3%/年),主要为终末期心力衰竭(n=43)或卒中(n=9)。相比之下,11例患者(0.4%)发生猝死,在发生危及生命的室性快速性心律失常者中装置故障发生率为2.4%。10年和20年无HCM相关死亡的生存率分别为97%和91%。在这项迄今最大的国际多中心研究中,纳入超过3300例连续接受ICD的HCM患者,装置治疗在1/6的患者中终止了可能致命的室性快速性心律失常,ICD患者的HCM相关死亡率较低。这些新数据证明了ICD措施的有效性,可能已有利地改变了全球许多HCM患者的自然病史。

22胃黏膜病变 (1篇)

临床研究 (1篇)

Journal of advanced research IF 17.1 2026-10-05 PMID: 42833600
Hypoxia following mucosal congestion in clinical practice causes a wide range of gastrointestinal symptoms and induces profound structural and functional perturbations in mitochondria-associated ER membranes (MAMs), which are subcellular compartments whose integrity and stability are regulated by FUN14 domain-containing protein 1 (FUNDC1). To investigate the effect of hypoxia-induced MAMs formation on gastric mucosal lesions in patients with severe hepatic disorders. Liver cirrhosis (LC) and hepatic failure (HF) were selected as representative severe hepatic diseases, and gastric mucosal tissues were collected. We applied the gastrointestinal symptom rating scale (GSRS) and endoscopic images to evaluate the possible relationship between gastrointestinal symptoms and mucosal lesions. Portal hypertension (PHT)-induced mouse models and hypoxia-induced cell models were also established. The roles of FUNDC1, hypoxia-induced MAMs formation and mitochondrial oxidative stress in mucosal epithelial injury were analyzed. Patients with LC or HF frequently experienced gastrointestinal symptoms, which were correlated with the progression of gastric mucosal lesions. Hypoxia induced the upregulated expression of HIF-1α in gastric mucosal tissues, which was directly associated with the FUNDC1 promoter region, thereby increasing FUNDC1 gene transcription. Moreover, METTL3-mediated m6A methylation of FUNDC1 established a posttranscriptional regulatory layer to collectively drive upregulation of FUNDC1 expression. In addition, the increased level of FUNDC1 facilitated the formation of MAMs, drove a metabolic shift toward increased glycolysis, and elicited mitochondrial reactive oxygen species (mtROS) production. Ultimately, this increase in mtROS generation promoted NINJ1 oligomerization/activation to exacerbate gastric epithelial cell death and mucosal injury. Under hypoxic conditions, FUNDC1-regulated MAMs formation and mitochondrial oxidative stress play pivotal roles in the development of gastric mucosal lesions.
中文摘要:临床实践中黏膜淤血后发生的缺氧可引起多种胃肠道症状,并诱导线粒体相关内质网膜(MAMs)发生显著的结构和功能紊乱,而MAMs是受FUN14结构域蛋白1(FUNDC1)调控其完整性和稳定性的亚细胞结构。为探讨缺氧诱导的MAMs形成对严重肝病患者胃黏膜病变的影响。选择肝硬化(LC)和肝衰竭(HF)作为代表性严重肝病,并收集胃黏膜组织。我们应用胃肠道症状评定量表(GSRS)和内镜图像评估胃肠道症状与黏膜病变之间可能的关系。还建立了门静脉高压(PHT)诱导的小鼠模型和缺氧诱导的细胞模型。分析了FUNDC1、缺氧诱导的MAMs形成和线粒体氧化应激在黏膜上皮损伤中的作用。LC或HF患者常出现胃肠道症状,这些症状与胃黏膜病变的进展相关。缺氧诱导胃黏膜组织中HIF-1α表达上调,HIF-1α直接与FUNDC1启动子区域结合,从而增加FUNDC1基因转录。此外,METTL3介导的FUNDC1 m6A甲基化建立了转录后调控层,共同驱动FUNDC1表达上调。另外,FUNDC1水平升高促进MAMs形成,驱动代谢向糖酵解增强转变,并引起线粒体活性氧(mtROS)产生。最终,mtROS生成增加促进NINJ1寡聚化/激活,从而加剧胃上皮细胞死亡和黏膜损伤。在缺氧条件下,FUNDC1调控的MAMs形成和线粒体氧化应激在胃黏膜病变的发生发展中起关键作用。

23脂肪性肝炎 (1篇)

临床研究 (1篇)

Journal of hepatology IF 40.1 2026-10-05 PMID: 42833311
Resmetirom, a thyroid hormone receptor beta agonist, improves metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis in patients with non-cirrhotic MASH. Risk genotypes of PNPLA3, HSD17B13, TM6SF2, MTARC1, MBOAT7, and SERPINA1 have been associated with altered susceptibility to metabolic dysfunction-associated steatotic liver disease (MASLD), MASH, fibrosis, cirrhosis, and/or hepatocellular carcinoma. We evaluated the impact of MASLD risk genotypes on baseline characteristics and the response to resmetirom vs. placebo with respect to MASH, fibrosis, MRI-proton density fat fraction (MRI-PDFF), and other biomarkers. Testing the effects of MASLD risk genotypes or combinations of high-risk alleles on liver biopsy, MRI-PDFF, and biomarker responses to resmetirom was a pre-specified analysis in 738 patients enrolled in the MAESTRO-NASH phase III trial who consented to DNA collection, were genotyped for all genes, and had liver biopsies at baseline and Week 52. At baseline, patients with high-risk genotypes of PNPLA3 or HSD17B13 had a lower frequency of metabolic risk factors, including type 2 diabetes mellitus and hypertension, than patients with low-risk genotypes. Interaction analyses and efficacy assessments indicated that resmetirom had similar positive effects on MASH resolution, fibrosis improvement on liver biopsy, MRI-PDFF response, and biomarkers at Week 52 in MAESTRO-NASH patients with high-risk genotypes of PNPLA3, HSD17B13, TM6SF2, MTARC1, and MBOAT7, either individually or as part of a composite genetic risk score. These effects were independent of sex, Hispanic ethnicity, and metabolic risk factors. Due to the limited sample size, the study was not powered to detect small effects of risk genotypes on resmetirom efficacy. Resmetirom's effects on MASH, liver fibrosis, MRI-PDFF, and MASH biomarkers in the MAESTRO-NASH trial were not significantly impacted by the presence of common MASH risk genotypes, suggesting that resmetirom's mechanism of action may help mitigate the deleterious effects of MASH risk variants. Number: NCT03900429 IMPACT AND IMPLICATIONS: Resmetirom has recently been approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). It leads to MASH resolution and improvement of fibrosis in patients with non-cirrhotic MASH. Patients with MASH have higher prevalence of certain genetic variants which can be associated with more severe disease. In this study we evaluated the relationship between the presence of select MASH risk genotypes (e.g. PNPLA3, TM6SF2, or HSD17B13) or the combined total of MASH genetic risk alleles on the response to resmetirom and placebo in 738 patients with non-cirrhotic MASH with serial liver biopsies at baseline and week 52. Within the limitation of study sample size, resmetirom's benefits on MASH resolution, fibrosis improvement and hepatic steatosis were independent of the presence of MASH genetic risk genotypes either alone or in combination.
中文摘要:Resmetirom是一种甲状腺激素受体β激动剂,可改善非肝硬化MASH患者的代谢功能障碍相关脂肪性肝炎(MASH)和肝纤维化。PNPLA3、HSD17B13、TM6SF2、MTARC1、MBOAT7和SERPINA1的风险基因型已被认为与代谢功能障碍相关脂肪性肝病(MASLD)、MASH、纤维化、肝硬化和/或肝细胞癌易感性的改变有关。我们评估了MASLD风险基因型对基线特征以及resmetirom与安慰剂相比在MASH、纤维化、MRI质子密度脂肪分数(MRI-PDFF)和其他生物标志物方面应答的影响。在MAESTRO-NASH III期试验中入组的738例患者中,检测MASLD风险基因型或高风险等位基因组合对肝活检、MRI-PDFF和生物标志物应答的影响是一项预先设定的分析,这些患者同意进行DNA采集,接受了所有基因的基因分型,并在基线和第52周进行了肝活检。基线时,PNPLA3或HSD17B13高风险基因型患者的代谢危险因素(包括2型糖尿病和高血压)频率低于低风险基因型患者。交互作用分析和疗效评估表明,在MAESTRO-NASH患者中,无论PNPLA3、HSD17B13、TM6SF2、MTARC1和MBOAT7的高风险基因型是单独存在还是作为复合遗传风险评分的一部分,resmetirom在第52周对MASH消退、肝活检纤维化改善、MRI-PDFF应答和生物标志物均具有相似的积极影响。这些影响独立于性别、西班牙裔族裔和代谢危险因素。由于样本量有限,本研究不足以检测风险基因型对resmetirom疗效的微小影响。在MAESTRO-NASH试验中,resmetirom对MASH、肝纤维化、MRI-PDFF和MASH生物标志物的影响未受到常见MASH风险基因型存在的显著影响,提示resmetirom的作用机制可能有助于减轻MASH风险变异的有害影响。编号:NCT03900429。影响与意义:resmetirom最近已获批用于治疗代谢功能障碍相关脂肪性肝炎(MASH)。它可使非肝硬化MASH患者实现MASH消退和纤维化改善。MASH患者中某些遗传变异的患病率较高,这些变异可能与更严重的疾病相关。在本研究中,我们评估了选定MASH风险基因型(例如PNPLA3、TM6SF2或HSD17B13)的存在或MASH遗传风险等位基因总和与resmetirom和安慰剂应答之间的关系,研究对象为738例非肝硬化MASH患者,他们在基线和第52周接受了系列肝活检。在研究样本量的限制内,resmetirom对MASH消退、纤维化改善和肝脂肪变性的益处独立于MASH遗传风险基因型的存在,无论是单独存在还是组合存在。

24心肌桥 (1篇)

临床研究 (1篇)

European heart journal IF 45.3 2026-10-05 PMID: 41873713
Myocardial bridging is the most common congenital coronary anomaly, characterized by an intramyocardial course of a segment of an epicardial coronary artery, with considerable variability in its depth and length. In most cases, MB is a benign anatomical variant without clinical significance, often asymptomatic and not requiring treatment. However, with the increasing use of coronary computed tomography angiography for coronary assessment, myocardial bridging is now more frequently identified during non-invasive imaging. It can also be diagnosed via invasive coronary angiography, where it appears as a dynamic systolic compression of the tunnelled artery segment, and further anatomical characterization can be enhanced by intravascular ultrasound or optical coherence tomography. Growing recognition of myocardial bridging's role in ischaemia with non-obstructive coronary arteries has heightened clinical interest in its prevalence, diagnostic strategies, and management approaches. As such, this narrative review provides clinicians with an updated, evidence-based guide to the diagnosis and therapeutic management of myocardial bridging, while also addressing ongoing controversies and areas of uncertainty.
中文摘要:心肌桥是最常见的先天性冠状动脉异常,其特征为一段心外膜冠状动脉走行于心肌内,且其深度和长度存在相当大的变异性。在大多数情况下,心肌桥是一种无临床意义的良性解剖变异,常无症状且无需治疗。然而,随着冠状动脉计算机断层扫描血管成像在冠状动脉评估中的应用日益增多,心肌桥目前在无创成像中被更频繁地发现。它也可通过有创冠状动脉造影诊断,在造影中表现为隧道段动脉的动态收缩期受压,而血管内超声或光学相干断层扫描可进一步增强对其解剖特征的描述。随着对心肌桥在非阻塞性冠状动脉缺血中作用的认识不断加深,临床对其患病率、诊断策略和管理方法的关注也有所增加。因此,本叙述性综述为临床医生提供了关于心肌桥诊断和治疗管理的更新、循证指南,同时也讨论了持续存在的争议和不确定领域。

25高原病 (1篇)

基础研究 (1篇)

MedComm IF 14.1 2026-10 PMID: 42830791
High-altitude diseases (HADs) encompass a spectrum of acute and chronic disorders-including acute mountain sickness, high-altitude cerebral edema, high-altitude pulmonary edema, high-altitude polycythemia, high-altitude pulmonary hypertension, and high-altitude heart disease-that arise from insufficient adaptation to hypobaric hypoxia. Despite their heterogeneous clinical manifestations, these conditions represent a continuum from acute adaptive stress to chronic maladaptive compensation, unified by persistent oxygen deprivation and dysregulated systemic homeostasis. G protein-coupled receptors (GPCRs), the largest superfamily of membrane receptors, have emerged as central regulators of hypoxia sensing, ventilatory control, vascular tone, barrier integrity, erythropoiesis, immune activation, and metabolic reprogramming. However, how specific GPCR subtypes and their downstream signaling networks coordinate adaptation versus maladaptation across distinct organ systems and disease stages remains incompletely defined. This review synthesizes recent mechanistic insights into GPCR-mediated pathways that govern neural, pulmonary, vascular, and hematologic responses to hypoxia. We examine the transition from protective to pathological signaling, highlight receptor-level divergence that enables therapeutic selectivity, and evaluate translational prospects for GPCR-targeted strategies, including biased agonism, receptor-specific modulation, and sex-based interventions. These advances establish a framework for precision therapies tailored to high-altitude populations.
中文摘要:高原病(HADs)涵盖一系列急性和慢性疾病,包括急性高山病、高原脑水肿、高原肺水肿、高原红细胞增多症、高原肺动脉高压和高原心脏病,这些疾病源于对低压性缺氧适应不足。尽管其临床表现异质,这些病症代表了从急性适应性应激到慢性适应不良性代偿的连续过程,其共同特征是持续性氧剥夺和全身稳态失调。G蛋白偶联受体(GPCRs)是最大的膜受体超家族,已成为缺氧感知、通气控制、血管张力、屏障完整性、红细胞生成、免疫激活和代谢重编程的核心调节因子。然而,特定GPCR亚型及其下游信号网络如何在不同的器官系统和疾病阶段协调适应与适应不良,仍未完全明确。本综述综合了近期关于GPCR介导的通路调控神经、肺、血管和血液系统对缺氧反应的机制性见解。我们考察了从保护性信号向病理性信号的转变,强调了能够实现治疗选择性的受体水平差异,并评估了GPCR靶向策略的转化前景,包括偏向性激动、受体特异性调节和基于性别的干预措施。这些进展为针对高原人群的精准治疗建立了框架。

26心脏瓣膜病/TAVR (1篇)

临床研究 (1篇)

JAMA network open IF 11.7 2026-10-01 PMID: 42832200
The optimal timing of mitral valve (MV) surgery in patients with asymptomatic severe primary mitral regurgitation (MR) remains uncertain because randomized clinical trials are lacking. To evaluate the association of early MV surgery with long-term survival in patients with asymptomatic severe primary MR using a target trial emulation framework. This cohort study used a clinical valve registry from 3 tertiary hospitals in South Korea between 2000 and 2022. Patients with asymptomatic severe primary MR were analyzed using a clone-censor-weight approach to emulate a target trial. A 6-month grace period after diagnosis was used to define treatment strategies. This analysis was conducted from September 2024 to January 2025. Early MV surgery (within 6 months of diagnosis) vs watchful waiting. The primary outcome was all-cause mortality and the secondary outcome, a composite of all-cause mortality or heart failure hospitalization. Inverse probability of censoring-weighted estimates of the per-protocol effect size included restricted mean survival time (RMST) differences as the primary measure and hazard ratios (HRs) as secondary measures. Among 802 patients (mean [SD] age, 55 [16] years; 476 men [59%]), 344 underwent early surgery, and 458 received watchful waiting. During a median (IQR) follow-up of 7.4 (4.1-11.6) years, 27 deaths occurred in the early surgery group and 103 in the watchful waiting group. At 5 years, early surgery was associated with an RMST gain of 66 days (95% CI, 19-129 days). The survival benefit persisted up to 15 years. Early surgery was also associated with a lower risk of all-cause mortality compared with watchful waiting (HR, 0.69; 95% CI, 0.41-0.94; P = .02). Similar associations were observed in patients without left ventricular decompensation (HR, 0.61; 95% CI, 0.31-0.96; P = .04) and in those with degenerative MR (HR, 0.66; 95% CI, 0.36-0.98; P = .04). In this multicenter cohort study with a target trial framework, early surgery was associated with improved long-term survival among patients with asymptomatic severe primary MR. These findings support consideration of earlier surgical intervention in contemporary clinical practice.
中文摘要:无症状重度原发性二尖瓣反流患者中二尖瓣手术的最佳时机仍不确定,因为缺乏随机临床试验。本研究旨在采用目标试验模拟框架,评估早期二尖瓣手术与无症状重度原发性二尖瓣反流患者长期生存之间的关联。这项队列研究使用了韩国3家三级医院2000年至2022年的临床瓣膜登记数据。采用克隆-删失-加权方法分析无症状重度原发性二尖瓣反流患者,以模拟目标试验。诊断后6个月的宽限期用于定义治疗策略。本分析于2024年9月至2025年1月进行。早期二尖瓣手术(诊断后6个月内)与观察等待进行比较。主要结局为全因死亡,次要结局为全因死亡或心力衰竭住院的复合结局。采用逆概率删失加权估计符合方案效应量,主要指标为限制性平均生存时间(RMST)差异,次要指标为风险比(HR)。在802例患者中(平均[SD]年龄55[16]岁;476例男性[59%]),344例接受早期手术,458例接受观察等待。在中位(IQR)随访7.4(4.1-11.6)年期间,早期手术组发生27例死亡,观察等待组发生103例死亡。5年时,早期手术与RMST增加66天相关(95% CI,19-129天)。生存获益持续至15年。与观察等待相比,早期手术还与较低的全因死亡风险相关(HR,0.69;95% CI,0.41-0.94;P = .02)。在无左心室失代偿的患者中(HR,0.61;95% CI,0.31-0.96;P = .04)以及退行性MR患者中(HR,0.66;95% CI,0.36-0.98;P = .04)也观察到类似关联。在这项采用目标试验框架的多中心队列研究中,早期手术与无症状重度原发性二尖瓣反流患者长期生存改善相关。这些发现支持在当代临床实践中考虑更早进行手术干预。

27缺血再灌注损伤 (1篇)

基础研究 (1篇)

Biomarker research IF 14.6 2026-10-01 PMID: 42823774
Ischemia-reperfusion injury (IRI) contributes to the pathogenesis of major diseases, including acute kidney injury, stroke, and myocardial infarction. Multiple forms of cell death, including apoptosis, necroptosis, pyroptosis, autophagy, and ferroptosis, are key contributors to IRI. The interplay among these cell-death programs adds to the complexity of the IRI landscape. Cell-death patterns differ markedly between the ischemic and reperfusion phases and across organs, reflecting the spatiotemporal and organ-specific features of IRI. Given the complex molecular mechanisms underlying IRI, multi-target small-molecule drugs, combination regimens, and nanodelivery systems have been explored, although most remain at the preclinical stage. In this review, we summarize the major cell-death modalities involved in IRI, their interconnected molecular targets and signaling pathways, and their phase-specific and organ-specific regulation. We further discuss the coordinated roles of non-coding RNAs, metabolic reprogramming, and epigenetic alterations in regulating cell death, as well as their therapeutic potential. Finally, we propose therapeutic strategies aimed at modulating crosstalk among cell-death modalities, with potential implications for individualized IRI therapy.
中文摘要:缺血再灌注损伤(IRI)参与急性肾损伤、脑卒中和心肌梗死等重大疾病的发病机制。凋亡、坏死性凋亡、焦亡、自噬和铁死亡等多种细胞死亡形式是IRI的关键促成因素。这些细胞死亡程序之间的相互作用增加了IRI病理图景的复杂性。缺血期与再灌注期以及不同器官之间的细胞死亡模式存在显著差异,反映了IRI的时空和器官特异性特征。鉴于IRI涉及的复杂分子机制,多靶点小分子药物、联合方案和纳米递送系统已得到探索,但大多数仍处于临床前阶段。在本综述中,我们总结了IRI涉及的主要细胞死亡模式、其相互关联的分子靶点和信号通路,以及其阶段特异性和器官特异性调控。我们进一步讨论了非编码RNA、代谢重编程和表观遗传改变在调控细胞死亡中的协同作用及其治疗潜力。最后,我们提出了旨在调控细胞死亡模式之间串扰的治疗策略,并可能对个体化IRI治疗具有意义。

28心肺疾病 (1篇)

临床研究 (1篇)

Nature cardiovascular research IF 12.6 2026-10-01 PMID: 42823459
Daily apparel could enable continuous, noninvasive monitoring of cardiopulmonary health for the early detection and treatment of cardiopulmonary diseases, the leading causes of death and disability worldwide. Here we develop an all-fiber wireless auscultation system seamlessly integrated into garments. An ~150-μm-diameter fiber contact microphone is sewn, knitted or woven into clothing to capture deep-body acoustic signals while overcoming acoustic impedance mismatch and electromagnetic noise. An ~500-μm knitted fiber computer enables real-time signal processing and Bluetooth transmission to a mobile device. A clinical study in 10 patients with heart failure and 20 neonates demonstrated cardiopulmonary sound capture, including qualitative examples of pathological acoustic features such as cardiac murmurs, S3 gallops and crackles. Comparative validation against a digital stethoscope confirms the garment's ability to suppress environmental noise for high-fidelity cardiopulmonary sound capture. In addition, the fiber integrated within the garment array enables spatial sound mapping of cardiac and pulmonary abnormalities for localized diagnostics.
中文摘要:日常服装有望实现对心肺健康的连续、无创监测,从而促进心肺疾病的早期发现和治疗,而心肺疾病是全球死亡和残疾的主要原因。在这里,我们开发了一种无缝集成到服装中的全纤维无线听诊系统。将直径约150微米的光纤接触式传声器缝制、针织或编织到衣物中,以捕获深部身体声学信号,同时克服声阻抗失配和电磁噪声。约500微米的针织纤维计算机可实现实时信号处理并通过蓝牙传输到移动设备。一项纳入10例心力衰竭患者和20名新生儿的临床研究展示了心肺声音捕获,包括病理性声学特征的定性示例,如心脏杂音、S3奔马律和湿啰音。与数字听诊器的对比验证证实了该服装能够抑制环境噪声,从而实现高保真心肺声音捕获。此外,集成在服装阵列中的纤维可实现心脏和肺部异常的空间声音映射,用于定位诊断。

29小细胞肺癌 (1篇)

临床研究 (1篇)

Journal for immunotherapy of cancer IF 11.7 2026-10-01 PMID: 42823088
Immune-checkpoint inhibitors (ICIs) plus chemotherapy have demonstrated survival benefits in extensive-stage small cell lung cancer (SCLC). The integration of immunotherapy with concurrent chemoradiotherapy (CCRT) may improve survival outcomes in limited-stage SCLC (LS-SCLC). This phase II randomized controlled study was designed to evaluate the efficacy and safety of toripalimab consolidation versus observation in patients with LS-SCLC after CCRT. We conducted this phase II, randomized controlled trial in patients with LS-SCLC who had completed CCRT. Eligible patients were randomized 1:1 to either toripalimab consolidation (240 mg every 3 weeks for up to 6 months) or observation. Randomization was stratified according to disease stage (I or II vs III) and the receipt of prophylactic cranial irradiation (PCI) (yes vs no). The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival (OS), objective response rate and toxicities. Between June 30, 2020, and May 31, 2024, a total of 98 patients were randomized to receive either toripalimab consolidation (n=49) or observation (n=49) after CCRT. The trial was prematurely terminated on May 31, 2024. Objective responses were observed in 14 of 23 patients (60.9%) in the toripalimab group and in 9 of 24 patients (37.5%) in the observation group. The median PFS was not reached in the toripalimab group, compared with 14.1 months (95% CI 2.8 to 25.4) in the observation group (HR, 0.55; 95% CI 0.31 to 0.96). The median OS was not reached with toripalimab, compared with 30.3 months (95% CI 20.4 to 40.2) with observation (HR, 0.39; 95% CI 0.19 to 0.80). Treatment-related toxicities were generally mild. Adverse events led to discontinuation of study drug in 6 of 48 patients (12.5%) in the toripalimab group. Grade 3 pneumonitis or radiation pneumonitis occurred in two patient (4.2%) in the toripalimab group and one patient (2.0%) in the observation group. No grade 4 or 5 adverse events occurred in either group. Subgroup analyses of PFS and OS favored toripalimab over observation across all predefined subgroups, including age, sex, Eastern Cooperative Oncology Group performance status, smoking status, disease stage, response to CCRT and the receipt of PCI. Consolidative toripalimab showed promising signals of improved PFS and OS with a manageable safety profile in patients with LS-SCLC. These findings warrant confirmation in larger, adequately powered randomized trials.
中文摘要:免疫检查点抑制剂联合化疗已在广泛期小细胞肺癌中显示出生存获益。将免疫治疗与同步放化疗整合可能改善局限期小细胞肺癌的生存结局。这项II期随机对照研究旨在评估特瑞普利单抗巩固治疗与观察相比在同步放化疗后局限期小细胞肺癌患者中的疗效和安全性。我们在已完成同步放化疗的局限期小细胞肺癌患者中开展了这项II期随机对照试验。符合条件的患者按1:1随机分配至特瑞普利单抗巩固治疗组(240 mg,每3周一次,最多6个月)或观察组。随机化按疾病分期(I或II期与III期)和是否接受预防性颅脑照射进行分层。主要终点为无进展生存期。次要终点包括总生存期、客观缓解率和毒性。2020年6月30日至2024年5月31日期间,共98例患者被随机分配至同步放化疗后接受特瑞普利单抗巩固治疗(n=49)或观察(n=49)。试验于2024年5月31日提前终止。特瑞普利单抗组23例患者中14例(60.9%)观察到客观缓解,观察组24例患者中9例(37.5%)观察到客观缓解。特瑞普利单抗组中位无进展生存期未达到,而观察组为14.1个月(95%置信区间2.8至25.4)(风险比0.55;95%置信区间0.31至0.96)。特瑞普利单抗组中位总生存期未达到,而观察组为30.3个月(95%置信区间20.4至40.2)(风险比0.39;95%置信区间0.19至0.80)。治疗相关毒性总体较轻。特瑞普利单抗组48例患者中6例(12.5%)因不良事件停用研究药物。特瑞普利单抗组2例患者(4.2%)和观察组1例患者(2.0%)发生3级肺炎或放射性肺炎。两组均未发生4级或5级不良事件。在所有预设亚组中,包括年龄、性别、美国东部肿瘤协作组体能状态评分、吸烟状况、疾病分期、对同步放化疗的反应和是否接受预防性颅脑照射,无进展生存期和总生存期的亚组分析均支持特瑞普利单抗优于观察。巩固性特瑞普利单抗在局限期小细胞肺癌患者中显示出改善无进展生存期和总生存期的有希望信号,且安全性可控。这些发现需在更大规模、具有足够检验效能的随机试验中加以确认。

30心血管代谢病 (1篇)

基础研究 (1篇)

Pharmacological research IF 12.2 2026-10-01 PMID: 42822554
Reticulon-3 (RTN3) was initially studied as an endoplasmic reticulum (ER)-resident reticulon family protein involved in membrane shaping, apoptosis, and amyloid precursor protein processing. More recent work has considerably expanded this view and now places RTN3 at the intersection of ER remodeling, selective ER-phagy, cargo trafficking, lipid handling, and stress signaling. This shift is especially relevant to pharmacology, because RTN3 appears to exhibit heterogeneous effects across tissues and disease states: RTN3 upregulation is maladaptive in obesity, nonalcoholic fatty liver disease, cardiac lipotoxicity, post-myocardial infarction heart failure, and some vascular conditions, whereas RTN3 loss aggravates renal injury, renal fibrosis, and pulmonary fibrosis. Viral infection and hepatocellular carcinoma further illustrate that RTN3 can either support membrane remodeling programs or constrain disease progression, depending on the biological environment. In this review, we reorganize RTN3 biology around mechanism-driven processes and discuss how these processes converge on cardiometabolic, fibrotic, infectious, and oncologic phenotypes. Current evidence suggests that RTN3 is better regarded as a membrane organizing regulator with therapeutic potential rather than a disease specific marker. However, future efforts to target RTN3 will likely need to consider tissue type and pathway specificity.
中文摘要:网状蛋白3(RTN3)最初是作为内质网(ER)驻留的网状蛋白家族蛋白被研究,参与膜塑形、凋亡和淀粉样前体蛋白加工。近期研究显著拓展了这一观点,现将RTN3置于内质网重塑、选择性内质网自噬、货物运输、脂质处理和应激信号传导的交汇点。这一转变对药理学尤为重要,因为RTN3在不同组织和疾病状态中似乎表现出异质性效应:RTN3上调在肥胖、非酒精性脂肪肝病、心脏脂毒性、心肌梗死后心力衰竭以及某些血管状况中具有适应不良性,而RTN3缺失会加重肾损伤、肾纤维化和肺纤维化。病毒感染和肝细胞癌进一步说明,RTN3既能支持膜重塑程序,也能限制疾病进展,具体取决于生物学环境。在本综述中,我们围绕机制驱动的过程重新组织RTN3生物学,并讨论这些过程如何汇聚于心脏代谢、纤维化、感染和肿瘤表型。当前证据表明,RTN3更适合被视为具有治疗潜力的膜组织调节因子,而不是疾病特异性标志物。然而,未来靶向RTN3的努力可能需要考虑组织类型和通路特异性。

31心脏瓣膜病 (1篇)

临床研究 (1篇)

Annual review of medicine IF 18.8 2026-10-01 PMID: 42822101
In the landscape of valvular heart disease, the tricuspid valve has traditionally been dubbed the forgotten valve. However, over the last several years, studies have demonstrated that tricuspid valve disease is increasing in prevalence due to a growing aging population, and tricuspid regurgitation, in particular, is associated with increased mortality and morbidity. Traditional surgical tricuspid valve replacement or repair is often an undesirable option for patients with severe tricuspid regurgitation due to the high rates of concurrent comorbidities seen in this patient population; accordingly, treatment has traditionally been largely confined to symptom management with medical therapy. More recently, however, the field has experienced a major paradigm shift toward transcatheter interventions. Pivotal trials evaluating transcatheter edge-to-edge repair and transcatheter tricuspid valve replacement have shown that these therapies safely achieve robust tricuspid regurgitation reduction, reduce heart failure hospitalization, and significantly improve patient-reported quality of life in the short term. These technologies have been key in providing treatment options for a large, previously underserved patient population, but further research is needed to establish the durability of these devices and to evaluate the cost-effectiveness of these interventions within a value-based healthcare framework.
中文摘要:在瓣膜性心脏病领域,三尖瓣历来被称为「被遗忘的瓣膜」。然而,过去几年中,研究表明,由于人口老龄化加剧,三尖瓣疾病的患病率正在上升,尤其是三尖瓣反流与死亡率和发病率增加相关。传统的三尖瓣置换或修复手术对于重度三尖瓣反流患者往往不是理想选择,因为该患者人群常合并多种疾病;因此,治疗传统上主要局限于药物对症治疗。不过,近年来该领域经历了向经导管介入治疗的重大范式转变。评估经导管缘对缘修复和经导管三尖瓣置换的关键试验显示,这些疗法可安全地显著减少三尖瓣反流、降低心力衰竭住院,并在短期内显著改善患者报告的生活质量。这些技术为一大群既往缺乏治疗选择的患者提供了治疗选择,但仍需进一步研究以确定这些器械的耐久性,并在基于价值的医疗框架内评估这些干预措施的成本效益。

32血栓性疾病 (1篇)

临床研究 (1篇)

Circulation IF 41.3 2026-10-01 PMID: 42817881
Antithrombotic therapy undertreatment includes omission, nonadherence, underdosing, and clinical circumstances that result in subtherapeutic antithrombotic levels. Antithrombotic undertreatment has profound implications for patient safety, public health, and healthcare costs. Due to deviation from evidence-based clinical practice, misperceptions of bleeding versus thrombotic risk, and inequities in healthcare access, many patients with atrial fibrillation, venous thromboembolism, or peripheral artery disease remain untreated or receive suboptimal anticoagulant dosing. Antithrombotic undertreatment has been shown to increase rates of ischemic stroke, systemic embolism, recurrent thrombosis, and mortality. Real-world data continue to highlight substantial gaps in care, which appear to be magnified in patients with inequity in social determinants of health. The emergence of antithrombotic stewardship, in concert with growing bodies of literature on antithrombotic agent underdosing, represents a transformative opportunity to address these gaps through structured, interprofessional, and evidence-based approaches. Through interdisciplinary collaboration, healthcare professionals are well positioned to enhance patient health and safety by recognizing and recommitting to reducing antithrombotic undertreatment.
中文摘要:抗栓治疗不足包括遗漏、不依从、剂量不足以及导致抗栓水平低于治疗水平的临床情况。抗栓治疗不足对患者安全、公共卫生和医疗费用具有深远影响。由于偏离循证临床实践、对出血风险与血栓形成风险的误解以及医疗可及性方面的不公平,许多心房颤动、静脉血栓栓塞或外周动脉疾病患者仍未接受治疗或接受次优的抗凝剂量。抗栓治疗不足已被证明会增加缺血性卒中、系统性栓塞、复发性血栓形成和死亡的发生率。真实世界数据持续凸显出医疗中的显著差距,而在健康社会决定因素方面存在不公平的患者中,这些差距似乎被放大。抗栓治疗管理的出现,加之关于抗栓药物剂量不足的文献日益增多,提供了一个变革性机会,通过结构化、跨专业和循证的方法来弥合这些差距。通过跨学科合作,医疗专业人员处于有利位置,能够识别并重新致力于减少抗栓治疗不足,从而增进患者健康与安全。

33实体瘤 (1篇)

临床研究 (1篇)

Signal transduction and targeted therapy IF 81.2 2026-10-01 PMID: 42816483
We developed a novel carbon nanoparticle-Fe (II) complex prepared via suspension injection (CNSI-Fe) to induce cancer cell ferroptosis through direct intratumoral delivery of ferrous iron. Preclinical studies have demonstrated that CNSI-Fe has promising antitumour effects, thereby prompting this first-in-human, single-arm, open-label, dose-escalation phase I trial in patients with refractory solid tumors. Primary objectives included assessments of safety and tolerability and the determination of dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD). Secondary objectives included the determination of preliminary antitumour efficacy and pharmacokinetics. Applying a 3 + 3 design across five doses (30-150 mg), a total of 19 enrolled patients received CNSI-Fe treatment. The MTD was not reached, and only one patient (in the 90 mg cohort) experienced DLT events. For all treated patients (n = 19), the common adverse events included injection site pain (89.5%), hypertension (52.6%), elevated serum iron levels (47.4%), and anemia (47.4%). Pharmacokinetic analysis revealed rapid iron absorption (peak time: 0.15-0.41 h) and clearance (half-life: 1.96-5.06 h), with peak serum concentrations ranging from 3520.33 to 13961.67 ng/mL. Preliminary efficacy estimates revealed an overall response rate of 10.5% and a disease control rate (DCR) of 84.2%. Notably, the DCR reached 100% in patients with lymph node and sarcoma lesions. Overall, CNSI-Fe demonstrated a favorable safety profile and promising antitumour activity (ClinicalTrials.gov identifier: NCT06048367), supporting further investigations in a phase II trial.
中文摘要:我们开发了一种通过混悬注射液制备的新型碳纳米颗粒-Fe(II)复合物(CNSI-Fe),通过直接瘤内递送亚铁离子诱导癌细胞铁死亡。临床前研究已显示CNSI-Fe具有良好的抗肿瘤作用,因此促成了这项在难治性实体瘤患者中开展的首个人体、单臂、开放标签、剂量递增I期试验。主要目标包括评估安全性和耐受性,并确定剂量限制性毒性(DLT)和最大耐受剂量(MTD)。次要目标包括确定初步抗肿瘤疗效和药代动力学。采用3+3设计,在五个剂量水平(30-150 mg)下,共有19例入组患者接受了CNSI-Fe治疗。未达到MTD,仅1例患者(90 mg队列)出现DLT事件。对于所有接受治疗的患者(n=19),常见不良事件包括注射部位疼痛(89.5%)、高血压(52.6%)、血清铁水平升高(47.4%)和贫血(47.4%)。药代动力学分析显示铁吸收迅速(达峰时间:0.15-0.41 h)和清除迅速(半衰期:1.96-5.06 h),峰值血清浓度为3520.33至13961.67 ng/mL。初步疗效估计显示总缓解率为10.5%,疾病控制率(DCR)为84.2%。值得注意的是,在淋巴结和肉瘤病变患者中,DCR达到100%。总体而言,CNSI-Fe表现出良好的安全性特征和有前景的抗肿瘤活性(ClinicalTrials.gov注册号:NCT06048367),支持在II期试验中进一步研究。

34瘫痪 (1篇)

临床研究 (1篇)

Nature neuroscience IF 20.3 2026-10 PMID: 42736415
Stroke and neurodegenerative diseases can impair speech and nonverbal gestures, limiting natural communication. Brain-computer interfaces (BCIs) aim to restore these functions by translating neural activity into commands for external devices, although prior work has primarily focused on decoding speech or gestures in isolation. Here we show that neural signals recorded with a single high-density electrocorticography implant can support simultaneous decoding of speech and gestures in people with paralysis. We first show that isolated upper-limb and orofacial movements can be reliably decoded among three participants. Using parallel speech and gesture decoders, we then enabled participants to control a personalized virtual avatar by attempting speech and gestures simultaneously or in isolation. Training models on both isolated and simultaneous data improved performance across behavioral contexts. These findings demonstrate that one cortical implant can support multi-effector control and provide a step toward BCIs that enable more natural communication for people with paralysis.
中文摘要:卒中和神经退行性疾病可损害言语和非言语手势,限制自然交流。脑机接口旨在通过将神经活动转化为外部设备的命令来恢复这些功能,不过以往工作主要集中于单独解码言语或手势。在此,我们表明,使用单个高密度皮层脑电图植入物记录的神经信号可支持对瘫痪患者言语和手势的同步解码。我们首先表明,在三位参与者中,可可靠解码孤立的上肢和口面部运动。随后,利用并行的言语和手势解码器,我们使参与者能够通过同时或单独尝试言语和手势来控制个性化的虚拟化身。在孤立和同步数据上训练模型,改善了不同行为情境下的性能。这些发现表明,单个皮层植入物可支持多效应器控制,并为实现使瘫痪患者能够更自然交流的脑机接口迈出了一步。

35其他(重症医学) (1篇)

临床研究 (1篇)

Intensive care medicine IF 22.0 2026-10 PMID: 42645558
Critical illness is characterised by activation of the sympathetic nervous system which plays an important adaptive role in maintaining cardiovascular stability and organ perfusion. However, excessive sustained adrenergic stimulation may become maladaptive, contributing to tachyarrhythmias, myocardial injury, immune dysregulation, metabolic derangements, and organ dysfunction. This state-of-the-art review evaluates the role of ß-blocker therapy as a potential strategy to modulate or counteract the adrenergic response in critically ill patients. Current data suggest that their use remains highly context-dependent and controversial. There are established benefits in selected scenarios, including acute myocardial infarction, tachyarrhythmias, hypertensive emergencies, thyroid storm, and prevention of variceal bleeds. In contrast, evidence is limited or conflicting in septic shock, traumatic brain injury, acute heart failure, burns and other critical care syndromes. Concerns include impairment of compensatory cardiovascular responses, reduction of cardiac output, hypotension, and compromised organ perfusion. Furthermore, the safety and efficacy of ß-blockade appear to depend on the type and dose of ß-blocker, patient phenotype, timing of initiation, hemodynamic reserve, and whether therapy represents continuation of chronic treatment, withdrawal and re-initiation, or de novo initiation during acute illness. This review highlights major gaps in knowledge, including the absence of reliable indicators to identify patients most likely to benefit, uncertainty regarding optimal treatment targets and monitoring strategies, and limited randomised evidence in heterogeneous ICU populations. A phenotype-driven, physiology-guided approach that accounts for hemodynamic status, sympathetic spectrum and timing of ß-blocker therapy is likely required to optimise outcomes.
中文摘要:危重症的特征是交感神经系统激活,其在维持心血管稳定和器官灌注方面发挥重要的适应性作用。然而,过度而持续的交感肾上腺素能刺激可能变为适应不良,从而促发快速性心律失常、心肌损伤、免疫失调、代谢紊乱和器官功能障碍。本前沿综述评估了β受体阻滞剂治疗作为调节或对抗危重症患者肾上腺素能反应的潜在策略所起的作用。现有数据提示,其使用仍高度依赖具体情境且存在争议。在某些特定情形下已确立获益,包括急性心肌梗死、快速性心律失常、高血压急症、甲状腺危象以及预防静脉曲张破裂出血。相比之下,在脓毒性休克、创伤性脑损伤、急性心力衰竭、烧伤及其他重症监护综合征中,证据有限或相互矛盾。相关顾虑包括损害代偿性心血管反应、降低心输出量、低血压以及影响器官灌注。此外,β受体阻滞的安全性和有效性似乎取决于β受体阻滞剂的种类与剂量、患者表型、启动时机、血流动力学储备,以及该治疗是慢性治疗的延续、停药后再启动,还是在急性疾病期间新启动。本综述强调了重要的知识空白,包括缺乏可靠指标以识别最可能获益的患者、最佳治疗目标与监测策略尚不明确,以及在异质性ICU人群中随机证据有限。可能需要一种以表型为驱动、以生理学为指导的方法,兼顾血流动力学状态、交感神经张力谱以及β受体阻滞剂治疗的时机,以优化结局。

36妊娠糖尿病 (1篇)

临床研究 (1篇)

Diabetes care IF 22.6 2026-10-01 PMID: 42585298
The association of gestational diabetes mellitus (GDM) subtypes with maternal cardiometabolic health is not known. We examined whether GDM subtypes were differentially associated with cardiometabolic health 10-14 years after delivery. We used data from the prospective Hyperglycemia and Adverse Pregnancy Outcome Follow-Up Study. The exposure was GDM subtype (insulin deficient, insulin resistant, mixed defect, unclassified). The outcomes were prediabetes or diabetes and, secondarily, hypertension, dyslipidemia, metabolic syndrome, and predicted cardiovascular disease. Of 4,693 women, 3.0% had insulin-deficient, 9.0% insulin-resistant, 1.6% mixed-defect, and 0.7% unclassified GDM. Compared with no GDM, all GDM subtypes except unclassified were associated with higher risk of prediabetes or diabetes (adjusted risk ratios 2.14-2.88), metabolic syndrome, and predicted cardiovascular disease. Only insulin-resistant GDM was associated with dyslipidemia. All GDM subtypes were associated with an increased risk of prediabetes or diabetes, metabolic syndrome, and high predicted cardiovascular disease 10-14 years after delivery.
中文摘要:妊娠期糖尿病(GDM)亚型与母亲心脏代谢健康之间的关联尚不清楚。我们研究了GDM亚型是否与分娩后10-14年的心脏代谢健康存在差异性关联。我们使用了前瞻性高血糖与不良妊娠结局随访研究的数据。暴露为GDM亚型(胰岛素缺乏型、胰岛素抵抗型、混合缺陷型、未分类)。结局为糖尿病前期或糖尿病,其次为高血压、血脂异常、代谢综合征和预测心血管疾病。在4,693名女性中,3.0%为胰岛素缺乏型,9.0%为胰岛素抵抗型,1.6%为混合缺陷型,0.7%为未分类GDM。与无GDM相比,除未分类外,所有GDM亚型均与糖尿病前期或糖尿病(校正风险比2.14-2.88)、代谢综合征和预测心血管疾病风险升高相关。仅胰岛素抵抗型GDM与血脂异常相关。所有GDM亚型均与分娩后10-14年糖尿病前期或糖尿病、代谢综合征以及预测心血管疾病风险较高的风险增加相关。

37脓毒性休克 (1篇)

临床研究 (1篇)

Intensive care medicine IF 22.0 2026-10 PMID: 42578996
The optimal timing of adjunctive vasopressin after norepinephrine escalation in septic shock remains uncertain. We emulated a target trial comparing ultra-early vasopressin initiation within 0-3 h with early initiation within > 3-6 h after the norepinephrine infusion rate reached 0.25 μg/kg/min or higher. We emulated a target trial using electronic health record databases (MIMIC-IV 2008-2022 and eICU-CRD 2014-2015). Adults with septic shock who reached the norepinephrine threshold before vasopressin use were eligible. We used the clone-censor-weight method to estimate cumulative incidence curves under the ultra-early and early initiation strategies and compared them via the weighted Cox model. Among 3810 eligible patients, after cloning, 744 clones adhered to the ultra-early strategy and 293 clones adhered to the early strategy. The weighted 28-day mortality risk was 48.1% under the ultra-early strategy and 53.0% under the early strategy (risk difference, - 5.0 percentage points; 95% confidence interval [CI] - 6.8 to - 3.2), with a restricted mean survival time difference of 1.58 days (95% CI 1.21-1.92) and a hazard ratio (HR) of 0.82 (95% CI 0.78-0.85). Ultra-early initiation was associated with lower renal replacement therapy (HR, 0.68; 95% CI 0.63-0.74), continuous renal replacement therapy (HR, 0.61; 95% CI 0.55-0.68), and medically treated arrhythmia (HR, 0.91; 95% CI 0.83-0.99), but not with lower acute kidney injury. Among adults with septic shock whose norepinephrine infusion reached 0.25 μg/kg/min or higher before vasopressin use, vasopressin initiation within 0-3 h was associated with lower 28-day mortality than initiation within > 3-6 h.
中文摘要:脓毒性休克患者在去甲肾上腺素剂量上调后,辅助性加压素的最佳启动时机仍不确定。我们模拟了一项目标试验,比较在去甲肾上腺素输注速率达到0.25 μg/kg/min或更高后0-3小时内启动加压素的超早期策略与>3-6小时内启动的早期策略。我们利用电子健康记录数据库(MIMIC-IV 2008-2022和eICU-CRD 2014-2015)模拟目标试验。纳入在使用加压素前去甲肾上腺素达到该阈值的成人脓毒性休克患者。我们使用克隆-删失-加权法估计超早期和早期启动策略下的累积发生率曲线,并通过加权Cox模型进行比较。在3810例符合条件患者中,克隆后分别有744个克隆遵循超早期策略,293个克隆遵循早期策略。超早期策略下的加权28天死亡风险为48.1%,早期策略下为53.0%(风险差,-5.0个百分点;95%置信区间[CI] -6.8至-3.2),限制平均生存时间差为1.58天(95% CI 1.21-1.92),风险比(HR)为0.82(95% CI 0.78-0.85)。超早期启动与较低的肾脏替代治疗(HR,0.68;95% CI 0.63-0.74)、连续性肾脏替代治疗(HR,0.61;95% CI 0.55-0.68)以及药物治疗的心律失常(HR,0.91;95% CI 0.83-0.99)相关,但与较低的急性肾损伤无关。在去甲肾上腺素输注达到0.25 μg/kg/min或更高后才使用加压素的成人脓毒性休克患者中,0-3小时内启动加压素与>3-6小时内启动相比,28天死亡率更低。

38糖耐量受损 (1篇)

临床研究 (1篇)

Diabetes care IF 22.6 2026-10-01 PMID: 42574058
To determine whether weight loss during the initial years following diagnosis of impaired glucose tolerance (IGT) is independently associated with reduced long-term mortality and cardiovascular risk. In the Da Qing Diabetes Prevention Study, 540 adults with IGT were categorized into three groups based on their weight change from baseline to the end of a 6-year lifestyle intervention trial: non-weight loss (n = 200), low weight loss (<5%, n = 163), and high weight loss (≥5%, n = 177). Participants were followed for 34 years to assess all-cause mortality, cardiovascular disease (CVD) mortality, and CVD events. Cox models were used to assess associations. Weight loss during the initial 6 years following IGT diagnosis was associated with reduced long-term risks of CVD events and mortality (P = 0.007-0.015). Compared with participants without weight loss, those with weight loss ≥5% had significantly lower risks of CVD death (hazard ratio [HR] 0.56, 95% CI 0.35-0.89), CVD events (HR 0.71, 95% CI 0.52-0.99), hospitalized heart failure (HR 0.48, 95% CI 0.26-0.88), and all-cause death (HR 0.67, 95% CI 0.48-0.95) after adjusting for age, sex, baseline weight, and other covariates. Furthermore, the high weight loss group showed delays in the median time to all-cause mortality and CVD mortality of 2.1 years and 6.5 years, respectively. Weight loss achieved in the early years after diagnosis of IGT in Chinese adults is associated with substantially lower long-term risks of CVD events and mortality, suggesting the critical importance of early weight management in individuals with prediabetes for improving long-term survival and cardiovascular health.
中文摘要:旨在确定在诊断糖耐量受损(IGT)后的最初几年内体重减轻是否与长期死亡率和心血管风险降低独立相关。在大庆糖尿病预防研究中,540名IGT成人根据其从基线至为期6年的生活方式干预试验结束时的体重变化被分为三组:未减重组(n=200)、低减重组(<5%,n=163)和高减重组(≥5%,n=177)。对参与者随访34年,以评估全因死亡、心血管疾病(CVD)死亡和CVD事件。采用Cox模型评估关联。IGT诊断后最初6年内的体重减轻与CVD事件和死亡长期风险降低相关(P=0.007-0.015)。与未减重者相比,在调整年龄、性别、基线体重及其他协变量后,减重≥5%者的CVD死亡风险(风险比[HR] 0.56,95% CI 0.35-0.89)、CVD事件风险(HR 0.71,95% CI 0.52-0.99)、因心力衰竭住院风险(HR 0.48,95% CI 0.26-0.88)和全因死亡风险(HR 0.67,95% CI 0.48-0.95)均显著更低。此外,高减重组的中位全因死亡时间和CVD死亡时间分别延迟2.1年和6.5年。中国成人在IGT诊断后早期实现的体重减轻与CVD事件和死亡的长期风险显著降低相关,提示对糖尿病前期个体进行早期体重管理对于改善长期生存和心血管健康具有关键重要性。

39神经系统疾病 (1篇)

基础研究 (1篇)

Ageing research reviews IF 15.5 2026-10 PMID: 42570705
Central nervous system (CNS) disorders are fundamentally linked to metabolic dysregulation within immune and glial cells. This review provides a systematic synthesis of immunometabolic reprogramming-encompassing glucose, lipid, and amino acid metabolism, and oxidative phosphorylation-in CNS-resident microglia, immunomodulatory astrocytes, and peripherally infiltrating immune cells (T cells, B cells, and neutrophils) across Alzheimer's disease, Parkinson's disease, multiple sclerosis, and ischemic stroke. Critically, rather than presenting all reported metabolic alterations as equivalently established, we introduce an evidence-transparency framework that systematically distinguishes the nature of supporting data-ranging from direct metabolic flux measurements (Seahorse, isotope tracing, lipidomics) and molecular correlates, to genetic/pharmacological perturbations, human tissue validation, and model-specific observations-enabling readers to independently assess the strength of each major conclusion. We further delineate aging as an active analytical dimension, demonstrating how age-related changes in mitochondrial quality control, lipid handling, redox buffering, and glial-immune crosstalk establish a permissive baseline that modifies disease-specific reprogramming trajectories. By integrating analyses of intercellular crosstalk, neuroinflammation, blood-brain barrier integrity, and oxidative stress, we illustrate both convergent and divergent metabolic mechanisms across diseases. Finally, we critically assess therapeutic strategies targeting immunometabolism, emphasizing shared translational obstacles including target selectivity, blood-brain barrier penetration, stage-dependent efficacy, and the inherent challenge of pathway pleiotropy. This review provides a conceptually grounded framework for interpreting immunometabolic evidence, navigating the gap between correlative findings and causal mechanisms, and guiding future hypothesis-driven therapeutic design for CNS disorders.
中文摘要:中枢神经系统疾病本质上与免疫细胞和胶质细胞内的代谢失调密切相关。本综述系统整合了免疫代谢重编程——涵盖葡萄糖、脂质和氨基酸代谢以及氧化磷酸化——在阿尔茨海默病、帕金森病、多发性硬化症和缺血性卒中中,中枢神经系统驻留的小胶质细胞、具有免疫调节作用的星形胶质细胞以及外周浸润免疫细胞(T细胞、B细胞和中性粒细胞)中的表现。关键在于,我们并未将所有已报道的代谢改变都视为同等确证,而是引入了证据透明度框架,系统区分支持性数据的性质——从直接的代谢通量测定(Seahorse、同位素示踪、脂质组学)与分子相关性指标,到遗传/药理学扰动、人体组织验证以及特定模型的观察结果——从而使读者能够独立评估每一项主要结论的证据强度。我们进一步将衰老确立为一个积极的分析维度,展示与年龄相关的线粒体质量控制、脂质处理、氧化还原缓冲以及胶质-免疫交互作用的变化如何建立一个允许性基线,进而修饰疾病特异性的重编程轨迹。通过整合对细胞间交互作用、神经炎症、血脑屏障完整性和氧化应激的分析,我们阐明了不同疾病间趋同与趋异的代谢机制。最后,我们批判性地评估了靶向免疫代谢的治疗策略,强调共同的转化障碍,包括靶点选择性、血脑屏障穿透、阶段依赖性疗效以及通路多效性这一固有挑战。本综述为解读免疫代谢证据、弥合相关性发现与因果机制之间的差距,以及指导未来中枢神经系统疾病中假设驱动的治疗设计提供了一个具有概念基础的框架。

40心脑血管共病 (1篇)

基础研究 (1篇)

Ageing research reviews IF 15.5 2026-10 PMID: 42546819
Aging is a fundamental driver of cardiovascular and cerebrovascular comorbidities, yet the mechanisms linking aging to concurrent heart and brain diseases remain incompletely understood. The neurovascular interface (NVI) refers to the structural and functional interface through which neural, vascular, and extracellular-matrix signals interact. In the CNS, this concept substantially overlaps with the classical neurovascular unit, whereas in the heart it refers to an emerging heart tissue-specific interface involving coronary microvessels, vascular cells, autonomic and sensory nerve fibers, cardiomyocytes, and extracellular-matrix components. Although direct experimental evidence that aging affects cardiovascular and cerebrovascular comorbidity through NVI is still accumulating, current evidence suggests that aging may disrupt shared neurovascular features. These changes are associated with hypertension, cerebral small vessel disease, heart failure, and related disorders. Moreover, genetic variants may act as susceptibility modifiers of neurovascular aging - from NOS3 regulating vascular tone to ADRB1 and COMT affecting autonomic balance. These variants are associated with cardiovascular and cerebrovascular disease risk and may represent upstream molecular determinants through which genetic susceptibility and aging-related stressors converge to alter NVI integrity and promote cardiovascular-cerebrovascular comorbidity. This review synthesizes current evidence on the structural and functional basis of the NVI, discusses how aging may disrupt its integrity, and evaluates its potential role as an integrative framework linking aging-related vascular, neural, inflammatory, and extracellular-matrix alterations to cardiovascular-cerebrovascular comorbidity. We also outline potential integrated strategies that may preserve interface function, including lifestyle interventions, senolytics, and gene-guided precision medicine.
中文摘要:衰老是心血管和脑血管共病的基本驱动因素,然而将衰老与同时发生的心脏和脑疾病联系起来的机制仍未被完全理解。神经血管界面(NVI)是指神经、血管和细胞外基质信号相互作用的结构和功能界面。在中枢神经系统中,这一概念与经典神经血管单元在很大程度上重叠;而在心脏中,它指一种新兴的心脏组织特异性界面,涉及冠状微血管、血管细胞、自主神经和感觉神经纤维、心肌细胞以及细胞外基质成分。尽管关于衰老通过NVI影响心血管和脑血管共病的直接实验证据仍在积累,但当前证据提示,衰老可能破坏共享的神经血管特征。这些变化与高血压、脑小血管病、心力衰竭及相关疾病有关。此外,遗传变异可能作为神经血管衰老的易感性修饰因素——从调节血管张力的NOS3到影响自主神经平衡的ADRB1和COMT。这些变异与心血管和脑血管疾病风险相关,并可能代表上游分子决定因素,遗传易感性与衰老相关应激源通过其汇聚,改变NVI完整性并促进心血管-脑血管共病。本综述综合了关于NVI结构和功能基础的当前证据,讨论了衰老如何可能破坏其完整性,并评估其作为整合框架的潜在作用,该框架将衰老相关的血管、神经、炎症和细胞外基质改变与心血管-脑血管共病联系起来。我们还概述了可能保护界面功能的潜在整合策略,包括生活方式干预、衰老细胞清除药物和基因指导的精准医学。

41非心脏手术 (1篇)

临床研究 (1篇)

British journal of anaesthesia IF 10.3 2026-10 PMID: 42538263
The predictive value of preoperative resting ECGs for cardiovascular events after noncardiac surgery is unclear. This study evaluated whether incorporating conventional ECG features or the output of a deep-learning algorithm for ECG waveform analysis (PreOpNet) improves risk prediction beyond established clinical risk scores. We conducted a secondary analysis of two prospective cohorts of patients undergoing major noncardiac surgery in China between 2019 and 2023. Eight prespecified conventional ECG features were extracted from ECG reports, and raw ECG waveforms were analysed using PreOpNet. The primary outcome was a composite of any cardiovascular events within 30 days after surgery; the secondary outcome was major adverse cardiac events (MACEs). We built nested logistic regression models based on clinical risk scores, with or without ECG findings. Predictive performance was evaluated using area under the receiver-operating-characteristic curve (AUC), risk reclassification metrics, and decision curve analyses. Among 6080 patients, 733 (12.1%) experienced postoperative cardiovascular events and 174 (2.9%) had MACEs. Adding conventional ECG features (ΔAUC 0.035) or PreOpNet (ΔAUC 0.032) to the Revised Cardiac Risk Index improved model discrimination modestly. When added to the Gupta Perioperative Myocardial Infarction or Cardiac Arrest risk score, both approaches yielded minimal gains (ΔAUC 0.010 for conventional ECG features; 0.006 for PreOpNet). Risk reclassification and decision curve analyses had limited incremental predictive value. Preoperative ECG findings, assessed by including conventional waveform features and the PreOpNet algorithm, provide limited incremental predictive value for cardiovascular risk assessment before noncardiac surgery.
中文摘要:术前静息心电图对非心脏手术后心血管事件的预测价值尚不明确。本研究评估了纳入常规心电图特征或用于心电图波形分析的深度学习算法(PreOpNet)的输出,是否能在现有临床风险评分之外改善风险预测。我们对2019年至2023年间在中国接受大型非心脏手术的两项前瞻性队列进行了二次分析。从心电图报告中提取8项预先设定的常规心电图特征,并使用PreOpNet分析原始心电图波形。主要结局为术后30天内任何心血管事件的复合终点;次要结局为主要不良心脏事件(MACE)。我们基于临床风险评分构建了嵌套逻辑回归模型,分别纳入或不纳入心电图发现。采用受试者工作特征曲线下面积(AUC)、风险重分类指标和决策曲线分析评估预测性能。在6080例患者中,733例(12.1%)发生术后心血管事件,174例(2.9%)发生MACE。将常规心电图特征(ΔAUC 0.035)或PreOpNet(ΔAUC 0.032)加入修订心脏风险指数后,模型区分度仅有适度改善。加入Gupta围术期心肌梗死或心脏骤停风险评分时,两种方法均仅带来极小增益(常规心电图特征ΔAUC 0.010;PreOpNet 0.006)。风险重分类和决策曲线分析的增量预测价值有限。通过纳入常规波形特征和PreOpNet算法评估的术前心电图发现,对非心脏手术前心血管风险评估提供有限的增量预测价值。

42急性脑损伤 (1篇)

临床研究 (1篇)

Intensive care medicine IF 22.0 2026-10 PMID: 42525086
Acute brain injury (ABI), including traumatic brain injury, ischemic and hemorrhagic stroke, is associated with high morbidity and mortality, which is driven not only by the primary brain injury, but also by the development of secondary cerebral insults. Among these, raised intracranial pressure (ICP) plays a central pathophysiological role, acting both as a consequence and a driver of ongoing brain injury through mechanical deformation and cerebral ischemia. Although invasive intracranial pressure (ICP) monitoring has a longstanding and ongoing role in neurocritical care management, the interpretation and clinical use of ICP remain controversial. Traditional management strategies rely on fixed ICP thresholds (e.g., > 22 mmHg) to trigger a standardized stepwise escalation of therapy; however, growing clinical evidence indicates that tolerance to ICP elevation varies widely across patients, disease entities, and physiological contexts. This review summarizes the physiological determinants of ICP, including intracranial compliance, cerebrospinal fluid dynamics, cerebral blood volume, and systemic factors, and describes the mechanisms underlying intracranial hypertension. We discuss limitations of using fixed ICP thresholds and highlight emerging concepts, such as ICP burden, waveform morphology, cerebral autoregulation, and functional brain monitoring, as tools to individualize ICP interpretation. The role of invasive and noninvasive ICP monitoring (nICP) modalities is reviewed, emphasizing the complementary value of nICP in guiding decision-making when invasive monitoring is unavailable or contraindicated. Particular attention is given to the integration of ICP within multimodal neuromonitoring frameworks assessing cerebral perfusion, oxygenation, and metabolism. Finally, we explore future perspectives, including the potential of artificial intelligence-based approaches to analyse complex neuromonitoring data, predict secondary insults, and move toward actionable, patientspecific therapeutic strategies. Collectively, these advances support a shift from a uniform, threshold-driven approach toward individualized, physiology-informed management of intracranial hypertension.
中文摘要:急性脑损伤(ABI),包括创伤性脑损伤、缺血性和出血性卒中,与高发病率和死亡率相关,这不仅由原发性脑损伤驱动,也由继发性脑损伤的发生所驱动。其中,颅内压(ICP)升高在病理生理中起核心作用,既可作为持续脑损伤的结果,也可通过机械变形和脑缺血成为其驱动因素。尽管有创颅内压监测在神经重症监护管理中具有长期且持续的作用,但ICP的解读和临床应用仍存在争议。传统管理策略依赖固定ICP阈值(如>22 mmHg)来触发标准化的阶梯式治疗升级;然而,越来越多的临床证据表明,患者、疾病类型和生理状态之间对ICP升高的耐受性差异很大。本综述总结了ICP的生理决定因素,包括颅内顺应性、脑脊液动力学、脑血容量和全身因素,并描述了颅内高压的机制。我们讨论了使用固定ICP阈值的局限性,并强调新兴概念,如ICP负荷、波形形态、脑自动调节和功能性脑监测,作为个体化解读ICP的工具。本文回顾了有创和无创ICP监测(nICP)方式的作用,强调在无法进行有创监测或有禁忌时,nICP在指导决策中的补充价值。特别关注将ICP整合到评估脑灌注、氧合和代谢的多模态神经监测框架中。最后,我们探讨未来前景,包括基于人工智能的方法在分析复杂神经监测数据、预测继发性损伤以及迈向可操作、患者特异性治疗策略方面的潜力。总体而言,这些进展支持从统一的阈值驱动方法转向个体化、基于生理的颅内高压管理。

43肥胖症 (1篇)

临床研究 (1篇)

Drugs IF 14.7 2026-10 PMID: 42479349
Orforglipron (Foundayo™) is an orally administered, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist being developed by Eli Lilly and Co. for use in long-term weight management and for the treatment of type 2 diabetes (T2D) among other indications. In April 2026, orforglipron received its first approval, in the USA, for use in combination with a reduced-calorie diet and increased physical activity for long-term weight management in adults with obesity or adults with overweight in the presence of one or more weight-related comorbid condition. Orforglipron has also been submitted for regulatory review in the EU for long-term weight management and T2D, in Japan for long-term weight management, and in Canada for T2D. In addition to long-term weight management and T2D treatment, orforglipron is currently under phase III clinical evaluation for use in the treatment of obstructive sleep apnoea, hypertension, stress urinary incontinence in females, osteoarthritis pain and peripheral arterial disease. This article summarises the milestones in the development of orforglipron leading to this first approval for long-term weight management in adults with obesity or overweight.
中文摘要:Orforglipron(Foundayo™)是一种口服非肽类胰高血糖素样肽-1(GLP-1)受体激动剂,由礼来公司开发,用于长期体重管理以及2型糖尿病(T2D)等适应症的治疗。2026年4月,orforglipron在美国获得首次批准,与减少热量饮食和增加体力活动联合,用于肥胖成人或伴有一种或多种体重相关合并症的超重成人的长期体重管理。Orforglipron还已在欧盟提交用于长期体重管理和T2D的监管审评,在日本提交用于长期体重管理,在加拿大提交用于T2D。除长期体重管理和T2D治疗外,orforglipron目前正在III期临床评价中,用于治疗阻塞性睡眠呼吸暂停、高血压、女性压力性尿失禁、骨关节炎疼痛和外周动脉疾病。本文总结了orforglipron开发过程中的里程碑,这些里程碑促成了其首次获批用于肥胖或超重成人的长期体重管理。

44动脉粥样硬化 (1篇)

基础研究 (1篇)

Ageing research reviews IF 15.5 2026-10 PMID: 42476319
The pathogenesis of atherosclerotic cardiovascular disease (ASCVD) is complex, involving a variety of immune and non-immune cells. The rising incidence of ASCVD presents significant challenges for therapeutic strategies. Traditional Chinese Medicine (TCM) and its active constituents demonstrate considerable potential in the treatment of ASCVD, owing to their holistic regulatory characteristics encompassing "multi-component, multi-target" mechanisms. This review systematically summarizes the mechanisms by which TCM and its bioactive ingredients exert anti-ASCVD effects through the modulation of endothelial cells, smooth muscle cells, platelets, cardiomyocytes, fibroblasts, and various immune cells, including T cells, neutrophils, monocytes, macrophages, mast cells, and dendritic cells. Furthermore, it outlines the clinical applications of TCM in managing ASCVD such as acute coronary syndrome, ischemic stroke, and stable coronary heart disease. Current limitations and future research directions are also discussed, offering insights for further investigation into TCM-based interventions for ASCVD.
中文摘要:动脉粥样硬化性心血管疾病(ASCVD)的发病机制复杂,涉及多种免疫细胞和非免疫细胞。ASCVD发病率的不断上升给治疗策略带来了重大挑战。中医药及其活性成分因具有「多成分、多靶点」的整体调控特点,在ASCVD治疗中展现出可观潜力。本综述系统总结了中医药及其生物活性成分通过调节内皮细胞、平滑肌细胞、血小板、心肌细胞、成纤维细胞以及多种免疫细胞(包括T细胞、中性粒细胞、单核细胞、巨噬细胞、肥大细胞和树突状细胞)发挥抗ASCVD作用的机制。此外,本文概述了中医药在管理ASCVD如急性冠脉综合征、缺血性脑卒中和稳定性冠心病中的临床应用。文中还讨论了当前局限性和未来研究方向,为进一步研究基于中医药的ASCVD干预措施提供思路。

45血管疾病 (1篇)

基础研究 (1篇)

Acta pharmacologica Sinica IF 10.4 2026-10 PMID: 42350779
Vascular diseases include disorders affecting arteries, veins, and capillaries, and remain the main cause of morbidity and mortality worldwide. The search for new therapeutic targets has led to the discovery of adenosine receptors as key regulators of the pathogenesis of several vascular conditions, including hypertension, atherosclerosis, abdominal aortic aneurysm, cerebral ischemia, and pathological angiogenesis. This review summarises the context-dependent functions of adenosine receptors in these diseases, with particular emphasis on mechanisms associated with endothelial-mesenchymal transition, vascular inflammation, and metabolic reprogramming. The therapeutic relevance of individual adenosine receptor subtypes is also discussed, including current preclinical evidence regarding receptor agonists and antagonists, as well as the potential value of combination-based approaches. Finally, current challenges and future research directions are considered, particularly the development of tissue-specific therapeutic strategies and the application of emerging technologies to improve the clinical translation of mechanistic findings.
中文摘要:血管疾病包括影响动脉、静脉和毛细血管的疾患,仍是全球发病和死亡的主要原因。对新治疗靶点的探索使腺苷受体被发现是多种血管疾病发病机制的关键调节因子,这些疾病包括高血压、动脉粥样硬化、腹主动脉瘤、脑缺血和病理性血管生成。本综述总结了腺苷受体在这些疾病中依赖语境的功能,特别强调与内皮-间充质转化、血管炎症和代谢重编程相关的机制。文中还讨论了各腺苷受体亚型的治疗相关性,包括目前关于受体激动剂和拮抗剂的临床前证据,以及联合治疗策略的潜在价值。最后,考虑了当前挑战和未来研究方向,特别是组织特异性治疗策略的开发以及应用新兴技术以改善机制发现的临床转化。

46慢性病 (1篇)

临床研究 (1篇)

Archives of toxicology IF 10.9 2026-10 PMID: 42228134
Per- and polyfluoroalkyl substances (PFAS) are persistent chemicals commonly found in consumer products. Despite growing concern over their health effects, their associations with chronic diseases in humans are still unclear. We included 10,093 participants to examine the associations between 8 PFAS and 40 chronic diseases. Multivariable logistic regression and restricted cubic spline (RCS) models were applied to evaluate linear and nonlinear associations, and mixture effects were further assessed using weighted quantile sum regression (WQS), quantile-based g-computation (q g‑comp), and Bayesian kernel machine regression (BKMR). Overall, we identified 16 significant PFAS-chronic disease associations after false discovery rate (FDR) correction, involving 7 PFAS and 6 chronic diseases. Specifically, each 1 ng/mL increase in perfluoroundecanoic acid (PFUnA) was associated with higher odds of heart attack (OR = 1.32, PFDR = 0.032), coronary heart disease (OR = 1.31, PFDR = 0.040), and non-melanoma cancer (OR = 1.22, PFDR = 0.046). Non-linear analyses showed that, 6 PFAS were significantly associated with colorectal cancer. PFAS mixture analyses consistently indicated increased risks of cardiovascular diseases, hypertension, high cholesterol, and metabolic dysfunction. Perfluorononanoic acid (PFNA) was identified as the dominant contributor to the positive mixture effect (31.8-52.7%), as evidenced by several machine learning methods. Our findings provide important evidence of associations between PFAS exposure and multiple chronic diseases, and may contribute to the development of precision management strategies for chronic diseases prevention.
中文摘要:全氟和多氟烷基物质(PFAS)是常见于消费品中的持久性化学物质。尽管对其健康影响的关注日益增加,但其与人类慢性疾病的关联仍不明确。我们纳入10,093名参与者,以探讨8种PFAS与40种慢性疾病之间的关联。采用多变量logistic回归和限制性立方样条(RCS)模型评估线性与非线性关联,并进一步使用加权分位数和回归(WQS)、基于分位数的g计算(q g-comp)和贝叶斯核机器回归(BKMR)评估混合效应。总体而言,在错误发现率(FDR)校正后,我们识别出16个显著的PFAS与慢性疾病关联,涉及7种PFAS和6种慢性疾病。具体而言,全氟十一烷酸(PFUnA)每增加1 ng/mL,与心脏病发作(OR = 1.32,PFDR = 0.032)、冠心病(OR = 1.31,PFDR = 0.040)和非黑色素瘤癌症(OR = 1.22,PFDR = 0.046)的较高比值比相关。非线性分析显示,6种PFAS与结直肠癌显著相关。PFAS混合物分析一致表明,心血管疾病、高血压、高胆固醇和代谢功能障碍的风险增加。全氟壬酸(PFNA)被确定为正向混合效应的主要贡献者(31.8-52.7%),这一点由多种机器学习方法证实。我们的发现为PFAS暴露与多种慢性疾病之间的关联提供了重要证据,并可能有助于制定慢性疾病预防的精准管理策略。